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Abstract 
With positive outcomes from medical treatments, monoclonal antibodies (mAbs) are to date 
the best-selling biologics in the pharmaceutical market. The fact that a lot of blockbuster drugs are 
facing the period of patent cliffs and patents of many of them are due to expire in the next 5 years, 
places an urgency for better, cheaper and more efficient bioproduction processes, as well as the 
development of novel drugs and biosimilars. To address to this issue, application of the Quality by 
Design paradigm that was introduced by the Food and Drug Administration (FDA) is of paramount 
importance. Medical values and safety of monoclonal antibodies have been reported to rely on the 
carbohydrate structures that are attached to the mAb N-linked glycosylation site on each constant 
region. Fc-N-linked glycosylation is considered as a critical quality attribute (CQA) of these 
therapeutic proteins under the scope of Quality by Design. It was also reported that different 
bioprocess conditions during recombinant mAb production directly impact glycan compositions and 
their distribution on the molecules, although the mechanism behind this change is not fully 
understood. This lack of understanding limits process design and optimisation. To address this issue 
we examined the effect of mild hypothermia (32C) and the different recombinant expression systems 
on mAb N-linked glycosylation, using experiments, flux balance analysis (FBA) and mechanistic 
modelling to identify resulting differences in cell metabolism. A defined mathematical model that 
mechanistically and quantitatively describes CHO cell behaviour and metabolism, mAb synthesis and 
its N-linked glycosylation profiles before and after the induction of mild hypothermia in SGE and 
TGE expression systems was also constructed, which we believe is the first quantitative model that 
relates mild hypothermia and TGE system to the four elements mentioned above. Not only does the 
model aid understanding of the way bioprocess conditions affect product quality, it also provides a 
platform for bioprocess design, control and optimisation in industry and helps the implementation of 
the Quality by Design principles. Results obtained from our computational studies suggested 
glycosyltransferases to be the key players for changes observed among different bioprocess 
conditions, based on results obtained from this thesis we then manipulated the expression of 
galactosyltransferase in particular, through a proof-of-concept experiment using miRNAs.  
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Notation 
 ECM : Extracellular matrix 
 Fin,feed : inlet flow rate of Feed C (CD EfficientFeed
TM
C AGT
TM
) 
 Fin, Glc : inlet flow rate of glucose only feed 
 Fout : Outlet flow rate of the bioreactor 
 Fout,NSD : NSD transport rate 
 Fout,nucloetide : Nucleotide transport rate 
 Fout,UDPGalNAc : UDPGalNAc transport rate 
 Fout,CMPNeu5Ac : CMPNeu5Ac transport rate 
 Fout,ATP : ATP transport rate 
 Fout,CTP : CTP transport rate 
 Fout,GTP : GTP transport rate 
 Fout,UTP : UTP transport rate 
 KA : mAb assembly rate constant 
 Kasn : Monod constant for growth with respect to asparagine 
 Kasp : Monod constant for growth with respect to aspartate 
 Karg : Monod constant for growth with respect to arginine 
 Kglc : Monod constant for growth with respect to glucose 
 Kglu : Monod constant for growth with respect to glutamate 
 KLac : Monod constant for growth with respect to lactate 
 Klysis : Specific lysis rate of CHO cells within the bioreactor 
 Klys : Monod constant for growth with respect to lysine 
 Kpro : Monod constant for growth with respect to proline 
 KPEI : Monod constant for growth with respect to PEI 
 Kd,amm : Constant for cell death by ammonia 
 KIamm : Inhibition constant for growth with respect to ammonia 
 KIlac : Inhibition constant for growth with respect to lactate 
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 𝐾𝑎𝑚𝑚,𝑔𝑙𝑛 : Monod constant for ammonia production from glutamine 
 KdHC : mRNA decay rate of mAb heavy chain 
 KdLC : mRNA decay rate of mAb light chain 
 KER : Rate constant for ER-to-Golgi antibody transport 
 KG : Rate constant for Golgi-to-ECM antibody transport 
 𝐾𝑔𝑙𝑐,𝐴𝑇𝑃 : Saturation constant of glucose with respect to ATP 
 𝐾𝑔𝑙𝑛,𝐴𝑇𝑃 : Saturation constant of glutamine with respect to ATP 
 𝐾𝑈𝑇𝑃,𝑔𝑙𝑐 : Saturation constant of UTP with respect to glucose 
 𝐾𝑈𝑇𝑃,𝑔𝑙𝑛 : Saturation constant of UTP with respect to glutamine 
 𝐾𝑈𝑇𝑃,𝐴𝑇𝑃 : Saturation constant of UTP with respect to ATP 
 𝐾𝐺𝑇𝑃,𝑔𝑙𝑐 : Saturation constant of GTP with respect to glucose 
 𝐾𝐺𝑇𝑃,𝑔𝑙𝑛 : Saturation constant of GTP with respect to glutamine 
 𝐾𝐺𝑇𝑃,𝐴𝑇𝑃 : Saturation constant of GTP with respect to ATP 
 𝐾𝐶𝑇𝑃,𝑔𝑙𝑐 : Saturation constant of CTP with respect to glucose 
 𝐾𝐶𝑇𝑃,𝑔𝑙𝑛 : Saturation constant of CTP with respect to glutamine 
 𝐾𝐶𝑇𝑃,𝐴𝑇𝑃 : Saturation constant of CTP with respect to ATP 
 𝐾𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐,𝑔𝑙𝑐 : Saturation constant of UDPGlcNAc with respect to glucose 
 𝐾𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐,𝑔𝑙𝑛 : Saturation constant of UDPGlcNAc with respect to glutamine 
 𝐾𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐,𝑈𝑇𝑃 : Saturation constant of UDPGlcNAc with respect to UTP 
 𝐾𝑈𝐷𝑃𝐺𝑙𝑐,𝑔𝑙𝑐 : Saturation constant of UDPGlc with respect to glucose 
 𝐾𝑈𝐷𝑃𝐺𝑙𝑐,𝑈𝑇𝑃 : Saturation constant of UDPGlc with respect to UTP 
 𝐾𝐺𝐷𝑃𝑀𝑎𝑛,𝑔𝑙𝑐 : Saturation constant of GDPMan with respect to glucose 
 𝐾𝐺𝐷𝑃𝑀𝑎𝑛,𝐺𝑇𝑃 : Saturation constant of GDPMan with respect to GTP 
 𝐾𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 : Saturation constant of UDPGalNAc with respect to UDPGlcNAc 
 𝐾𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 : Saturation constant of CMPNeu5Ac with respect to UDPGlcNAc 
 𝐾𝑔𝑙𝑛,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 : Saturation constant of glutamine with respect to CMPNeu5Ac 
 𝐾𝑈𝐷𝑃𝐺𝑎𝑙,𝑈𝐷𝑃𝐺𝑙𝑐 : Saturation constant of UDPGal with respect to UDPGlc 
 𝐾𝐺𝐷𝑃𝐹𝑢𝑐,𝐺𝐷𝑃𝑀𝑎𝑛 : Saturation constant of GDPFuc with respect to GDPMan 
 𝐾𝑖,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 : Competitive product inhibition constant 
 𝐾𝑖,𝐺𝐷𝑃𝐹𝑢𝑐 : Non-competitive product inhibition constant 
 𝐾𝑖,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 : Transport inhibition of CMPNeu5Ac by UDPGlcNAc 
 𝐾𝑜𝑢𝑡,𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 : Consumption rate of nucleotide 
 𝐾𝑇𝑃,𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 : Saturation coefficient of nucleotide transport 
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 𝐾𝑇𝑃,𝑁𝑆𝐷 : Saturation coefficient of NSD transport 
 𝐾𝑇𝑃,𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐 : Saturation coefficient of UDPGalNAc transport 
 𝐾𝑇𝑃,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 : Saturation coefficient of CMPNeu5Ac transport 
 𝐾𝑇𝑃,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 : Saturation coefficient of UDPGlcNAc transport 
 𝐾𝑇𝑃,𝑈𝐷𝑃𝐺𝑙𝑐 : Saturation coefficient of UDPGlc transport 
 𝐾𝑇𝑃,𝑈𝐷𝑃𝐺𝑎𝑙 : Saturation coefficient of UDPGal transport 
 𝐾𝑇𝑃,𝐺𝐷𝑃𝑀𝑎𝑛 : Saturation coefficient of GDPMan transport 
 𝐾𝑇𝑃,𝐺𝐷𝑃𝐹𝑢𝑐 : Saturation coefficient of GDPFuc transport 
 𝐾𝑑,𝑀𝑎𝑛𝐼 𝐷 : Enzyme dissociation constant of ManI on substrate Man6 
 𝐾𝑑,𝑀𝑎𝑛𝐼𝐼 𝐴 : Enzyme dissociation constant of ManII on substrate Man5 
 𝐾𝑑,𝐺𝑛𝑇𝐼𝐼  : Enzyme dissociation constant of GnTII on substrate CoreGlcNAc1 
 𝐾𝑑,𝐺𝑎𝑙𝑇 𝑎1𝐴  : Enzyme dissociation constant of GalT on substrate CoreGlcNAc2 (-1,3 arm) 
 𝐾𝑑,𝐺𝑎𝑙𝑇 𝑎1𝐵  : Enzyme dissociation constant of GalT on substrate CoreGlcNAc2 (-1,6 arm) 
 𝐾𝑑,𝐺𝑎𝑙𝑇 𝑎2𝐴  : Enzyme dissociation constant of GalT on substrate CoreGlcNAc2Gal1 (-1,6 arm) 
 𝐾𝑑,𝐹𝑢𝑐 𝐴  : Enzyme dissociation constant of FucT on substrate CoreGlcNAc2 
 𝑘𝑇,[𝐴𝑠𝑛] : Menten constant of asparagine transport into the cell from culture medium 
 𝑘𝑇,[𝐺𝑙𝑐] : Menten constant of glucose transport into the cell from culture medium 
 𝑘𝑇,[𝐿𝑎𝑐] : Menten constant of lactate transport into the cell from culture medium 
 𝐿𝐶 : mAb light chain 
 mglc : maintenance coefficient of glucose 
 pgln : synthesis coefficient of glutamine 
 NHC : mAb heavy chain DNA copy number 
 NLC : mAb light chain DNA copy number 
 𝑁𝑔𝑙𝑐,𝐴𝑇𝑃  : Number of glucose required for ATP synthesis 
 𝑁𝑔𝑙𝑐,𝐺𝑇𝑃  : Number of glucose required for GTP synthesis 
 𝑁𝑔𝑙𝑐,𝑈𝑇𝑃  : Number of glucose required for UTP synthesis 
 𝑁𝑔𝑙𝑐,𝑈𝐷𝑃𝐺𝑙𝑐  : Number of glucose required for UDPGlc synthesis 
 𝑁𝑔𝑙𝑐,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐  : Number of glucose required for UDPGlcNAc synthesis 
 𝑁𝑔𝑙𝑐,𝐺𝐷𝑃𝑀𝑎𝑛  : Number of glucose required for GDPMan synthesis 
 𝑁𝑔𝑙𝑛,𝐴𝑇𝑃  : Number of glutamine required for ATP synthesis 
 𝑁𝑔𝑙𝑛,𝐺𝑇𝑃  : Number of glutamine required for GTP synthesis 
 𝑁𝑔𝑙𝑛,𝑈𝑇𝑃  : Number of glutamine required for UTP synthesis 
 𝑁𝑔𝑙𝑛,𝐶𝑇𝑃  : Number of glutamine required for CTP synthesis 
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 𝑁𝑔𝑙𝑛,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐  : Number of glutamine required for UDPGlcNAc synthesis 
 𝑁𝑔𝑙𝑛,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐  : Number of glutamine required for CMPNeu5Ac synthesis 
 𝑁𝐴𝑇𝑃,𝐶𝑇𝑃  : Number of ATP required for CTP synthesis 
 𝑁𝐴𝑇𝑃,𝐺𝑇𝑃  : Number of ATP required for GTP synthesis 
 𝑁𝐴𝑇𝑃,𝑈𝑇𝑃  : Number of ATP required for UTP synthesis 
 𝑁𝑔𝑙𝑦𝑐,𝑐𝑒𝑙𝑙 : Total number of glycan per cell 
 𝑁𝑁𝑆𝐷,𝑔𝑙𝑦𝑐 : Number of NSD consumed per host cell N-linked glycan 
 𝑁𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐,𝑔𝑙𝑦𝑐 : Number of UDPGalNAc consumed per host cell N-linked glycan 
 𝑁𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐,𝑔𝑙𝑦𝑐 : Number of CMPNeu5Ac consumed per host cell N-linked glycan 
 𝑁𝑁𝑆𝐷,𝑚𝐴𝑏 : Number of NSD consumed per mAb Fc-glycan 
 𝑁𝑔𝑙𝑦𝑐,𝑚𝐴𝑏 : Number of glycan per a molecule of mAb 
 PEI : 25kDa linear polyethylenimine transfection reagent 
 qasn : Specific rate of asparagine consumption 
 qasp : Specific rate of aspartate consumption 
 qarg : Specific rate of arginine consumption 
 qamm : Specific rate of ammonia production 
 qglc : Specific rate of glucose consumption 
 qglu : Specific rate of glutamate consumption 
 qgln : Specific rate of glutamine consumption 
 qlac : Specific rate of lactate consumption 
 qys : Specific rate of lysine consumption 
 qpro : Specific rate of proline consumption 
 qmAb : Specific rate of mAb production 
 rNSD: NSD synthesis rate from glucose or/and glutamine 
 rnucleotide : rate of nucleotide synthesis  
 rATP: rate of ATP synthesis  
 rGTP: rate of GTP synthesis  
 rCTP: rate of CTP synthesis  
 rUTP: rate of UTP synthesis  
 rUDPGlcNAc: UDP-GlcNAc synthesis rate from glucose and glutamine 
 rUDPGlc: UDP-Glc synthesis rate from glucose 
 rGDPMan: GDP-Man synthesis rate from glucose 
 rUDPGalNAc: UDP-GalNAc synthesis rate from UDP-GlcNAc 
 rCMPNeu5Ac: CMP-Neu5Ac synthesis from UDP-GlcNAc 
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 rUDPGal: UDP-Gal synthesis rate from UDP-Glc 
 rGDPFuc: GDP-Fuc synthesis rate from GDP-Man 
 rmet,glc: rate of other biochemical reactions based on glucose 
 rmet,gln: rate of other biochemical reactions based on glutamine 
 RHC : rate of mAb heavy chain consumption in mAb assembly  
 RLC : rate of mAb light chain consumption in mAb assembly  
 SHC : transcription rate of mAb heavy chain  
 SLC : transcription rate of mAb light chain  
 THC : translation rate of mAb heavy chain  
 TLC : translation rate of mAb light chain  
 V : Volume of cell culture 
 𝑉𝑚𝑎𝑥,𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 : Maximum turnover rate of nucleotide 
 𝑉𝑚𝑎𝑥,𝐴𝑇𝑃 : Maximum turnover rate of ATP 
 𝑉𝑚𝑎𝑥,𝐶𝑇𝑃 : Maximum turnover rate of CTP 
 𝑉𝑚𝑎𝑥,𝐺𝑇𝑃 : Maximum turnover rate of GTP 
 𝑉𝑚𝑎𝑥,𝑈𝑇𝑃 : Maximum turnover rate of UTP 
 𝑉𝑚𝑎𝑥,𝑁𝑆𝐷 : Maximum turnover rate of NSD 
 𝑉𝑚𝑎𝑥,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 : Maximum turnover rate of UDPGlcNAc 
 𝑉𝑚𝑎𝑥,𝑈𝐷𝑃𝐺𝑙𝑐 : Maximum turnover rate of UDPGlc 
 𝑉𝑚𝑎𝑥,𝐺𝐷𝑃𝑀𝑎𝑛 : Maximum turnover rate of GDPMan 
 𝑉𝑚𝑎𝑥,𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐 : Maximum turnover rate of UDPGalNAc 
 𝑉𝑚𝑎𝑥,𝑈𝐷𝑃𝐺𝑎𝑙 : Maximum turnover rate of UDPGal 
 𝑉𝑚𝑎𝑥,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 : Maximum turnover rate of CMPNeu5Ac 
 𝑉𝑚𝑎𝑥,𝐺𝐷𝑃𝐹𝑢𝑐 : Maximum turnover rate of GDPFuc 
 𝑉𝑐𝑒𝑙𝑙 : volume of a CHO cell 
 Xv : Viable cell density in the bioreactor 
 Xt : Total cell density in the bioreactor 
 𝑌𝑎𝑟𝑔,𝑔𝑙𝑢 : Yield of arginine on glutamate 
 𝑌𝑔𝑙𝑢,𝑔𝑙𝑛 : Yield of glutamate on glutamine 
 𝑌𝑔𝑙𝑛,𝑔𝑙𝑢 : Yield of glutamine on glutamate 
 𝑌𝑙𝑎𝑐,𝑔𝑙𝑐 : Yield of lactate on glucose 
 𝑌𝑙𝑦𝑠,𝑔𝑙𝑢 : Yield of lysine on glutamate 
 𝑌𝑝𝑟𝑜,𝑔𝑙𝑢 : Yield of proline on glutamate 
 𝑌𝑥𝑣,𝑎𝑠𝑛 : Yield of biomass on asparagine 
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 𝑌𝑥𝑣,𝑎𝑠𝑝 : Yield of biomass on aspartate 
 𝑌𝑥𝑣,𝑎𝑟𝑔 : Yield of biomass on arginine 
 𝑌𝑥𝑣,𝑎𝑚𝑚 : Yield of biomass on ammonia 
 𝑌𝑥𝑣,𝑔𝑙𝑐 : Yield of biomass on glucose 
 𝑌𝑥𝑣,𝑔𝑙𝑢 : Yield of biomass on glutamate 
 𝑌𝑥𝑣,𝑔𝑙𝑛 : Yield of biomass on glutamine 
 𝑌𝑥𝑣,𝑙𝑎𝑐 : Yield of biomass on lactate 
 𝑌𝑥𝑣,𝑙𝑦𝑠 : Yield of biomass on lysine 
 𝑌𝑥𝑣,𝑝𝑟𝑜 : Yield of biomass on proline 
 𝜀1 : ER glycosylation efficiency factor 
 𝜀2 : Golgi glycosylation efficiency factor 
 flim,: Nutrient limitation 
 finh,: Product inhibition 
  : Specific CHO cell growth rate 
 d : Specific CHO cell death rate 
 max : Maximum specific growth rate 
 d,max : Maximum specific death rate 
  /MW: Molecular weight of mAb 
 UDP-GlcNAc: Intracellular uridine diphosphate N-acetylglucosamine concentration 
 UDP-Glc: Intracellular concentration of uridine diphosphate glucose concentration 
 GDP-Man: Intracellular concentration of guanosine diphosphate mannose 
 UDP-GalNAc: Intracellular uridine diphosphate N-acetylgalactosamine concentration 
 CMP-Neu5Ac: Intracellular cytosine monophosphate N-acetylneuraminic acid concentration 
 UDP-Gal: Intracellular uridine diphosphate galactose concentration 
 GDP-Fuc: Intracellular guanosine diphosphate fucose concentration 
 [ATP] : Intracellular concentration of adenosine triphosphate 
 [GTP] : Intracellular concentration of guanosine triphosphate 
 [CTP] : Intracellular concentration of cytidine triphosphate 
 [UTP] : Intracellular concentration of uridine triphosphate 
 [Asn] : Extracellular concentration of asparagine 
 [Asp] : Extracellular concentration of aspartate 
 [Arg] : Extracellular concentration of arginine 
 [Glc] : Extracellular concentration of glucose 
 [Glu] : Extracellular concentration of glutamate 
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 [PEI] : Concentration of PEI 
 [HC ]: mAb heavy chain concentration 
 [LC] : mAb light chain concentration 
 [HC2LC2]ER : Fully assembled mAb molecule in the ER 
 [HC2LC2]G : Fully assembled mAb molecule in the Golgi apparatus 
 [mHC] : mRNA production of mAb heavy chain 
 [mLC] : mRNA production of mAb light chain 
 [mAb] : secreted mAb concentration  
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TM
 
 [Glcin,Glc] : inlet glucose concentration in in glucose-only feed  
 [Glcint] : intracellular concentration of glucose 
 [Glnint] : intracellular concentration of glutamine 
 [mHC] : mRNA production of mAb heavy chain 
 ManI: -1,2 Mannosidase I 
 GnTI: -1,3 N-acetylglucosaminyl transferase I 
 ManII: -1,3/-1,6 Mannosidase II 
 GnTII: -1,6 N-acetylglucosaminyl transferase II 
 FucT: -1,6 Fucosyltransferase (also known as FUT8) 
 GalT: -1,4 Galactosyltransferase 
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Chapter 1
Introduction 
Since the approval of the first chimeric monoclonal antibody by the U.S. Food and Drug 
Administration (FDA) in 1986, a total of 44 monoclonal antibody (mAb) products were approved and 
marketed. This class of biopharmaceutical product is emerging at a significant rate, with an approval 
rate of approximately 4 to 5 products per year by the FDA (Ecker et al. 2015). According to the global 
sales forecast report on biologics by EvaluatePharma in 2014, mAb products will be five of the top 10 
best-selling products in the world by 2020. Humira, an anti-tumour necrosis factor  mAb that is 
used to treat Crohn’s disease, remains as the top selling worldwhile product (Figure 1) 
(EvaluatePharma 2014). However, 2015-2020 are indeed challenging years for the biopharmaceutical 
industry, product patents of at least 13 blockbuster mAbs including Humira, Remicade, Rituxan, 
Lucentis and many others are at risk of patent expiry (Mullard 2012). This imposes urgency to 
improve the turnover rate of current mAb development, as well as developing novel biologics and 
biosimilars for post-patent recovery. To date more than 300 mAb product candidates are in the 
industrial R&D pipeline, with Nivolumab being the top most valuable R&D project and the most 
exciting anti-cancer product that targets programmed cell death-1 pathway (EvaluatePharma 2014). In 
all ways, to keep up with the fast growing demand for prescription drugs and to ease the risk of the 
upcoming patent cliff, it is essential for the pharmaceutical industry to investigate efficient production 
methods with an aim of increasing product yield and efficacy, and to shorten production period. 
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Figure 1. Top 10 selling pharmaceutical products in the world. This is modified from the sales forecast report of 
(EvaluatePharma 2014). 
 
 To fulfil this aim, the biopharmaceutical sector can no longer rely on the traditional “Quality 
by Testing (QbT)” methodology, where quality of products from experiments is only assessed at the 
end of the process and products are discarded if they fail to meet specification set by the FDA, 
without looking into the reason for the failure (Hubert et al. 2014). Not only does QbT increase drug 
production cost, it also lengthens the time required to pass all stages of clinical trials and for the 
product to be released into the market. As a result, in 2006 the U.S. FDA encouraged the 
implementation of the “Quality by Design (QbD)” paradigm. QbD relates critical quality attributes 
(CQAs) of the target protein to bioprocess parameters. Through prior knowledge of the product in 
different bioprocess conditions, relevant parameters can be altered accordingly in defined product 
design spaces along the production process and quality can be incorporated into the final products 
(Rathore and Winkle 2009). To satisfy the principle of QbD during pharmaceutical production 
requires a thorough understanding of the relationship between process parameters and the CQA of the 
target product.  
 In mammalian cells, nascent polypeptides are subject to post-translational modifications to 
give functionality; such modifications also generate variations within the same species. Protein 
glycosylation is a commonly observed protein modification. In the case of Immunoglobulin G (IgG), 
N-linked glycosylation of mAb has been extensively studied and oligosaccharides are found on the 
Asn297 on the CH2 domain of each heavy chain within its Fc-region. Although it is less studied, Fab 
regions of mAb molecules are also glycosylated. Fab regions recognise and bind to target antigens to 
initiate immunomodulation and their antigen binding affinity and avidity are dependent upon the N-
glycan structure of Fab fragments (Man Sung et al. 1993). The Fc-domain of the mAb is functionally 
important owing to the activation of downstream immune effector mechanisms upon binding to 
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different types of Fc receptors. Oligosaccharide chains on the CH2 domains of both heavy chains 
affect the protein structure of the binding site and sometimes glycans themselves are involved in the 
receptor-binding to initiate effects. However, cell metabolism and the process of mAb production 
including mAb productivity and glycosylation are cell-line, bioprocess condition and product 
dependent. As a result, product quality can be built into the Fc region during mAb manufacturing to 
modulate its immune effector function. During recombinant IgG production, mAb glycoforms are 
regarded as a CQA. Improved understanding of how a certain process condition influences the mAb 
Fc glycosylation therefore allows specific design of experiment (DoE) and consistant generation of 
mAb molecules with the desired function. In return, it improves product yield and efficacy, alongside 
with reduced manufacturing time and cost (Kozlowski and Swann 2006).  
 The main focus of this study was to thoroughly investigate the impact of mild hypothermic 
cell culture temperatures and transient gene expression on mAb productivity and mAb Fc N-linked 
glycosylation. These bioprocess conditions were specifically chosen, as they had the potential to 
increase the specific productivity of recombinant products, as well as shorten the time-frame for mAb 
production. In brief, mild hypothermia during cell culture (e.g. temperature shift from 37C to 30 - 
33C) is a common industrial practice that is used to increase mAb production yield during the 
fermentation process (Yoon et al. 2006). By lowering the cell culture temperature, it provides a 
prolonged period of time at high cell density and viability, which typically results in a higher integral 
viable cell density as well as higher mAb titre. On the other hand, transient gene expression (TGE) is 
a fast emerging methodology employed during bioproduction. Traditionally, plasmids of recombinant 
DNA are transfected and expressed within mammalian hosts in a stable manner through stable gene 
expression (SGE), where target genes are integrated into the host cell genome. This method generates 
high volumetric yield of recombinant materials, but the process of rProtein synthesis is time-
consuming and labour-intensive. As opposed to SGE, TGE is an alternative DNA transfection 
methodology where target genes of interest are temporarily expressed within host cells without 
genome integration. This method reduces the time required for clonal selection and cell line 
expansion, which in turn, speeds up the overall production process. Despite the usefulness of both 
conditions discussed, each bears its own limitations which could have negative effects on the CQAs 
of products under the examined bioprocesses. 
Within this context, the main goal of this work was to establish linkages between process 
conditions and CQAs through experimental and computational analyses. We aimed to create a 
thorough understanding of the impact of each condition on intracellular mechanisms with respect to 
five main indicators: CHO cell growth profile, nutrient and amino acid metabolism, mAb synthesis, 
nucleotide and NSD metabolism and mAb Fc N-linked glycosylation. Only through complete 
understanding of how one or a combination of different conditions affect the cellular behaviour, cell 
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metabolism and product synthesis, one can identify the underlying causes of differences arising from 
each bioprocess condition, and design experiments accordingly to generate optimal products.  
In addition to experimental analyses, computational approaches are becoming increasingly 
useful for systems analysis, interpretation of experimental data and to generate estimates for product 
quality post-fermentation. The use of modelling tools allows us to examine specific parameters that 
would otherwise be difficult to investigate experimentally, such as the kinetic properties of enzymes 
involved in N-linked glycosylation. In this study we analysed the metabolic distribution of carbon 
within cells that were under the influence of each bioprocess condition, through flux balance analysis. 
In conjunction with the FBA study, mechanistic models that are capable of describing the five aspects 
of intracellular mechanisms mentioned above were developed for conditions that were examined in 
this study. The proposed mechanistic models were to be developed based on existing models from 
Kontoravdi et al. (2010b) and Jimenez del Val et al. (2011). With an aim to compare the respective 
model outputs from each expression system under different culture temperatures, the developed 
models provided insights into how differences in product quality arise from the two expression 
systems. By developing mechanistic models that are capable of representing the biological systems 
under SGE and TGE, we aimed to close the loop between model outputs and experimental system and 
provide a platform for bioprocess design, control and optimisation in industry and will assist the 
implementation of the Quality by Design principles.  
The thesis commences with a thorough review of important literature in Chapter 2 that 
focuses on mAb N-linked glycosylation, this includes its biosynthetic process, structure and function 
of these attached sugar molecules, their impacts of product glycosylation on drug efficacy, and 
describing the relationship between bioprocess conditions and mAb glycosylation, with the main 
focus on mild hypothermic culture temperature and transient gene expression system. The chapter 
continues with a description of potential approaches that can be applied to identify the underlying 
mechanisms of cellular processes upon culturing mammalian cells under different bioprocess 
conditions, which will include the use of various experimental approaches, understanding the cellular 
metabolic distribution of nutrients and energy through flux balance analysis studies, as well as a 
description on mechanistic mathematical models from past relevant literatures, the thesis will outline 
the construction and the assumption of models that were developed to describe host cell dynamics, 
mAb synthesis, NSD metabolism and the process of N-linked Fc-glycosylation within the Golgi 
apparatus. The thesis continues by outlining a list of experimental methods that are practised 
throughout the entire research project in Chapter 3. Our research commences with an investigation of 
the impact of mild hypothermia on mAb glycosylation in stable CHO transfectants, through the 
combination of experimental and mathematically analyses presented in Chapter 4 and 5. With similar 
analytic approaches, the work in the thesis is further extended in Chapter 6 and 7 to examine the effect 
of transient gene expression on product quality, and a full comparison between stable and transient 
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gene expression systems, with respect to cellular metabolism, product production and glycosylation, is 
carried out. Based on the knowledge and understanding that is obtained from the research, a proof-of-
concept experiment described in Chapter 8 is developed with an aim to improve mAb glycosylation 
through manipulating the expression of key glycosyltransferases. Finally the thesis closes with an 
overall conclusion, which includes the presentation of the main findings of the work and comments on 
future studies that can potentially be carried out to further improve our understanding of similar 
matters within the field of biopharmaceutical production in Chapter 9.  
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Chapter 2
Literature Review 
2.1. Monoclonal antibodies – structure and endogenous 
function  
Monoclonal antibodies (mAbs), also known as Immunoglobulins (Igs), are glycoprotein 
molecules that play an important role in the human immune system. They are formed of four 
polypeptide chains, two identical heavy and two identical light chains, which form a Y-shape (Figure 
2). Igs are heterogeneous in their structures and functions, in which variations arise from differences 
in the amino-acid sequence of the heavy chains. Each heavy chain consists of one variable domain 
that is responsible for antigen recognition, and various constant regions that trigger immune response. 
Isotypes of mAb molecules differ by the number of constant domains, e.g. IgG, IgD, IgE and IgA 
have three constant domains whereas IgM has four. On the other hand, each light chain has one 
variable and one constant domain only. The C-termini of the heavy chains are joined together by 
disulphide bonds at the hinge region and form the crystallizable fragment (Fc) of the mAb, while 
variable regions of light chains are brought into line with those of the heavy chains to form the 
antigen-binding fragment (Fab) region. To date, IgGs are the most widely studied antibodies and are 
further grouped into IgG1, IgG2, IgG3 and IgG4 according to their respective abundances in human 
serum. Owing to its large quantity in serum (~75% of all immunoglobulins) (Kukrer et al. 2010), 
recombinant mAbs produced are mostly subgroups of IgGs. 
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Figure 2. Monoclonal antibody IgG structure. A. IgG mAb possesses a “Y-shape” structure, which comprises two 
identical heavy and two identical light chains that are joined together by disulfide bonds. Each IgG molecule has two 
Fab fragments for antigen binding, and one Fc region for functional effector activation. B. X-ray crystallography 
derived IgG ribbon structure. One N-linked oligosaccharide chain is attached to the Asn 297 amino acid residue of 
each of the heavy chain CH2 IgG backbone (Lehninger et al. 2008). 
Upon an invasion of pathogens into the human body, our cells trigger a series of immune 
responses which stimulate the plasma B-cells to produce antibodies with Fab regions that are specific 
for the targeted antigens. While the Fab region of the mAb recognizes and binds to the antigen, 
clearance of the pathogen depends on mechanism of the Fc region. Focusing on the IgG isotypes, 
binding to the Fc region of IgGs can activate various immune effector functions. An example is 
antibody-dependent cellular cytotoxicity (ADCC), which lyses and kills antigens with granules  
secreted by granulocytes such as NK cells or neutrophils, when the Fc of the mAb-antigen immune 
complex is bound by the FcIII receptor on NK cells or FcII-A receptor on neutrophils respectively 
(Janeway 2005). Alternatively complement-dependent cytotoxicity (CDC) is activated, in which the 
Fc of the antigen-bound mAb binds to the C1 complement complex to activate the complement 
system. The pathogen is eventually engulfed and eliminated by the membrane attack complex formed 
during the complement process (Janeway 2005). Moreover, Kaneko et al. showed that the 
glycosylation pattern on the Fc region of an IgG changes between a pro- and an anti-inflammatory 
response; this regulates the immune system (Kaneko et al. 2006). 
2.2. Monoclonal antibodies as a class of therapeutics 
(biologics) 
Owing to the specificity and functionality towards target pathogens in triggering immune 
responses, mAbs are excellent candidates as therapeutics for various numbers of diseases. Drug 
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production is slowly and increasingly shifting from the generation of chemically defined-small 
molecules to pharmaceutical products that are produced in mammalian hosts (biologics). In the case 
of monoclonal antibodies, technology involved in mAb generation has advanced dramatically since 
the development of the first mAb in mice in 1975 (Kohler and Milstein 1975). The hybridoma 
technique developed by Kohler and Milstein in 1975 involved the fusion of immortal myeloma cells 
with B-lymphocytes from murine spleen cells that were immunised with specific antigen. To increase 
target specificity, Boulianne et al. (1984) generated chimeric humanised mAb production in mice and 
in 1994 mAb were successfully synthesized from the transgenic humanised murine model (Green et 
al. 1994). To bypass the necessity for animal immunisation, recombinant expression of fully 
humanised mAb products was then developed using phase display (Clementi et al. 2012). Throughout 
the history of mAb production, a lot of efforts has gone into cell line development, host cell 
identification, establishment of clonal libraries, as well as investigations into different expression 
systems, in order to improve the efficiency of product production. At least 30 approved mAbs were 
synthesized in the past 35 years and they are clinically active; these include the blockbuster products 
Humira and Renucade which are anti-inflammatory drugs that inhibit the TNF- receptor; anti-
cancer mAbs such as Rituxan and Herceptin which target specific types of cancer, or Avastin 
that limits cancer cell metastasis; or many others that function against autoimmunity, viral infection or 
diabetes, or treatments towards neurodegenration such as Alzheimer’s disorder (Kyriakopoulos and 
Kontoravdi 2014b).  
2.3. Fc N-linked glycosylation of therapeutic mAbs 
In addition to product yield, mAb efficacy and safety are important factors in 
biopharmaceutical production, which is highly influenced by the oligosaccharide-chains that are 
attached to the Fc-region of a mAb molecule.  In mammalian cells, nascent polypeptides are subject to 
post-translational modifications to give functionality; such modifications also generate variations 
within the same species. Protein glycosylation is a commonly observed protein modification. Two 
types of protein glycosylation exist: asparagine-linked (N-linked) and serine/threonine-linked (O-
linked). While O-linked glycosylation is not common in secreted proteins and in the case of mAbs 
reports are mostly related to human IgA1 (Allen et al. 1995). On the other hand, N-linked 
glycosylation of IgG has been extensively studied and oligosaccharides are found on the Asn297 on the 
CH2 domain of each heavy chain within its Fc-region. Protein glycosylation is also observed on the 
variable (V) regions of the IgG light and heavy chains. For instance mass spectrometric analysis 
showed that the IgG-Fab region of an anti-melanoma mouse IgG3 monoclonal antibody exhibited 
hypergalalactosylation and sialylation (Muthing et al. 2003). However, owing to the relatively low 
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abundance of Fab-glycosylation in IgG (an average of around 15-20%), N-linked Fc-oligosaccharides 
remains the main focus in this study.      
2.3.1. Synthetic process of N-linked glycosylation 
N-linked glycosylation involves a N-acetylglucosamine (GlcNAc) molecule covalently attached 
(-linkage) to the asparagine residue of the protein with an amino-acid sequence Asn-Xaa-Ser/Thr, 
where X represents any amino acid except proline. N-linked glycosylation commences in the ER 
where the dolichol-linked precursor oligosaccharide (GlcNAc2Man9Glc3) is synthesized in the ER 
lumen; and then transferred en bloc onto the nascent polypeptide chain by an 
oligosaccharyltransferase. Next, glycan-bound protein polypeptide undergoes the folding process with 
the terminal glucose (Glc) residues acting as a quality control to ensure correct protein folding. In 
brief, two glucose molecules are removed from the core GlcNAc2Man9Glc3 attached on the nascent 
polypeptide by glucosidases I & II, leaving the glycan core monoglucosylated. The monoglucocylated 
glycoprotein interacts with lectins on calnexin and calreticulin to initiate the Calnexin-Calreticulim 
cycle for correct protein folding. When bound to calnexin and calreticulin chaperone proteins, the 
glycoprotein is catalysed by the thiol-disculphide oxidoreductase ERp57 and encourages the 
formation of disulphide bonds on the bound-glycoprotein. The glycoprotein is protected from any pre-
mature degradation during the folding process when bound to calnexin and calreticulin. The cleavage 
of the remaining single glucose by glucosidase II releases the glycoprotein from the complex. If the 
protein is correctly folded, it exits the ER and is transported into the Golgi apparatus for downstream 
processing. However, a single glucose molecule can be re-added by UDP-Glc:glucosyltransferase 
(UGGT) to protein that is not properly folded and re-enter into the Calnexin-Calreticulin cycle 
(Ellgaard and Helenius 2003). In addition to UGGT and chaperone proetins which aid protein folding, 
ER-manosidase I (ERManI) recognises terminally misfolded-proteins within the ER, trimming one 
1,2-linked mannose residue to yield Man8 structure.  ERManI involves highly in the process of 
Endoplasmic-reticulum-associated protein degradation (ERAD), in which the removal of a single 
mannose initiates subsequent degradation of misfolded proteins (Avezov et al. 2008). While within 
the Golgi apparatus, mannose (Man) residues are trimmed from the oligosaccharide to give a 
GlcNAc2Man5 structure in the cis-Golgi; addition of GlcNAc and further Man sugar trimming take 
place in the medial Golgi; downstream sugar-transfer reactions such as the additions of galactose 
(Gal), fucose (Fuc) and N-acetylneuraminic acid/sialic acid (Neu5Ac) in the trans-Golgi generate IgG 
with complex glycan patterns. The glycoprotein is now ready to be secreted into the extracellular 
matrix for harvesting (Taylor and Drickamer 2003) (Figure 3). 
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Many precise enzymatic reactions are required in order to accurately process the attached 
oligosaccharides, these include glycosidases that remove and transferases which add sugar residues 
onto the growing oligosaccharide chain. Both glycosidases and transferases are substrate specific and 
only act on specific glycan linkages. For instance, mannosidase I removes terminal mannose residues 
that are in 1,2 linkages in oligo-mannose oligosaccharide Man9(GlcNAc)2, while mannosidase II 
hydrolyses both 1,3 linkages and 1,6 linked terminal mannoses in mannosyl-oligosaccharides. 
There are also five different N-acetylglucosaminyltransferases that catalyse the addition of N-
acetylglucosamine (GlcNAc) residues during N-linked glycosylation, in which each enzyme works 
upon specific mannosyl-glycoproteins and attaches GlcNAc residues with precise beta-linkages 
(Krambeck and Betenbaugh 2005). Since the availability of enzymes and co-substrates relies on 
intracellular conditions, variations in glycan pattern arise. There are two main types of glycan 
variation in general: 1. glycan macro-heterogeneity, which refers to the glycosylation site occupancy 
along the amino-acid sequence of the polypeptide chain; and 2. Glycan micro-heterogeneity that 
denotes the differences in glycan pattern of an oligosaccharide chain during processing inside the 
Golgi apparatus. In addition to enzyme availability, the availability of nucleotide sugar donors (NSDs) 
also contributes to glycan variations. NSDs are glycosyl-donors and protein glycosylation reactions 
rely on the presence of these ‘activated sugars’; as a result, the availability of NSD species have a 
direct impact on the mAb glycosylation. 
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Figure 3. mAb glycoprotein processing. Upon mAb polypeptides and oligosaccharide precursor synthesis, glycans are 
en bloc transfer onto Asn297 of the HC polypeptides. mAb is assembled and folded and initial glycan trimming 
happens with 3 terminal Glc and 1 Man removed. mAb-GlcNAc2Man8 is transported into the Golgi apparatus for 
downstream glycan processing. Mannose trimming generates mAb-GlcNAc2Man5 structure in the cis-Golgi; 1 
GlcNAc is added, followed by 2 Man trimming and second GlcNAc addition in the medial- Golgi. In the trans-Golgi, 1 
Fuc, 2 Gal and 2 NeuAc are added to yield bi-antennary structure for IgG. Glycoprotein is then packed inside a 
vesicle and is secreted into the ECM for functions. mAb: monoclonal antibody; rER: rough endoplasmic reticulum; 
 Glc: Glucose ( ); GlcNAc: N-acetyl-glucosamine ( ); Man: mannose ( ); Gal: Galactose ( ); Fuc: fucose ( ); 
NeuAc: sialic acid ( ); ECM: extracellular matrix. 
 
2.3.2. Nucleotide sugar donors (NSDs) – building blocks for protein 
glycosylation 
Nucleotide sugar donors are substrates of sugar transferases during glycan processing. Each 
NSD molecule comprises one nucleotide and one sugar residue. Table 1 shows common structures of 
NSD molecules that are involved in mAb glycosylation, which are normally UDP-glucose (UDP-
Glc), UDP-galactose (UDP-Gal), UDP-N-Acetylhexosamine (UDP-HexNAc) including UDP-
GlcNAc and UDP-GalNAc; GDP-mannose (GDP-Man) and GDP-fucose (GDP-Fuc), together with 
CMP-N-acetylneuraminic acid (CMP-Neu5Ac), or in other word, CMP-sialic acid. In the case of IgG, 
UDP-GlcNAc molecules are mostly responsible for glycan branching, while glycan elongation is 
usually carried out by the addition of species such as UDP-Gal and CMP-Neu5Ac. In theory, 
mammalian cells can generate all types of sugar from carbon and nitrogen sources e.g. glucose or 
fructose, and various amino acids; and extracellular feeding of different carbon sources affects the 
overall NSD production and consequently alters protein glycosylation. However the actual NSD 
synthetic pathway is more complex than that (Murrell et al. 2004), where competitive enzymatic 
inhibition and product inhibition is common within the network. Figure 4 illustrates a simplified 
diagram of the NSD synthetic pathway, which indicates the consumption of glucose, galactose, 
fructose and glutamine within the NSD biosynthetic network. It also shows the synthetic pathway of 
each NSD species (labelled in different colour schemes). 
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Table 1. Common nucleotide sugar donor (NSD) observed during IgG N-linked glycosylation. GDP-Man and UDP-
GlcNAc are transported into the ER, while UDP-Gal, UDP-GlcNAc, GDP-Fuc and CMP-sialic acid are found 
transported into the Golgi apparatus for glycan processing. UDP: Uridine-diphosphate; GDP: Guanidine-
diphosphate; CMP: Cytidine-monophosphate; GlcNAc: N-acetyl-glucosamine ( ); Man: mannose ( ); Gal: 
Galactose ( ); Fuc: fucose ( ); NeuAc: sialic acid ( ); ECM: extracellular matrix. 
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Figure 4. NSD biosynthetic pathway in mammalian cells. Raw materials that are required for NSD metabolism are 
sugar residues: glucose (Glc), galactose (Gal), glucosamine (GlcN), fucose (Fuc) and mannose (Man), as well as 
nucleotide-precursors. NSD products are transported in the ER or the Golgi for protein glycosylation. Apart from 
CMP-Neu5Ac which is synthesized within the nucleus, the rest of the NSD species are produced in the cytosol. 
Synthetic pathways for various NSDs are labelled in the following colour scheme to indicate their sources: Red: UPD-
Glc; Yellow: UDP-Gal; Light green: GDP-Man; Olive green: UDP-GlcA; Pink: GDP-Fuc; Blue: UDP-GlcNAc; 
Brown: UDP-GalNAc; Purple: CMP-Neu5Ac. This is  modified from Murrell et al. (2004). 
2.3.3. N-linked glycosylation – structure and function 
All N-linked glycans possess a common core structure which comprises two GlcNAc and 
three mannose residues (Asn-GlcNac2Man3), with two GlcNAc bound to the asparagine of the protein 
backbone in the -1,4 conformation, followed by a -1,4 linkage by the first mannose and two extra 
mannoses additions each via -1,3 and -1,6 linkages which form two arms to initial glycan bi-
antennary structure (Figure 5 A). Depending on the availability of glycosyltransferases and NSDs, 
other residues are added onto the oligosaccharide during glycan processing in the Golgi apparatus. 
High-mannose structures are produced when solely mannose residues are added to both arms (Figure 
5 B). Complex glycan pattern may have two or more antennae with various other sugar types 
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extending from the core-structure, or fucose residues directly attached to the protein backbone-bound 
GlcNAc (Figure 5 C). Hybrid structure, on the other hand, represents a partially under-processed 
glycan structure, with predominantly mannose residues on one single branch (Figure 5 D). In general, 
Chinese hamster ovary (CHO) cells are the most industrially used host cells. The commercially CHO-
derived IgGs are nearly 90 % core-fucosylated; they are sometimes sialylated (~ 10%) and are usually 
bi-antennary. However, CHO cells do not naturally possess bisecting-GlcNAc (Kobata 2000; Liu et 
al. 2011). Figure 6 illustrates some common types of Fc-glycosylation patterns that are observed in 
IgG generated from CHO cells. 
 
 
Figure 5. Three main types of N-linked glycan structure. A. The conserved core structure of N-linked glycans. B. 
High-mannose N-glycan structure, with mannose residues (Man5 – Man9 in mammalian cells) added to the core 
structure. C. Complex structure of N-glycosylation. Different types of sugar residues are added to the non-reducing 
end of the core mannoses. Bi- or multi- antennary structures can be observed, together with core fucosylation. D. 
Hybrid N-glycan is the combination between high-mannose and complex-glycan structure. Glc: Glucose ( ); 
GlcNAc: N-acetyl-glucosamine ( ); Man: mannose ( ); Gal: Galactose ( ); Fuc: fucose ( ); NeuAc: sialic acid (
). 
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Figure 6. Common glycan structures found on Fc-region of IgG expressed in CHO cells. Fc-glycan of IgG produced 
by CHO cells are usually b-antennary, ranges from single non-reducing GlcNAc addition to the N-glycan core, to 
galactose and sialic acid residues on either/both arms. Core fucosylation can be observed in any stage of Fc-glycan 
processing. GlcNAc: N-acetyl-glucosamine ( ); Man: mannose ( ); Gal: Galactose ( ); Fuc: fucose ( ); NeuAc: 
sialic acid ( ). 
Regardless of the type of glycoprotein, sugars that are attached contribute to protein folding, 
stability, trafficking, biological activities and serum clearance. Firstly, glycan addition aids protein 
folding, where terminal glucose molecules assist glycoprotein folding via the calnexin-calreticulum 
cycle in the ER (Taylor and Drickamer 2003). In addition, other study demonstrated that a single 
attachment of high-mannose sugar chain onto the asparagine24 of Ribonuclease B (RNaseB) 
increased ribonuclease stability, through reduced chemical exchanges between its protein amide 
hydrogen protons which encouraged a more thermodynamically stable structure (Joao et al. 1992). 
Moreover, protein clearance rate is directly related to the stability of the molecules. Furthermore, 
intracellular signaling through adenylate cyclase activation, is only possible when pituitary hormones 
are glycosylated (Taylor and Drickamer 2003). 
In terms of mAb functionality, binding of the Fc-domains to different types of Fc receptors 
activate downstream immune effectors through cascade reactions. Oligosaccharides attached on the 
CH2 domains of both heavy chains can alter the protein structure of the binding site, and the sugars 
themselves may sometimes be involved in receptor-binding. Depending on the type of sugar pattern 
on a mAb molecule, its immune activity varies. For example, Shinkawa et al. (2003) discovered that 
the absence of core fucosylation could lead to an increase in ADCC activity of approximately 50-fold. 
With the help of the IgG-FcRIIIa crystal structure, studies in 2011 revealed that the high affinity 
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achieved in non-fucosylated mAb species, was mediated by the proximal carbohydrate-carbohydrate 
interaction between the mAb molecule and the FcRIIIa receptor (Figure 7 A), where the presence of 
a core-fucose was demonstrated to extend the substrate-receptor distance (Figure 7 B) (Ferrara et al. 
2011). In addition, Zou et al. (2011) argued that bisecting GlcNAc also contribute to enhanced ADCC 
activity since an increase in IgG-Fc-FcRIIIa binding was observed independently of core 
fucosylation.  
 
Figure 7. Interaction interphases between A. non-fucosylated Fc-fragment (blue), or B. fucosylated Fc-domain 
(magenta), and the glycosylated Fc-receptor (cyan in (A) and dark violet in (B). The core fucose in the fucosylated 
species is highlighted in yellow. Distances of hydrogen bonds between the receptor and the Fc-fragments are shown. 
This is taken from Ferrara et al. (2011). 
 
On the other hand, Hodoniczky et al. (2005) demonstrated that terminal galactosylation in the 
Fc-region of a mAb molecule increased CDC activity. This was explained by the higher affinity of the 
mAb Fc-fragment to the C1q complement molecule, which was observed upon the stable interaction 
between terminal galactose and Fc-amino acids, initiated through a Fc-conformational change (Figure 
8). Moreover, galactosylated IgG1 molecules increase CDC receptor binding by enhancing structural 
rigidity via the interaction between terminal galactose molecules and lysine246 of the IgG (Houde et 
al. 2010; Raju 2008).  
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Figure 8. Hydropholic and hydrophilic interactions between Fc-glycan and Fc-amino-acid residues in the crystal 
structures of G2 and G0 mAb species. A. Crystal structure of mAb Fc-G2. A total of six hydrogen-bonds were 
observed between G2-sugar residues and Fc-backbone. B. Only 2 H-bonds were found between Fc-G0 sugars and its 
amino acids. G2-terminating oligosaccharides give mAb a stable Fc structure for CDC activation. These are taken 
from Raju (2008). “Permission is granted by the right holder Elsevier to reproduced this image for this thesis” 
While mAb galactosylation improves CDC activity, terminal sialic acid residues on the 
oligosaccharide chain increase mAb serum half-life (Hossler et al. 2009). Moreover, sialic acids also 
serve as immune modulators by exerting an anti-inflammatory response upon the interaction between 
the -2,6 attached Neu5Ac molecules on the intravenous immunoglobulin (IVIG) and the FcRIIB 
inhibitory receptor (Kaneko et al. 2006). In contrast, high mannose structure on the Fc domain of an 
IgG molecule increases serum clearance in human (Goetze et al. 2011), which can potentially reduce 
the effective period of the drug within a human body. 
Changes in mAb Fc-sialylation, galactosylation and fucosylation are often key biomarkers in 
many autoimmune and inflammatory diseases. For example, IgG molecules found in patients with 
rheumatoid arthritis are N-linked sialyted and fucosylated, but they lack terminal galactosylation, 
where approximately 50% are observed to be non-galactosylated (Parekh et al. 1985). As a result it 
alters the conformational structure of these mAb molecules and consequently affects IgG-leukocyte 
interaction to initiate proper immune responses (Krapp et al. 2003). Similarly, a drop in mAb Fc-
galactosylation is also observed in patients with osteoarthritis, Lambert-Eaton myasthenic syndrome 
and myasthenia gravis (Selman et al. 2011). These studies show the importance of IgG Fc-
galactosylation in immunology.  
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2.4. The impact of bioprocess condition on mAb synthesis 
and glycosylation 
The previous section illustrates the importance of mAb glycosylation in activating immune 
responses in medical treatments. However, it is difficult to control and produce mAb molecules with 
one specific glycoform. Protein glycosylation within the ER and the Golgi apparatus relies on several 
factors including the abundance of different NSD species and the availability and catalytic efficiency 
of glycosyltransferases. These factors are very prone to vary with changes in the culture conditions 
during recombinant mAb production. As a result thorough understanding of the impact of each 
bioprocess condition on mAb production, including protein glycosylation, will be a good first-step to 
employing the Quality by Design strategy. In this part of the chapter, common bioprocess conditions 
or practices, such as the use of different host cell lines, the levels of culture pH, osmolarity, 
temperature, gaseous exchange and feeding and media supplementation will be discussed. These will 
be followed by a single section that will describe in detail how transient gene expression (TGE) 
affects product production, with respect to the method of transfection, and a combination of different 
cell culture process parameters that are practiced under the TGE system.  
2.4.1. Host cell lines 
Owing to the ability to obtain human-like post-translational modifications, mammalian cells 
are by far the most commonly employed cell type during recombinant mAb production. The most 
frequently used commercial cell lines for mAb synthesis include Chinese hamster ovary (CHO) and 
mouse NS0 myeloma cells.  Since mammalian cells of different types originate from different species, 
they possess diverse levels of cellular machinery (e.g. enzyme expression) and metabolic activity, and 
the heterogeneity of mAb Fc-glycoforms of IgG molecules generated from different types of 
mammalian cell lines is therefore high. For example, despite the fact that both CHO and NS0 cells are 
capable of producing mAb with galactosylated bi-antennary sugar structures, CHO cells process the 
addition of terminal galactose residues through -1,4-linkages, whereas NS0 cells possess the -1,3 
glycosyltransferase that CHO cells do not and form bi-galactosylation Gal-1,3Gal-1,4GlcNAc on 
one antenna (Umana et al. 1999b). It was later revealed by Hills et al. (2001a) that a possible steric 
hindrance of -1,4 galactosyltransferases, or lower binding affinity of this enzyme to UDP-Gal than 
-1,3 galactosyltransferases, could have contributed to the different linkages. Most importantly, -1,3 
galactose linkages are immunogenic in humans (Jenkins et al. 1996). Furthermore, both -1,3 
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fucosyltransferase and N-acetylglucosaminyltransferase III (GnTIII) enzymes are not present in CHO 
cells and peripheral fucose and bisecting GlcNAc additions are therefore not possible (Butler 2006).  
In addition, humans only generate terminal N-acetylneuraminic acids (NANAs) while other 
species, such as rhesus monkey, goat and rat are capable of producing N-glycosylneuraminic acids 
(NGNAs) (Raju et al. 2000). Since NGNA-bearing glycoproteins produced in mouse NS0 cells are 
immunogenic in humans, CHO cells are better hosts for recombinant mAb production. However CHO 
cells are incapable of generating Neu5Ac addition via -2,6 linkages which are essential for activation 
of anti-inflammatory response in humans (Butler 2006). 
On the other hand, other organisms such as yeast Pichia pastoris, produce mAb molecules 
with multi-antennary high mannose structures on their Fc-regions, which can trigger immunogenic 
responses in humans (Liu et al. 2011). Insect cells are not able to process sialic acid addition owing to 
the absence of enzymes for CMP-Neu5Ac NSD production. They also lack GnTII glucosyltransferase 
and some other transport proteins that are necessary for NSD transport within the lumen of the Golgi 
apparatus (del Val et al. 2010); making insect cells a less favourable host for recombinant mAb 
production. Plants, on the other hand, have special glycosyltransferases that can generate sugar 
patterns such as xylose, which are immunogenic and glycoengineering is therefore necessary in order 
to produce human-like Fc-glycosylation (Castilho et al. 2011; Tekoah et al. 2004). Furthermore, 
bacterial systems lack the post-translational machinery for N-linked glycosylation; but humanized 
yeasts and bacteria with engineered machineries can produce proteins with human-like qualities. For 
instance, an enteropathogenic bacterium Campylobacter jejuni was discovered to possess the ability 
for N-linked glycosylation (Linton et al. 2002) Wacker and colleagues made use of this unique 
property of C. jejuni and reconstituted a functional N-linked glycosylation pathway into Escherichia 
coli by transferring the pgl gene cluster that encodes N-linked-equivalent glycosyltransferases 
(Wacker et al. 2002). Schwarz et al. (2010) modified this system based on the knowledge of the lipid-
linked oligosaccharide (LLO) and replaced the bacterial Bacillosamine-Asn linkages with an 
eukaryotic GlcNAc-Asn linkages. This glycoengineering approach was later transferred to Salmonella 
enterica serovar Typhimurium (Wacker et al. 2006). 
2.4.2. Feeding of nutrients, amino acids and other media supplements 
Glucose (Glc) and glutamine (Gln) are the main carbon and nitrogen sources during most cell 
culture. Glucose is the main carbon source for most mammalian cells and it has been shown to have a 
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great impact on the glycan-macroheterogeneity on recombinant glycoproteins (Nyberg et al. 1999). 
All NSD species, including UDP-Glc, UDP-Gal and UDP-GlcNAc which play important roles in 
mAb glycosylation in CHO cultures, are all biosynthesized indirectly from glucose and other 
glycolytic intermediates. Glucose depletion therefore directly reduces the NSD pool for glycan-
synthesis. Glycan microheterogeneity is also affected upon glucose and glutamine limitation. 
Truncated glycan structures with reduced terminal sialic acid addition and increased mannosylation 
were observed in medium containing less than 0.7 mM glucose and 0.1 mM glutamine in IFN- 
producing CHO cell lines (Chee Furng Wong et al. 2005). On the other hand, glucose and glutamine 
are required for CMP-Neu5Ac synthesis. Synthesized UDP-GlcNAc molecules are converted into 
ManNAc which is a substrate for CMP-Neu5Ac production. As a result, the reduced level of UDP-
GlcNAc lowers the CMP-Neu5Ac availability. D-Glucosamine supplementation can directly increase 
the UDP-GlcNAc pool, but its negative impacts on CMP-Neu5Ac synthesis suggests the presence of 
product inhibition where high UDP-GlcNAc concentration limits CMP-Neu5Ac transport into the 
Golgi-network for glycan processing (Pels Rijcken et al. 1995) and only extracellular supplement of 
ManNAc can bypass the transport inhibition and increase the yield of sialic acid. The impact of 
glucose starvation on intracellular UDP-HexNAc concentrations was also found in the study 
conducted by Fan et al. (2015). Alongside, they also observed increased concentrations of UDP-Glc 
and UDP-Gal, accompanied by a higher occupancy of galactose in the attached glycans during 
glucose starvation. Moreoever, changes in cellular activities such as energy metabolism, cytoskeleton, 
protein expression and cell signalling were observed when cells entered a limited glucose uptake 
phase in perfusion cultures (Wingens et al. 2015). 
Tailored feedings to improve NSD contents for protein galactosylation were attempted in 
2001 by Hills et al. (2001b) by galactose supplementation in the culture medium. Despite 5-fold 
increase in UDP-Gal level, minimal change in -1,4 galactosylation was observed. Ever since then, 
different feeding strategies were examined. In 2011, a mixture of manganese chloride, galactose and 
uridine has also been shown to improve mAb terminal galactosylation. Gramer et al. (2011) 
demonstrated through experimental studies, that 8 times the amount of 1 mM uridine, 0.002 mM 
manganese chloride (MnCl2) and 5 mM galactose mixture improved the overall product 
galactosylation by 18% and 24% in two distinctive cell lines. CHO cell performance was suggested to 
remain unchanged at this level of uridine-MnCl2-Gal supplementation, although slight cell growth 
impedance was observed when the mixture was 20 times higher or beyond. Despite enhancing protein 
galactosylation by increasing the intracellular UDP-Gal concentration, it activates intracellular 
sialidase activity which can lead to Fc-desialylation (Butler 2006). In addition, Grainger and James 
(2013) adjusted concentrations of manganese, galactose and uridine in culture media by the use of the 
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design of experiment sreponse surface modelling (DoE-RSM) developed by the group, and positive 
result in galactosylation was achieved.  
Amino acids are essential for cell growth and a lot of intracellular mechanisms, such as 
nucleic acid production, energy generation through the TCA cycle, intracellular signalling. Amino 
acids are also crucial building blocks for protein translation, and the production of all host cell 
proteins including key enzymes, and in the case of biopharmaceutical industry, the recombinant 
products. In comparison to batch CHO cell culture, cells that were fed with designed feeds achieved a 
50% higher product yield when 40% of nutrients were added on top of the designed feeds 
(Kyriakopoulos and Kontoravdi 2014b). Histidine (His), tryptophan (Trp) and asparagine (Asn) were 
shown in this study to be always depleted in CHO cell cultures; this suggests high demands of these 
amino acids for cell growth and protein synthesis.  
Other chemical supplements, such as sodium butyrate, valproic acid (VPA) or dimethyl 
sulfoxide (DMSO) were shown to increase mAb productivity, by introducing cell cycle arrest and 
stabilizing the heavy and light chain mRNAs. Some studies looked into the effect of sodium butyrate 
addition on mAb glycosylation, they showed that 1 mM sodium-butyrate induced a two-fold increase 
in -2,6 sialylation of -2,6 sialyltransferase-engineered CHO-expressing interferon- (Lamotte et al. 
1999). At the same time, 1 mM valproic acid was demonstrated to halt cultured cells at the G1 growth 
phase and attenuated sialyltransferase activity, this provided a transient suppression of -2,3 Neu5Ac 
addition onto glycan chains of C6-glioma (Bacon et al. 1997). In addition, valproic acid was 
demonstrated to increase the expression of chaperones in the ER and the cytosol to regulate protein 
folding, such as chaperones binding immunoglobulin protein (BiP), protein disulfide-isomerase (PDI), 
calreticulin and heat-shock protein 70 (HSP-70) (Kim et al. 2005). DMSO is sometimes added during 
cell culture to improve cell viability and product yield. In the case of L1/Ig5-6 (cell adhesion molecule 
with Ig domain 5 & 6) that were expressed in the insect Spodoptera frugiperda cells, Gouveia et al. 
(2010) achieved a slight increase in high-mannose glycoforms upon DMSO addition. 
2.4.3. Metabolic wastes and cell culture pH 
Mammalian cells secret ammonia and lactate as metabolic by-products. Not only do the 
accumulation of ammonia and lactate in culture medium affect cell growth and protein yields, it is 
also suggested to influence product glycosylation. Firstly, ammonia and lactate directly affect cell 
culture pH and the pH within the Golgi apparatus. This affects activities of many relevant host cell 
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enzymes, including glycosyltransferases that are responsible for protein glycosylation. Rothman et al. 
(1989) showed that N-linked glycosylation of IgGs that were expressed in hybridoma cell line altered 
upon a pH shift within the Golgi apparatus. Another study also demonstrated that at pH 6.9, a very 
mild acidic environment contributed by lactate accumulation which is very common during 
fermentation, the lowest sialic acid content was found in IgG3 that were expressed in murine cell lines 
(Muthing et al. 2003). One of the most noticeable changes upon increased levels of ammonia in cell 
culture is the reduced level of terminal sialytion. Studies showed that 15 mM of ammonia increased 
UDP-GlcNAc and UDP-GalNAc production, which in turn inhibited sialic acid transport through 
competitive inhibitions. In addition, a rise in the UDP-GalNAc level was shown to limit the 
availability of UDP-Gal molecules that are necessary for protein galactosylation (Butler 2006).  
2.4.4. Levels of DOT, pCO2 and medium osmolarity 
Dissolved oxygen tension (DOT) is another culture parameter that affects mAb Fc-
glycosylation. A non-constant DOT was shown to impede hybridoma cell growth, without 
significantly affecting the overall mAb production yield (Serrato et al. 2004). Results in this study 
showed that at low dissolved oxygen tension at 10% DOT (where normal in vivo DOT is 12.5 - 25.0% 
(Richter et al. 1972)) reduced Fc-galactosylation in hybridoma cells (Kunkel et al. 1998) and 
decreased sialyltransferase activity in CHO cells were observed (Chotigeat et al. 1994). The observed 
effects can be explained by the reduced consumption of glucose which eventually lowered the UDP-
Gal concentration pool, alongside with increased production of lactate which shifted culture pH and 
consequently affect intracellular enzymatic activities. Serrato et al. (2004) however observed an 
increase in mAb Fc-sialylation from oscillating DOT, which was shown to reduce the steric hindrance 
of sialyltransferase and increased protein sialylation.  
On the other hand, not only does high medium osmolarity impede cell viability, changes in 
both medium osmolarity and in CO2 partial pressure (pCO2) altered the Fc-glycosylation pattern on 
mAb molecules. Schmelzer and Miller (2002) demonstrated a 20% decrease in IgG2a-mannose 
contents, with either increase in pCO2 (from 40 to 195 mmHg) or a rise in osmolarity (from 320 to 
435 mOsm/kg). In addition to decreases in mannosylation, high medium osmolarity induced by 
sodium chloride (NaCl) addition was shown to reduce the Fc-galactose profile in IgG2a, while 
surprisingly high level of pCO2 yielded the opposite effect.  Hyperosmostic stress, on the other hand, 
affect cell growth and mAb productivity. Shen et al. (2010) demonstrated substantial increases in the 
specific productivity of Fc-fusion-protein upon the induction of hyperosmostic conditions in batch 
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CHO cell culture, but the overall titre remained unchanged due to the reduction in viable cell 
concentration (Reddy and Miller 1994; Shen et al. 2010). In 2012, with the combination of 
experimental and computational approaches, Ho et al. (2012b) showed a positive correlation between 
hyperosmotic conditions and mAb production in GS-NS0 cells, where she showed 100% increase in 
the specific IgG mRNA transcription rates were accompanied by the improvement observed in the 
specific product productivity (qP). Interestingly, reduction in medium osmolarity from 300 mOsm kg
-1
 
to 150 mOsm kg
-1
 was also shown to enhance qmAb by 128% in CHO cultures, by increasing the total 
cytoplasmic pool of IgG mRNAs by 1.4-fold (Lee and Lee 2001).  
2.4.5. Mild hypothermic cell culture temperature 
Mild hypothermia during cell culture (e.g. temperature shift from 36.5C to 32C) is 
commonly employed to increase the specific recombinant product productivity (Kantardjieff et al. 
2010; Yee et al. 2009). Cells are normally cultured at physiological temperature during the start of the 
fermentation until desired viable cell density is obtained; the temperature is then lowered to mild 
hypothermic levels (ranges from 28C to 34C), where the rates of cell growth are compensated by 
the increases in qP. The magnitude of the increase in qP varies among experiments, where the fold-
change of productivity fluctuates from 0- to 14-fold (Becerra et al. 2012) and such impact is likely to 
be highly cell line and product dependent. A study from Becerra et al. (2011) attempted to investigate 
the reason for non-improved qP during mild hypothermic conditions, and concluded that increase in qP 
was not promoted when high growth rate of host cells was achieved.  
Despite the usefulness of mild hypothermic temperatures in recombinant protein production, 
there is no single theory that solely explains how this effect arises. The first theory behind this impact 
is related to cell growth, where cells experience a partial cell cycle arrest at the G1/G0 phase upon the 
introduction of mild hypothermia (Sunley et al. 2008), alongside with increase in product 
productivity.  By maintaining high cell viability, lowering culture temperature provides a prolonged 
cell growth period and a higher integral viable cell density is achieved. At the same time, some studies 
also showed that cell apoptosis was delayed in mild hypothermic cultures (Moore et al. 1995; Moore 
et al. 1997). A substantial number of studies were carried out and results showed that the defence 
mechanism of cells against programmed cell death was stronger, where the expression of bcl-2, an 
anti-apoptotic protein increased at 30C (Slikker et al. 2001). In addition to prolonged cell viability, 
other cell mechanisms, such as cytoskeleton reorganization, were suggested to change at reduced 
culture temperatures. Transcriptomic studies showed that at 32C, cytoskeleton-related filament genes 
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including Ckap4, Arpc5, Mid1ip1 and Vim were overexpressed to assist vesicle transport, the process 
of endocytosis and subsequently protein secretion (Yee et al. 2009). In addition, mild hypothermic 
conditions were shown to have affected protein synthesis from transcription level, where the mRNA 
decay rates of recombinant species were lower at reduced temperatures (Fox et al. 2005). Other 
studies also observed an increase in the recombinant EPO protein yield in response to the higher EPO 
mRNA level (Yoon et al. 2003). This observation was not limited to just gene transcription, proteomic 
studies revealed that expression of proteins responsible for cell growth regulation, anti-apoptosis, 
cytoskeleton organisation, protein chaperones, as well as CAP-independent translational machinery, 
were up-regulated to improve protein translation (Baik et al. 2006; Kumar et al. 2008). As a result, 
effects of mild hypothermic conditions are rather extensive, and it is not just limited to improving qP.   
Although the effect of mild hypothermia on mAb Fc-glycosylation is still under investigation, 
studies suggested that its impact on product quality is indeed cell line and product dependent. While 
some studies observed no significant difference in product glycosylation between physiological and 
mild hypothermic conditions (Bollati-Fogolin et al. 2005; Yoon et al. 2003), other studies showed that 
EPO glycoproteins expressed at mild hypothermic temperature (32
o
C) in CHO cells were less 
branched and had lower sialic acid contents (Ahn et al. 2008). Moreover, Nam et al. (2008) observed 
an increase in sialic acid and decrease in fucosylation in CHO cell expressing secreted human 
placental alkaline phosphatase (SEAP). It is highly possible that gene expression of 
glycosyltransferases or NSD biosynthetic enzymes are affected at lower temperature, possibly by 
retaining cells within the G0/G1 phase of cell cycle (Marchant et al. 2008).  
2.4.6. Cell line engineering 
In addition to monitoring and adjusting process parameters, engineered recombinant protein 
glycosylation through overexpression or silencing of target genes, for instance genes for different 
glycosyltransferases, is a very popular approach to achieve desired glycoforms on noval mAb and 
biosimilars. Such attempts aimed to produce mAbs with specific biological functions or to avoid the 
expression of mAbs with glycan structures that are potentially immunogenic to humans. In addition to 
the availability of NSD species, expression level and activity of glycosyltransferases control the 
processing of oligosaccharides attached on recombinant products. Table 2 shows a list of glycosidases 
and glycosyltransferases that are active in mAb Fc-glycosylation. The most targeted enzymes in Table 
2 that are involved in glyco-engineering are N-acetylglucosaminyltransferase (GnT), 
galactosyltransferase (GalT), fucosyltransferase (FucT) and sialyltransferase (SiaT), since additions of 
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branched GlcNAc, terminal Gal, core Fuc and terminal Neu5Ac residues are the most influential 
components in determining the efficacy of a drug.  In 1999, the first attempt to overexpress N-
acetylglucosylaminlytransferases III and V (GnT III & V) in a tetracycline-regulated manner was 
carried out, with an aim to introduce bisecting GlcNAc and multi-antennary structures to products 
produced in CHO-DUKX cells. Despite the huge success in generating the desired glycoforms, the 
overexpression of GnT III & V enzymes greatly impeded cell growth (Umana et al. 1999a). In the 
same year, Weikert et al. (1999) suggested the possibility of genetically-engineering CHO cells to 
obtain glycoforms with terminal galactose or sialic acid residues, which encouraged CDC activity and 
modulated inflammation. The group showed that by overexpressing human -1,4 
galactosyltransferase (GalT) or -2,3 sialyltransferase (SiaT) gene in CHO cells, the level of terminal 
galactosylation was increased and more than 90% of IgG Fc-regions were sialylated (Weikert et al. 
1999). In addition, siRNA expression against -1,6 fucosyltransferase (FUT8) gene  reduced the 
expression of the target FucT and produced mAb molecules with approximately 60% reduction in Fc-
fucosylation. This increased ADCC activity by 100-fold (Mori et al. 2004). Genetic engineering is 
therefore proven to have high potential in adapting the QbD principle, but process optimisation is 
indeed necessary to minimise possible side-effects that could be generated from engineered cell lines. 
In 2011, the assembled genomic data of CHO-K1 cells was for the first time available to the 
public and this marked a big break-through in the field of recombinant protein production in 
mammalian cells. Within the 2.45 Gb of the genomic sequence analysed, 24,383 genes, including 
genes that are involved in glycosylation, viral susceptibility etc. are predicted (Xu et al. 2011). Ever 
since then a lot of studies were conducted to improve the data set of the CHO transciptome (Rupp et 
al. 2014). Moreover, many new experimental ideas and concepts emerged from this discovery; one of 
these emerging fields is microRNA. MicroRNAs (miRNAs) are short non-coding RNAs that play a 
role in regulating mammalian gene expression (Bartel 2004) and their potential in regulating cellular 
networks and processes is high. Advances in miRNA technology and the CHO genome analysis 
enable us to investigate the functionality of miRNAs in CHO cells. The application of miRNAs in 
mAb bioprocessing aims to improve mAb production in terms of its quality and quantity becomes 
possible.  
 Studies from both Lin et al. (2011) and Maccani et al. (2014) profiled miRNA expression 
between non-producing and rProtein-producing cell lines, and among expressing cell lines. Results 
from their studies showed that significant differences in miRNA expression were predominately 
between producers and non-producers. miRNA genes such as miR-21-5p and miR-10b-5p, which are 
responsible for controlling cell proliferation, cell death and migration are expressed differently in 
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recombinant protein producing cells (Krichevsky and Gabriely 2009; Lin et al. 2012). In 2014, Jadhav 
et al. (2014a) generated stable CHO cell lines with over-expressions of miR-17 or miR-17-inclusive 
clusters, and they managed to achieve an improvement in cell growth rates and rProtein productivity 
from these engineered cell lines. These studies highlighted the huge potential of miRNA in the field of 
bioprocessing, as well as the possibility of manipulating key process enzymes through miRNA 
control.  
 
Table 2. List of enzymes that are commonly employed during N-linked Fc-glycosylation in homo sapiens.  
Enzyme EC number Substrate Location 
oligosaccharyl-transferase EC 2.1.1.119 dolichol phosphate-GlcNAc2Man9Glc3 
Endoplasmic 
reticulum 
mannosyl-oligosaccharide 
glucosidase 
EC:3.2.1.106 Asn-GlcNAc2Man9Glc3 
Endoplasmic 
reticulum 
-1,3-glucosidase I EC:3.2.1.84 Asn-GlcNAc2Man9Glc2 
Endoplasmic 
reticulum 
-1,3-glucosidase II EC:3.2.1.84 Asn-GlcNAc2Man9Glc 
Endoplasmic 
reticulum 
Endoplasmic reticulum 
mannosyl-oligosaccharide 1,2--
mannosidase I 
EC:3.2.1.113 
Asn-GlcNAc2Man9 
Asn-GlcNAc2Man(8-6) (at high enzyme 
concentration) 
Endoplasmic 
reticulum 
mannosyl-oligosaccharide -1,2-
mannosidase 
EC:3.2.1.113 Asn-GlcNAc2Man(9-6) 
cis-Golgi 
apparatus 
-mannosidase II EC:3.2.1.114 Asn-GlcNAc2Man5GlcNAc 
medial Golgi 
apparatus 
-1,3-mannosyl-glycoprotein -
1,2-N-
acetylglucosaminyltransferase I 
EC:2.4.1.101 Asn-GlcNAc2Man5 
medial Golgi 
apparatus 
-1,6-mannosyl-glycoprotein -
1,2-N-
acetylglucosaminyltransferase II 
EC:2.4.1.143 Asn-GlcNAc2Man3GlcNAc 
medial Golgi 
apparatus 
core -1,6-fucosyltransferase EC:2.4.1.68 Asn-GlcNAc2Man3GlcNAc2 
medial Golgi 
apparatus 
-1,4-galactosyltransferase 
EC:2.4.1.22/9
0/38 
Asn-GlcNAc2Man3GlcNAc2 
trans-Golgi 
apparatus 
Asn-GlcNAc2FucMan3GlcNAc2 
Asn-GlcNAc2Man3GlcNAc2Gal 
Asn-GlcNAc2FucMan3GlcNAc2Gal 
-galactoside -2,6-
sialyltransferase 
EC:2.4.99.1 
Asn-GlcNAc2Man3GlcNAc2Gal2 
trans-Golgi 
apparatus 
Asn-GlcNAc2FucMan3GlcNAc2Gal2 
Asn-GlcNAc2Man3GlcNAc2Gal2NeuAc 
Asn-GlcNAc2FucMan3GlcNAc2Gal2NeuAc 
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2.5. Transient gene expression in recombinant protein 
production 
 Transient gene expression (TGE) is becoming industrially relevant and a more popular 
method for recombinant protein expression mostly due to its capability of fast rProduct production, in 
comparison to the traditional stable transfection methods. CHO and human kidney HEK-293 cell lines 
are typical mammalian hosts for the transient system. However the main obstacle of this approach, for 
CHO cells in particular, is the relatively low protein yield that one can achieve. As a result, a lot of 
studies focus on ways to improve mAb productivity through TGE optimization, which includes 
improving transfection efficiency, determining the best transfection method/reagent for each cell type, 
as well as exploring impacts of culture parameters (temperature, pH, nutrient supply etc.) on mAb 
production and Fc-glycosylation in the TGE system. 
 
Figure 9. Factors that are known to affect mAb production yield in transient gene expression. 
Owing to the huge drawback of TGE in production yield, the main goal of most studies 
focused on methods to increase rProtein productivity. Figure 9 shows key parameters that are 
considered during TGE process optimization. Results showed that the amount of mAb protein 
production in TGE was highly dependent on the actual transient transfection method, the expression 
vector in which mAb heavy and light chains were expressed, together with other culture parameters 
such as culture temperature, osmolarity and supplement addition. 
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2.5.1. Transient gene transfection methodology 
Target genetic material can be taken up by host cells in two main ways: delivery through 
chemical or physical approaches. There are several chemical transfection reagents, e.g. 
polyethylenimine (PEI), lipofectamine
TM
 2000, TransIT-PRO
TM
 and calcium phosphate. Of these, Sou 
et al. (2013) evaluated the first three chemical transfection reagents mentioned above and 
demonstrated TransIT-PRO
TM
 to be the more efficient reagent, but it was not the most-cost-effective 
option. As a result, polyethylenimine still remains the preferred option; it provides efficient 
transfection (40 - 90%) in most cell lines and it is cost-effective (Ehrhardt et al. 2006; Morrow 2008).  
PEI works by forming polyplexes with target DNA which give it an overall positive charge, 
interact with the negatively charged host cell membrane and foreign DNA is eventually taken up into 
the cell (Figure 10 D). With the use of 1:4 DNA to linear 25 kDa PEI ratio during transfection of 
CHO-DG44 cells, Rajendra et al. (2011a) achieved a mAb yield of 250 mg/L in 0.5 L batch cultures 
over 14 days. Other studies demonstrated a 3-fold increase in mAb titre in cultured CHO-T cells with 
a DNA:PEI ratio of 1:4, when compared to cation-lipid transfection reagent Freestyle
TM
 MAX 
(Codamo et al. 2011a). The high transfectability of PEI-mediated transient transfection in HEK293 
cells was so shown to achieve IgG protein titres of up to 1 g/L (Backliwal et al. 2008b). Owing to the 
relatively lower cost of PEI and its possibility for large-scale protein expression, PEI has become a 
standard chemical transfection reagent used in TGE in industry.  
Lipofectamine
TM
 2000, on the other hand, is a cation-lipid formulation transfection reagent 
that forms liposomes in aqueous media. These liposomes trap DNA within them, form complexes that 
fuse with the host cell plasma membrane for DNA entry into the cytoplasm (Figure 10 C). With the 
use of Lipofectamine
TM
 2000, Epi-CHO expression plasmid and the introduction of mild hypothermic 
condition, Codamo et al. (2011b) obtained a mAb titre of 140 mg/L. Despite the high mAb 
productivity achieved in this study, transfection efficiency from using Lipofectamine
TM
 2000 was not 
sustained in prolonged high cell density cultures, and the high reagent cost makes Lipofectamine
TM
 
not economically viable for large-scale operation.  
TransIT-PRO
TM
 employs both mechanisms of action and works by forming lipopolyplexes 
with DNA, which then form electrostatic interactions with the negatively charged cell membrane. 
These lipopolyplexes are thought to be taken into the cell via endocytosis. The use of this reagent 
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involves an optional proprietary transfection booster PROBoost which was shown to enhance gene 
expression in a medium-dependent manner. 
Electroporation, on the other hand, is a non-chemical/physical transfection method which 
utilizes external electrical field pulses to permeabilize host cell membrane and allow DNA plasmid of 
interest to enter into the cell (Figure 10 B). Electroporation is suggested to be an efficient method for 
TGE in both human embryonic kidney HEK293 and CHO cells. The advantage of electroporation 
over chemical transfection reagents is the high transfection efficiency and the low cytotoxicity. 
Maurisse et al. (2010) achieved a transient gene transfection efficiency of 93% with GFP-plasmid in 
HEK293 cells, while 100% transfection efficiency and a 1.5-fold increase in mAb productivity were 
achieved in IgG heavy and light chain DNA plasmids transfected CHO-S cells through repeated cycle 
of transient transfections (Pichler et al. 2011). Moreover, with a combination of an optimized 
electroporation transfection method and commercial feedings, Cain et al. (2013) generated a mAb 
volumetric yield of 200-600 mg/L in an engineered CHOS-XE cell line.  
 
Figure 10. Different methods of DNA delivery in TGE. A. Calcium-phosphate precipitation. DNA is co-precipitated 
with CaPO4, complex is phagocytosed by and released into the host cell. B. Electroporation. Application of external 
pulses induces potential difference on the cell membrane, this creates tiny pores on membrane for the entry of target 
DNA into the cell. C. Lipofection. LipofectamineTM forms complex with target DNA, the complex is endocytosed in to 
the cell, endosome lyses and DNA material is released. D. Polyfection. PEI is mixed with target DNA and PEI-DNA 
complex enters into the cell via ligand-mediated endocytosis. Endosomal-release of DNA happens inside the cell.  
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2.5.2. HC:LC ratio and expression vector  
 Co-transfection of heavy (HC) and light (LC) chains in two separate expression vectors into 
mammalian hosts, or the incorporation of both HC and LC into a single vector under the control of 
multiple promoters, are common plasmids used in TGE (Bebbington et al. 1992; Brezinsky et al. 
2003). However, the lack of control over the expression levels of each gene in these circumstances 
results in non-expressing clonal production and a huge variation in HC:LC ratio among clones. mAb 
HC:LC ratio maintenance is clearly a factor that affects the final product concentration and therefore 
optimum ratio is necessary. Studies from Ho et al. (2012a) suggested the optimal HC:LC ratio in mAb 
expression and protein aggregation prevention in CHO-K1 cells to be 1:4, while 1:3 was 
recommended in CHO-S cells (Cain et al. 2013). To improve the transfection efficiency of multiple 
genes, a method with internal ribosomal entry site (IRES) element was introduced. IRES is a 
nucleotide sequence that enables a 5’ cap-independent translation initiation to initiate mRNA 
translation without the need of passing through the start codon. By positioning the IRES element 5’ of 
the target gene, it initiates the process of translation by attracting the eukaryotic ribosome to the 
mRNA molecule. Figure 11 A illustrates ways in such two IRES elements are incorporated, with one 
being placed before the HC/LC first gene and the other before the selection marker gene. Such 
gene/IRES arrangement forms a tricistronic expression vector which enhanced mAb expression by 
10-fold (Ho et al. 2012a). Results from this study also showed that by placing the LC gene as the first 
gene of interest, it generated a further 2-fold increase in protein yield than that with HC being placed 
first. In this case, the use of multiple IRES elements exerted a tight control over the HC:LC ratio 
among clones, this increased the production of fully assembled mAb, and dramatically reduced the 
number of non-expressing clones. 
The Epi-CHO expression system is another approach to maximize mAb production. Epi-CHO 
expression comprises one DNA vector with a Polymavirus origin (PyOri) and an Epstein Barr-Virus 
nuclear antigen-1 (EBNA-1), which is transfected into CHO cells (Figure 11 B) (Codamo et al. 
2011b). Not only does this system maintain consistent HC:LC ratio, the combined use of the Epi-
CHO system and optimized bioprocesses generated a 4-fold increase in mAb concentration per g of 
DNA transfected, in contrast to the non-Epi-CHO system (Codamo et al. 2011a), and yielded a mAb 
titre of around 140 mg/L. PyOri and EBNA-1 encourage episomal replication of DNA in suspension 
cultures and segregation of DNA into daughter cells, respectively, via better plasmid-nuclear matrix 
contacts and thus increases the levels of mAb expression and product titre (Kunaparaju et al. 2005). 
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Figure 11. Expression vectors employed in mAb expression in TGE. A. Expression vectors with the use of two 
internal ribosomal entry site (IRES) elements, which are responsible for the transcription of genes in the 2nd cistron 
and the selection marker gene. The 1st cistron is controlled by the CMV and it can either be HC or the LC gene. B. 
The Epi-CHO expression vector design comprises of Epstein Barr-Virus nuclear antigen-1 (EBNA-1) and the 
Polymavirus (Py) origin (PyOri) elements. CMV: Cytomegalovirus; HC: heavy chain; LC: light chain; SpA: simian 
virus 40 early polyadenylation signal. 
By engineering a CHO cell line that co-expresses both the EBNA-1 and an EBV origin of 
replication (OriP), and a recombinant GS gene expression system that is now widely employed in 
CHO cells to improve rProtein yields (Courtete et al. 2012). Daramola et al. (2014) managed to 
achieve a high-yielding TGE system that constantly expresses around 150 mg/L of IgG product, under 
a non-optimised TGE transfection method. This simple change in expression vector is shown to be a 
very successfully, rapid and scalable TGE system.With improvements in both DNA transfection and 
culture process, including optimising the PEI:DNA ratio and reducing culture temperatures to 34C, 
the group achieved a 300-fold increases in product expression and generated nearly 2 g/L of secreted 
IgG in a 6 L Wave-bioreactor.  
2.5.3. Post-translational regulatory element 
In addition to the impact of expression vectors on TGE-rProtein production, vector 
optimization with the use of post-translational regulatory elements (PTREs) is another approach that 
can employed to enhance recombinant expression. In brief, the expression of rProtein per copy of 
target is often determined by rates of mRNA synthesis and degradation, translation and post-
translational modification (Kaufman 2000). PTREs such as native introns and the incorporation of 
woodchunk hepatitis virus regulatory elements (WPRE) were reported to enhance product expression 
in TGE. For example, by improving mRNA stability and secretion, a full length mammalian 
cyotomaegalovirus (CMV) with intron A provided a very high level of both transient mRNA and 
protein expression in CHO-K1 (Xia et al. 2006). Moreover, WPRE within the expression vector alone 
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increased the efficiency of mRNA transport, RNA processing and translation (Wulhfard et al. 2008). 
This system obtained a 10-fold increase in transient IgG protein titres under mild hypothermic 
conditions (Zhu 2012).  
2.5.4. Transfection cell density  
CHO cell density upon transient gene transfection is another culture parameter that can be 
considered when optimizing the TGE system for mAb production. Studies conducted by Backliwal et 
al. (2008b) showed that a high cell density of HEK 293 cells of around 2 x 10
7
 cells/ml, increased 
transient gene expression regardless of medium type. Rajendra et al. (2011b) specifically examined 
the effect of transfection cell density on TGE and the group demonstrated the highest volumetric mAb 
production with an IgG titre of almost 190 mg/L, was achieved at a CHO cell density of 4 x 10
6
 
cells/ml. However, the effect of host cell density on mAb production is rather heterogeneous, it is 
highly cell-line, product and bioprocess dependent, and hence process optimization is necessary. 
2.5.5. Hyperosmolarity in TGE 
Similar to its impact of rProtein expression on stable transfectants, hyperosmolarity is 
suggested to be a cost-effective way to improve production yields in TGE. Studies in hybridoma cell 
culture showed a positive correlation between mAb titres and culture osmolarity in TGE (Lin et al. 
1999). These effects were translated into CHO-DG44 rProtein expression where a 4-fold increase in 
mAb titre was achieved upon a single rise in hyperosmotic pressure from 320 mOsm/kg to 490 
mOsm/kg with an addition of 90 mM NaCl in BioWhittaker™ proCHO5 medium (Zhang et al. 
2010b). Increasing medium osmolarity delayed cell growth, increased cell viability, induced partial 
cell cycle arrest and increased HC and LC mRNA stabilities (Zhang et al. 2010b). However as 
suggested earlier in this chapter, the counter-effects of hyperosmolarity on host cell growth were 
shown to limit further mAb production and process optimization was required. Ryu et al. (2000) 
demonstrated a positive impact of glycine betaine, an osmo-protective agent, on mAb production, in 
which the addition of glycine betaine in hyperosmolar medium improved cell growth by an extra 50% 
- 75% and protein productivity by 40%. Previous studies examined the mechanism of glycine betaine 
in hyperosmotic conditions and it was suggested that this chemical agent might function through 
thermodynamic stabilization of macromolecules that are essential in cell growth and cell proliferation 
(Oyaas et al. 1995).  
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2.5.6. Mild hypothermia in TGE 
The effect of mild hypothermic culture temperature in TGE systems appears to be more 
potent than that in the stable gene expression (SGE) system. A TGE study by Galbraith et al. (2006) 
generated a 3-fold increase in the accumulated mAb titres when CHO-K1SV cells were maintained at 
32C post transfection. Two years after this study, Wulhfard and colleagues brought Galbraith’s 
experiments further and showed that a temperature shift 4 h after transfection provided the best mAb 
yield, with approximately 10-fold increase in titre at 31C; although the effect of mild hypothermia 
was shown to be expression vector dependent (Wulhfard et al. 2008). In addition, this group also 
observed an increase in the integral cell viability, but reduction in both nutrient consumption and 
metabolic waste production upon mild hypothermia, which was coupled with increased mAb heavy 
and light chain mRNA transcription. Marchant et al. (2008) looked into the mechanism of increased 
cell viability at mild hypothermic temperature in TGE and revealed that cells entered prolonged G0/G1 
at 32C (Table 3). The induced partial cell cycle arrest enables higher viable cell density with a 
prolonged survival period. The mild cold-stress helped stabilize and increase the HC and LC mRNA 
contents and improved mRNA translation and mAb folding with an up-regulation in chaperone 
expression (Cain et al. 2013). Furthermore, genetic changes have been monitored during temperature 
shift where a non-coding RNA molecule micro-RNA mir-7 expression was massively down-regulated 
at 32C and SEAP productivity was raised compared to CHO-K1 cells cultured at 37C. This was the 
first attempt to link culture condition, genetic variation and recombinant protein productivity (Barron 
et al. 2011).  
 
Table 3. Cell cycle distribution of GS-CHO cells expressing IgG4 at 37C and 32C (Table adapted from (Marchant et 
al. 2008)). Five different time-points were analysed. Black shade: Go/G1-phase; black and white squares: G2-phase; 
white shade: S-phase of cell cycle. “Permission is granted by the right holder Springer to reproduced this image for 
this thesis” 
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2.5.7. Chemical supplementation in TGE 
Studies demonstrated that the supplementation of 1.25% DMSO during cell culture in TGE 
has significantly improved mAb expression by almost 100%, in which DMSO was suggested to help 
maintaining DNA stability post-transfection. A similar effect was observed when 3 mM of lithium 
acetate (LiAc) was introduced during cell culture (Ye et al. 2009). The addition of both chemicals 
mentioned was performed 72 h post-transfection and feedings occurred every 2 to 4 days, in 
combination with glucose, amino acids and vitamin supplements. Alternatively, addition of 2.5 mM 
valproic acid (VPA) or 2 mM sodium butyrate boosted mAb production in CHO-DG44 cells by 3.5- 
to 4-fold during transient expression (Backliwal et al. 2008c; Wulhfard et al. 2010). VPA and sodium-
butyrate are histone-deacetylation inhibitors and the process of histone acetylation directly influences 
gene transcription rate. In these studies, VPA or sodium-butyrate addition increased the RNA 
polymerase accessibility to histone, thus enhanced gene transcription and possibly assisted mRNA 
stabilization (Wulhfard et al. 2010). Similar to valproate, lithium and butyrate also induce the 
expression of chaperones which assist protein folding during mAb production. 
2.5.8. Overexpression of accessory genes 
The overexpression of other genes or accessary proteins such as X-box protein-1 unspliced or 
XBP-1 spliced isoform (XBP-1 or XBP-1S), endoplasmic reticulum oxidoreductase (ERO1-L) and 
Torsin A are also suggested to promote mAb protein expression in TGE. XBP-1 is a transcription 
factor that control cell differentiation and protein folding, and its spliced form XBP-1S is activated 
during unfolded protein response (UPR) to alleviate stress within the endoplasmic reticulum and 
induces biosynthesis within the ER (Lee et al. 2003). ERO1-L, on the other hand, catalyses the 
formation of disulfide bonds on protein disulfide isomerase (PDI), which plays an important role in 
protein folding and redox signaling (Sevier and Kaiser 2006). While Torsin A is an adenosine 
triphosphatase (ATPase)/heat-shock protein hsp104 that encourages protein de-aggregation. Studies 
showed that XBP-1 overexpression in mAb-expressing CHO-T cells under hypothermic condition 
increased total mAb concentration by 36% (Codamo et al. 2011a). Cain et al. (2013) later 
overexpressed both XBP-1S and ERO1-L in CHO-S cells and achieved 5.3- to 6.2-fold increases in 
recombinant mAb production. Despite the usefulness of overexpressed ERO1-L in the TGE system, 
no/negative effects in rProtein expression were observed in stable gene expression (SGE) systems 
(Mohan and Lee 2010). The different impact of ERO1-L overexpression observed in TGE and SGE 
could be due to disulfide bond formation being hindered by the high plasmid dosage in TGE (which is 
lower in SGE), thus it effectively increased recombinant protein productivity. Torsin A, in addition, 
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improved IgG4 production to a similar extent as XBP-1 (Josse et al. 2010). Co-expression of an anti-
apoptotic protein Bcl-xL in CHO-S undergoing TGE also  showed reduced levels of cell apoptosis 
and increased the overall rProtein titre by 100% (Zustiak et al. 2014). 
2.5.9. Impact of TGE on mAb Fc-glycosylation 
Fc-glycosylation of mAb expressed in cells undergoing TGE is rarely examined and to date 
only a few studies have directly compared protein glycosylation patterns of stably- and transiently 
expressed mAbs. It is highly likely that oligosaccharide contents of mAb vary between stable and 
transient gene expressions. Cellular stress can affect mAb folding in TGE, the retention time of the 
mAb within the ER might lengthen, and this could potentially affect glycan macroheterogeneity. 
Under mild hypothermic conditions in TGE, significant changes in galactose abundance were 
observed, where mAb proteins generated under TGE contained reduced levels of G1F and G2F 
glycoforms, than those that were stably expressed (Galbraith et al. 2006). Moreover, addition of 
DMSO or LiAc in BioWhittaker™ UltraCHO media in mAbs synthesized under TGE possessed 
higher abundance of G1F and G2F structures but a reduced level of G0F glycan contents, when 
compared to those from the non-chemical supplement transient pool. High fractions of high mannose 
structures were also observed (Ye et al. 2009).  
2.6. Flux balance analysis – towards the understanding of 
cellular metabolic distribution 
Nearly all cellular processes are directly or indirectly linked to the cellular metabolic pathway 
of a living organism, which contains enormous numbers of biological and chemical reactions 
involving the synthesis and activities of thousands of enzymes, metabolites, proteins and signalling 
molecules. Metabolic networks are the basis of life and they control cell growth and cell division, 
generate responses towards extracellular changes, and manage the process of reproduction. In the case 
of rProtein production, the rates of each reaction in metabolic networks of the host cells control how 
key metabolites are being processed within a cell and the amount of materials that flow from one 
reaction to another in a defined time period. Through cell metabolism one can determine the amount 
of nutrients and amino acids that are converted into useful metabolites such as nucleic acids, 
nucleotides and NSD species that are essential for protein glycosylation. Thorough understanding of 
the flow of each metabolite based on reactions within intracellular metabolic networks enables 
researchers to determine where and how each metabolite is being utilised under a set of bioprocess 
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conditions, in order to generate feeding plans that aim to optimise a certain process and improve both 
quality and quantity of the synthesized products.  
There are two approaches to analyse metabolic flux distribution, these include flux balance 
analysis which is a constraint-based method, or metabolic flux analysis method. Flux balance analysis 
(FBA) is based on constraints that are normally the cellular inputs and outputs that are observed 
experimentally during cell culture. In FBA, metabolic networks are represented by a number of mass 
balances. By using the specified model structure and its model constraints, the FBA suggests the 
metabolic flux distribution of a cell at a specified steady state by optimising an indicated parameter, 
such as cell growth or rProtein production (Chen et al. 2011). In addition, FBA can also guide genetic 
engineering efforts to direct carbon and nitrogen fluxes towards product generation. On the other 
hand, metabolic flux analysis (MFA) is based on measurements of internal carbon and energy fluxes, 
which are usually determined through isotopic labelling (Srour et al. 2011). Isotopic labelling works 
through feeding cell cultures with a known amount of labelled substrates, and determining 
concentrations of labelled metabolic intermediates and end products are analysed. MFA can also be 
based on stoichiometric fluxes. This approach is data driven with external rate measurements in small-
scale network models (Antoniewicz 2015). By using complex computational tools, resulting flux 
maps of metabolic networks are estimated, based on optimised balances between internal fluxes and 
labelled and external flux measurements (Chen et al. 2011).  
Both approaches can successfully describe intracellular metabolic fluxes, but only to a limited 
degree based on the way each method is set up. FBA manages to describe metabolic flux within the 
optimised solution space, any others outside this indicated space are not estimated, and as a result it is 
essential to have the right network in FBA in order to ensure the validity of the model. Moreover, 
FBA is limited to just estimating internal fluxes and does not provide concentration values. In 
contrast, isotopic labelling-based MFA is usually quantitative. Results from the MFA show the exact 
measurements of intracellular metabolites from 
13
C-labelling which bear the labelled element and it 
enables the direct trace of consumed materials through the metabolic network. However, the main 
drawback of the MFA method is that only the exchange of fluxes that contained the certain type of 
isotopic element, such as 
13
C-isotope for carbon measurements, can be revealed; flows of other non-
targeted metabolism therefore are excluded in the study and they cannot be traced. Furthermore, the 
experimental set-up of isotopic labelling is not as straightforward as those in the FBA studies, where 
only simple concentration measurements are required to constrain the FBA model. Isotopic labelling 
experiments are extremely useful and precise, but equipment and labour-training required might not 
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be readily available in every research environment and complex computational tools are required to 
analyse and deduce the map of fluxomes.  
2.7. Mechanistic mathematical models 
To establish mechanistic models that represent biological activities, such as the synthesis of 
mAb molecules within the host cells, detailed understanding of dynamic cellular processes like cell 
growth, and metabolism, the process of transcription, translation and secretion of recombinant 
proteins, as well as the process of protein assembly and post-translational modification within the ER 
and the Golgi apparatus are essential. Structured models for mammalian cell system account for the 
intracellular processes, while unstructured models treat the biological system as a black box. These 
models can also be segregated or unsegregated, according to whether the cell population is considered 
to be heterogeneous or homogeneous, respectively (Sidoli et al. 2006). 
2.7.1. Modelling host cell dynamics and rProtein synthesis  
 A host cell dynamics model describes cellular activities along the period of cell culture in 
bioproduction. It usually describes changes of cellular activities such as cell growth, cell metabolism 
including nutrients, wastes, amino acid metabolism, as well as protein synthesis through gene 
expression, product translation, assembly and secretion. The first mathematical model for mAb 
production was developed by Bibila and Flickinger (1991). They developed a structured unsegregated 
steady-state kinetic model that described the process of mAb synthesis, assembly and secretion in 
murine hybridoma cells. The model includes heavy and light chain gene copy numbers, their 
respective rates of gene transcription and mRNA decay. The model developed by Bibila and 
Flickinger (1991) also includes HC and LC polypeptide balances, the kinetics of the mAb assembly 
reactions in both cell growth exponential and stationary phases in a batch culture mode, and the rate 
of antibody secretion from the ER to the Golgi apparatus. The model assumes mAb assembly occurs 
according to these reactions: H+HH2, H2+LH2L, H2L+LH2L2, where [H2] and [H2L] were the 
assembly intermediate concontrations. This reaction network is known to hold true for IgG1 products. 
This inital model comprised 16 equations with 31 model parameters, where parameters are either 
measured experimentally or derived from existing literature. This model provides the basis for 
predicting effects of gene dosage, rates of specific cell growth, IgG assembly and mAb secretion.  
2.7MECHANISTIC MATHEMATICAL MODELS 38 
 
 
 In 2000, Jang and Barford developed an unstructured model that described cell growth and 
production of mAb in hybridoma cell lines. In brief, the model includes material balances for 
hybridoma cell growth and mAb synthesis, glucose and glutamine consumption, and lactate and 
ammonia production under batch or fed-batch modes (Jang and Barford 2000). This model assumes 
that viable cells were divided into non-cycling (G0 or arrested in G1 phase) and cycling (DNA 
replicable cells) cell cycle phases, where the model assumes G1 arrested viable cells to contribute to 
an increase in mAb productivity in fed-batch culture. This model has successfully predicted cellular 
behaviour in the late exponential growth phase capturing reduced cell growth, nutrient uptake and 
waste production. However, the main drawback is the inability to simulate amino acid metabolism, 
which cell growth and other cellular reactions are highly dependent upon. This imposes a problem in 
representing the metabolism of macromolecules.  
 Kontoravdi et al. (2005) combined models of Bibila and Flickinger (1991) and Jang and 
Barford (2000), and generated a single model that monitors both mAb synthesis and cellular 
metabolisms in hybridoma cells. In addition to the inlet and outlet concentrations of glucose and 
glutamine, their maintenance coefficients are also included in this model to better capture cell 
metabolism. This was inspired by Abbott and Clamen (1973) which demonstrated a direct positive 
relationship between cellular maintenance and protein yield coefficient. Instead of considering the 
model as one single cell, Kontoravdi et al. (2005) adapted the total cell model from Tatiraju et al. 
(1999), as well as substituting the concept of cell cycle dependent mAb synthesis with the 
differentiation between proliferating and non-proliferating cells in the model. This is a hybrid 
unstructured/structured model, which considers the reactions of cellular metabolism to occur in one 
open cellular environment, but mAb production in a structured environment, commencing from gene 
transcription in the cell nucleus, protein translation in the cytosol and cell membrane of the ER, 
followed by polypeptide assembly and protein processing in the ER and Golgi apparatus, and IgG 
secretion in the ECM. Furthermore, global parameter sensitivity analysis (GSA) was conducted based 
on the Sobol’ method and experimentally determined parameters were reduced from 30 to 8 in this 
model. This significantly reduced the number of model validation experiments. 
 Shifting from hybridoma cell lines, O'Callaghan et al. (2010) constructed a mathematical 
model that described mAb IgG4 synthesis and secretion in different GS-CHO cell lines. This model 
did not focus on cell dynamics or metabolism, but concentrated on mRNA and polypeptide production 
of heavy and light chains as well as their respective mRNA stabilities. It examines the effects of HC 
and LC mRNA translation and mAb assembly, on the specific rate of productivity of heavy (qHC2) and 
light chain (qLC2) mRNA, as well as IgG4 (qIgG4). Based on the theoretical models of Percy et al. 
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(1975) in which the covalent assembly of different IgG molecules was dependent on the probability of 
disulphide bond-formation between heavy-heavy chains or between heavy-light chains, two potential 
assembly models of IgG4 were developed. The first model describes mAb assembly in the fashion of 
H+HH2, H2+LH2L, H2L+LH2L2, while the second model assumes mAb assembly to follow the 
2 x (H+LHL), HL+HLH2L2 pathway (Figure 12). Model simulations in this study showed that an 
excess in LC transcription and translation was observed, and it was HC mRNA and protein production 
that was direcly proportional to mAb synthesis rate. Moreover, the empirical model developed by 
McLeod et al. (2011) attempted to distinguish the limitation of cellular processes on GS-CHO-
producing mAb synthesis and model estimation from this group suggested that processes such as mAb 
folding, assembly and secretion did not significantly affect mAb production, but it was gene 
transcription that exerted a significant control on antibody production. 
 
Figure 12. The two mAb assembly routes of mAb examined in O’Callaghan models. The first assembly route 
proposes that two heavy chains assemble first, followed by the sequential addition of the two remaining light chains. 
The second mAb assembly route suggests the formation of heavy-light chain hybrids, followed by the combination of 
the two hybrids to form fully assembled mAb.  
In addition to developing cell dynamics models that estimate cell growth and cellular 
behaviour as well as mAb synthesis as a whole, some model frameworks were developed to predict 
changes in cellular behaviour under a target condition. For instance, Fox et al. (2004) developed a 
mathematical model that predicted the optimal time point to introduce mild hypothermia during cell 
culture in order to generate maximal rProtein production yield. In this proposed model, he assumed 
that various parameters related to cell growth and product synthesis changed from one culture 
temperature to another, and two separate parameter sets were employed in his model that 
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corresponded to physiological and mild hypothermic temperatures, respectively. The separate 
parameter set approach was later adapted by Munzer et al. (2015) in his unstructured cell dynamics 
model, in which cell cycle was taken into account when determining the best temperature shift time 
point for maximal product productivity.  
 The use of mathematical modelling tools are not only limited to products that are generated 
from stable cell lines, but also those that are transiently expressed. By removing material balances that 
represented recombinant gene transcription and mRNA decay in the mAb synthetic model developed 
specifically for CHO cells by O'Callaghan et al. (2010), and at the same time coupling the model with 
terms of cell growth and UPR-regulated protein folding, the model was capable of describing the 
production of seven “difficult to express” mAbs. The modified model also identified the induction of 
the unfolded protein response (UPR) to be the factor that increased rates of mAb folding and 
assembly, but reduced cell proliferation (Pybus et al. 2014a). The model managed to monitor and 
predict the impact of UPR induction on transient mAb expression in UPR-engineered CHO cell lines, 
which makes it a potential predictive tool for cell line engineering. In the same year, Pybus et al. 
(2014b) developed a mathematical model that predicts transient mAb production based on the amino 
acid/mRNA sequences of the constant regions on both heavy and light chains. This modelling 
methodology served as an in silico screening tool for transient protein expression during early mAb 
development.  
2.7.2. mAb N-linked Fc-glycosylation models 
Systems biology and computational tools are useful when it comes to process optimisation. 
Mathematical models are therefore developed based on this principle to aid experimental design. In 
1996, the first model that described N-linked glycan attachment in mAb molecules was developed by 
Shelikoff et al. (1996). This structured kinetic model of glycosylation focuses on Fc-glycan macro-
heterogeneity and describes the initial attachment of oligosaccharide precursors onto potential N-
linked glycosylation sites on the nascent polypeptide chain in the ER. The model assumes that the 
process of glycosylation happens co-translationally; Shelikoff et al considered the ER as a plug-flow 
reactor (PFR) and initial glycosylation occurred proximal to the ER membrane. Predictions generated 
from this model for glycosylation site occupancy are dependent upon the level of sugar substrate 
within the system, the catalytic activity of membrane-bound glycosyltransferases under first order 
kinetics, as well as the competition between protein folding and glycan attachment. Despite the 
inability of this model to generate quantitative predictions, it qualitatively suggested that fractional 
glycosylation site occupancy was dependent on the rate of mRNA elongation, in which optimal 
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elongation rate provided a balance between protein folding and mAb glycosylation. A more recent 
computational model on macro-heterogeneity was developed in 2005. This model made use of a 
neural network and deduced the probability of site occupancy based on the amino sequence around 
the glycosylation site (Senger and Karim 2005). Dependent on the application, the model developed 
by Senger and Karim (2005) requires fewer parameter inputs, which is a very useful method when the 
enzyme kinetic mechanism of glycan attachment is not required.  
In contrast, micro-heterogeneity of N-linked glycosylation, which describes changes of 
glycoform within the sugar chain attached to the glycoprotein, was first modelled by Umaña and 
Bailey in 1997 (Umana and Bailey 1997). Their model considered only the central reaction network 
of glycan biosynthesis, where core glycan and subsequent additions of GlcNAc and Gal residues were 
involved (Figure 13). This model contained a total of 33 sugar residues, 33 reactions and eight 
enzymes, and assumed the Golgi apparatus network as four continuously-stirred tank reactors 
(CSTRs) (Figure 14), where contents within each Golgi compartments were homogeneous. Enzyme 
kinetics for glycosyltransferases involved in this model was represented by simple Michaelis-Menten 
kinetics without consideration on any product or competitive inhibition. This model provided 
qualitative predictions on the distribution of different glycan structures based on the expression and 
the localisation of N-linked glycan related enzymes, as well the length of Golgi retention period of 
these enzymes. Through knock-out experiments on glycosyltransferases, the model was capable of 
predicting the effect of glycan engineering on glycan structure distribution. However, this model 
neglected the contribution of nucleotide sugar donors and has limited the ability to consider the 
impact of extracellular environment on N-linked glycosylation. Despite these limitations, this model 
provided a basis for the development of future N-linked glycosylation models. 
 Krambeck & Betenbaugh in 2005 extended the glycosylation model developed by Umaña and 
Bailey, where the model considered the addition of other sugar residues such as core fucose and sialic 
acid onto the bi-antennary structure, or other possible extended antennae with galactosamine addition 
(Krambeck and Betenbaugh 2005). Similar to the Umaña’s model, the model of Krambeck considered 
the Golgi apparatus as four consecutive CSTRs (Figure 14), but the number of overall reactions 
increased to 22,871 including 7,565 glycan structures. To accommodate the addition of extra sugar 
species, kinetic parameters for fucose and sialic acid transferases were included in this model. While 
Umaña’s model only considered simple Michaelis-Menten enzyme kinetics, Krambeck’s model took 
into account competitive inhibition, and assumed constant enzyme kinetics among the four Golgi 
compartments. Model parameters were adjusted in this model to generate matching simulations to 
experimental data of the target glycoprotein and the model was capable of describing the effect of 
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glycoengineering on mAb glycosylation. However, Krambeck assumed the same level of nucleotide 
sugar donors entering into each Golgi compartment. As a result the direct impact of cellular 
metabolism on mAb glycosylation could not be assessed. Later in 2009, Krambeck and colleagues 
improved the existing model by introducing additional enzymes. Together with a molecular mass cut-
off through MALDI-TOF mass spectrometry, this group managed to predict about 10,000 sugar 
structures in their model, which enabled complete sets of glycan structures and enzymatic reactions 
within a mass-range to be revealed (Krambeck et al. 2009). Improvements in this model enabled 
glycan analysis in diseased cells.  
 
 
Figure 13. The central reaction network of IgG Fc-N-linked glycosylation. This reaction network only considers 
enzymes and reactions that are involved in forming GlcNAc terminating-N-glycan structure (GlcNAc2Man3GlcNAc2-
Asn297). In total 33 reactions and 8 different enzymes are involved. This is adapted from Umana and Bailey (1997). 
“Permission is granted by the right holder John Wiley & Sons, Inc to reproduced this image for this thesis” 
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Figure 14. Schematic of the Golgi apparatus as 4 CSTRs. Umana and Bailey (1997), Krambeck and Betenbaugh 
(2005), Krambeck et al. (2009) and Hossler et al. (2007) considered the Golgi apparatus as 4 CSTRs in their proposed 
mathematical models for mAb Fc-N-glycosylation. This taken from del Val et al. (2010). “Permission is granted by 
the right holder American Institute of Chemical Engineers to reproduced this image for this thesis” 
 
By using similar kinetic parameters with the previous two models, Hossler et al. (2007) 
developed two mathematical models based on certain assumptions on the Golgi structure.  The first 
model employed a similar approach as the previous two and considered the Golgi apparatus as four 
CSTRs, while the second model considered the Golgi as a series of four PFRs. Hossler and colleagues 
compared predictions on mAb glycosylation between the two developed models and their 
observations suggested that model simulations generated from the PFR approach better represented 
experimental results, especially in predicting the abundance of high-mannose structures. In addition, 
the model assumed each Golgi compartment to have a different enzyme distribution and NSD 
concentration. The localisation of glycosyltransferases helped optimise the amount of terminal glycan 
structure. Lastly, competitive inhibition was included in the kinetic rate expressions. Compared to 
previous models, this model allowed better understanding of the actual N-linked glycosylation process 
and enabled better predictions of experimental data. By incorporating the information on enzyme 
localisation, the model had high potential of describing the genetic manipulation on these enzymes, 
which made it very useful for the field of glycoengineering.  
 In 2011, Jimenez del Val and collaborators extended Hossler’s model and introduced the 
Golgi network as one single PFR, which is in line with the concept of Golgi maturation (Figure 15) 
(Jimenez del Val et al. 2011). In addition to including nucleotide sugar donors as substrates for Fc-
glycosylation, the kinetic rate expression of each glycosyltransferase involved, as well as rates of 
NSD transport protein moving from cell cytosol into the lumen of Golgi apparatus, were taken into 
account in their model construction. Moreover, the concept of recycling glycosyltransferases and 
transport proteins was also included within the PFR model. In terms of glycosyltransferase enzyme 
kinetics, reported competitive and product inhibitions were included along with known kinetic 
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mechanisms, such as sequential and random Bi-Bi enzyme reactions. Unknown parameters from both 
enzymatic and protein transport processes were directly estimated for this model. The model aimed to 
establish a link between intracellular N-glycosylation processes and cellular mechanisms. As a result, 
computational simulations were capable of generating a more thorough description of commercial 
recombinant mAb N-glycosylation structures. At the same time the model was able to predict glycan 
patterns of the recombinant product after the genetic knockout of the fucosyltransferase gene, 
replicating pre-existing experimental data. This model offers the potential of examining the effect of 
extracellular bioprocess conditions on the Fc-glycosylation profile.  
 
Figure 15. Golgi apparatus maturation in single PFR model. Jimenez del Val et al. (2011) considered the entire Golgi 
apparatus network as one PFR. Glycoproteins transit from the cis-Golgi to the trans-Golgi network, in which 
enzymes, NSD and processed glycoproteins are transported between compartments via vesicles, along the PFR 
(dotted lined). Figure adapted from Jimenez del Val et al. (2011). “Permission is granted by the right holder 
American Institute of Chemical Engineers to reproduced this image for this thesis” 
2.7.3. Combined mathematical model of cellular processes and mAb N-
linked Fc-glycosylation model 
The work by Kontoravdi et al. (2007) is believed to be the first report that attempted to relate 
mAb Fc-glycosylation to cellular metabolic networks, by combining the cell dynamics model that was 
developed in 2005 with the Umaña and Bailey’s glycosylation model to generate a single 
mathematical model that described cellular processes, metabolism and Fc-N-glycosylation of mAb. 
Model simulations showed successful predictions for nutrient consumption and protein synthesis, and 
generated predictions for their effect on mAb Fc-glycosylation. Despite the simplified version of the 
Umaña and Bailey model, this was the first attempt to extend the effect of bioprocess conditions on 
the intracellular glycosylation processes.  
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Based on the model structure of the N-linked glycosylation model developed by Jimenez del 
Val et al. (2011), Jedrzejewski et al. (2014) further integrated the model with a kinetic cell growth 
module, where the model described nucleotide sugar donor (NSD) synthesis based on the 
consumption of glucose and glutamine during the fermentation process. This approach directly relates 
the process of Fc-glycosylation to cell metabolism, which is subject to vary upon changes in the 
extracellular environment. Jedrzejewski and colleagues demonstrated that the model was capable of 
describing time-course concentration profiles of both nucleotide and NSD synthesis, as well as 
accurately predicted mAb Fc-glycan patterns in a hybridoma cell line. Instead of relating cell 
metabolism and Fc-glycosylation by using absolute concentrations of nutrients and metabolites, 
Kaveh et al. (2013) coupled nutrient metabolism to NSD synthesis and N-linked Golgi glycosylation 
via metabolic flux analysis (MFA). This model approach enabled accurate predictions on the trend of 
mAb Fc-glycosylation in CHO cultures.  
By coupling cellular metabolic networks to NSD synthesis and protein glycosylation, these 
models are crucial steps towards in silico analysis of the impact of bioprocess condition during cell 
culture on mAb production and glycosylation.   
2.8. Discussion and project motivation 
 In this chapter, literature review was presented covering the topics of protein glycosylation 
and its effect on protein drug efficacy, as well as experimental investigations on the impact of 
bioprocess conditions on the antibody glycosylation. This was followed by an overview of 
computational efforts to describe protein glycosylation in the ER and the Golgi apparatus and the 
latest efforts to develop predictive tools that link the extracellular environment with the final product 
glycoforms.  
 Given the research questions arising from this review, the main aim of our research was to 
investigate the impact of different bioprocess conditions on mAb Fc-glycosylation. Of particular 
interest, was the effect of mild hypothermia and the implications of transient gene expression 
compared to the standard process of fed-batch culture of CHO cells stably expressing monoclonal 
antibodies. As mentioned within the content of this chapter, many studies have focused on 
understanding the underlying mechanism behind the advantageous effect of mild hypothermic 
conditions on recombinant protein production. However, the relationship among mild hypothermic 
conditions, changes in cell metabolism, mAb synthesis as well as Fc-glycosylation, is not well 
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established. The same problem applies to transient gene expression, where cell metabolism is already 
shown to be very different from the traditional stable method but very little is known about the impact 
of cellular changes on Fc-glycosylation. As a result, the first part of our study focused on the 
following points: 
 Identifying contributing factors to mAb production and mAb Fc-glycosylation changes under 
mild hypothermic conditions, through detailed examination of changes within host cell 
metabolic pathways by experimental and FBA study, and  
 Comparing mAb synthesis and Fc-glycosylation in TGE systems at different cell culture 
temperatures with the respective profiles in SGE systems. 
Despite advances in model development in terms of representing cellular activities under 
certain bioprocess conditions, most models describe their impacts under a single aspect and very few 
of them relate process conditions to cellular performance and product quality through a single model, 
especially when it comes to modelling the impact of transient gene expression on product 
glycosylation. As a result, the second part of this thesis attempts to fill this gap and develops a 
biological mathematical model that mechanistically describes the impact of mild hypothermia or 
transient gene expression on product glycosylation, as a result of changes in cell metabolism. The 
proposed model is developed with an aim to capture the variation in Fc-glycosylation in response to 
changes in the extracellular environment. By satisfying this intention, the model will help revealing 
limitation in cellular activity that CHO cells are experiencing under a specific culture condition. By 
identifying the bottlenecks within each bioprocess, improvements can be implemented into the 
manufacturing process and this will satisfy the quality by design regime. Our proposed mathematical 
model will serve as a useful analytic tool in host cell characterisation, as well as a predictive tool for 
Fc-glycosylation under different bioprocess conditions.  
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Chapter 3
Experimental materials and methods 
3.1. Cell culture 
3.1.1. Cell line, maintenance and storage 
IgG-producing (SGE) or blank (TGE) Chinese hamster ovary CHO-T cell lines (MedImmune, 
Cambridge, UK) were revived separately and cultured in CD-CHO medium (Life Technologies, 
Paisley, U.K.) with starting concentrations of 25.81 mM of glucose and 1.36 mM of glutamate in 
cultures.  In the case of the IgG-producing cells for SGE, cells were supplemented with 50 M 
methionine sulfoximine (MSX) during the first and second passages only. Depending on the culture 
volume, cells were grown in Erlenmeyer flasks or in roller bottles (Corning Inc., NY, USA) at 150 
rpm in humidified 36.5C incubator with 5% CO2 supply and were subcultured in fresh medium every 
three days at a seeding density of 3 x 10
5
 viable cells/mL. Cell concentration and cell viability were 
measured by ViCell (Beckman Coulter, CA, U.S.A.). For storage, cell pellet containing 1 x 107 
viable cells were resuspended in 1 mL of freezing agent which consisted of 92.5% CD-CHO medium 
and 7.5% dimethyl sulfoxide (DMSO; Sigma-Aldrich, Dorset, UK). Cell vials were stored at -80C 
for 20 h in a Nalgene Mr Frosty prior to being transferred to liquid nitrogen (-160C) for long term 
storage.  
 
3.1. CELL CULTURE 48 
 
 
3.1.2. Cell system and Operation 
All experiments mentioned in this thesis, with an exception of the glycosyltransferase 
manipulation experiment described in Chapter 8 where Erlenmeyer flasks were used, were carried out 
in triplicate 1.5 L stirred tank DASGIP bioreactors (DASGIP Technology, Juelich, Germany).  After 
three cell passages, CHO cells were transferred into the bioreactor system with an initial culture 
volume of 0.9 L and a viable cell density of 8 x 10
5
 cells/mL in each vessel. Within the 14-day cell 
culture period, the pH was maintained at 6.9±0.1 and culture temperature was maintained at 36.5C, 
or with a temperature shift to 32C at various points of cell culture depending on the experiment, as 
indicated in Table 4. The stirring speed was at 150 rpm and CO2 air concentration was maintained at 
5% v/v. On days 2, 4, 6, 8, 10 and 12 of the culture period, the cultures were supplemented with 10% 
v/v CD EfficientFeedTM C AGT
TM
 Nutrient supplement (Life Technologies, Paisley, U.K.), or with 
10% v/v of a proprietary feed x (MedImmune, Cambridge, U.K.) as indicated in Table 5. Excessive 
foaming was eased by 5 mL additions of 15% antifoam C (Sigma-Aldrich, Dorset, U.K.).   
 
Table 4. Timing of temperature shift in each experiment with different bioprocess conditions. 
Chapter number Bioprocess condition Time of temperature shift to 32C 
4, 6, 8 SGE, physiological Does not apply 
4, 6, 8 SGE, mild hypothermia Day 6 
6 TGE, physiological Does not apply 
6 TGE, mild hypothermia Day 2 (24 h post-DNA transfection) 
8 
miRNA transfection,    
mild hypothermia 
Day 6 
8 
null vector transfection, 
mild hypothermia 
Day 6 
 
Table 5. Type of nutrient supplement in each experiment with different bioprocess conditions. 
Chapter number Bioprocess condition 10 % v/v CD EfficientFeed
TM C AGTTM 
4, 6, 8 SGE, physiological √ 
4, 6, 8 SGE, mild hypothermia √ 
6 TGE, physiological √ 
6 TGE, mild hypothermia √ 
8 
miRNA transfection,   
mild hypothermia 
√ 
8 
null vector transfection, 
mild hypothermia 
√ 
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3.2. Transient gene expression (TGE) 
3.2.1. Transfection method 
Transient transfections were performed in the TGE experiment in Chapter 6 and 
glycosyltransferase manipulation experiment in Chapter 8. Transient transfection in the former was 
carried in each bioreactor 24 h after cell inoculation (day 1), at a cell density of 2 x 10
6
 cells/mL, 
while DNA/miRNA vectors were transfected in each shake flask culture on day 5, at a viable cell 
concentration of 1 x 10
7
 cells/mL. Table 6 shows the respective type and amount of DNA vectors 
transfected in each experiment. To transfect, respective amount of DNA vectors were mixed with 125 
mM NaCl-diluted linear PEI 25,000 Da (Polysciences Europe GmbH, Germany) in a ratio of 5:1 
PEI:DNA. The mixture was incubated for 2 min at room temperature prior to additions to the cells. 
Transfection protocol (not vector construction) was adapted from Daramola et al. (2014). 
 
Table 6. Type and amount of vectors used in transient gene expression in each experiment. 
Chapter 
number 
Bioprocess 
condition 
DNA/miRNA plasmid 
Amount of 
vector 
transfected 
(g) 
Culture 
volume at 
transfection 
(L) 
6 
TGE, 
physiological 
Human IgG heavy chain (HC HuG1) 
Human IgG light chain (LC 
HuKappa)                                                  
(MedImmune, Cambridge, UK) 
1 mg of total 
DNA per 1L of 
culture 
volume
0.9 
6 
TGE, mild 
hypothermia 
8 
miRNA 
transfection,  
mild hypothermia 
cgr-miR-500 in pcDNA4/TO vector                                           
cgr-miR-501-5p in pcDNA4/TO 
vector 
cgr-miR-181d in pcDNA4/TO 
vector 
0.05, 0.10, 
0.25 & 0.50 
mg of each 
miRNA vectors 
per 1L of 
culture in 4 
separate 
conditions 
0.1 
8 
null transfection, 
mild hypothermia 
pcDNA4/TO vector 
0.15 mg per 
1L of culture 
volume 
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3.2.2. miRNA vector construction 
Table 7 shows miRNA sequences for cgr-miR-500, cgr-miR-501-5p and cgr-miR-181d. 
Each designed miRNA sequence with compatible sticky ends for EcoRI and PstI (Sigma-Aldrich, 
Dorset, UK) was inserted between the EcoRI and PstI sites in three separate pcDNA4/TO expression 
vectors. After vector verification through DNA sequencing, each miRNA containing vector was 
progagated in E.coli DH5 and purified by the Qiagen Plasmid Maxi Kit (Qiagen, Manchester, UK) 
according to the manufacturer’s instructions.  
 
Table 7. miRNA sequences. 
Chapter 
number 
miRNA 
Accession 
number 
Sequence 
8 
cgr-miR-500 MIMAT0023974 5'-AAUGCACCUGGGCAAGGGUUC-3' 
cgr-miR-501-5p MIMAT0023975 5'-AAUCCUUUGUCCCUGGGUGGAAAUGC-3' 
cgr-mir-181d MI0020423 
5'-
GUCACAAUCAACAUUCAUUGUUGUCGGUGGGUU
GUGAUGAGGAGGCCAGACCCACCGGGGGAUGAAU
GUCACUGUGGCUGG-3' 
3.3. Analytical assays 
On a daily basis, samples of 10 mL were withdrawn for polypeptide, nucleotide sugar donor 
(NSD), and heavy and light chain DNA/mRNA and glycosyltransferase mRNA analyses. Samples 
were centrifuged for 5 min at 200 rpm in an Eppendorf microfuge.  Supernatants were stored at -80C 
and cell pellets were washed twice with PBS prior to storage at -80C. Extracellular nutrient and mAb 
concentrations were quantified in clarified supernatants. 
3.3.1. Nutrients, metabolites and secreted mAb concentrations 
Extracellular concentrations of glucose, lactate and ammonia in supernatant samples were 
determined using the YSI Bioprofiler 800 (NOVA Biomedical, MA, U.S.A.). Extracellular amino 
acid quantification was performed with a Waters Acquity ultra-performance liquid chromatography 
3.3ANALYTICAL ASSAYS 51 
 
 
(UPLC, Waters, Hertfordshire, U.K.) using the AccQ-tag kit according to the manufacturer’s 
instructions. Secreted mAb titre was determined using a Protein-A affinity chromatography method. 
Specific consumption and production rates of nutrients and metabolites were calculated by plotting 
the integral viable cell concentration (IVCC) against the cumulative concentration as in 
Kyriakopoulos et al. (2013). 
3.3.2. DNA and RNA extraction and cDNA preparation 
Total DNA and RNA content of each sample was extracted from pellets containing 5 x 10
6
 
cells according to the manufacturer’s protocols for the All prep DNA/RNA mini purification kit 
(Qiagen, Manchester, U.K.). Using 1 L of the RT Primer Mix of the QuantiTect Reverse 
Transcription Kit (Qiagen, Manchester, U.K.), 300 ng of extracted total RNA from each sample was 
reversed transcribed into cDNA according to the manufacturer’s instructions. 
3.3.3. mAb heavy and light chain, glycosyltransferase mRNA 
quantification 
To determine the DNA copy number and mRNA expression levels of mAb heavy (HC HuG1) 
and light chains (LC HuKappa), as well as 8 glycosyltransferases, namely 2 N-
acetylglucosaminyltransferases (GnTI and GnTII), 3 galactosyltransferases (-GalTI, II and III), 
fucosyltransferase (FucT), UDP-Gal transporter and UDP-GlcNAc transporter, quantitative real-time 
polymerase chain reaction (qRT-PCR) was performed in each sample. Each cDNA sample transcribed 
in (3.3.2) was analysed in triplicate using PCR. PCR experiments were carried out in a 96 well-plate 
using 5 L of 2x SYBR Green Supermix (Sigma-Aldrich, Dorset, U.K.), 0.64 L of cDNA and 500 
nM of each primer pair and ddH2O to make a total of 10 L of reaction volume per well. Non-
template controls were carried out for each PCR. PCR experiments were initiated with SYBR Green 
activation at 95 C for 3 min followed by 40 cycles of 95C for 30 s, 60C for 75 s and 72C for 30 s. 
DNA melting curve was performed from 65C to 95C (read every 0.3C) to verify product integrity. 
Results were compared to the Ct-number of house-keeping gene -actin for relative analysis, while 
DNA copy number was calculated from a calibration curve of known DNA concentrations.  Table 8 
shows the primer sequences of glycosyltransferases and those of heavy and light chains are available 
on request. 
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Table 8. Forward and reverse primer pairs used in qRT-PCR experiments. 
Chapter 
number 
Type 
Glycosyltra
nsferase 
Accession 
Number 
Primer pair sequence 
4,6,8 
N-
acetylglucosaminyl-
transferase 
GnT I 
 
5’-CTGGGTGTCATGGATGACCT-3’       
5’-CTAATTCCAGCTAGGATC-3’ 
GnT II 
 
5’-GATGATTATAACTGGGACTGG-3’   
5’-TGACTCAATTTGGGCACTCTG-3’ 
Galactosyltransferase 
-Gal T I AF318896 
5’-GACCTGGAGCTTTTGGCAAA-3’     
5’-GGGATAATGATGGCCACCTTG-3’ 
-Gal T II AY117536 
5’-CCTTCTCTGCCTGCTGCACT-3’     
5’-CTGGGCTTCGGATACTGAAGC-3’ 
-Gal T III AY117537 
5’-AACTGCCATAATTGTGCCCC-3’  
5’-TGCCATATGCAAGCTGCTG-3’ 
Fucosyltransferase FucT 
 
5’-TATGGCACCCAGCGAACACTC-3’             
5’-TTCACCTGACCAGTGTCCAG-3’ 
Nucleotide sugar 
transporter 
UDP-Gal 
Transporter 
AF299335 
5’-ACACACTCAAGCTCGCGGT-3’               
5’-TGTCACCTGGAAAGTGGCAG-3’ 
UDP-
GlcNAc 
Transporter 
 
5’-CAGGAGTTGCTTTTGTACAG-3’    
5’-GCTGTGAGAACTGCCATGAG-3’ 
3.3.4. Determination of heavy and light chain mRNA half-lives 
To estimate the stability of heavy and light chain mRNA molecules in SGE, duplicate shake 
flask experiments were performed at both 36.5C and 32C. On day 6, 65 M of the transcription 
inhibitor DRB (5,6 dichloro-1 -D-ribofuranosyl benzinmidazole, Sigma-Aldrich, Dorset, U.K.) 
dissolved in 100% ethanol (VWR, Lutterworth, U.K.) was added to block cell transcription. The same 
volume of ethanol was added to control cultures at both temperatures to compensate for the effect of 
ethanol on the cells. 5 x 10
6
 cells/mL were collected from each culture at 0, 3, 6, 9, 12 hours after the 
inhibitor/ethanol additions. Transcribed cDNA from each sample was quantified by qRT-PCR. 
Results were normalized to a standard curve generated with known amounts of the HC/LC plasmids 
and their respective Ct-values. mRNA levels were determined from the standard curve and decay rates 
were calculated. 
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3.3.5. Intracellular mAb polypeptides and assembly intermediate 
analysis 
Pellets from 2 x 10
6
 viable cells were washed with 0.9% NaCl solution at 4C before being 
resuspended in 125 L of CellLyticTM M solution (Sigma-Aldrich, Dorset, U.K.) supplemented with 
1% (v/v) protease inhibitor cocktail (Sigma-Aldrich, Dorset, U.K.). Extraction method is adapted 
from Ho et al. (2012b). Mixtures were incubated at room temperature for 10 min with shaking prior to 
centrifugation at 18,000 x g for 15 min to pellet cell debris. Soluble protein-containing supernatant 
was stored at -80C prior to Western blot analysis. One part of 4x NuPAGE sample buffer was added 
to 3 parts of each sample and 100, 10, 1 & 0.1 g of purified IgG controls (provided by MedImmune, 
Cambridge, U.K.). Samples and standards were run on a 4 - 20% Precast Protein gel (Thermo 
Scientific, Horsham, U.K.) in Tris-HEPES running buffer at 115 V for 50 min. The polyacrylamide 
gel was washed twice with dH2O before being transferred in a semi-dry transfer system (Bio-Rad, 
Hertfordshire, U.K.) onto a methanol-activated PVDF transfer membrane (Milipore, Watford, U.K.) 
at 0.3 A for 40 min. Upon successful transfer, the blot was prepared using the WesternBreeze 
Chemiluminescent Anti-Goat-Kit (Life Technologies, Paisley, U.K.) according to the manufacturer’s 
instructions, with 1:1000 horseradish peroxidase (HRP)-conjugated goat anti-human IgG Fc (Jackson 
Immunoresearch, PA, U.S.A.) and a 10 min exposure time (FujiFilm, Bedford, U.K.). The intensity of 
each band was quantified using MYImageAnalysis Software Manual (Thermo Scientific, Horsham, 
U.K.) and concentration in each sample was compared to the IgG protein standards. 
3.3.6. Analysis of galactosyltransferase III (GalTIII) protein expression 
2 x 10
7
 viable cells were pelleted and rinsed with 4C PBS prior to cell lysis in 200 L of M-
PER Mammalian protein extraction reagent (Thermo Scientific, Horsham, U.K.) supplemented with 
1% (v/v) protease inhibitor cocktail (Sigma-Aldrich, Dorset, U.K.). Sampled were gently shaken for 
10 min before sonication on ice using 3 times of 5 seconds, with 25 seconds intervals in between each 
sonication and an amplitude power of 20. Cell debris was removed by centrifugation at 14,000 x g for 
15 min. Membrane protein-containing supernatant was stored at -80C prior to Western blot analysis 
as described in (3.3.4), with an exception of an additional 10 min incubation at 100°C before gel 
electrophoresis. -1,4-Gal-T3 Antibody (N20) (Santa Cruz Biotechnology, Texas, USA) was used as 
primary antibody for Western blotting and protein concentration in each sample was compared to 
known concentrations of -1,4Gal-T3 (N20) blocking peptide (Santa Cruz Biotechnology, Texas, 
USA). 
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3.3.7. Extraction of intracellular NSD and analysis 
Intracellular nucleotide sugars were extracted by an acetonitrile extraction method (Dietmair 
et al. 2010; Viant et al. 2005). In brief, 400 L of ice cold 50% v/v aqueous acetonitrile was added to 
a cell pellet containing 2 x 10
6
 cells. The mixture was incubated on ice for 10 min before 
centrifugation at 18,000 x g for 5 min at 0C. Supernatant was dried thoroughly using a SpeedVac 
(Savant Inc. Laboratory, MI, U.S.A.). Dried samples were resuspended in 150 L of deionised water 
and were filtered using 0.2-m syringe filter units (Fisher Scientific, Loughborough, U.K.) before 
HPAEC analysis. The NSD analytical method was based on del Val et al. (2013), using a CarboPac 
PA-1 column with a PA-1 guard column (Dionex, CA, USA). Elution of samples, namely 10 
nucleotides - ATP, CTP, GTP, UTP, AMP, ADP, CMP, GMP, UMP and UDP, as well as 9 nucleotide 
sugar compounds- CMP-Neu5Ac, UDP-GalNAc, UDP-GlcNAc, UDP-Gal, UDP-Glc, GDP-Glc, 
GDP-Fuc, GDP-Man and UDP-GlcA, was performed using a gradient of E1 (3 mM NaOH) and E2 
(1.5 M sodium acetate in 3 mM NaOH) buffers as mobile phases. Detection of all species was carried 
out at two absorbance wavelengths: 271.6 nm for all cysteine-bearing species and 262.1 nm for all 
other compounds. The elution profile of each of these species is shown in Appendix I Figure 1 and is 
also presented in del Val et al. (2013). 
3.3.8. mAb glycan analysis 
Purified mAb samples with concentration range of 1.25 - 7.5 mg/mL were prepared for glycan 
analysis using the ProfilerPro Glycan Profiling Kit (PerkinElmer, MA, U.S.A.). 8 L of each sample 
was first denatured in the Denaturing Plate containing 3 L of denaturing solution for 10 min at 70C. 
11 L of denatured material was transferred to Peptide-N-Glycosidase F (PNGase F) Plate and was 
incubated at 37C for 1 h to cleave the glycan from the protein. 8 L of the digested sample was 
transferred to the Labelling Plate and was incubated at 55C for 2 h for glycan labelling, where 
glycans were derivitised with charged fluorophores. Dried samples were reconstituted in 100 L of 
molecular grade water and glycan analysis was performed by the LabChip GXII instrument 
(PerkinElmer, MA, U.S.A.). Glycan samples are separated in this method based on a microchip based 
capillary electrophoresis. The chip contains a set of micro-channels that are linked to both the 
separation channel and the buffer well, in which one of the micro-channels connects to a capillary 
below that sip samples through from the sampling plate during experiment. Micro-channels contain 
either buffers or sieving gel and each glycan sample moves along the sieving gel based on its 
electrophoretic mobility, and it produces a migration profile which is dependent on the charge, mass 
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and structure properties such as different glycosidic linkages,  or  bondings and the composition of 
the saccharide itself. The migration time of each glycan species is normalised to that of the glucose 
peaks in the glycan ladder by the LabChip GXII software to yield the size of the peaks, while at the 
same time each sample glycan peak is identified by comparing them to the migration time of known 
glycan standards that are analysed in the buffer as the samples. This glycan analytic method is capable 
of resolving glycan structures including high mannoses, hybrid and complexed structures.  
3.4. Flux balance analysis 
The R workspace (R Development Core Team 2010) and the Sybil package (Gelius-Dietrich 
et al. 2013) were used to perform the FBA. The metabolic network was constructed based on the one 
proposed by Carinhas et al. (2013) using the biomass composition proposed by Selvarasu et al. (2012) 
for CHO cells, but excluding cystine. The final model consisted of 120 metabolites, 97 intracellular 
reactions and 57 transport equations, as shown in the Appendix I Table 1 and also presented in 
Kyriakopoulos and Kontoravdi (2014a). The model was optimised by assuming maximum biomass 
and IgG accumulation during exponential phase, and maximum IgG accumulation at stationary phase. 
The FBA was constrained by the experimentally measured extracellular fluxes of amino acids, 
glucose, lactate, ammonia and observed growth rate and specific productivity. Specifically, the upper 
and lower bounds were set within one standard deviation of experimentally measured fluxes while 
those fluxes that were not measured  were set at ±20% from those reported in (Carinhas et al. 2013). 
In order to examine the glucose fluxes to nucleotide and NSD production for glycosylation, GlcNAc, 
GalNAc, Man, Fuc, Gal and Neu5Gc were added in the biomass equation. The amount of each NSD 
necessary for host cell protein and recombinant product glycosylation, was estimated based on the MS 
glycan study in North et al. (2010), the occurring frequency of N- and O-linked glycans on host cell 
proteins based on Apweiler et al. (1999), and the mAb glycan entity in this study. These data were 
then used to calculate the respective stoichiometric coefficients (mmol per gram of dry cell weight, 
mmol/gDCW) that were incorporated in the biomass equation and used in the FBA analysis. 
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Chapter 4
How does mild hypothermia affect 
recombinant monoclonal antibody 
glycosylation in stable transfectants? 
As illustrated in Chapter 2, the glycan compositions and their distribution on the recombinant 
monoclonal antibodies (mAbs) are directly impacted by the bioprocess conditions during mammalian 
cell culture. To understand further the mechanism behind this change, it is necessary to investigate 
and identify any relevant changes in cell metabolism among different bioprocess conditions. This 
chapter will examine the effect of mild hypothermia during cell culture on mAb N-linked 
glycosylation, using the experimental framework that was outlined in Chapter 3. “Permission is 
granted from Wiley Periodicals, Inc. to use the all materials from the granted publication in this 
Chapter” 
4.1. Background and aims 
In order to keep up with the increasing demand of monoclonal antibodies in the 
pharmaceutical market, one has to increase the specific productivity of recombinant protein (qprod) via 
optimisation of industrial bioprocesses is necessary. To address this issue, biphasic culture methods 
based on temperature shift are often used as an approach to increase recombinant protein (rProtein) 
yield. It was reported by Nam et al. (2008) that a temperature shift from 37C to 33C in suspension 
Chinese Hamster ovary (CHO) cell culture increased the specific productivity of recombinant secreted 
human placental alkaline phosphate (SEAP) by 8-fold. In response to the cold-shock, CHO cells 
experienced reduction in the rate of nutrient consumption and production of biological waste (Chuppa 
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et al. 1997). It  was also reported that CHO cell population was partially arrested in G0/G1 phase of 
cell cycle upon the induction of mild hypothermia (Marchant et al. 2008), together with reduced rate 
of decay in transcriptional species and changes in protein translation, folding and trafficking 
efficiencies (Cain et al. 2013). As a result with the improvement in rProtein yield, mild hypothermic 
conditions (30C - 34C) are frequently employed in industrial practices (Wulhfard et al. 2008).  
Despite the positive outcomes of mild hypothermia in rProtein production, few investigations 
have been made into its effects on protein glycosylation, and in the case of an IgG, the N-linked 
glycan pattern on the Fc-domain. As discussed in Chapter 2, the carbohydrate moieties on the mAb 
Fc-regions determine the binding affinity of mAbs to their respective Fc receptors and subsequent 
ability to activate downstream immune responses. The final composition of these sugars is susceptible 
to changes, and is dependent on the expression levels and the activities of glycosyltransferases, as 
well as the availability of nucleotide sugar donors (NSDs) within a cell, which are in turn affected by 
different nutrient feedings and cell metabolism.  Changes along the cell metabolic pathway in 
response to temperature shift can therefore impact mAb glycosylation.  
To ensure the efficacy of a target drug, one must control the consistency in mAb quality and 
this can be fulfilled through thorough understanding of the relationship between cell metabolism, 
mAb synthesis and Fc-glycosylation in sub-physiological temperatures. In this chapter, we examined 
the impact of mild hypothermia on an IgG-expressing cell line and compared the culture performance 
at different temperatures with respect to cell growth, metabolic profiles including nutrients, biological 
wastes, amino acids and NSDs, mAb synthesis such as heavy and light chain mRNA and assembly 
intermediates, mAb glycan profiles and glycosyltransferase expression levels. To better understand 
and generate a bigger picture of the intracellular metabolic network, we performed flux balance 
analysis (FBA) based on the data sets from both temperatures and calculated the differences in 
metabolic flux changes upon the induction of mild hypothermia.  
4.2. Results 
4.2.1. CHO cell culture behaviour and mAb production profile during 
mild hypothermia 
To investigate the impact of mild hypothermia, two sets of experiments were carried out: 14-
day CHO cell fed-batch culture at 36.5C, or with a temperature shift from 36.5C to 32C on day 6 
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(late exponential phase). Day 6 is chosen as the temperature shift day because it is the time period 
between cells leaving exponential growth phase and entering into stationary phase; the introduction of 
mild hypothermia to cells at that period ensures sufficiently high cell density for recombinant protein 
production, at the same time compromising for the decrease in cell concentration that mild 
hypothermic condition induces. Figure 16 A and Figure 16 B show the growth profiles of CHO cell 
cultures and the volumetric and specific mAb productivities at both temperatures. When compared to 
culture at 36.5C, cells that are temperature-shifted to 32C maintain a high viability of 98.2% on 
harvest day, with only a 10.0% reduction in their IVCC. Reduction in viable cell concentration 
observed at 32C is most likely a result of lower rate of cell growth. The prolonged cell viability and 
slower rate of cell growth observed could be explained by the work of Marchant et al. (2008), in 
which the group demonstrated cells undergo a partial cell cycle arrest in mild hypothermic conditions 
and cell division was delayed.  
 
 
Figure 16. Cell growth, volumetric titre and specific productivity (qmAb) of secreted IgG at 36.5C and with a 
temperature shift to 32C. Viable cell concentration and cell viability profiles were measured along the period of cell 
culture (A), together with the qmAb  which was calculated based on terminal secreted product and accumulated mAb 
concentration profile of both temperatures (B). (C). Dynamic qmAb profile after the induction of mild hypothermic 
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condition. Results are average measurements at 36.5C (n=6) and 32C (n=3). The error bars represent the standard 
deviation of the samples. TS: Temperature shift. 
Along with increased cell viability, a 25% rise in the specific mAb productivity (qmAb) is 
observed in 32C cultures. Figure 16 C shows the dynamic profile of qmAb upon the induction of mild 
hypothermia. Our analysis here clearly shows that the rate of mAb synthesis per cell is enhanced at 
32C. To better elucidate the reason for the increase in qmAb at lower temperature, intracellular species 
produced in the mAb synthesis process were experimentally quantified. The results show that the HC 
mRNA expression level is higher at 32C (Figure 17 A and Figure 17 B), and the overall net 
concentrations of H2 and H2L mAb assembly intermediates increase by at least 2-fold upon 
temperature shift (Figure 17 C and Figure 17 D), these together contribute to the 25% rise in secreted 
mAb production. In both mRNA and polypeptide concentrations, our results also suggest the HC to be 
the rate-determining species for mAb synthesis, with the increase in HC mRNA transcripts at 32C 
being advantageous for overall mAb production. This is in good agreement with the findings of 
O'Callaghan et al. (2010), which concluded that qmAb was controlled mostly by the rate of HC 
translation. In addition, a lower culture temperature is shown to stabilise both HC and LC mRNA, 
with 14% and 22% reductions in HC and LC mRNA decay rates (Table 9), respectively. Our findings 
correlate with that in Oliveira and McCarthy (1995)., which demonstrated the relationship between 
mRNA degradation  and attenuation in protein translation. Despite increased net difference in H2L 
between the two temperatures, the fact that comparable LC mRNA concentrations and rapid decrease 
of H2L level on day 12 were observed in this study suggests that the rate of light chain addition is 
slower at 32C, thus resulting in the accumulation of intracellular H2L species and limiting further 
increase in mAb productivity.  
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Figure 17. Concentration profiles of heavy (A) and light chain (B) mRNA and H2 (C), H2L (D) intracellular assembly 
intermediates of IgG molecules at 36.5C and 32C TS. Results were average measurements at 36.5C (n=6) and 32C 
TS (n=3). The error bars represent the standard deviation of the samples. TS: Temperature shift. 
 
Table 9. Overview of heavy and light chain mRNA stability at 36.5C and with temperature shifted to 32C on day 6.  
 
 
4.2.2. The impact of mild hypothermia on NSD synthesis and mAb 
glycosylation 
To evaluate product quality, the final secreted mAb Fc-glycan profile was analyzed on days 8, 
10, 12 and 14 for both temperatures using the LabChip method described in Chaper 3. With respect to 
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time, the terminal glycan structures observed in harvest products are comparable to those on days 8, 
10 and 12. With mild hypothermia, alongside the increase in mAb protein titre, we observe a 
significant increase in the proportion of IgG molecules with underprocessed glycan structures, with 
approximately 3% and 17% increase in G0 and G0F, respectively and  15% and 3% reduction in G1F 
and G2F, respectively on day 12 (Figure 18 A).   
At cellular level, the rate of mAb galactosylation is determined. In good agreement with the 
phenotypic quality of the secreted mAb, Figure 18 B suggests that the rate of mAb galactosylation per 
cell per day is significantly lower at 32C, with an average of 35% reduction in the addition rate of 
galactose residues on each assembled mAb molecule.   
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Figure 18. Glycan profile of the secreted IgG. (A). Fractions of 6 glycan structures: Man5, G0, G0F, G1F, G2 and 
G2F on the secreted IgG products were determined. (B). Rate of mAb galactosylation. Results were average 
measurements at 36.5C (n=6) and 32C (n=3). The error bars represent the standard deviation of the samples. 
Statistical significance was calculated using a Student’s t-test and was represented by: p0.05(*), p0.01(**) and 
p0.001(***). TS: Temperature shift. 
Murrell et al. (2004) demonstrated the complexity of the intracellular NSD synthetic pathway, 
where the type of sugar source (glucose, galactose, mannose etc.) and the uptake rate affected the 
production of nucleotide sugars (Figure 4, Chapter 2), building components for protein glycosylation. 
The availability of glutamine in the system is also critical for nucleotide synthesis. Quantification of 
the intracellular NSD concentrations is therefore necessary to understand the relationship between 
CHO cell metabolism and product glycosylation. UDP-Glc is essential in the initiation of N-linked 
glycosylation due to its role in the generation of the dolichol-linked precursor oligosaccharide 
(GlcNAc2Man9Glc3) in the ER lumen. The intracellular concentration of UDP-Glc remains similar at 
exponential phase. However, due in part to reduced consumption of glucose during mild hypothermia, 
the amounts of UDP-Glc, UDP-Gal and UDP-GlcNAc (essential for glycan branching and elongation) 
within the cells largely decrease upon temperature shift (Figures 19 A-C). The sudden increase in 
UDP-Gal on day 14 however, could have resulted from the conversion of UDP-Glc, which exhibits a 
concomitant decrease.  Despite the useful analysis described above, fluctuating levels of UDP-Gal and 
substantial number of non-detected data points in Figure 19 C reduces the confidence of the data. It is 
therefore not appropriate to rely solely on the data in Figure 19 and an alternative analysis of cell 
metabolic distribution by flux balance analysis is examined later in this chapter. 
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Figure 19. NSD profiles of the secreted IgG. Concentrations of UDP-Glc (A), UDP-GlcNAc (B) and UDP-Gal (C) 
were measured experimentally. Results were average measurements at 36.5C (n=6) and 32C (n=3). The error bars 
represent the standard deviation of the samples. Any values that are under detection limit of the HPLC method 
decribed in Chapter 3 are regarded as 0.0. Statistical significance was calculated using a Student’s t-test and was 
represented by: p0.05(*), p0.01(**) and p0.001(***). TS: Temperature shift. 
4.2.3. Impact of mild hypothermia on expression of genes related to N-
glycosylation 
From the glycan analysis we observe a decrease in the galactosylated glycan structures in the 
secreted mAb produced at 32C. In addition to cell metabolic adjustments induced by mild 
hypothermia, which affects the availability of key NSDs for glycoform formation, the expression of 
the glycosyltransferases that perform the glycan processing can also be a contributing factor to glycan 
alternation.  A number of studies have reported changes in the host cell proteome upon sub-
physiological temperature culturing (Underhill and Smales (2007); Baik et al. (2006); Dietmair et al. 
(2012)), including changes to ER chaperone levels, metabolism, and transport. It is therefore 
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worthwhile to examine the effect of mild hypothermia on the expression of proteins involved in N-
linked glycosylation. In this chapter we investigated the mRNA expression levels of 6 NSD 
glycosyltransferase enzymes, namely 2 N-acetylglucosaminyltransferases (GnTI and GnTII), which 
are involved in glycan branching, 3 galactosyltransferases (-GalTI, II and III) and fucosyltransferase 
(FucT). In addition, we examined the mRNA expression levels of 2 transporters for UDP-Gal and 
UDP-GlcNAc, which are responsible for exchange of their respective NSDs between the Golgi 
apparatus and the cell cytosol. Figure 20 describes the transcript expression profiles at both 
temperatures. The glycosyltransferases GnTII, -GalTI, -GalTIII, and FucT show significantly lower 
mRNA expression levels at 32C. Significant decreases in the transcript level of GnTII at 32C shows 
that under stable gene expression, formation of bi-antennary glycan structures could be limited by the 
reduced culture temperature. On the other hand, GnTI, -GalTII and the two transporters examined do 
not show major variation in their expression levels, apart from a drop in mRNA level of UDP-
GlcNAc transporter at day 14 of the cultures subjected to mild hypothermia.  
 
Figure 20. Expression profile of the enzymes involved in N-linked glycosylation. Results were average measurements 
at 36.5C (n=6) and 32C (n=3). The error bars represent the standard deviation of the samples. Statistical 
significance was calculated using a Student’s t-test and was represented by: p0.05(*), p0.01(**) and 
p0.001(***).TS: Temperature shift. 
Within all three GalT enzymes examined in this chapter, GalTIII appears to be most affected 
by mild hypothermia. As a result, protein expression of GalTIII was further examined. Our results 
show that the downregulation of the -GalTIII gene expression observed at 32C is further supported 
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by the reduction in -1,4-GalT-III protein expression in cells cultured in mild hypothermic condition 
(Figure 21).  The increase in -GalTIII protein on day 14 could be in response to the rise in UDP-Gal 
within the cells (Figure 19 C). Despite observing decreases in the protein expression of GalTIII, in 
this case we cannot be absolutely certain that it is entirely GalTIII that catalyses the addition of 
galactose residues and the expression levels of GalTI and GalTII should also be included in future 
experiments.  
 
Figure 21. The relative difference in galactosyltransferase III (-GalTIII) protein expression. Results were average 
measurements at 36.5C (n=6) and 32C (n=3). The error bars represent the standard deviation of the samples. 
Statistical significance was calculated using a Student’s t-test and was represented by: p0.05(*), p0.01(**) and 
p0.001(***).TS: Temperature shift. 
4.2.4. The impact of mild hypothermia on CHO cell metabolism 
through FBA and experimental studies 
Prompted by the reduction in NSD availability observed at 32C and the low reliability of the 
experimentally determined UDP-Gal data, FBA was applied to understand how lower culture 
temperature impacted CHO cell metabolism. Prior to performing the FBA, the consumption and 
production rates of each exometabolite were calculated with the rate calculation code of 
Kyriakopoulos (2014). Table 10 shows the calculated production and consumption rates of each 
exometabolite during the exponential and stationary phase at both temperatures. The overall amino 
acid and glucose exchanges from the extracellular environment are higher at exponential than at 
stationary phase. By comparing the two temperatures at stationary phase, we can see reductions in the 
consumption rates of most metabolites at 32C, including amino acids isoleucine, leucine and valine 
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in which approximately 50% reduction in their consumption rates are observed.  Also, a shift from 
lactate production to consumption is suggested, which correlates well with experimental data. The rate 
of IgG production is also higher at 32C. In addition, the increase consumption rate of ammonia at 
32C corresponds well to the increase production of glutamine. The FBA was then constrained with 
the rates of exometabolites, maximum qmab and growth rate () during exponential (days 3-6) growth 
and maximum qmab and exometabolite uptake/production rates only at late exponential/stationary 
phase (days 7-10).  
Table 10. Average specific metabolic production and consumption rates for 36.5C and with temperature shifted to 
32C on day 6. Average rates were calculated from n=6 and n=3 at 36.5C and with temperature shift, respectively. 
 
Results from the FBA (Figure 22) show that during exponential growth, the flux of glucose 
entering the TCA cycle through glycolysis is less than that during stationary phase, when there is 
VALUE STDEV VALUE STDEV VALUE STDEV 32°C vs 36.5°C
Ala 196.2 12.2 110.7 28.8 15.1 3.1 -86.3
Amm -8.5 9.9 -1.7 10.2 -60.3 1.4 3549.8
Arg -38.9 5.1 -13.3 5.5 -20.9 2.4 57.1
Asn -175.9 10.2 -50.0 3.5 -72.6 4.1 45.1
Asp -186.8 18.1 -158.3 12.0 -122.9 6.8 -22.3
Glc -696.0 245.4 -545.1 83.8 -268.9 49.0 -50.7
Gln 17.5 5.6 43.3 5.1 149.0 1.4 244.2
Glu -33.5 3.7 -21.4 3.3 -11.8 1.8 -44.8
Gly 29.8 7.5 27.8 8.1 22.5 0.8 -19.1
His -14.3 3.0 -4.2 3.9 -5.4 2.2 28.9
Ile -53.9 8.1 -33.7 8.1 -13.3 5.4 -60.6
Lac 82.2 76.5 -109.8 61.8 -321.6 7.9 192.9
Leu -117.9 14.8 -75.6 15.1 -33.0 6.3 -56.3
Lys -59.6 8.7 -20.9 9.9 -36.4 5.3 74.0
Met -15.9 2.3 -5.8 2.5 -4.9 2.0 -15.9
Phe -26.1 3.6 -10.2 3.8 -8.4 2.2 -17.4
Pro -43.5 4.6 -17.9 6.1 -21.3 4.1 18.5
Ser -162.2 14.8 -58.4 13.9 -63.4 5.7 8.5
Thr -42.5 6.1 -18.0 7.3 -11.1 4.0 -38.4
Trp -9.2 2.0 -3.7 2.3 -2.6 2.0 -28.8
Tyr -34.0 3.8 -12.4 3.3 -8.3 2.1 -33.5
Val -74.6 9.1 -44.1 10.3 -26.5 4.9 -39.9
IgG 15.5 0.7 7.7 1.7 12.8 1.0 67.0
μ 0.3 0.0 0.02 0.0 0.0 0.0 -100.0
% difference
1Exponential phase: day 3-6. 2Stationary phase: day 7-10. 3TS: Temperature shift.
Negative value: consumption. Positive value: production.
Red: % increase in species at 32C. Black: % decrease in species at 32C.
36.5C
Specific growth rate (day-1)
36.5C 32C (TS3)
Stationary phase2Exponential phase1 
Consumption/production rate (femtomol/cell/day)
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increased storage of carbon as glycogen.  There are also higher fluxes from the TCA cycle into 
biomass, IgG, amino acid and energy generation to sustain exponential cell growth. At 36.5C, the 
flux of glucose from glycolysis to the TCA cycle during stationary phase increases and the TCA cycle 
is more efficient, with reduced flow of species toward biomass/IgG production. However upon mild 
hypothermia, lactate becomes the main fuel for the TCA cycle, with no carbon loss to glycogen 
production. This metabolic shift from glucose to lactate is supported by the dramatic drop in 
extracellular lactate concentration observed experimentally (Figure 23 B).  
While most of the product generated from glycolysis is consumed within the TCA cycle at 
36.5C, at 32C less energy is spent on the TCA cycle and the consumption of glutamate is higher 
(Figure 23 D). Glutamate fluxes towards glutamine and aspartate syntheses increases with mild 
hypothermia, which contributed to the increase in IgG production. Moreover, the conversion rate from 
glucose-6-phosphate into ribulose-5-phosphate (R5P) and NADPH is 21 times lower at 32C. This 
contributes to reduced synthetic rates of nucleotide, NSD and lipids. Table 11 illustrates the lower 
fluxes of carbon and energy sources entering all the three synthetic pathways at 32C, accompanied 
by increased production of glutamine and a high exchange rate of glutamine from the cell cytosol to 
the extracellular environment. In addition, the synthesis of UDP-N-acetylhexosamine (UDP-GlcNAc, 
UDP-GalNAc) requires glutamine and a reduced flux of glutamine into nucleotide/NSD synthesis is 
suggested by the FBA, which can explain the decrease in UDP-GlcNAc concentration measured 
experimentally. 
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Figure 22. Central carbon metabolism of CHO cells at exponential growth (days 3-6), stationary phase (days 7-10) at 
36.5C and stationary phase coupled with mild hypothermia. Thickness of an arrow indicates the relative flux within 
the system. This is simplified to include carbon lost to glycerol, glycogen and lactate production, together with 
nucleotide, NSD, lipid and key amino acid synthesis.  
 
 
 
Table 11. FBA estimated flux values in nucleotide synthesis, lipid synthesis and protein glycosylation during 
stationary phase at 36.5C and 32C. 
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On the other hand through experiments, CHO cells were shown to be metabolically less active 
when the temperature was lowered to 32C at late exponential phase. Glucose is the main carbon 
source in the cultures and at 32C we observe a reduction in glucose consumption, reflected by the 
higher extracellular glucose concentration in Figure 23 A. This coincides with the estimation from the 
FBA where less glucose enters into glycolysis. On the other hand, an increase in extracellular 
ammonia concentration is measured upon temperature shift (days 6 - 10), but this levels out at 36.5C 
on day 10, when most ammonia is consumed to generate glutamine (Figure 23 C). 
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Figure 23. An overview of extracellular metabolite concentrations. Concentration profiles of extracellular glucose 
(A), lactate (B), ammonia (C) and glutamate consumption profile (D) when CHO cells were culture at 36.5C or 
under mild hypothermia at 32C introduced on day 6. Results were average measurements at 36.5C (n=6) and 32C 
(n=3). The error bars represent the standard deviation of the samples. TS: Temperature shift. 
4.3. Discussion 
The adaptation that CHO cells undergo in response to mild hypothermia leads to significant 
changes in the productivity and the glycoform composition of the mAb. The prolonged cell viability 
observed in this study could be explained by the work of Marchant et al. (2008), which demonstrated 
that cells experienced a partial cell cycle arrest upon mild hypothermia. As a result, more energy is 
generated within the TCA cycle to sustain other intracellular activities, such as mAb protein synthesis 
and trafficking which promoted recombinant mAb production.  
As one would expect at exponential growth, higher proportions of energy and amino acids are 
consumed for biomass formation, while reduced energy utilization for cell growth is observed at 
stationary phase. During mild hypothermia, there is an increased net flux of amino acids into IgG 
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protein synthesis, which is illustrated by a 25% rise in the rate of mAb production. As a result of 
slower cell metabolism, more energy becomes available to be channelled towards protein production, 
which could have consequently led to reduced availability for protein glycosylation.  
In addition, the reduced consumption of glucose that is experimentally observed is mirrored 
by a lower influx of extracellular glucose into glycolysis as shown by the FBA, where a metabolic 
shift to lactate consumption is triggered by the reduced production of NADH. This is to maintain the 
TCA cycle efficiency during stationary phase. However, the synthesis of nucleotides and nucleotide 
sugars relies on the availability of glucose and glycolysis species namely glucose-6-phosphate and 
fructose-6-phosphate, together with R5P generated from the pentose-phosphate pathway, which is 
fuelled from glycolysis. The reduced metabolic rates in these suggested pathways results in lower 
synthetic rates of the glycosylation substrates. Moreover, the transcript levels of GnTII, -GalTs and 
FucT are shown to be lower under mild hypothermia, accompanied by reduced -GalT protein 
expression.  Therefore, a decrease in NSD synthesis, particularly UDP-Gal, together with lower 
glycosyltransferase expression levels limits the production of glycan profiles requiring terminal 
galactosylation. Given that some previous studies observed no significant effect of mild hypothermia 
on product glycosylation (Ahn et al. (2008); Bollati-Fogolin et al. (2005); Yoon et al. (2003)), we 
conclude that the effect of mild hypothermia could be product and/or cell line, as well as bioprocess 
condition specific. Barb and Prestegard (2011) suggested that lower temperature impacts Fc-N-glycan 
mobility; this in turn could affect the accessibility of the glycan chain to glycosyltransferases. 
However, further investigation would be necessary to verify this. 
In addition, lipid synthesis relies on availability of G6P, AcCoA and various amino acids. The 
decrease in lipid synthesis calculated by the FBA is in good agreement with findings from Ahn and 
Antoniewicz (2012), where higher producing cell lines synthesize fewer lipids.  The lower availability 
of lipids could affect the generation of cell membrane and transport vesicles, which are important for 
the Golgi apparatus structure and the embedment of NSD transporters and glycosyltransferases on the 
Golgi membrane to initiate functions.  
By combining experimental data with the FBA approach, we can begin to understand the link 
between the increase in mAb synthesis, the deceleration in cell metabolism and reduced maturation of 
mAb glycan structures during mild hypothermia. Figure 24 provides a summary of how mAb 
glycosylation can be influenced in biphasic culture temperature. The decrease in cell metabolism 
reduces NSD synthesis, which along with lower glycosyltransferase expression (-GalT in particular) 
directly impacts the process of protein glycosylation. Under mild hypothermia, a higher proportion of 
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energy and amino acid consumption is used for product formation rather than NSD synthesis. By 
exploring this relationship, it may be possible to predict changes in glycan structure based on the 
effects of different bioprocess conditions on cell metabolism, as well as develop improved feeding 
strategies and cell line engineering to target specific glycan patterns. 
 
 
Figure 24. A summary of the impact of mild hypothermia on mAb glycosylation. 
 
4.4. Concluding remarks 
By exploring the impact of mild hypothermia on mAb Fc-glycosylation through cell 
metabolism in this chapter, we observed a counter-balance between mAb production and 
glycosylation. Mild hypothermic conditions that are introduced at late exponential/early stationary 
phase resulted in increase in recombinant IgG production, but lower rates of cell metabolism. The 
product quality, however, is influenced by culture temperature, with a higher fraction of the under-
processed glycan structures and a reduced number of terminal galactosylation species found in the 
secreted IgG produced at 32C. The relationship between lower cell metabolic rates, an increased IgG 
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titre and the variation in product glycosylation is better established through the use of the FBA.  
Calculated fluxomes revealed an overall lower cell metabolism at 32C during stationary phase, 
together with decreased fluxes of carbon, energy and glutamine into nucleotide, NSD and lipid 
syntheses. More energy and metabolites are estimated to contribute to a higher mAb productivity 
(Yoon et al. 2006), which further limits the amount of  resources available for mAb glycosylation. 
Furthermore, expression levels of key enzymes for N-linked glycan branching and elongation are 
downregulated, this contributes to the generation of under-processed glycan structures such as G0 and 
G0F and restricts the addition of terminal galactoses in the secreted product, lowering the efficacy of 
the IgG molecule. This chapter allows better understanding of the behaviour of CHO cells in mild 
hypothermic conditions and demonstrated its impact on mAb Fc-glycosylation. The knowledge and 
findings obtained from this chapter prepare a platform for investigations in later chapters, where a 
mechanistic approach is used to nail down the fundamental understanding of the effect of mild 
hypothermia on CHO cells.  
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Chapter 5
Computational analysis of mAb 
glycosylation in response to mild 
hypothermia in stable CHO 
transfectants 
In addition to experimental and flux balance analyses, a defined mathematical model that 
mechanistically and quantitatively describes CHO cell behaviour and metabolism, mAb synthesis and 
its N-linked glycosylation profiles before and after the induction of mild hypothermia was 
constructed. The use of mathematical modelling aims to aid understanding of the way bioprocess 
conditions affect product quality, estimate biological rates that would be difficult to determine 
experimentally, and estimate acceptable ranges of process parameters, which will be beneficial for 
bioprocess design, control and optimisation.  
The proposed model consists of four modules that describe CHO cell growth with nutrient 
metabolism, mAb synthesis, nucleotide sugar donor (NSD) metabolism and mAb Fc glycosylation. 
Each module is a separate model and they are linked together via common parameters and variables to 
form a final complex entity that describes mAb Fc N-linked glycoforms. Figure 25 shows each 
component and its interactions within the complex model, as well as lists of model outputs that link 
one module to another. In brief, the model commences with the description of CHO cell growth, 
extracellular nutrient metabolism and mAb synthesis. Parameters estimated for this module  are fed 
into the nucleotide and NSD model (Figure 25), adapted from Jimenez del Val (2013), which 
describes the NSD synthetic network based on the nutrient (e.g. glucose and glutamine) input from the 
cell dynamics module. Lastly the outputs from the NSD model listed in Figure 25, are integrated into 
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the glycan model developed by Jimenez del Val et al. (2011) and to describe N-linked Fc glycan 
patterns on mAb. This chapter describes the development of the modular model and compared the 
model outputs between the physiological and mild hypothermia temperatures. 
 
Figure 25. The modularity of the developed mathematical model and the interactions of each individual component 
within the overall model. Common model parameters that are fed from one module to another are also indicated. 
5.1. Cell culture dynamics model 
 The cell culture dynamics model is modified from previous work on antibody-
producing hybridoma cell culture (Kontoravdi et al. 2010a). The first unstructured part describing fed-
batch cell culture is constructed based on Monod kinetics; it describes cell growth and death based on 
the extracellular concentrations of glucose and amino acids, together with metabolic waste such as 
ammonia and lactate. The process of mAb synthesis, starting from mRNA transcription, polypeptide 
translation to mAb secretion, is illustrated in the structured part of the model and this synthetic 
process is described based on the HC2-LC-LC assembly method. 
5.1.1. Cell growth and death 
This part of the model comprises of material balances that describe the viable and total cell 
populations inside a bioreactor. Glucose, lactate and certain amino acids, namely asparagine, 
aspartate, glutamine, glutamate, arginine, lysine and proline, are assumed to be the key nutrients that 
determine the specific cell growth rate, while ammonia are the main metabolites that determine the 
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specific cell death rate. The bioreactor is assumed to be well mixed. The volume of the cell culture is 
dependent on the inlet and outlet flow rates and can be described as: 
𝑑𝑉
𝑑𝑡
= 𝐹𝑖𝑛,𝑓𝑒𝑒𝑑 + 𝐹𝑖𝑛,𝐺𝑙𝑐 − 𝐹𝑜𝑢𝑡 …Eq. 1 
where, V indicates the total culture volume within the reactor and Fin, feed, Fin, Glc, Fout are the inlet flow 
rate of Feed C (CD EfficientFeed
TM
 C AGT
TM
), that of the glucose only feed, and the outlet flow rate 
of the bioreactor, respectively. The material balance for the viable cell population is: 
𝑑(𝑉𝑋𝑉)
𝑑𝑡
= 𝜇𝑉𝑋𝑣 − 𝜇𝑑𝑉𝑋𝑣 − 𝐹𝑜𝑢𝑡𝑋𝑣 …Eq. 2 
where, Xv is the viable cell density in the bioreactor (cell/L) and , d are the specific CHO cell 
growth and death rates (h
-1
), respectively. The material balance for the total cell population in the 
bioreactor includes: 
𝑑(𝑉𝑋𝑡)
𝑑𝑡
= 𝜇𝑉𝑋𝑣 − 𝐾𝑙𝑦𝑠𝑖𝑠 𝑉(𝑋𝑡 − 𝑋𝑣) − 𝐹𝑜𝑢𝑡𝑋𝑡 
…Eq. 3 
where, Klysis describes the specific lysis rate of CHO cells within the bioreactor, while Xt represents the 
total cell concentration (cell/L).  
Glucose, lactate and specific amino acids are regarded as the growth limiting factors, while 
metabolic wastes namely ammonia and lactate serve as the growth inhibiting factors. Owing to the 
absence of glutamine in the media and feeds, glutamine is not considered to be growth-limiting. 
Monod type kinetics is used to determine the specific growth rate () using the following equations:  
𝜇 = 𝜇𝑚𝑎𝑥𝑓𝑙𝑖𝑚 𝑓𝑖𝑛ℎ 
 …Eq. 4 
where, max is the maximum specific growth rate (h
-1
) and flim, finh are the nutrient limitation and 
product inhibition, respectively. flim, finh are defined as: 
𝑓𝑙𝑖𝑚 = (
[𝐺𝑙𝑐]
𝐾𝑔𝑙𝑐 + [𝐺𝑙𝑐]
) (
[𝐿𝑎𝑐]
𝐾𝑙𝑎𝑐 + [𝐿𝑎𝑐]
) (
[𝐴𝑠𝑛]
𝐾𝑎𝑠𝑛 + [𝐴𝑠𝑛]
) (
[𝐴𝑠𝑝]
𝐾𝑎𝑠𝑝 + [𝐴𝑠𝑝]
) 
(
[𝐺𝑙𝑢]
𝐾𝑔𝑙𝑢 + [𝐺𝑙𝑢]
) (
[𝐴𝑟𝑔]
𝐾𝐴𝑟𝑔 + [𝐴𝑟𝑔]
) (
[𝐿𝑦𝑠]
𝐾𝐿𝑦𝑠 + [𝐿𝑦𝑠]
) (
[𝑃𝑟𝑜]
𝐾𝑝𝑟𝑜 + [𝑃𝑟𝑜]
) 
…Eq. 5 
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𝑓𝑖𝑛ℎ = (
𝐾𝐼𝑎𝑚𝑚
𝐾𝐼𝑎𝑚𝑚 + [𝐴𝑚𝑚]
) (
𝐾𝐼𝑙𝑎𝑐
𝐾𝐼𝑙𝑎𝑐 + [𝐿𝑎𝑐]
) 
…Eq. 6 
where, [Glc], [Lac], [Asn], [Asp], [Glu], [Arg], [Lys], [Pro] and [Amm] represent the extracellular 
concentrations of glucose, lactate, asparagine, aspartate, glutamate, arginine, lysine, proline and 
ammonia (mM), respectively. Kglc,  Klac,  Kasn,  Kasp,  Kglu, Karg, Klys, Kpro are the Monod constants for 
growth with respect to glucose, lactate, asparagine, aspartate, glutamate, arginine, lysine and proline 
(mM), respectively, while KIamm and KIlac are the inhibition constants for ammonia and lactate (mM), 
respectively. 
Owing to the nature of CHO cells, which consume both glucose and lactate as carbon sources 
at different points of the culture period, lactate is included as both a limiting and an inhibition factor 
for growth in equation 5 and 6. In the case of cell death, ammonia is assumed to be the main 
contributing factor and the specific death rate (d) is described as the equation below: 
𝜇𝑑 =
𝜇𝑑,𝑚𝑎𝑥
1 + (
𝐾𝑑,𝑎𝑚𝑚
[𝐴𝑚𝑚]
)
  …Eq. 7 
where, d,max  is the maximum specific death rate (h
-1
), and Kd,amm is the constant for cell death by 
ammonia (mM).   
5.1.2. CHO cell metabolism 
By assuming perfect mixing, good control of pH, culture temperature and the levels of 
dissolved oxygen, gases and carbon dioxide within the bioreactor environment, nutrients, namely 
glucose, lactate and amino acids are the main carbon and nitrogen sources for cell biomass formation, 
mAb production and other cellular processes such as NSD, lipid and host protein syntheses. The 
following material balances describe concentrations of nutrients and waste products: 
For glucose: 
𝑑(𝑉[𝐺𝑙𝑐])
𝑑𝑡
= 𝑞𝑔𝑙𝑐𝑋𝑣𝑉 + 𝐹𝑖𝑛,𝑓𝑒𝑒𝑑[𝐺𝑙𝑐𝑖𝑛,𝑓𝑒𝑒𝑑] + 𝐹𝑖𝑛,𝑔𝑙𝑐[𝐺𝑙𝑐𝑖𝑛,𝑔𝑙𝑐] − 𝐹𝑜𝑢𝑡[𝐺𝑙𝑐] …Eq. 8 
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𝑞𝑔𝑙𝑐 = −
𝜇
𝑌𝑥𝑣,𝑔𝑙𝑐
− 𝑚𝑔𝑙𝑐 
…Eq. 9 
where, [Glc], [Glcin,feed] and [Glcin,glc] represent glucose concentrations in culture medium, inlet 
glucose concentration in CD EfficientFeed
TM
 C AGT
TM
  and in glucose-only feed, respectively. qglc 
indicates the specific rate of glucose consumption (mmol cell
-1
h
-1
), 𝑌𝑥𝑣,𝑔𝑙𝑐 is the yield of biomass on 
glucose (cell mmol
-1
), while mglc is the maintenance coefficient of glucose (mmol cell
-1
h
-1
) which 
conceptually represents the consumption of glucose for other metabolic activities that are not cell 
growth related.  
Despite lactate being a by-product from glucose metabolism, it is consumed by cells when 
they experience a metabolic shift from lactate production to lactate consumption, and serves as an 
additional carbon source. The lactate concentration and its specific rate of production are shown in the 
equations below: 
𝑑(𝑉[𝐿𝑎𝑐])
𝑑𝑡
= 𝑞𝑙𝑎𝑐𝑋𝑣𝑉 − 𝐹𝑜𝑢𝑡[𝐿𝑎𝑐] …Eq. 10 
𝑞𝑙𝑎𝑐 = 𝑞𝑔𝑙𝑐𝑌𝑙𝑎𝑐,𝑔𝑙𝑐 − (
𝜇
𝑌𝑥𝑣,𝑙𝑎𝑐
+ 𝑘𝑇,[𝐿𝑎𝑐 ][𝐿𝑎𝑐 ]) (
[𝐿𝑎𝑐 ]
[𝐿𝑎𝑐 ] + 𝐾𝑙𝑎𝑐
) 
…Eq. 11 
where, qlac is the specific rate of lactate consumption (mmol cell
-1
h
-1
), 𝑌𝑥𝑣,𝑙𝑎𝑐 indicates the yield of 
biomass on lactate (cell mmol
-1
), 𝑘𝑇,[𝐿𝑎𝑐]is the Michaelis-Menten constant of lactate transport into the 
cells from culture medium (h
-1
) and Klac is the Monod constant with respect to lactate.  
 In equation 11, the term (
[𝐿𝑎𝑐]
[𝐿𝑎𝑐]+𝐾𝑙𝑎𝑐
) functions as a modulator for lactate 
production/consumption upon main carbon metabolic shift to lactate during late exponential growth 
phase. When [Lac]  Klac, (
[𝐿𝑎𝑐]
[𝐿𝑎𝑐]+𝐾𝑙𝑎𝑐
) is close to 1, it encourages lactate consumption. Inversely when 
[Lac]  Klac , Klac dominates the term and the value of (
[𝐿𝑎𝑐]
[𝐿𝑎𝑐]+𝐾𝑙𝑎𝑐
) is small and thus limits lactate 
consumption. 
 In addition to glucose and lactate, amino acids play a significant role in cell maintenance, 
metabolism and protein production. Amino acid metabolism also contributes to ammonia 
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accumulation, which in turn impacts cell death. The material balances described below track the 
concentrations of various amino acids in the bioreactor throughout the culture period. Firstly, for 
asparagine: 
𝑑(𝑉[𝐴𝑠𝑛])
𝑑𝑡
= 𝑞𝑎𝑠𝑛𝑋𝑣𝑉 + 𝐹𝑖𝑛,𝑓𝑒𝑒𝑑[𝐴𝑠𝑛𝑖𝑛,𝑓𝑒𝑒𝑑] − 𝐹𝑜𝑢𝑡[𝐴𝑠𝑛] …Eq. 12 
𝑞𝑎𝑠𝑛 = −
𝜇
𝑌𝑥𝑣,𝑎𝑠𝑛
− 𝑘𝑇,[𝐴𝑠𝑛][𝐴𝑠𝑛] 
…Eq. 13 
where, [Asnin,feed] is the concentration of asparagine in CD EfficientFeed
TM
 C AGT
TM
 (mM) and qasn is 
the specific rate of asparagine consumption (mmol cell
-1
 h
-1
). 𝑌𝑥𝑣,𝑎𝑠𝑛 denotes to the yield of biomass 
on asparagine (cell mmol
-1
), while 𝑘𝑇,[𝐴𝑠𝑛] is the constant for asparagine transport into the cells from 
culture medium (h
-1
). 
Similarly for aspartate: 
𝑑(𝑉[𝐴𝑠𝑝])
𝑑𝑡
= 𝑞𝑎𝑠𝑝𝑋𝑣𝑉 + 𝐹𝑖𝑛,𝑓𝑒𝑒𝑑[𝐴𝑠𝑝𝑖𝑛,𝑓𝑒𝑒𝑑] − 𝐹𝑜𝑢𝑡[𝐴𝑠𝑝] …Eq. 14 
𝑞𝑎𝑠𝑝 = 𝑞𝑎𝑠𝑛𝑌𝑎𝑠𝑝,𝑎𝑠𝑛 −
𝜇
𝑌𝑥𝑣,𝑎𝑠𝑝
 …Eq. 15 
where, [Aspin,feed] is the concentration of aspartate in CD EfficientFeed
TM
 C AGT
TM
 (mM) and qasp is 
the specific rate of aspartate consumption (mmol cell
-1
 h
-1
). 𝑌𝑥𝑣,𝑎𝑠𝑝 and Yasp,asn denote the yield of 
biomass on asparagine (cell mmol
-1
) and the yield of aspartate from asparagine (mmol/mmol), 
respectively.  
For glutamate: 
𝑑(𝑉[𝐺𝑙𝑢])
𝑑𝑡
= 𝑞𝑔𝑙𝑢𝑋𝑣𝑉 + 𝐹𝑖𝑛,𝑓𝑒𝑒𝑑[𝐺𝑙𝑢𝑖𝑛,𝑓𝑒𝑒𝑑] − 𝐹𝑜𝑢𝑡[𝐺𝑙𝑢] …Eq. 16 
𝑞𝑔𝑙𝑢 = 𝑞𝑔𝑙𝑛𝑌𝑔𝑙𝑢,𝑔𝑙𝑛 − 𝑞𝑔𝑙𝑢𝑌𝑔𝑙𝑛,𝑔𝑙𝑢 − 𝑞𝑔𝑙𝑢𝑌𝑎𝑟𝑔,𝑔𝑙𝑢 − 𝑞𝑔𝑙𝑢𝑌𝑙𝑦𝑠,𝑔𝑙𝑢 − 𝑞𝑔𝑙𝑢𝑌𝑝𝑟𝑜,𝑔𝑙𝑢 −
𝜇
𝑌𝑥𝑣,𝑔𝑙𝑢
 …Eq. 17 
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where, [Gluin,feed] is the concentration of glutamate in CD EfficientFeed
TM
 C AGT
TM
 (mM) and qglu is 
the specific rate of aspartate consumption (mmol cell
-1
 h
-1
). Some amino acids are consumed to yield 
other molecules that are essential for cellular processes. To represent this, 𝑌𝑥𝑣,𝑔𝑙𝑢, Yglu,gln, Ygln,glu, Yarg,glu. 
Ylys,glu and Ypro,glu. are used to denote the yield of biomass on glutamate (cell mmol
-1
), and the yields of 
glutamate on glutamine, glutamine on glutamate, arginine on glutamate, lysine on glutamate and 
proline on glutamate (mmol/mmol), respectively.  
The material balance for glutamine is given as: 
𝑑(𝑉[𝐺𝑙𝑛])
𝑑𝑡
= 𝑞𝑔𝑙𝑛𝑋𝑣𝑉 − 𝐹𝑜𝑢𝑡[𝐺𝑙𝑛] …Eq. 18 
𝑞𝑔𝑙𝑛 = 𝑞𝑔𝑙𝑢𝑌𝑔𝑙𝑛,𝑔𝑙𝑢 −
𝜇
𝑌𝑥𝑣,𝑔𝑙𝑛
+ 𝑝𝑔𝑙𝑛 (
[𝐴𝑚𝑚]
[𝐴𝑚𝑚] + 𝐾𝑎𝑚𝑚,𝑔𝑙𝑛
) 
…Eq. 19 
where, qgln is the specific rate of aspartate consumption (mmol cell
-1
 h
-1
). 𝑌𝑥𝑣,𝑔𝑙𝑛 and Ygln,glu denote the 
yield of biomass on glutamine (cell mmol
-1
) and the yield of glutamine from glutamate (mmol/mmol), 
respectively. pgln is the glutamine producing coefficient of (mmol cell
-1 
h
-1
) and 𝐾𝑎𝑚𝑚,𝑔𝑙𝑛 is the 
Monod constant for ammonia production from glutamine.  
In addition, for arginine, lysine and proline we can write the following material balances: 
𝑑(𝑉[𝐴𝑟𝑔])
𝑑𝑡
= 𝑞𝑎𝑟𝑔𝑋𝑣𝑉 + 𝐹𝑖𝑛,𝑓𝑒𝑒𝑑[𝐴𝑟𝑔𝑖𝑛,𝑓𝑒𝑒𝑑] − 𝐹𝑜𝑢𝑡[𝐴𝑟𝑔] …Eq. 20 
𝑞𝑎𝑟𝑔 = 𝑞𝑔𝑙𝑢𝑌𝑎𝑟𝑔,𝑔𝑙𝑢 −
𝜇
𝑌𝑥𝑣,𝑎𝑟𝑔
 …Eq. 21 
𝑑(𝑉[𝐿𝑦𝑠])
𝑑𝑡
= 𝑞𝑙𝑦𝑠𝑋𝑣𝑉 + 𝐹𝑖𝑛,𝑓𝑒𝑒𝑑[𝐿𝑦𝑠𝑖𝑛,𝑓𝑒𝑒𝑑] − 𝐹𝑜𝑢𝑡[𝐿𝑦𝑠] 
…Eq. 22 
𝑞𝑙𝑦𝑠 = 𝑞𝑔𝑙𝑢𝑌𝑙𝑦𝑠,𝑔𝑙𝑢 −
𝜇
𝑌𝑥𝑣,𝑙𝑦𝑠
 …Eq. 23 
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𝑑(𝑉[𝑃𝑟𝑜])
𝑑𝑡
= 𝑞𝑝𝑟𝑜𝑋𝑣𝑉 + 𝐹𝑖𝑛,𝑓𝑒𝑒𝑑[𝑃𝑟𝑜𝑖𝑛,𝑓𝑒𝑒𝑑] − 𝐹𝑜𝑢𝑡[𝑃𝑟𝑜] 
…Eq. 24 
𝑞𝑝𝑟𝑜 = 𝑞𝑔𝑙𝑢𝑌𝑝𝑟𝑜,𝑔𝑙𝑢 −
𝜇
𝑌𝑥𝑣,𝑝𝑟𝑜
 …Eq. 25 
where, [Argin,feed], [Lysin,feed] and [Proin,feed] are concentrations of arginine, lysine and proline in CD 
EfficientFeed
TM
 C AGT
TM
 (mM), respectively. qarg, qlys and qpro are specific rates of arginine, lysine 
and proline consumption (mmol cell
-1
 h
-1
). While 𝑌𝑥𝑣,𝑎𝑟𝑔, 𝑌𝑥𝑣,𝑙𝑦𝑠 and 𝑌𝑥𝑣,𝑝𝑟𝑜 denote to the yield of 
biomass on arginine, lysine and proline (cell mmol
-1
).  
 These amino acids are chosen to be included in this model as they are most significant 
contributors to ammonia accumulation. Cells produce and consume ammonia to produce asparagine, 
aspartate, glutamine and glutamate in particular, within cellular metabolic pathways, as illustrated in 
Figure 26.  
 
Figure 26. Intracellular metabolic network of various amino acids and their contributions to ammonia metabolism. 
According to the network described above, the material balance of extracellular ammonia can 
be written as: 
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𝑑(𝑉[𝐴𝑚𝑚])
𝑑𝑡
= 𝑞𝑎𝑚𝑚𝑋𝑣𝑉 − 𝐹𝑜𝑢𝑡[𝐴𝑚𝑚] …Eq. 26 
𝑞𝑎𝑚𝑚 = −𝑞𝑔𝑙𝑛 − 𝑞𝑎𝑠𝑛𝑌𝑎𝑠𝑝,𝑎𝑠𝑛 − 𝑞𝑎𝑟𝑔 +
𝜇
𝑌𝑥𝑣,𝑎𝑚𝑚
 …Eq. 27 
where, qamm and 𝑌𝑥𝑣,𝑎𝑚𝑚 represent the specific rate of ammonia production (mmol cell
-1
 h
-1
) and the 
yield of viable cells on ammonia, respectively. 
5.1.3. mAb synthesis 
The third part of this model describes the mAb synthetic process. Given the first two elements 
of the model are developed in an unstructured manner, a structured model is constructed to describe 
mAb production based on the transcription and translation of heavy and light chains, as well as the 
formation of relevant assembly intermediates. It also describes the transport of mAbs from the 
endoplasmic reticulum (ER), along the Golgi apparatus to the extracellular matrix (ECM) for 
secretion. Reaction rates in this part of the work are largely based on mass action kinetics. The model 
assumes the absence of fragmented heavy and light chains, and it follows the HC2-LC-LC assembly 
pathway for mAb synthesis (Bibila and Flickinger 1991):  
2HCHCHC   
LCHCLCHC 22   
222 LCHCLCLCHC   
The material balances for heavy and light chain mRNA production within the ER are defined as: 
𝑑[𝑚𝐻𝐶]
𝑑𝑡
= 𝑁𝐻𝐶𝑆𝐻𝐶 − 𝐾𝑑𝐻𝐶[𝑚𝐻𝐶] − 𝜇[𝑚𝐻𝐶] …Eq. 1 
𝑑[𝑚𝐿𝐶]
𝑑𝑡
= 𝑁𝐿𝐶𝑆𝐿𝐶 − 𝐾𝑑𝐿𝐶[𝑚𝐿𝐶] − 𝜇[𝑚𝐿𝐶] 
…Eq. 2 
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In equation 28 and 29, mRNA production of heavy and light chains ([mHC] and [mLC], 
respectively) are defined based on the heavy and light chain DNA copy numbers NHC and NLC (gene 
copy/cell), the transcription rates of both species SHC and SLC (mRNA/gene
/
h), the rate of cell growth  
and the mRNA decay rates of both chains KdHC and KdLC (h
-1
). In addition, the free intracellular heavy 
and light chain material balances produced within the ER are defined as: 
𝑑[𝐻𝐶]
𝑑𝑡
= [𝑚𝐻𝐶]𝑇𝐻𝐶 + 𝜇[𝑚𝐻𝐶] − 𝑅𝐻𝐶  …Eq. 3 
𝑅𝐻𝐶 =
2
3
𝐾𝐴[𝐻𝐶]
2 
…Eq. 31 
𝑑[𝐿𝐶]
𝑑𝑡
= [𝑚𝐿𝐶]𝑇𝐿𝐶 + 𝜇[𝑚𝐿𝐶] − 𝑅𝐿𝐶  
…Eq. 32 
𝑅𝐿𝐶 = 2𝐾𝐴[𝐻𝐶2]
 [𝐿𝐶] + 𝐾𝐴[𝐻𝐶2𝐿]
 [𝐿𝐶] …Eq. 33 
where, [HC] and [LC] represent the polypeptide concentrations of heavy and light chains (chain/cell) 
These two species are described based on mRNA concentrations of heavy and light chains, translation 
rates THC and TLC (chain/mRNA/h), rate of cell growth, while RHC and RLC are the rates of heavy and 
light chain consumption in assembly (chain/cell/h). Based on the HC2-LC-LC mAb assembly 
sequence, RHC and RLC are defined by the polypeptide concentrations and KA, which indicates the 
assembly rate constant (molecule/cell/h).  
Similarly, the intracellular ER balances are performed on the assembly intermediates as: 
𝑑[𝐻𝐶2]
𝑑𝑡
=
1
3
𝐾𝐴[𝐻𝐶2] − 2𝐾𝐴[𝐻𝐶2][𝐿𝐶] − 𝜇[𝐻𝐶2] …Eq. 4 
𝑑[𝐻𝐶2𝐿𝐶]
𝑑𝑡
= 2𝐾𝐴[𝐻𝐶2][𝐿𝐶] − 𝐾𝐴[𝐻𝐶2𝐿𝐶][𝐿𝐶] − 𝜇[𝐻𝐶2𝐿𝐶] 
…Eq. 35 
where, [HC2], [HC2LC] are the concentrations of the assembly intermediates in the ER 
(molecule/cell).  
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Fully assembled mAb molecules pass along the ER and the Golgi apparatus as [HC2LC2]ER 
and [HC2LC2]G (molecule/cell) respectively, for post-translational modification. Their material 
balances can be defined as: 
𝑑[𝐻𝐶2𝐿𝐶2]𝐸𝑅
𝑑𝑡
= 𝐾𝐴[𝐻𝐶2𝐿][𝐿𝐶] − 𝐾𝐸𝑅[𝐻𝐶2𝐿𝐶2]𝐸𝑅 − 𝜇[𝐻𝐶2𝐿𝐶2]𝐸𝑅 …Eq. 5 
𝑑[𝐻𝐶2𝐿𝐶2]𝐺
𝑑𝑡
= 𝜀1𝐾𝐸𝑅[𝐻𝐶2𝐿𝐶2]𝐸𝑅 − 𝐾𝐺[𝐻𝐶2𝐿𝐶2]𝐺 − 𝜇[𝐻𝐶2𝐿𝐶2]𝐺 
…Eq. 37 
where, KER and KG are rate constants for ER-to-Golgi antibody transport and Golgi-to-ECM antibody 
transport (h
-1
), respectively, while 𝜀1 dictates the ER glycosylation efficiency factor (dimensionless).  
Upon successful post-translational modification, fully assembled mAb molecules are secreted 
into the ECM and expressed as [mAb] and the material balance is described as: 
𝑑[𝑚𝐴𝑏] 𝑉
𝑑𝑡
= 𝑞𝑚𝐴𝑏𝑋𝑣𝑉 − 𝐹𝑜𝑢𝑡[𝑚𝐴𝑏] …Eq. 6 
𝑞𝑚𝐴𝑏 = 𝑌𝑚𝐴𝑏, 𝜀2𝜆𝐾𝐺[𝐻𝐶2𝐿𝐶2]𝐺 …Eq. 39 
where, qmAb is the specific mAb production rate (mg/cell/h),  is the molecular weight of mAb (g/mol), 
and 2 is the Golgi glycosylation efficiency factor. YmAb, refers to the yield of mAb product under a 
given cell growth rate (mg h
-1
). 
A feeding time schedule is included in this model to represent the 10% v/v commercial CD 
EfficientFeed
TM
 C AGT
TM
 feed and glucose only feed (a full time schedule can be found in the 
Appendix II Table 1). By incorporating Xv and  in equations 28 to 39, it becomes possible to capture 
the synthetic network of mAb based on the cellular behaviours, while detailed material balances from 
mRNA transcription, to polypeptide translation and product transport enable estimations of 
parameters such as product assembly and secretion rates that would otherwise be difficult to 
determine experimentally.  
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5.2. Nucleotide and NSD metabolic model 
In order to relate extracellular conditions to intracellular NSD metabolism, the current cell 
dynamic model is limited and a new extension of the model is required. The computational outputs 
from the cell dynamic model are implemented in a NSD model, previously developed by Dr Ioscani 
Jimenez del Val, is based on simple Michaelis-Menten saturation kinetics (Jimenez del Val 2013). In 
brief, this NSD model is constructed based on the assumption that glucose and glutamine are the only 
nutrient supporting the NSD synthetic pathway. This model does not account for every reaction within 
the NSD pathway; synthetic pathways of each NSD species are lumped together in a way that only 
rate-limiting pathways are being considered, as illustrated in Figure 27. This model accounts for 9 
species within the NSD metabolic network, namely Glcint, Glnint, UDP-GlcNAc, UDP-Glc, GDP-Man, 
UDP-GalNAc, CMP-Neu5Ac, UDP-Gal, GDP-Fuc. The NSD model presented in this Chapter is 
adapted from that described above (Jimenez del Val 2013) with most of the material balances 
remaining unchanged. The following features have been added: 
 
1. A glutamine synthesis term incorporated in the intracellular gluctamine material balance to 
account for the nature of the GS-CHO cell line. 
 
2. Material balances for four nucleotides: ATP, UTP, CTP and GTP.  
 
3. Terms for NSD production from nucleotides in the rate of NSD synthesis (𝑟𝑁𝑆𝐷). 
 
4. Within each of the NSD transport term (𝐹𝑜𝑢𝑡,𝑁𝑆𝐷), and consumption terms for host cell 
glycan structures, where the previous model only accounted for NSD consumption for 
antibody product glycosylation.  
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Figure 27. Reduced NSD biosynthetic pathway (Jedrzejewski et al. 2014). Lumped reaction for each NSD 
biosynthetic reaction from glucose and glutamine is identified by different coloured arrows, where blue represents 
single UDP-GlcNAc reaction, red for single UDP-Glc reaction, yellow for UDP-Gal, green for GDP-Man, pink for 
GDP-Fuc orange for UDP-GalNAc and purple for CMP-Neu5Ac.  
 
5.2.1. Nucleotide metabolic model 
The biosynthesis of NSDs requires two components: nutrients (e.g. glucose and glutamine) 
and nucleotides. The intracellular concentrations of glucose and glutamine are defined in Equation 40 
to 43 below: 
𝑑[𝐺𝑙𝑐𝑖𝑛𝑡]
𝑑𝑡
=
𝑞𝑔𝑙𝑐
𝑉𝑐𝑒𝑙𝑙
−(𝑁𝑔𝑙𝑐,𝐴𝑇𝑃𝑟𝐴𝑇𝑃 + 𝑁𝑔𝑙𝑐,𝐺𝑇𝑃𝑟𝐺𝑇𝑃 + 𝑁𝑔𝑙𝑐,𝑈𝑇𝑃𝑟𝑈𝑇𝑃 +
𝑁𝑔𝑙𝑐,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐𝑟𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 + 𝑁𝑔𝑙𝑐,𝑈𝐷𝑃𝐺𝑙𝑐𝑟𝑈𝐷𝑃𝐺𝑙𝑐 + 𝑁𝑔𝑙𝑐,𝐺𝐷𝑃𝑀𝑎𝑛𝑟𝐺𝐷𝑃𝑀𝑎𝑛 +
𝑟𝑚𝑒𝑡,𝑔𝑙𝑐) 
…Eq. 40 
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where, [Glcint] and [Glnint] represent the intracellular concentration of glucose and glutamine, 
respectively. [Glcint] is expressed in [mM], while a conversion factor of 1e3 is included in [Glnint] as 
it is expressed in [µM]. Vcell is the average volume of the CHO cell (dm
3
). Nglc,nucleotide and Ngln,nucleotide 
indicate the concentration of intracellular glucose or glutamine required for each named nucleotide 
synthesis (mmol/mmol). Similarly Nglc,NSD and Ngln,NSD represent the consumption of intracellular 
glucose and glutamine in respective NSD production (mmol/mmol). Moreover, rmet,glc and rmet,gln 
indicate other biochemical reactions where intracellular glucose and glutamine are consumed as fglc  
and fgln.  
In order to more accurately estimate each NSD concentration within a cell, it is helpful to 
consider the dynamics of ATP, UTP, GTP and CTP concentrations in the NSD model. Material 
balances for ATP, UTP, GTP and CTP are defined by the production and consumption of these four 
species during NSD production only, but not accounting for other species within the nucleotide 
synthetic pathways, such as nucleoside mono- or di-phosphates, or other amino acids. Equations 44 to 
47 described below show the material balances for intracellular nucleotides: 
𝑑[𝐺𝑙𝑛𝑖𝑛𝑡]
𝑑𝑡
=
𝑞𝑔𝑙𝑛
𝑉𝑐𝑒𝑙𝑙
(
𝑞𝑔𝑙𝑛,𝑠𝑦𝑛
𝑞𝑔𝑙𝑛
− 1) − (𝑁𝑔𝑙𝑛,𝐴𝑇𝑃𝑟𝐴𝑇𝑃 + 𝑁𝑔𝑙𝑛,𝐶𝑇𝑃𝑟𝐶𝑇𝑃 +
𝑁𝑔𝑙𝑛,𝐺𝑇𝑃𝑟𝐺𝑇𝑃 + 𝑁𝑔𝑙𝑛,𝑈𝑇𝑃𝑟𝑈𝑇𝑃 + 𝑁𝑔𝑙𝑛,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐𝑟𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 +
𝑁𝑔𝑙𝑐,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐𝑟𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 + 𝑟𝑚𝑒𝑡,𝑔𝑙𝑛) 
…Eq. 41 
𝑟𝑚𝑒𝑡,𝑔𝑙𝑐 = 𝑞𝑔𝑙𝑐
𝑓𝑔𝑙𝑐
𝑉𝑐𝑒𝑙𝑙
 …Eq. 42 
𝑟𝑚𝑒𝑡,𝑔𝑙𝑛 = 𝑞𝑔𝑙𝑛
𝑓𝑔𝑙𝑛
𝑉𝑐𝑒𝑙𝑙
 …Eq. 43 
𝑑[𝐴𝑇𝑃]
𝑑𝑡
= 𝑟𝐴𝑇𝑃 − (𝑁𝐴𝑇𝑃,𝐶𝑇𝑃 𝑟𝐶𝑇𝑃 + 𝑁𝐴𝑇𝑃,𝐺𝑇𝑃 𝑟𝐺𝑇𝑃 + 𝑁𝐴𝑇𝑃,𝑈𝑇𝑃 𝑟𝑈𝑇𝑃) − 𝐹𝑜𝑢𝑡,𝐴𝑇𝑃 …Eq. 44 
𝑑[𝑈𝑇𝑃]
𝑑𝑡
= 𝑟𝑈𝑇𝑃 − 𝑟𝐶𝑇𝑃 − 𝑟𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 − 𝑟𝑈𝐷𝑃𝐺𝑙𝑐 − 𝐹𝑜𝑢𝑡,𝑈𝑇𝑃 
…Eq. 45 
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where, 𝑁𝐴𝑇𝑃,𝐶𝑇𝑃 , 𝑁𝐴𝑇𝑃,𝐺𝑇𝑃  and 𝑁𝐴𝑇𝑃,𝑈𝑇𝑃  (mmol/mmol) represent the number of ATP required during 
CTP, GTP and UTP synthesis, respectively. 𝑟𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒  (h
-1
) represents the overall rate of nucleotide 
synthesis and they are defined by: 
where, 𝑉𝑚𝑎𝑥,𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 is the maximum turnover rate  (
𝑚𝑚𝑜𝑙𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒
𝐿𝑐𝑒𝑙𝑙 ℎ𝑟
) and 𝐾𝑥,𝑦 is the saturation constant 
of species x with respect to species y (mM). The synthetic rates of nucleotides therefore relate the 
intracellular concentrations of glucose and glutamine, while in the case of UTP, GTP and CTP their 
productions are also dependent on ATP as an energy source. 
 
 
 
 
𝑑[𝐺𝑇𝑃]
𝑑𝑡
= 𝑟𝐺𝑇𝑃 − 𝑟𝐺𝐷𝑃𝑀𝑎𝑛 − 𝐹𝑜𝑢𝑡,𝐺𝑇𝑃 
…Eq. 46 
𝑑[𝐶𝑇𝑃]
𝑑𝑡
= 𝑟𝐶𝑇𝑃 − 𝑟𝐺𝐷𝑃𝑀𝑎𝑛 − 𝐹𝑜𝑢𝑡,𝐶𝑇𝑃 
…Eq. 47 
𝑟𝐴𝑇𝑃 = 𝑉𝑚𝑎𝑥,𝐴𝑇𝑃 (
[𝐺𝑙𝑐𝑖𝑛𝑡 ]
𝐾𝑔𝑙𝑐,𝐴𝑇𝑃 + [𝐺𝑙𝑐𝑖𝑛𝑡 ]
) (
[𝐺𝑙𝑛𝑖𝑛𝑡 ]
𝐾𝑔𝑙𝑛,𝐴𝑇𝑃 + [𝐺𝑙𝑛𝑖𝑛𝑡 ]
) …Eq. 48 
𝑟𝑈𝑇𝑃 = 𝑉𝑚𝑎𝑥,𝑈𝑇𝑃 (
[𝐺𝑙𝑐𝑖𝑛𝑡 ]
𝐾𝑈𝑇𝑃,𝑔𝑙𝑐 + [𝐺𝑙𝑐𝑖𝑛𝑡 ]
) (
[𝐺𝑙𝑛𝑖𝑛𝑡 ]
𝐾𝑈𝑇𝑃,𝑔𝑙𝑛 + [𝐺𝑙𝑛𝑖𝑛𝑡 ]
) (
[𝐴𝑇𝑃]
𝐾𝑈𝑇𝑃,𝐴𝑇𝑃 + [𝐴𝑇𝑃]
) 
…Eq. 49 
𝑟𝐺𝑇𝑃 = 𝑉𝑚𝑎𝑥,𝐺𝑇𝑃 (
[𝐺𝑙𝑐𝑖𝑛𝑡 ]
𝐾𝐺𝑇𝑃,𝑔𝑙𝑐 + [𝐺𝑙𝑐𝑖𝑛𝑡 ]
) (
[𝐺𝑙𝑛𝑖𝑛𝑡 ]
𝐾𝐺𝑇𝑃,𝑔𝑙𝑛 + [𝐺𝑙𝑛𝑖𝑛𝑡 ]
) (
[𝐴𝑇𝑃]
𝐾𝐺𝑇𝑃,𝐴𝑇𝑃 + [𝐴𝑇𝑃]
) 
…Eq. 50 
𝑟𝐶𝑇𝑃 = 𝑉𝑚𝑎𝑥,𝐶𝑇𝑃 (
[𝐺𝑙𝑛𝑖𝑛𝑡 ]
𝐾𝐶𝑇𝑃,𝑔𝑙𝑛 + [𝐺𝑙𝑛𝑖𝑛𝑡 ]
) (
[𝐴𝑇𝑃]
𝐾𝐶𝑇𝑃,𝐴𝑇𝑃 + [𝐴𝑇𝑃]
) (
[𝑈𝑇𝑃]
𝐾𝐶𝑇𝑃,𝑈𝑇𝑃 + [𝑈𝑇𝑃]
) 
…Eq. 51 
5.2NUCLEOTIDE AND NSD METABOLIC MODEL 89 
 
 
The transport rate of each nucleotide  (𝐹𝑜𝑢𝑡,𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒) is defined as: 
where, 𝐾𝑜𝑢𝑡,𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 is the consumption rate of nucleotide (h
-1
) and 𝐾𝑇𝑃,𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 denotes to the 
saturation coefficient of nucleotide transport (mM).  
5.2.2. NSD synthetic model 
With material balances for nucleotide synthesis described above, it is now possible to relate 
NSD production with both nutrients and nucleotide dynamics within the cell throughout the culture 
period. By using the same set of material balances for intracellular NSDs as described in Jimenez del 
Val (2013), we modified the 𝑟𝑁𝑆𝐷 equations and included nucleotide consumption terms for the 
production of each NSD species. The updated NSD synthetic rates are now defined in equation 53 to 
59.  
𝐹𝑜𝑢𝑡,𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 = 𝐾𝑜𝑢𝑡,𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 (
[𝑁𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒]
𝐾𝑇𝑃,𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 + [𝑁𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒]
) …Eq. 52 
𝑟𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 =
𝑉𝑚𝑎𝑥,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 (
[𝐺𝑙𝑐𝑖𝑛𝑡 ]
𝐾𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐,𝑔𝑙𝑐+[𝐺𝑙𝑐𝑖𝑛𝑡 ]
) (
[𝐺𝑙𝑛𝑖𝑛𝑡 ]
𝐾𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐,𝑔𝑙𝑛+[𝐺𝑙𝑛𝑖𝑛𝑡 ]
) (
[𝑈𝑇𝑃]
𝐾𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐,𝑈𝑇𝑃+[𝑈𝑇𝑃]
)  
…Eq. 53 
𝑟𝑈𝐷𝑃𝐺𝑙𝑐 = 𝑉𝑚𝑎𝑥,𝑈𝐷𝑃𝐺𝑙𝑐 (
[𝐺𝑙𝑐𝑖𝑛𝑡 ]
𝐾𝑈𝐷𝑃𝐺𝑙𝑐,𝑔𝑙𝑐 + [𝐺𝑙𝑐𝑖𝑛𝑡 ]
) (
[𝑈𝑇𝑃]
𝐾𝑈𝐷𝑃𝐺𝑙𝑐,𝑈𝑇𝑃 + [𝑈𝑇𝑃]
) 
…Eq. 54 
𝑟𝐺𝐷𝑃𝑀𝑎𝑛 = 𝑉𝑚𝑎𝑥,𝐺𝐷𝑃𝑀𝑎𝑛 (
[𝐺𝑙𝑐𝑖𝑛𝑡 ]
𝐾𝐺𝐷𝑃𝑀𝑎𝑛,𝑔𝑙𝑐 + [𝐺𝑙𝑐𝑖𝑛𝑡 ]
) (
[𝐺𝑇𝑃]
𝐾𝐺𝐷𝑃𝑀𝑎𝑛,𝐺𝑇𝑃 + [𝐺𝑇𝑃]
) 
…Eq. 55 
𝑟𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐 = 𝑉𝑚𝑎𝑥,𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐 (
[𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐]
𝐾𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐 + [𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐]
) 
…Eq. 56 
𝑟𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 =
(
𝑉𝑚𝑎𝑥,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 [𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐]
𝐾𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐+[𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐]
) (
[𝐶𝑇𝑃]
1+
[𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐]
𝐾𝑖,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐
) (
 [𝐺𝑙𝑛𝑖𝑛𝑡]
𝐾𝑔𝑙𝑛,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐+[𝐺𝑙𝑛𝑖𝑛𝑡]
)  
…Eq. 57 
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where, 𝑉𝑚𝑎𝑥,𝑁𝑆𝐷 is the maximum turnover rate  (
𝑚𝑚𝑜𝑙𝑁𝑆𝐷
𝐿𝑐𝑒𝑙𝑙 ℎ𝑟
) and 𝐾𝑥,𝑦 is the saturation constant of 
species x with respect to species y (mM).While all rates of NSD syntheses relate to concentrations of 
nutrients and nucleotides, 𝑟𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 and 𝑟𝐺𝐷𝑃𝐹𝑢𝑐  also account for competitive product inhibition 
constants 𝐾𝑖,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 and non-competitive inhibition constant  𝐾𝑖,𝐺𝐷𝑃𝐹𝑢𝑐, respectively (mM).  
In addition to modifying material balances that define the rates of NSD synthesis, the third 
change in the model involves the incorporation of NSD consumption for host cell protein 
glycosylation in material balances that define the rate of NSD transport into the Golgi apparatus. The 
following material balance defines the transport rates for UDP-GlcNAc, UDP-Glc, UDP-Gal, GDP-
Fuc and GDP-Man: 
Equation 60 consists of two parts: the first part contains a Michealis-Menten saturation 
kinetics term that includes a transport protein saturation constant 𝐾𝑇𝑃,𝑁𝑆𝐷 (mM), as illustrated by 
(Jimenez del Val 2013). The latter shows transport terms for NSD consumption rates for both host cell 
and antibody product glycosylation, which are functions of cell growth and specific mAb 
productivity, respectively. Based on the calculations from Harrison et al. (2002)  and Selvarasu et al. 
(2012) on the average host cell weights and biomass composition, together with the qmAb of our 
secreted IgG molecules that were experimentally determined, the total number of glycan per cell 
(𝑁𝑔𝑙𝑦𝑐,𝑐𝑒𝑙𝑙) (mmol/cell) and the number of NSD consumed per host cell N-linked glycan (𝑁𝑁𝑆𝐷,𝑔𝑙𝑦𝑐) 
(mmolNSD/mmolglycan) were calculated (Raman et al. 2006). In addition, the number of NSD consumed 
per mAb Fc-glycan 𝑁𝑁𝑆𝐷,𝑚𝐴𝑏 (mmolNSD/mmolglycan) was calculated from Fc-glycan compositions that 
were experimentally determined, while 𝑁𝑔𝑙𝑦𝑐,𝑚𝐴𝑏, which is the number of glycan per a molecule of 
product (molgly molmAbFc
-1
), is always 2 in the case of an IgG. 
𝑟𝑈𝐷𝑃𝐺𝑎𝑙 = 𝑉𝑚𝑎𝑥,𝑈𝐷𝑃𝐺𝑎𝑙 (
[𝑈𝐷𝑃𝐺𝑙𝑐]
𝐾𝑈𝐷𝑃𝐺𝑎𝑙,𝑈𝐷𝑃𝐺𝑙𝑐 + [𝑈𝐷𝑃𝐺𝑙𝑐]
) 
…Eq. 58 
𝑟𝐺𝐷𝑃𝐹𝑢𝑐 = (
𝑉𝑚𝑎𝑥,𝐺𝐷𝑃𝐹𝑢𝑐 [𝐺𝐷𝑃𝑀𝑎𝑛]
𝐾𝐺𝐷𝑃𝐹𝑢𝑐,𝐺𝐷𝑃𝑀𝑎𝑛 (1+
[𝐺𝐷𝑃𝑀𝑎𝑛]
𝐾𝐺𝐷𝑃𝐹𝑢𝑐,𝐺𝐷𝑃𝑀𝑎𝑛
+(
[𝐺𝐷𝑃𝑀𝑎𝑛]
𝐾𝐺𝐷𝑃𝐹𝑢𝑐,𝐺𝐷𝑃𝑀𝑎𝑛
  
[𝐺𝐷𝑃𝐹𝑢𝑐]
𝐾𝑖,𝐺𝐷𝑃𝐹𝑢𝑐
)+
[𝐺𝐷𝑃𝐹𝑢𝑐]
𝐾𝑖,𝐺𝐷𝑃𝐹𝑢𝑐
)
)  
…Eq. 59 
𝐹𝑜𝑢𝑡,𝑁𝑆𝐷 =
[𝑁𝑆𝐷]
𝐾𝑇𝑃,𝑁𝑆𝐷+[𝑁𝑆𝐷]
[(
𝜇
𝑉𝑐𝑒𝑙𝑙
𝑁𝑔𝑙𝑦𝑐,𝑐𝑒𝑙𝑙𝑁𝑁𝑆𝐷,𝑔𝑙𝑦𝑐) + (
𝑞𝑚𝐴𝑏
𝑉𝑐𝑒𝑙𝑙
𝑁𝑔𝑙𝑦𝑐,𝑚𝐴𝑏𝑁𝑁𝑆𝐷,𝑚𝐴𝑏
1
𝑀𝑊
)]
 
  …Eq. 60 
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In the case of UDP-GalNAc and CMP-Neu5Ac, material balances for their NSD transport 
rates are different. Since our CHO cell line does not consume UDP-GalNAc for product 
glycosylation, the consumption term for UDP-GalNAc on mAb glycan is therefore omitted and its 
rate of transport is defined as: 
The same case applies to CMP-Neu5Ac, where our product is not sialylated, therefore only 
NSD consumption for host cell proteins is being considered. In addition, owing to the competitive 
product inhibition of the CMP-Neu5Ac Golgi transporter protein by the presence of UDP-GlcNAc 
(Pels Rijcken et al. 1995), a transport inhibition term of CMP-Neu5Ac by UDP-GlcNAc 
(𝐾𝑖,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐) is included in the material balance for the rate of CMP-Neu5Ac transport 
and it is defined as: 
 By considering as well the consumption rates of NSDs on host cell protein glycans, the 
updated NSD model better describes the distribution of each NSD species towards product 
glycosylation, which eventually provides a better estimation towards mAb Fc-glycan prediction in the 
final glycosylation model.   
5.3. Golgi N-linked glycosylation model 
Estimated outputs from the NSD model are next fed into a Golgi N-linked mAb Fc-
glycosylation model that was adapted from the developed model by Jimenez del Val et al. (2011) to 
relate CHO cellular metabolism to the process of mAb glycosylation within the Golgi apparatus. 
While the model developed by Jimenez del Val et al. (2011) considers the concentration of NSD 
species within the Golgi apparatus by including the rate of transport of each NSD species into the 
Golgi apparatus, the adapted model that is used in this thesis relates the cyotosolic concentration of 
NSD species directly to the Golgi N-linked model. The adapted model is capable of estimating the 
𝐹𝑜𝑢𝑡,𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐 = (
[𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐]
𝐾𝑇𝑃,𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐 + [𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐]
) (
𝜇
𝑉𝑐𝑒𝑙𝑙
𝑁𝑔𝑙𝑦𝑐,𝑐𝑒𝑙𝑙𝑁𝑈𝐷𝑃𝐺𝑎𝑙𝑁𝐴𝑐,𝑔𝑙𝑦𝑐)
 
 
…Eq. 61 
𝐹𝑜𝑢𝑡,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 =
[𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐]
𝜇
𝑉𝑐𝑒𝑙𝑙
𝑁𝑔𝑙𝑦𝑐,𝑐𝑒𝑙𝑙𝑁𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐,𝑔𝑙𝑦𝑐 
𝐾𝑇𝑃,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐 (1 +
[𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐]
𝐾𝑇𝑃,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐
+
[𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐]
𝐾𝑖,𝐶𝑀𝑃𝑁𝑒𝑢5𝐴𝑐,𝑈𝐷𝑃𝐺𝑙𝑐𝑁𝐴𝑐
)
 …Eq. 62 
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antibody product Fc-glycoforms through describing the process of glycosylation within the Golgi 
apparatus of a cell. The model is constructed based on a Golgi cisternae maturation regime, where the 
Golgi apparatus is modelled as a single, continuous plug-flow reactor (PFR). The model assumes 
successful assembly of mAb with the endoplasmic reticulum and addition of the glycan precursor. 
The mAb molecule then travels along each compartment of the Golgi in a similar manner as flow of 
material in a PFR. The localisation of each glycosyltransferase and transport protein is optimised 
using data from Rabouille et al. (1995), and each appears in a sequential manner within the Golgi 
apparatus. Material balances for the catalytic reactions of the glycosyltransferases within this model 
are developed based on three main kinetic mechanisms:  ManI & II follow the simple Michaelis-
Menten kinetics with competitive and product inhibitions; GnTI & II and GalT also possess the 
kinetic mechanism above, but they work in a sequential Bi-Bi order; FucT on the other hand follows 
the random-order Bi-Bi kinetics with competitive and product inhibitions taken into account. The 
glycan model is a 3-dimentional model that describes Fc-glycoform maturation with respect to cell 
culture time as well as length of the Golgi apparatus.  
To better adapt this glycan model to experimental conditions in our case, some model inputs 
were modified. Specifically, the overall CHO cell volume and the glycan concentration of mAb 
entering the Golgi apparatus are re-calculated based on mAb concentration achieved in each 
condition, while the minimal concentrations of glycosyltransferases required for the assumption of 
100% processing by the model, are re-estimated. Since our adapted model includes cytosolic 
concentration of NSD species, re-estimation of saturation constants of each glycosyltransferase is 
therefore essential.  
5.4. Comparing model simulation results between 
physiological and mild hypothermic conditions 
The model described above was then simulated in gPROMS v.4.0.0 (Process Systems 
Enterprise Ltd), for two experimental conditions: SGE fed-batch culture at 36.5C or with a 
temperature shift to 32C induced on day 6 (late-exponential phase). By using the same model 
structure for both conditions, model simulation results from two parameter sets were compared across 
the two process conditions.  
5.4COMPARING MODEL SIMULATION RESULTS BETWEEN PHYSIOLOGICAL AND 
MILD HYPOTHERMIC CONDITIONS 
93 
 
 
5.4.1. CHO cell culture dynamics and mAb production estimation and 
discussion 
Both parameter sets of the model were simulated and their respective parameters were 
estimated from the experimental profiles for nutrients, metabolites, total and viable CHO cell 
concentrations and mAb synthesis including product transcripts and polypeptides. Figure 28 A and 
Figure 28 B show that simulated results from our cell dynamic model represent our fed-batch 
experimental data on viable and total cell densities well at both temperatures, correctly capturing the 
slight reduction in cell density upon temperature shift. In addition, glucose, lactate and ammonia are 
described effectively by both sets of parameter values of the model (Figures 29 A – C), including all 
feeding points, nutrient consumption rates and the metabolic shift from lactate production to 
consumption upon the induction of mild hypothermia. The model simulations for various amino acids 
are also in good agreements with our experimental concentrations, showing that the consumption of 
these amino acids is lower at reduced temperature. The model also manages to predict the increase of 
glutamine in culture medium at 32C (Figures 30 A – G).  
 
 
Figure 28. Comparison of model simulation to experimental data for viable (A) and total cell concentrations (B) from 
fed-batch CHO cell cultures at 36.5C (red) or at mild hypothermic condition post late exponential growth phase 
(blue).  
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Figure 29. Comparison of model generated fits to experimental data for extracellular glucose (A) extracellular lactate 
(B) and extracellular ammonia (C) concentrations from fed-batch CHO cell cultures at 36.5C (red) or at mild 
hypothermic condition post late exponential growth phase (blue).  
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Figure 30. Comparison of model generated fits to experimental data for extracellular asparagine (A), aspartate (B), 
arginine (C), glutamate (D), glutamine (E), lysine (F) and proline (G) concentrations from fed-batch CHO cell 
cultures at 36.5C (red) or at 32C induced at late exponential growth phase (blue).  
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 Predictions for the process of mAb product synthesis are generated from both parameter sets 
in the cell dynamic model. Figures 31 A & Figure 31 B illustrate model simulations of HC and LC 
mRNAs. For the first 150 h before temperature shift, our model over-estimates slightly on the HC 
mRNA species but provides reasonably good fits for LC mRNA. Upon the introduction of mild 
hypothermia, simulated results are over-estimated and are not being in complete agreement with each 
experimental time point, where simulated results reached plateaus instead of gradual decreases that 
our experiment results suggested. Despite the miss-fittings, our simulated results of HC and LC 
mRNAs follow the same trend and results are in the same numerical range as the experimental data. 
Assembly intermediate polypeptides H2 and H2L are described well by our models, where the 
increased net concentrations of both intermediate species under mild hypothermic conditions are well 
captured. In the case of the secreted mAb product, our model manages to provide good fits to the 
experimental results, as shown in Figure 32. The total volumetric concentration of mAb is correctly 
predicted to be higher at the reduced temperature, despite the simulated final value being slightly 
lower than the experimental results. 
 
Figure 31. Comparison of model simulation outputs to experimental data for intracellular HC mRNA (A), LC mRNA 
(B), H2 polypeptide (C) and H2L assembly intermediate (D) concentrations from fed-batch CHO cell cultures at 
36.5C (red) or at 32C induced at late exponential growth phase (blue).  
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Figure 32. Comparison of model simulation outputs to experimental data for secreted volumetric mAb concentration 
in fed-batch CHO cell cultures at 36.5C (red) or at 32C induced at late exponential growth phase (blue).  
 By using two different sets of parameter values but the same model structure for the two 
culture temperatures examined, it becomes possible to understand more on how experimental 
differences arise between the two conditions, e.g. variations in mAb production, by comparing the 
two sets of model outputs. Table 12 shows the estimated process parameters for the different culture 
temperature sets. Under mild hypothermic conditions, rate for the overall maximum cell growth is 
higher with reduced rate of maximum cell death, in order to sustain prolonged cell growth at 32C. In 
accordance with our experimental data, the estimated yield of lactate from glucose is reduced 
dramatically, which reflects the lactate metabolic shift from production to consumption at 32C. In the 
case of mAb synthesis, estimated model outputs indicate that at lower culture temperature, the mRNA 
decay rates of both HC and LC are expected to be lower; this is in good agreement with experimental 
results indicated in Chapter 4 and with the studies by O'Callaghan et al. (2010). The polypeptide 
assembly rate of mAb is estimated to be lower at 32C, which could suggest a reduced rate of 
collision between the mAb polypeptide molecules at the lower temperature. Also it correlates well 
with our experimental analysis in Chapter 4, where reduced assembly rate of mAb and an 
accumulation of H2L species were speculated. In addition, rates for HC and LC transcription, mAb 
polypeptide translate, transport of mAb from ER to Golgi and from Golgi to extracellular matrix 
(ECM), are all estimated to be higher during mild hypothermia by the model. These support the 
increased levels of mAb transcription and translation. Estimation of 1 and 2 is the first attempt to 
determine the efficiency of product glycosylation with respect to the mAb production; they represent 
the ER and Golgi glycosylation efficiency factors, respectively. At 32C, both 1 and 2 are estimated 
to be lower and these are first indications from the model that mAb glycosylation could be affected by 
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changes in culture temperature. The full list of model parameters and variables from both models can 
be found in the Appendix II Table 2. 
 
Table 12. Comparison of estimated parameters from SGE models between two temperatures. This includes 
parameter values for cell growth, metabolism and mAb production.  
Parameter 36.5 
o
C 
95% conf. 
internals 
32 
o
C (Day 6) 
95% conf. 
internals 
Units 
Growth/death related 
max 1.10 x 10
-1
 2.90 x 10
-2
 7.49 x 10
-1
 3.20 x 10
-2
 h
-1
 
d,max 9.70 x 10
-2
 1.10 x 10
-2
 3.96 x 10
-2
 2.00 x 10
-3
 h
-1
 
Klysis 4.47 x 10
-1
 1.10 x 10
-2
 2.14 x 10
-1
 5.70 x 10
-2
 h
-1
 
Metabolism related 
Ylac,glc 2.00 2.40 x 10
-1
 5.32 x 10
-3
 1.30 x 10
-3
 mmol mmol
-1
 
mAb synthesis related 
KA 1.38 x 10
-1
 5.82 x 10
-2
 1.94 x 10
-3
 1.80 x 10
-4
 molecule cell
-1
 h
-1
 
KER 4.56 x 10
2
 3.70 x 10
2
 9.03 x 10
2
 35.10 h
-1
 
KG 2.00 x 10
3
 5.73 x 10
2
 2.30 x 10
4
 1.26 x 10
2
 h
-1
 
SH 15.90 2.10 1.11 x 10
2
 7.40 mRNAs gene
-1
 h
-1
 
SL 93.10 15.00 1.58 x 10
2
 5.30 mRNAs gene
-1
 h
-1
 
TH 1.35 1.20 2.17 9.50 x 10
-2
 chain mRNA
-1
 h
-1
 
TL 3.84 x 10
-1
 1.10 x 10
-1
 5.66 x 10
-1
 2.80 x 10
-2
 chain mRNA
-1
 h
-1
 
Kh 9.77 x 10
-3
 5.90 x 10
-5
 1.68 x 10
-3
 2.30 x 10
-4
 h
-1
 
Kl 1.15 x 10
-3
 4.75 x 10
-5
 1.13 x 10
-3
 3.80 x 10
-4
 h
-1
 
mAb post-translational modification related 
2 11.10 6.70 x 10
-2
 6.14 6.00 x 10
-2
 n/a 
5.4.2. Intracellular nucleotide and NSD model estimation and 
discussion 
This part of the model describes the concentration profiles of nucleotides (ATP, UPT, GTP & 
CTP) and six NSD species, namely UDP-Glc, UDP-Gal, UDP-GlcNAc, UDP-GalNAc, GDP-Man 
and GDP-Fuc, where their productions are based on CHO cell behaviour, nutrient and amino acid 
metabolisms from each condition. To achieve this, CHO cell dynamics and NSD models are linked 
together, by feeding in model outputs from the cell dynamics module (Appendix II Table 2), into the 
NSD model. NSD model simulation was performed with gPROMS v.4.0.0. Based on the consumption 
of nutrients and metabolites of CHO cells from each culture temperature, model simulations are 
compared to experimentally measured data, while variables that corresponded to the experimental 
data were estimated from both conditions mentioned in Figure 25 and they are analysed here. 
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Figures 33 A – I present model simulation results for cell cultures at 36.5C and 32C. Nine 
species are involved in the parameter estimation. The model simulations show that when cells are 
cultured at mild hypothermic temperature, the net intracellular concentrations of nucleotides, namely 
ATP, GTP and UTP, are higher. The accumulation in intracellular ATP is related to reduced cell 
growth and cell metabolism in response to mild hypothermia, where fewer ATP molecules are 
required as energy source to maintain cellular activities. In addition, fewer ATP molecules are 
produced when glucose consumption is lower at 32C. This is supported by the reduced efficiency of 
lactate production from glucose, estimated by our cell dynamics model. In this case, both sets of 
parameter values from each condition represent the intracellular mechanisms well and model 
simulations are in good agreement with experimental data in all species investigated.  
In the case of NSD metabolism, our model captures the reduction of intracellular 
concentrations of UDP-Glc, UDP-Gal, UDP-GlcNAc, UDP-GalNAc and UDP-Fuc, which are 
determined to be lower experimentally.  Despite the good fits of model simulations to experimental 
measurements, discrepancies are observed in GDP-Fuc and GDP-Man, where the current model fails 
to predict the peak concentrations of these two species. Since the production of GDP-Fuc is dependent 
on the concentration of GDP-Man within the synthetic network, the lumped pathway that is used in 
the NSD model might not be adequate to predict species generated from this pathway. Considering 
our material balance for GDP-Man does not account of the mannose salvage pathway, one can 
therefore argue that GDP-Man is predicted to be over-consumed in our model, even though there are 
experimental reports suggesting that the mannose-salvage pathway reduces net consumption of 
mannose and its derivatives (Berg et al. 2006).  
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Figure 33. Comparison of nucleotide and NSD profiles from model simulations to experimental data in fed-batch 
CHO cell cultures at 36.5C (red) or at 32C induced at late exponential growth phase (blue). This includes the 
intracellular concentrations of ATP (A), GTP (B), UTP (C), UDP-Glc (D), UDP-Gal (E), UDP-GlcNAc (F), UDP-
GalNAc (G), GDP-Fuc (H) and GDP-Man (I).   
Values of Vmax and Km for enzymes involved in the NSD synthetic process are estimated in 
this NSD model. Table 13 shows the estimated set of parameter values when CHO cells are cultured 
at a sub-physiological temperature. At 32C, the overall value of Vmax for enzymes responsible for 
UDP-Gal synthesis is reduced and its Km value is higher, which suggest that the reduced 
concentration of UDP-Gal observed at 32C could be attributed to the lower estimated efficieny of the 
UDP-Gal-related enzyme during NSD synthesis (Table 14), and higher amounts of species required 
for reaction saturation at 32C. These results agree with literature studies in which researchers showed 
a positive correlation between Kcat and temperature (Thomas and Scopes 1998). A full list of 
parameter values for the NSD model can be found in Appendix II Table 3. 
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Table 13. Comparison of estimated parameters from NSD models between two temperatures. This includes 
parameter values for nucleotide and NSD syntheses.  
Parameter 36.5 
o
C 
95% conf. 
internals 
32 
o
C (Day 6) 
95% conf. 
internals 
Units 
Nucleotide related 
Vmax, ATP synthetic pathway 13.70 2.00 x 10
-1
 2.11 5.10 x 10
-1
 mmol Lcell
-1
 h
-1
 
Vmax, GTP synthetic pathway 44.20 1.10 2.68 x 10
3
 4.70 mmol Lcell
-1
 h
-1
 
Vmax, UTP synthetic pathway 34.90 1.10 9.26 x 10
2
 21.00 mmol Lcell
-1
 h
-1
 
NSD related 
 
KTP,UDPGlc synthetic pathway 4.11 x 10
-3
 1.90 x 10
-4
 1.00 x 10
-30
 1.00 x 10
-34
 mM 
KTP,UDPGal synthetic pathway 4.68 x 10
-2
 5.40 x 10
-3
 3.47 x 10
-4
 2.49 x 10
-5
 mM 
KTP,UDPGlcNAc synthetic pathway 1.00 x 10
-30
 1.00 x 10
-34
 9.76 4.80 x 10
-5
 mM 
KTP,GDPMan synthetic pathway 1.00 x 10
-2
 3.80 x 10
-3
 1.40 1.27 mM 
KTP,GDPFuc synthetic pathway 1.25 x 10
-1
 4.80 x 10
-3
 7.42 x 10
-2
 1.60 x 10
-1
 mM 
Vmax, UDPGlc synthetic pathway 5.00 x 10
-1
 1.25 x 10
-3
 5.84 x 10
-1
 1.70 x 10
-2
 mmol Lcell
-1
 h
-1
 
Vmax, UDPGal synthetic pathway 2.26 x 10
-3
 9.20 x 10
-4
 1.00 x 10
-30
 1.00 x 10
-34
 mmol Lcell
-1
 h
-1
 
Vmax, UDPGlcNAc synthetic pathway 2.17 9.00 x 10
-2
 7.66 1.40 x 10
-1
 mmol Lcell
-1
 h
-1
 
Vmax,GDPMan synthetic pathway 6.57 x 10
-1
 9.53 x 10
-3
 5.28 x 10
-1
 1.96 x 10
-3
 mmol Lcell
-1
 h
-1
 
Vmax,GDPFuc synthetic pathway 11.70 2.88 5.37 4.39 x 10
-2
 mmol Lcell
-1
 h
-1
 
KUDPGlc,glc synthetic pathway 6.66 x 10
2
 74.00 10.50 12.00 mM 
KUDPGal,glc synthetic pathway 4.73 x 10
-1
 9.10 x 10
-3
 4.40 x 10
2
 4.30 x 10
1
 mM 
KUDPGlcNAc,glc synthetic pathway 1.82 x 10
-1
 3.00 x 10
-3
 4.53 x 10
-1
 2.1 x 10
-2
 mM 
KGDPMan,glc synthetic pathway 1.71 x 10
2
 1.10 5.62 x 10
3
 6.50 mM 
KGDPFuc,glc synthetic pathway 8.80 x 10
2
 39.00 6.19 x 10
3
 1.90 x 10
2
 mM 
 
Table 14. Enzymatic efficiencies of NSD synthetic enzymes.  
NSD synthetic enzyme catalytic efficiency (h
-1
) 
NSD -related 
synthetic 
pathway 
36.5 
o
C 32 
o
C (Day 6) 
UDPGlc 7.51 x 10
-4
 5.56 x 10
-2
 
UDPGal 4.77 x 10
-3
 2.27 x 10
-33
 
UDPGlcNAc 11.90 16.90 
GDPMan 3.85 x 10
-3
 9.39 x 10
-3
 
GDPFuc 1.33 x 10
-2
 8.67 x 10
-4
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5.4.3. Golgi N-linked glycosylation model estimation and discussion 
Model outputs from both cell culture dynamics and the NSD model were incorporated into 
the Golgi N-linked glycosylation model developed by (Jimenez del Val et al. 2011) and the combined 
model was simulated in gPROMS version 4.0.0 for both temperatures. Without changing any part of 
the Golgi model structure, values of key parameters such as dissociation constants and minimal 
concentrations of various glycosyltransferases were re-estimated for CHO cells that were cultured at 
36.5C and with a shift to 32C, under the assumption that 100 % of mAb produced are glycosylated 
and macro-heterogeneity is not considered to be limiting in this model. 
 Figures 34 A and B show the comparison between experimental and simulated distribution of 
the cumulative N-linked mAb Fc-glycan structures on days 10, 12 and 14 for culture temperature of 
36.5C and 32C, respectively. The three chosen time points correspond to late stationary and decline 
phases, where significant changes in mAb productivity are shown to take place experimentally 
between the two culture temperatures. Simulation results from both set of parameter values of the 
model compare well with their respective experimental data and any differences in values are within 
3.5% in all cases (Table 15). Intrigued by the experimental variations in transcript expression of 
glycosyltransferases (Figure 35), Km values and the concentrations of these enzymes were re-
estimated. Our results show that both sets of process variables of the SGE model manage to capture 
changes in galactosylation in Fc region of our secreted mAb molecules between the two temperatures 
examined with sufficient accuracy, as well as the slight decreases in Man5 species.  
 
Figure 34. Comparison between experimentally and model simulated determined fractions of the cumulative N-
linked glycoforms of secreted mAb for three time points during cell culture, when CHO cells were cultured at 36.5C 
(A), or at 32C (B) when mild hypothermic condition was introduced during late exponential growth phase.  
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Table 15. Percentage differences between model-simulated and experimentally measured values of N-linked glycan 
fractions for mAb Fc-regions, for CHO cells that were cultured at 36.5C and 32C.  
 
Deviation from experimental data (%) 
  
Man5 G0 G0F G1F G2 G2F 
36.5C 
Day 10 0.53 1.07 1.58 0.19 0.09 0.07 
Day 12 0.38 0.74 2.26 2.84 0.05 0.60 
Day 14 0.13 0.64 0.88 0.01 0.03 0.34 
32C 
Day 10 0.32 0.18 0.89 0.36 0.01 0.02 
Day 12 0.11 1.34 3.16 1.48 0.02 0.24 
Day 14 0.83 1.52 1.28 1.01 0.00 0.07 
In addition, parameter estimation was performed for the dissociation constants as well as the 
enzyme concentrations of Man I & II, GnT I & II, GalT and FucT. Table 16 compares estimated 
parameter values between the two conditions. Model outputs suggest that the concentrations of 
mannosidases (Man I & II) and fucosyltransferases (FucT) are comparable in CHO cell cultured at 
either temperature, but lower levels of galactosyltransferases (GalT) are predicted in order to generate 
reduced fractions of galactose-bearing glycoforms at 32C. Despite the comparable concentrations of 
Man I and Man II suggested by the model, decreases in their respective dissociation constants are 
estimated, low Kd values suggest a higher affinity of enzyme towards their substrate and it is likely to 
contribute to an overall drop in Man5 glycan structure at 32C. Moreover, the concentration of GnT II 
is estimated to be lower from the set of parameter values at 32C. This is also accompanied by a 
significantly higher Kd value, which proposes that UDP-GlcNAc addition is affected by both the 
kinetics and enzyme concentration. This model estimation correlates well with the reduced transcript 
expression of GnTII observed experimentally in Chapter 4. Despite the well correlated model outputs 
to the experimental results, the model here estimated that a higher FucT concentration is required to 
achieved an increase in G0F profile when the culture temperature is reduced to 32°C, this contradicts 
with our experimentally measured mRNA level where a decrease in mRNA transcript level is 
observed under mild hypothermic conditions (Figure 35 A). Without validation of model output with 
measured concentrations of FucT protein expression, it is hard to conclude whether the conflicting 
results are owing to a change in enzyme concentration, or other kinetic factors such as kcat or ligand 
binding affinity in this particular case. Since enzyme concentration and Kd value are highly correlated, 
it is also possible that another set of parameter values would also generate the same model simulation. 
But most importantly in the case of GalT, at 32C, our predicted model output suggests that the 
concentration of GalT is significantly lower, while its kd values appear to be higher than the values 
estimated at 36.5C. This comparison proposes that, changes in GalT concentration also play a role in 
limiting product galactosylation, together with the reduced kcat values that one might observed at 
lower culture temperature.  
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Lastly we compared the estimated values of glycosyltransferase concentrations from both sets 
of model inputs, to those that were determined experimentally. Although our experimental results are 
not quantitative, and only relative differences between conditions are taken into account, variations of 
parameter values between the two temperatures, however, possess a similar trend to those that are 
measured through q-rt-PCR studies in Chapter 4. Figure 35 A & Figure 35 B show reduced levels of 
GalT and FucT mRNA, as well as lowered GalTIII protein expression at 32C, which correlate well 
with the estimated decrease in GalT and FucT concentrations by our glycan model. This comparison 
shows that the proposed model has high capability in representing the biological system in CHO cells, 
and generates prediction of mAb quality, and its effects in mild hypothermic conditions. This modular 
model introduces us to the possibility in closing the loop between model simulation and experimental 
system. To achieve this however, we must next validate the model against an independent set of 
experimental data to ensure the capability of the model in other data sets. 
 
Table 16. Estimated enzyme concentrations and their respective dissociation constants at both temperatures. 
 
Parameter 36.5 
o
C 
95% conf. 
internals 
32 
o
C (Day 6) 
95% conf. 
internals 
Units 
 
Glycosyltransferase concentrations 
Man I 9.70 x 10
-2
 1.31 x 10
-2
 1.24 x 10
-1
 8.50 x 10
-2
 M 
Man II 1.82 x 10
-1
 3.50 x 10
-2
 1.94 x 10
-1
 7.30 x 10
-3
 M 
GnT I 6.05 2.10 x 10
-1
 7.69 x 10
-1
 6.80 x 10
-4
 M 
GnT II 1.14 2.50 x 10
-1
 7.75 x 10
-1
 1.30 x 10
-4
 M 
GalT 12.60 1.70 6.66 4.10 x 10
-2
 M 
FucT 13.30 8.43 45.54 5.96 M 
Substrate Enzyme dissociation constants 
 
Man6 Kd,Man I D 4.44 x 10
-1
 1.60 x 10
-2
 2.67 x 10
-1
 3.10 x 10
-2
 M 
Man5 Kd,Man II A 3.45 x 10
-5
 1.84 x 10
-6
 4.44 x 10
-5
 4.71 x 10
-9
 M 
CoreGlcNAc1 Kd,GnT II 5.31 4.20 x 10
-1
 1.16 x 10
2
 13.00 M 
CoreGlcNAc2 (-
1,3 arm) 
Kd,GalT a1A 3.00 x 10
4
 1.95 x 10
3
 2.29 x 10
4
 3.15 x 10
3
 M 
CoreGlcNAc2 (-
1,6 arm) 
Kd,GalT a1B 6.26 2.73 11.60 2.54 M 
CoreGlcNAc2Gal1 
(-1,6 arm) 
Kd,GalT a2A 2.23 x 10
3
 2.67 x 10
2
 3.38 x 10
2
 4.80 x 10
2
 M 
CoreGlcNAc2 Kd,Fuc A 1.34 x 10
4
 9.34 x 10
2
 1.34 x 10
4
 3.00 x 10
2
 M 
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Figure 35. Measured expression levels of glycosyltransferases at physiological temperature or at 32C. (A). mRNA 
expression levels of GalTs and FucT. (B). GalTIII protein expression profile.  
5.5. Conclusions 
This chapter describes the modification and adaptation of a modular model that can 
successfully replicate the experimental results of CHO cell culture in terms of cell growth, cell 
metabolism, recombinant mAb production and glycosylation under two culture temperatures, 36.5C 
and with a shift to 32C on day 6. Through model parameter estimation, comparison between the two 
model outputs becomes possible, enabling us to understand to a greater extent the performance of 
intracellular mechanisms upon mild hypothermia. Comparison between estimated values by the model 
for the two conditions show that at a reduced temperature the increase in specific mAb productivity is 
mostly due to increased rates of transcription, translation and product secretion. Despite changes in 
cell growth and metabolism observed during experimentation and through FBA studies in Chapter 4, 
our modelling study suggests that glycosyltransferase levels are the critical factor determining the 
variation in Fc-glycan profiles between the two culture temperatures. As a result, manipulation of 
glycosyltransferase expression can be a potential way to attain the Fc-glycan patterns that one would 
get at physiological temperature, but still retain the advantageous higher qprod of mild hypothermic 
conditions.  
 
 
DIFFERENCES IN RECOMBINANT MAB GLYCOSYLATION BETWEEN STABLE AND 
TRANSIENT GENE EXPRESSION SYSTEMS 
106 
 
 
  
Chapter 6
Differences in recombinant mAb 
glycosylation between stable and 
transient gene expression systems 
After thorough examination on the impact of mild hypothermia on product glycosylation by 
both experimental and computational approaches in Chapter 4 and 5, in this chapter the angle of 
investigation is shifted to the study of an emerging method of rProtein production, the transient gene 
expression system. This chapter aims to compare the differences in the Fc-glycoforms that are derived 
from mAbs produced using example industrial stable (SGE) and transient (TGE) gene expression 
protocols.  
6.1. Background and aims 
Despite stable gene expression (SGE) being used as the standard manufacturing method of 
therapeutic recombinant proteins, it remains time-consuming and labour-intensive. These 
characteristics are unfavourable when fast production of recombinant products is required. On the 
other hand, transient gene expression (TGE) is well suited for this case. Without the need for clonal 
selection and repeated cycles of cell expansion, TGE can rapidly deliver recombinant proteins within 
10 - 18 days as opposed to traditional SGE systems which can require more than 6 months from 
transfection to the generation of stable clones (Pham et al. 2006). TGE is especially useful for the 
rapid provision of materials to support discovery, early stage development and pre-clinical studies. 
However, the low recombinant protein titre achievable in TGE has been a significant limitation of this 
method. As a result, there is increased focus on optimising TGE production yields to attain yields 
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similar to SGE. Through extensive studies on expression vector development (Codamo et al. 2011b), 
transfection methods and process optimisation (Cain et al. 2013; Codamo et al. 2011a), up to 2 g/L of 
recombinant protein can now be achieved with Chinese Hamster Ovary (CHO) cells (Cain et al. 2013) 
and human embryonic kidney 293 (HEK293) cells (Backliwal et al. 2008a).  
However, few studies have directly compared the glycosylation profile between monoclonal 
antibodies (mAbs) produced in stable and transient gene expression systems. Owing to the difference 
in the nature of the gene materials and the process of gene expression between the two systems (Kim 
and Eberwine 2010), it is possible that the oligosaccharide content of mAb products varies between 
the two systems. Under mild hypothermia in TGE, significant changes in galactose abundance were 
observed (Galbraith et al. 2006), which could lead to differences in the level of mAb galactosylation 
between the two systems.  
Ensuring comparable product characteristics between TGE and SGE systems is clearly of 
paramount importance, since relatively minor differences between transfection methods can affect cell 
growth, mAb productivity and glycosylation. Most importantly, it is important to ensure sufficient 
similarity between end products generated under SGE and TGE, as transiently produced products are 
often used in pre-clinical studies. Dependent on advances in TGE, if materials generated from 
transient gene expression are to be used in clinical study in the future, consistency in recombinant 
product quality achieved with this method is vital. To this end, this chapter aims to compare the Fc-
glycosylation of mAbs produced through SGE and TGE using standard industrially-relevant protocols 
adapted from Daramola et al. (2014). This study compares mAb production in CHO cells cultured at 
physiological temperature (36.5C) in SGE and in TGE with and without a shift to mild hypothermia 
(32C). The first part of this chapter compares changes in cell metabolic behaviour, mAb productivity 
and glycosylation between the two systems. Subsequently, we attempt to identify key factors that 
contributed to these differences through experimental and flux balance analyses, which would be 
useful for process optimisation. 
6.2. Results  
Part 1 - Cellular responses to mild hypothermia in TGE 
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6.2.1. CHO cell growth profile and mAb synthesis in TGE system 
With the plasmid transfection method as described in Chapter 3, which was adapted from 
Daramola et al. (2014), two experiments were carried out: one set of triplicate 14-day fed-batch 
cultures of the parental CHO cell line at 36.5C transfected with IgG heavy and light chain plasmid 
DNA and another set of identical triplicate cultures subjected to a temperature shift from 36.5C to 
32C 24 h post-transfection. Similar to the effect described in Chapter 4, CHO cells undergoing TGE 
in mild hypothermic conditions experience a delay in cell growth, where the integral viable cell 
concentration (IVCC) is lower than those cultured at physiological temperature. Upon DNA 
transfection, CHO cells at 32C suffer from a 7% drop in their cell viability in response to the toxicity 
of the transfection reagent (PEI) and the mild hypothermic temperature. They later recover and exhibit 
a more prolonged stationary phase with relatively constant viable cell density (Figure 36 A). Despite 
the reduction in IVCC, cells at 32C achieved a prolonged higher viability, with 85% viability at 
harvest vs 70% viability for cells cultured at 36.5C. 
 
 
Figure 36. Cell growth, volumetric titre and specific productivity (qmAb) of secreted IgG at 36.5C and with a 
temperature shift to 32C in TGE cells. Viable cell concentration and cell viability profiles were measured along the 
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period of cell culture (A), together with the qmAb  which was calculated based on terminal secreted product and 
accumulated mAb concentration profile of both temperatures (B). (C). Dynamic qmAb profile of TGE at 36.5C and at 
32C. Results are average measurements at 36.5C (n=3) and 32C (n=3). The error bars represent the standard 
deviation of the samples.  
Figure 36 B shows the volumetric and specific mAb productivities at the two temperatures 
examined in TGE. Despite a slightly higher volumetric yield observed in TGE system at 36.5C, our 
results show that qmab is reduced by 40% in TGE carried out at physiological temperature as compared 
to TGE with a temperature shift. Specifically, the specific mAb productivity is only 4.1 pg cell
-1
 day
-1
 
on harvest day when cells are maintained at 36.5C, when compared to 7.2 pg cell-1 day-1 under mild 
hypothermic conditions. The dynamic profile of qmAb in Figure 36 C shows that higher qmAb is 
achieved at 32C from day 10 of cell culture. To investigate the difference in mAb productivity, we 
examined the DNA copy number, mRNA and polypeptide expression levels at both temperatures. 
Figure 37 A and Figure 37 B show that upon plasmid transfection, cells in TGE at 32C exhibit 
slightly higher transcription efficiency than at 36.5C. At a transcription level, Figure 37 C and Figure 
37 D illustrate that both heavy and light chain mRNA copy numbers are higher at 32C, with 
maximum HC and LC mRNA levels observed on day 10. This coincides very well with the 
dynamic qmAb profile where its rate at 32.5C is accelerated on day 10. In addition, overall 
increases in H2 and H2L assembly intermediate concentrations are obtained when cells are cultured at 
32C (Figure 37 E and Figure 37 F), with significant increased amount of H2L species beyond day 10, 
where qmAb is substantially higher at 32C. The fact that continuous increase in H2L 
concentrations is observed suggests that the addition of LC does not appear to be limiting at 32C. 
Our results show that mild hypothermic conditions are beneficial in the TGE in terms of achieving 
higher qmAb at both transcriptional and translational levels.  
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Figure 37. Concentration profiles of heavy and light chain DNA copy number (A & B), heavy and light chain mRNA 
(C & D), as well as H2 and H2L (E & F) intracellular assembly intermediates of IgG molecules in TGE at 36.5C and 
TGE at 32C 24 h post-transfection. Results are averaged measurements at 32C (n3) and 36.5C (n3) in TGE. The 
error bars represent the standard deviation of the samples. 
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6.2.2. The impact of mild hypothermia on NSD metabolism and mAb 
glycosylation in the TGE system 
Firstly, we examined whether product glycosylation was affected by mild hypothermic 
temperature in the TGE system by comparing the secreted mAb Fc-glycan profiles at 36.5C and at 
32C on days 10, 12 and 14. When comparing the final quality of our secreted mAb in TGE at the two 
temperatures chosen, surprisingly and in contrast to the results in Chapter 4 with stable gene 
expression, the induction of mild hypothermia did not cause many significant changes in the 
abundance of individual mAb glycan structures at different time points or between the two 
temperatures examined. The only exceptions are the Man5 and G0 species, in which there were slight 
increases in cultures conducted under mild hypothermic conditions (Figure 38 A). However, when the 
rate of mAb galactosylation under each condition was considered, differences between TGE at 36.5C 
and 32C became more pronounced. Results in Figure 38 B suggest that the rate of mAb 
galactosylation is significantly higher in CHO cells that are cultured at 32C under TGE. This is also a 
first indication that CHO cells respond to mild hypothermic temperature differently in different gene 
expression systems.  
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Figure 38. Glycan profile of the secreted IgG. (A). Fractions of 6 glycan structures: Man5, G0, G0F, G1F, G2 and 
G2F on the secreted IgG products in TGE cells were determined. Results were average measurements at 36.5C (n=3) 
and 32C (n=3). (B). Rate of mAb galactosylation. The error bars represent the standard deviation of the samples. 
Statistical significance was calculated using a Student’s t-test and was represented by: p0.05(*), p0.01(**) and 
p0.001(***). TS: Temperature shift. 
As discussed in Chapter 4, NSD metabolism determines the availability of building 
components for protein glycosylation. Figure 39 A to Figure 39 C show the net intracellular 
concentrations of UDP-Glc, UDP-GlcNAc and UDP-Gal in the two temperatures examined. Our 
results show that UDP-Glc and UDP-Gal levels vary in TGE between 36.5C and 32C, with slightly 
higher concentrations of both species observed at 32C. These variations could result from the 
difference in specific glucose uptake rate observed at the later stage of the process in TGE at 32C 
(Figures 41 A & B). Similar to Chapter 4, the UDP-Gal profile shown in Figure 39 B contains data 
points that are under the detection limit of our current HPLC method and they are regarded as value 
0.0 pmol/cell on the profile. Owing to this technical limitation, flux balance analysis was being 
performed to further illustrate the synthesis of NSD species. Despite these increases, comparable 
levels of UDP-GlcNAc were obtained at both temperatures (Figure 39 C). 
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Figure 39. NSD profile of the secreted IgG in TGE. Experimentally determined concentrations of UDP-Glc (A), UDP-
Gal (B) and UDP- GlcNAc (C). Results are averaged measurements at 36.5C (n3) and 32C (n3) in TGE. The 
error bars represent the standard deviation of the samples. 
 
6.2.3. Expression profile of N-glycosylation related genes in TGE 
In addition to the availability of nucleotide sugar donors (NSDs), the other factor that affects 
glycan processing is the expression and activity of glycosyltransferases and NSD transporters that are 
involved in N-linked product glycosylation. Given the different concentrations of intracellular UDP-
Gal but similar glycan profiles between the two temperatures examined, one must look into the 
expression level of glycosyltransferases to explain the glycan results. We examined the same sets of 
glycosyltransferases as in Chapter 4. Figure 40 A shows that the gene expression levels of -GalTII & 
III and FucT are higher at 36.5C than those at 32C in TGE. Increase in transcription is further 
accompanied by the higher protein expression level of -GalTIII at 36.5C (Figure 40 B). 
Interestingly we also observed a rise in mRNA expression of GnTII in TGE under mild hypothermic 
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condition. The fact that GnTII was being massively up-regulated at 32C in TGE (as observed in this 
study at transcription level) suggested that the addition of UDP-GlcNAc for bi-antennary glycan 
structure could also be a crucial factor that promotes mAb glycan processing and provides enough 
substrate for later mAb galactosylation in the TGE system at 32C, resulting in increased rate of mAb 
galactosylation per cell (Figure 38 B). Higher GnTII expression at 32C could also link to the 
comparable net concentration of UDP-GlcNAc that was observed between the temperatures in Figure 
3 C, where higher consumption of UDP-GlcNAc might be involved.    
 
Figure 40. (A) Gene expression profile of N-linked related glycosylation enzymes. mRNA expression levels of 6 
glycosyltransferases, namely GnTI, GnTII, GalTI, GalTII, GaTIII and FucT, were determined. (B) Relative 
difference in galactosyltransferase III (-GalTIII) protein expression. Results are averaged measurements at 36.5C 
6.2RESULTS 115 
 
 
(n3) and 32C (n3) in TGE. The error bars represent the standard deviation of the samples. Statistical significance 
was calculated using a Student’s t-test and was represented by: p0.05(*), p0.01(**) and p0.001(***). 
6.2.4. Changes in CHO cell metabolism in response to mild 
hypothermic temperature in the TGE system 
To further clarify the difference in rates of mAb galactosylation and NSD profiles between 
the two chosen temperatures, it is worthwhile looking into the metabolic profile of cells under these 
conditions. As the main carbon source for CHO cells, glucose consumption profiles shown in Figure 
41 A are significantly different between the two temperatures. The overall glucose consumption per 
cell is around 60% higher in cells undergoing TGE at 32C than its counterpart at 36.5C, with a 1.6-
fold increase in its peak glucose consumption achieved on day 11 at 32C. In addition to changes in 
glucose intake, lactate consumption is high at 32 C, with an average of 74% of the lactate produced 
during exponential phase being consumed. However, at physiological temperature, lactate 
consumption is very low with only 12% of lactate being taken up. Cells also produce 1.4-fold more 
lactate at 36.5C than the transient transfectants that are cultured at 32C (Figures 41 B & C). The 
60% reduction in glucose demand per cell and 1.4-fold rise in lactate production in CHO cells 
undergoing TGE at 36.5C are reflective of the exponential cell death and lowered cell metabolism at 
36.5C. Since NSD metabolism is directly influenced by the availability of the carbon source, changes 
observed in the intracellular pool of NSD species can be attributed to variation in nutrient metabolism 
upon different culture temperatures. 
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Figure 41. An overview of nutrient utilisation. Concentration profiles of glucose consumption per viable cell (A), the 
extracellular lactate concentration (B) when CHO cells were expressed in TGE at 36.5C and at 32C 24 h post 
transfection. (C). Lactate consumption/production per viable cell concentration profile in TGE at 36.5C and at 32C 
induced 24 h post-transfection. Results are averaged measurements at 32C (n3) and 36.5C (n3) in TGE. The 
error bars represent the standard deviation of the samples. 
6.2.5. Examining cell metabolism in TGE at different temperatures 
through flux balance analysis (FBA) 
Despite the usefulness of the NSD study, it can only provide information about the net 
intracellular concentration of each species, but not distinguishing between over- or under-production 
and over- or under-consumption of these species. To further elucidate the effect of different 
temperatures on product glycosylation in TGE, metabolic fluxes were calculated using FBA. From the 
experimental data, we calculated the consumption and production rates of each measured species 
using the method presented in Kyriakopoulos (2014). The rates calculated for the stationary phase at 
both temperatures (Table 17) show that at 36.5C transient transfectants behave very differently from 
those at 32C. In good correlation to experimental results, calculated metabolic rates in Table 17 
suggest that cells cultured at 32C in TGE consume both substantially high levels of glucose and 
lactate. In the case of amino acids, the consumption of asparagine at 32C is nearly 3-fold higher, 
where 1/3 of the Asn consumed is converted into aspartate. But slightly slower consumption of most 
other amino acids, e.g. isoleucine, lysine, serine, phenylalanine and tyrosine, are observed at 32C. 
Most importantly, the rate of mAb synthesis is higher at 32C, which is in good agreement with the 
76% increase in qmAb.  
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Table 17. Average specific metabolic production and consumption rates for TGE at 36.5C and with temperature-
shifted to 32C. Results are averaged measurements at 36.5C (n3) and 32C (n3) in TGE.  
 
The FBA was then constrained with these calculated rates of exometabolites, maximum qmAb 
and growth rate ().  Despite not having an obvious stationary phase in the TGE system at 36.5C, we 
analysed carbon fluxes in the decline phase and compared them to those at the same time point for the 
32C system, which was still at stationary stage. In line with experimental results, Figure 42 shows 
that cells at 36.5C consume less glucose and most carbon fluxes end up in lactate production rather 
than being utilized in the TCA cycle for cell growth and maintenance. Unlike cells at 32C, those at 
36.5C experience minimal level of lactate consumption. A higher amount of amino acids are fed 
back into the TCA cycle and less is available for mAb production, which occurs mostly at exponential 
growth phase. On the other hand, cells at 32C consume a much higher amount of asparagine, which 
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contributes to increased amino acid flux into the TCA cycle, glutamine and aspartate synthesis during 
the stationary mAb-producing phase. At 36.5C, the overall carbon and nitrogen fluxes going towards 
nucleotide, NSD and lipid syntheses are lower (Table 18). Surprisingly, at physiological temperature, 
we observe an increase in metabolic flux towards UDP-N-acetylhexosamine production. This is 
reflected by high UDP-GlcNAc levels experimentally (Figure 40 C), where the abundance of nitrogen 
source could be resulted from a combination of cell death, higher glutamine and ammonia productions 
(Valley et al. 1999). 
 
 
Figure 42. Central carbon metabolism of CHO cells at stationary phase in TGE at 32C and decline phase at 36.5C. 
Thickness of an arrow indicates the relative flow of the carbon source within the system. This figure is simplified to 
include carbon lost to glycerol, glycogen and lactate production, together nucleotide, NSD, lipid and key amino acid 
synthesis.  
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Table 18. FBA estimated flux values in nucleotide synthesis, lipid synthesis and protein glycosylation during 
stationary phase in TGE at 32C and decline phase at 36.5C. 
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6.3. Results 
Part 2 - Comparing product quality produced under SGE 
and TGE processes 
After examining the impact of mild hypothermia on cell metabolism and mAb glycosylation 
in the TGE system, in this part of the chapter, we aim to compare the product produced by SGE to 
that by the TGE system under two conditions for each expression system. These four processes are: a 
14-day fed-batch culture of IgG-expressing CHO cells at 36.5C and the same process with a 
temperature shift to 32C during late exponential growth phase in SGE; and 14-day fed-batch culture 
of the parental CHO cell line with plasmid transfection on day 1 at 36.5C and the same process with 
a temperature shift to 32C 24 h post-transfection. The TGE transfection protocol was adapted from 
the protocol in Daramola et al. (2014). 
6.3.1. CHO cell growth and mAb synthesis in SGE and TGE systems 
One of the differences between the two expression systems related to their growth profiles. 
Stably transfected cells achieve 26% but 3-fold higher in their maximum viable cell concentration 
than TGE cells cultured at 36.5C and 32C, respectively. Despite lower integral of viable cell 
concentration (IVCC) in the TGE system, cells cultured at 32C exhibited a more prolonged 
stationary phase with relatively constant viable cell density after recovery from the toxicity of the 
transfection reagent and the mild hypothermic temperature (Figure 43 A). On the other hand, cells that 
undergo TGE at 36.5C do not achieve the same cell density as those in SGE during exponential 
growth, but the rate of cell death is higher than the other three conditions, which is reflected by the 
accelerated drop in cell viability.  
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Figure 43. Comparing cell growth profile and secreted IgG productivity between SGE (36.5C or 32C TS) and TGE 
(36.5C or 32C TS). (A). Viable cell concentration and cell viability of both expression systems. (B). Volumetric and 
specific mAb productivity on day 14. Results are averaged measurements at 36.5C (n6) and 32C (n3) in SGE; 
36.5C (n=3) and 32C (n3) in TGE. The error bars represent the standard deviation of the samples. TS: 
temperature shift. 
The low volumetric yield is always the main constraint in transient gene expression (Baldi et 
al. 2007; Wurm 2004) and we observed the same trend in this work. Specifically, the volumetric 
product yield in TGE is approximately 4-fold lower than that achieved in the SGE system. In addition, 
the qmAb in TGE at 32C in this study is around 40% lower than that of the stably expressing cell line 
at 36.5C, and it is half of that of the stable transfectants in mild hypothermic conditions (Figure 43 
B). By quantifying the intracellular species produced during mAb synthesis, our results show that, 
unlike the SGE system, transiently expressing cells do not have a constant DNA copy number of 
heavy or light chains, as expected. Their DNA copy number peaked within 2 days of transfection, 
followed by a gradual reduction along the culture period (Figures 44 A & B). In response to the rate 
of DNA uptake, both heavy and light chain mRNA expression and the concentration of H2L mAb 
assembly intermediates are significantly lower under the TGE system, particularly in the system 
maintained at 36.5C (Figures 44 C – F). Moreover, different profiles of the assembly intermediates 
between the two systems suggest that the rate of mAb synthesis varies between exponential and 
stationary phases. Peaks of H2 and H2L concentrations are observed between days 8 to 12 in SGE at 
both temperatures. In contract, these concentrations rise steadily in TGE at 32C throughout the 
culture period. Differences in profile can be the result of reduced mAb assembly rate during TGE 
which it slows the throughputs of assembled mAb species. Cells undergoing SGE undergo a longer 
exponential growth phase than their counterpart in TGE at 32C; transiently transfected cells enter 
stationary phase 48 h after the induction of mild hypothermia. The prolonged stationary phase in TGE 
6.3RESULTS 122 
 
 
allowed cells to synthesize mAb at a constant rate, while cells stably expressing mAbs exhibit two 
stages of production at different rates. Overall, our results show higher transcription, translation and 
product secretion in SGE at both these stages, contributing to the higher specific mAb productivity in 
SGE.  
 
Figure 44. Concentration profiles of heavy and light chain DNA copy number (A & B), heavy and light chain mRNA 
(C & D), as well as H2 and H2L (E & F) intracellular assembly intermediates of IgG molecules in SGE at 36.5C and 
32C, and TGE at 36.5C or 32C 24 h post-transfection. Results are averaged measurements at 36.5C (n6) and 
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32C (n3) in SGE; 36.5C (n=3) and 32C (n3) in TGE. The error bars represent the standard deviation of the 
samples. TS: temperature shift. 
6.3.2. Comparing the mAb Fc-glycan profiles and NSD metabolism 
between SGE and TGE 
In addition to the differences in cell growth and mAb productivity, we sought to examine 
whether there was any variation in glycosylation profiles under TGE. We compared mAb Fc-glycan 
profiles of both expression systems on days 10, 12 and 14. When examining quality of our secreted 
mAb products, despite minimal differences in glycan profiles between 36.5C and 32C in TGE 
observed in Part 1, significant changes were found between the SGE and TGE systems. Specifically, 
in Figure 45 A we observe a decrease in product galactosylation when compared to mAb produced in 
SGE at 36.5C, where the proportion of more processed glycoforms namely G1F and G2F, is 
significantly lower in the mAb produced by the TGE system. In addition, the fraction of Man5 species 
was approximately 6-fold higher in the TGE experiments. However, when compared to the stable 
transfectants that undergo mild hypothermia, mAb produced from cells in TGE, at 32C in particular, 
achieve a remarkably lower fraction of G0F, higher in Man5, G0 and G2 species (Figure 45 B).  Not 
only does the level of galactosylation is similar in products produced by cells undergoing SGE at 
32C and TGE at 36.5C, there are very few variations in the mAb glycan profiles produced under 
these two conditions.  However, when rate of galactose addition within a single cell is concerned, 
there is no doubt that rate of mAb galactosylation is significantly higher in SGE than in TGE in all 
cases examined in this study (Figure 45C). Our results here clearly indicate that cells are 
metabolically different under different gene expression systems and cells response to mild 
hypothermia differently in SGE than in TGE. 
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Figure 45. mAb Fc-glycan profile of the secreted IgG. (A). Comparison of mAb Fc glycan profile among SGE at 
36.5C, TGE at 36.5C and 32C TS. (B). Comparison of mAb Fc glycan profile among SGE at 32C TS, TGE at 
36.5C and 32C TS. Fractions of Man5, G0, G0F, G1F, G2 and G2F were experimentally measured in stably and 
transiently expressed cell lines. (C). Rate of mAb galactosylation in all four conditions examined (SGE vs. TGE). 
Results are averaged measurements at 36.5C (n6) and 32C (n3) in SGE; 36.5C (n=3) and 32C (n3) in TGE.  
The error bars represent the standard deviation of the samples.  Statistical significance was calculated using a 
Student’s t-test and was represented by: p0.05(*), p0.01(**) and p0.001(***). 
In the case of NSD metabolism, Figures 46 A – C show that the overall concentrations of 
UDP-Glc, UDP-Gal and UDP-GlcNAc are higher under TGE at 32C only but not at 36.5C, when 
compared to those in SGE at 36.5C or 32C. Higher net concentrations of NSDs observed in TGE at 
32C can be a result of increases in specific glucose and lactate uptake rates during stationary phase 
(see Figures 49 A & B). However, with the exception of UDP-GlcNAc, concentrations of UDP-Glc 
and UDP-Gal during stationary growth phase in TGE at 36.5C are similar to those in SGE when cells 
are cultured at the same temperature. Minimal changes in mAb Fc-glycan observed between SGE at 
32C and TGE at physiological temperature are in this case reflected by the small variations in NSD 
levels. As mentioned before, UDP-Gal profile shown in Figure 46 B contains data points that are 
under the detection limit of our current HPLC method and they are regarded as value 0.0 pmol/cell on 
the profile. This technical limitation indeed reduces the confidence of this data set, and to overcome 
this issue metabolic distribution of cells was examined later in the chapter. 
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Figure 46. Concentration profiles of NSD species in SGE and TGE cells in physiological and mild hypothermic 
conditions. Concentrations of UDP-Glc (A), UDP-Gal (B) and UDP-GlcNAc (C) of the four conditions were 
experimentally determined. Results are averaged measurements at 36.5C (n6) and 32C (n3) in SGE; 36.5C (n=3) 
and 32C (n3) in TGE. The error bars represent the standard deviation of the samples. 
6.3.3. Differences in N-glycosyltransferase expression between SGE 
and TGE systems 
Given the different profiles of intracellular nucleotide sugar concentrations among all four 
conditions, we turned to the quantification of glycosyltransferase expression in order to identify the 
cause of differences in glycan structures between the two systems. Figure 47 A compares gene 
expression levels of N-linked glycosyltransferases of both temperatures in TGE and SGE at 36.5C. 
We observed a significant reduction in GnTI, - GalTIII and FucT in TGE at 32C compared to the 
expression levels of these genes in SGE at 36.5C. In addition, mRNA level of GnTII were 
comparable between SGE at 36.5C and TGE at 32C, with the exception of TGE at 36.5C in which 
its GnTII transcript levels were the lowest among the three conditions. If these are translated into 
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equivalent changes at protein level, our results suggest that reduction of GnTI at both temperatures in 
TGE could have contributed to the larger fraction of Man5. The combination of reduced levels in 
GnTI & II and GalTI & III could in part contribute to the lowest rate of mAb galactosylation observed 
among the four conditions. While in the case TGE at 32C, despite the lower level of GnTI, bi-
antennary glycan branching of mAb was salvaged by the comparable expression levels of GnTII to 
some extent, but mAb galactosylation was still affected by the reduced GalTII &III mRNA 
transcription, resulting in but lower portions of G1F and G2F in TGE at 32C. Limited mAb 
galactosylation at 32C is further explained by the reduced protein expression of galactosyltransferase 
(Figure 48 A). On the other hand, the transcript level of FucT is significantly higher in TGE at 36.5C 
compared to its level at SGE at 36.5C and TGE at 32C. This might explain the increase in G0F 
levels in mAb produced under TGE at 36.5C. Despite observing a decrease in protein galactosylation 
in TGE compared to SGE at 36.5C, protein expression of -GalTIII is shown to be at similar levels 
in both systems at 36.5C. The results here suggest that galactosylation is not limited by the 
expression of galactosyltransferase in TGE at 36.5C, but by the expression of GnTI & II, or other 
potential factors such as  the availability of UDP-Gal. . 
Comparing now the enzyme expression profiles from TGE at both temperatures to those of 
SGE at 32C, Figure 47 B shows that apart from day 10 where the expression of GnTI in TGE were 
lower than that of SGE at 32C, comparable results among all three conditions were observed for the 
rest of the time points. This piece of result correlates well with the gradual decrease of Man5 level 
from day 10 to 14 in mAbs produced under TGE. Also while similar mRNA levels of GnTII were 
obtained between SGE at 32C and TGE at 36.5C, the up-regulation in GnTII mRNA expression in 
TGE at 32C was believed to contribute to the increased fractions of G0 in mAbs secreted at 32C in 
TGE. However, fluctuation among the expression of the three GalT species is observed, showing no 
specific general trend; This is in line with the glycan results which showed no significant variation in 
galactosylation between TGE and SGE at 32C. In addition, Figure 48 B suggests similarity in -
GalTIII protein expression levels between SGE and TGE at 32C. Our results show that enzyme 
expression in our case is only subjected to changes upon temperature shift and that the expression of 
-GalTIII in TGE at 36.5 is comparable to that in SGE at the same temperature.  
The fact that rates of mAb galactosylation in cells cultured under TGE remained lower than 
their counterparts in SGE, there are several hypothesis for this. Firstly when  1. the availability of 
UDP-Gal is limited ( in the case of TGE at 36.5C); or 2. Lower expression levels of GnTI and FucT 
could be limiting the amount of substrate for GalT to work on (TGE at both 36.5C and 32C). 3. In 
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the case of TGE at 32C, increased expression of GnTII could have resulted in more G0F species for 
mAb galactosylation. But the expression level of the GalT enzymes (GalT expression was down-
regulated in SGE and TGE at 32C) still remained as an important factor that limit galactose addition. 
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Figure 47. Comparison of gene expression profile of N-linked related glycosylation enzymes among all conditions. (A) 
mRNA expression levels of 6 glycosyltransferases, namely GnTI, GnTII, GalTI, GalTII, GaTIII and FucT, were 
measured and species from both temperature in TGE are compared to those in SGE at 36.5C. (B) Difference in 
glycosyltransferase gene expression among TGE at 36.5C and 32C to SGE at 32C TS. Results are averaged 
measurements at 36.5C (n6) and 32C (n3) in SGE; 36.5C (n=3) and 32C (n3) in TGE.The error bars represent 
the standard deviation of the samples. Statistical significance was calculated using a Student’s t-test and was 
represented by: p0.05(*), p0.01(**) and p0.001(***). 
 
Figure 48. -GalTIII protein expression profiles. (A) Comparison of species among both temperature in TGE and 
that in SGE at 36.5C. (B) Difference in -GalTIII protein expression among TGE at 36.5C and 32C and SGE at 
32C TS. Results are averaged measurements at 36.5C (n6) and 32C (n3) in SGE; 36.5C (n=3) and 32C (n3) in 
TGE.The error bars represent the standard deviation of the samples. Statistical significance was calculated using a 
Student’s t-test and was represented by: p0.05(*), p0.01(**) and p0.001(***) 
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6.3.4. Experimental analysis of cell metabolism in SGE and TGE  
To further clarify the reason for differences arise in mAb Fc-glycan patterns between products 
from SGE and TGE systems, the metabolic profile of cells cultured under these processes were 
experimentally examined. Figure 49 A illustrates the overall glucose consumption per cell in the four 
conditions. Our results show that glucose consumption rates are very comparable among cells 
undergoing SGE at both temperatures and TGE at 36.5C. However in the TGE system at 32C, the 
specific glucose consumption during stationary growth phase is 2.7-fold higher compared to that in 
SGE. In addition, CHO cells produced and consumed lactate differently between the two expression 
systems at different temperatures. Lactate production occurs in exponential phase of both systems, 
however only cells that are cultured in mild hypothermic conditions experience a metabolic shift from 
lactate production to lactate consumption. TGE cells cultured at 32C consume 74% of the total 
amount of lactate produced, while cells undergoing SGE at 32C utilise 97% of the peak amount 
produced (Figure 49 B). At 32C, cells undergoing TGE consume glucose and lactate at a ratio of 
1.78:1, while in the case of SGE at 32C the ratio is 0.96:1. Despite the higher consumption of 
glucose in SGE at 32C, the overall consumption of sugar in TGE is higher in mild hypothermic 
conditions, in order to fuel cell maintenance and protein production during stationary growth.  
 
Figure 49. Glucose consumption and lactate concentration profiles. Concentration profiles of glucose consumption 
per viable cell (A) and extracellular lactate (B) when CHO cells were expressed in SGE at 36.5C or at 32C, and in 
TGE at 36.5C or at 32C 24 h post transfection. Results are averaged measurements at 36.5C (n6) and 32C (n3) 
in SGE; 36.5C (n=3) and 32C (n3) in TGE. The error bars represent the standard deviation of the samples. 
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6.3.5. Flux balance analysis studies 
The FBA studies in Part 1 showed that carbon fluxes towards nucleotide and NSD syntheses 
were minimal in TGE cells regardless of temperature changes. Part 2 focuses on comparing the 
calculated carbon fluxes between the SGE and TGE cells at exponential and stationary phases. From 
the results we aimed to identify the contributing factors that affect product glycosylation.  
The FBA was constrained with the calculated production and consumption rates during 
exponential and stationary phases for both expression systems in all conditions in Tables 19 A & B. 
Our results show that at exponential phase, consistent with the difference in cell growth profiles 
between the two systems, the specific consumption of glucose and amino acids and the specific IgG 
production rate are lower in TGE than in SGE. The only exception is asparagine, the consumption of 
which is 78% higher in cells undergoing TGE, together with almost 100% increase in glutamine 
production. In line with the experimental data, the carbon flux going towards lactate production is 
significantly higher under TGE during exponential growth phase. The calculated fluxes suggest a 
different carbon intake and distribution within the TGE system before the induction of mild 
hypothermia.  
In contrast, Table 19 B shows the calculated fluxes at stationary phase for all four conditions. 
Our results show that the specific glucose consumption rate is higher in the TGE system at stationary 
phase. When compared to both temperatures in SGE, the consumption of most amino acids, such as 
asparagine, glycine, leucine, methionine, proline and serine is higher in transiently transfected cells.  
The calculated flux for glutamine production, however, is higher in TGE only when compared to SGE 
at physiological temperature, but remains lower when compared to the flux in stable transfectants at 
32C. With robust amino acid metabolism, ammonia production in cells cultured under TGE is higher 
than both SGE conditions. Lactate consumption is low in TGE at 36.5C, with cells consuming higher 
amount of lactate in TGE at 32C. Cells undergoing SGE at 32C achieved the highest rate of lactate 
consumption out of all conditions examined. In the case of mAb productivity, the specific IgG 
productivity is higher in SGE at stationary phase at both temperatures; it is in agreement with our 
experimental results where the qmab in TGE is often lower. 
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Table 19 A. Average specific metabolic production and consumption rates for SGE at 36.5C and at 32C T\S, and 
TGE at 36.5C and 32C TS, at exponential phase. Results are averaged measurements at 36.5C (n6) and 32C 
(n3) in SGE; 36.5C (n=3) and 32C (n3) in TGE. 
 
Consumption/production rate 
(femtomol/cell/day) 
 
Exponential phase 
 
36.5/32C 36.5/32C 
 
SGE TGE 
 
VALUE STDEV VALUE STDEV 
Ala 196.2 12.2 55.7 6.9 
Amm -8.5 9.9 146.4 9.6 
Arg -38.9 5.1 -14.9 3.1 
Asn -175.9 10.2 -313.9 14.7 
Asp -186.8 18.1 139.4 12.4 
Glc -696.0 245.4 -362.5 126.2 
Gln 17.5 5.6 35.7 2.4 
Glu -33.5 3.7 -3.8 3.3 
Gly 29.8 7.5 22.6 3.1 
His -14.3 3.0 0.7 2.7 
Ile -53.9 8.1 -15.1 5.7 
Lac 82.2 76.5 1461.6 188.1 
Leu -117.9 14.8 -75.2 6.9 
Lys -59.6 8.7 -24.9 5.7 
Met -15.9 2.3 -14.4 2.7 
Phe -26.1 3.6 -12.4 2.8 
Pro -43.5 4.6 -43.6 5.4 
Ser -162.2 14.8 -81.8 9.2 
Thr -42.5 6.1 -14.3 5.5 
Trp -9.2 2.0 -7.0 2.6 
Tyr -34.0 3.8 -7.1 3.1 
Val -74.6 9.1 -46.6 6.0 
IgG 15.5 0.7 1.9 0.1 
 
Specific growth rate (day-1) 
μ 0.3 0.0 0.3 0.0 
Negative value: consumption. Positive value: 
production. 
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Table 19 B. Average specific metabolic production and consumption rates for SGE at 36.5C and at 32C T\S, and 
TGE at 36.5C and 32C TS, at stationary phase. Results are averaged measurements at 36.5C (n6) and 32C (n3) 
in SGE; 36.5C (n=3) and 32C (n3) in TGE. 
 
Consumption/production rate (femtomol/cell/day) 
 
Stationary phase 
 
36.5C 32C 36.5C 32C 
 
SGE TGE 
 
VALUE STDEV VALUE STDEV VALUE STDEV VALUE STDEV 
Ala 134.0 18.8 15.1 3.1 106.8 24.0 152.0 20.0 
Amm -17.4 6.3 -60.3 1.4 18.0 13.0 38.8 26.0 
Arg -19.5 3.2 -20.9 2.4 -13.5 3.0 5.0 7.0 
Asn -63.9 3.2 -72.6 4.1 -118.0 4.0 -308.0 18.0 
Asp -171.0 7.3 -122.9 6.8 -80.5 21.0 159.2 21.0 
Glc -412.0 74.7 -268.9 49.0 -346.5 91.0 -480.5 222.0 
Gln 30.6 3.6 149.0 1.4 47.5 2.0 64.8 5.0 
Glu -24.3 1.6 -11.8 1.8 -9.4 4.0 2.4 4.0 
Gly 23.5 4.1 22.5 0.8 87.4 3.0 72.4 2.0 
His -6.2 2.3 -5.4 2.2 -0.5 2.0 18.7 5.0 
Ile -39.5 5.0 -13.3 5.4 -27.4 8.0 -1.9 14.0 
Lac -45.5 11.0 -321.6 7.9 481.4 91.0 -262.7 132.0 
Leu -89.1 8.0 -33.0 6.3 -94.7 14.0 -97.5 21.0 
Lys -30.6 6.0 -36.4 5.3 -23.6 5.0 -1.8 11.0 
Met -8.5 1.0 -4.9 2.0 -12.1 2.0 -14.2 4.0 
Phe -14.4 2.0 -8.4 2.2 -14.2 3.0 -7.6 5.0 
Pro -25.0 4.0 -21.3 4.1 -25.6 4.0 -27.8 10.0 
Ser -78.2 9.0 -63.4 5.7 -156.7 10.0 -123.5 21.0 
Thr -24.2 4.0 -11.1 4.0 -16.8 5.0 2.8 11.0 
Trp -5.1 1.0 -2.6 2.0 -5.0 2.0 -1.6 4.0 
Tyr -18.4 1.0 -8.3 2.1 -9.1 2.0 6.1 6.0 
Val -53.5 6.0 -26.5 4.9 -56.3 8.0 -51.4 14.0 
IgG 10.7 1.0 12.8 1.0 0.0 0.0 5.8 1.0 
 
Specific growth rate (day-1) 
μ 0.1 0.0 0.0 0.01 -0.1 0.03 0.0 0.01 
Negative value: consumption. Positive value: production. 
 
Figures 50 A - C show the metabolic fluxes of stably (36.5C & 32C) and transiently 
(36.5C & 32C) transfected CHO cells at exponential and stationary phases, respectively. During 
exponential growth, almost all pyruvate is converted into lactate and little went into the TCA cycle for 
energy production in the TGE system. In contrast, the glucose is utilised more efficiently by CHO by 
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channelling it through the TCA cycle in stable transfectants. The overall flux towards ATP and 
NADH generation in the TGE system is around half of that in the SGE system. In addition, fluxes 
towards nucleotide, nucleotide sugar and lipid syntheses are marginally lower in TGE at exponential 
phase.  
During stationary phase, Figures 50 A and B illustrate that glucose metabolism in glycolysis 
and TCA cycle in TGE at 32C are twice as efficient as that in SGE at either 36.5C or 32C. This 
does not apply, however, to cells in TGE at 36.5C where cells enter exponential decline. As a result 
of mild hypothermia, lactate acted as an additional carbon source in both SGE and TGE systems 
(Ivarsson et al. 2014). Cells cultured at 32C in both systems show higher fluxes of lactate entering 
the TCA cycle than those that are cultured at physiological temperature. Changes in lactate 
metabolism in mild hypothermic conditions are also reflected by reduced extracellular lactate 
concentrations that are experimentally observed. Fluxes from various amino acids that enter the TCA 
cycle for glutamine synthesis and energy generation are higher within TGE at 32C in order to attain 
its robust TCA cycle, sustain the prolonged cell growth in TGE at 32C, as well as contribute to mAb 
synthesis. However, in the case of TGE at 32C, despite the higher overall carbon fluxes entering the 
cell, the carbon flux distribution towards mAb synthesis is around 50% lower than those in SGE at 
both temperatures. In addition, glucose metabolism towards nucleotide, NSD and lipid syntheses is 
low in transiently transfected cells. Cells in the TGE system only exhibited approximately 20% of the 
corresponding flux of stable transfectants towards protein glycosylation (Tables 20 A and B). The 
only exception is UDPNAG in TGE at 36.5C: the flux towards this species is comparable to that in 
SGE at physiological temperature and this is reflected by the similar net concentration of UDP-
GlcNAc in these two conditions (Figure 46 C). In addition, glutamine is a crucial component for 
UDP-N-acetyl-hexosamine synthesis (UDP-GlcNAc, UDP-GalNAc). Carbon and nitrogen fluxes 
towards UDPNAG synthesis are high in TGE at 36.5C, while those at 32C are comparatively low 
and indeed lower than those in SGE. The reduction in nucleotide/NSD synthesis in TGE at 32C is 
further emphasized by the reduced flux of glutamine into these synthetic pathways suggested by the 
FBA. 
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Figure 50. Central carbon metabolism of CHO cells at exponential growth (A) in SGE and TGE at both 
temperatures, (B) stationary growth phase in SGE at 36.5C and 32C TS and (C) stationary phase in TGE at 36.5C 
and 32C TS. Thickness of an arrow indicates the relative flow of the carbon source within the system. This figure is 
simplified to include carbon lost to glycerol, glycogen and lactate production, together nucleotide, NSD, lipid and key 
amino acid synthesis.  
 
Table 20 A. FBA estimated flux values in nucleotide synthesis, lipid synthesis and protein glycosylation during 
exponential phase in SGE and TGE. 
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Table 20 B. FBA estimated flux values in nucleotide synthesis, lipid synthesis and protein glycosylation during 
stationary phase in SGE (36.5C) and TGE (32C). 
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6.4. Discussion 
Variation in IgG gene expression levels between the stable and transient systems has led to 
significant differences, not only with respect to specific IgG productivity, but it also partially 
contributes to changes within cell metabolism, the timeframe for mAb production and the product 
glycoforms. Cells in the TGE system were exposed to PEI, a cytotoxic transfection reagent, at the 
start of cell culture. Its negative impact was reflected in the drop in cell viability at early exponential 
phase but cells later recovered from the stress imposed by the transfection reagent. At the same time, 
cells displayed high levels of lactate production and comparatively lower flux entering the TCA cycle 
during exponential phase as suggested by the FBA study. This was in contrast to SGE cells where the 
gene of interest was already incorporated into the host genome and cells had re-established a new 
steady state, in which most glucose was converted into useful metabolites. With the introduction of 
mild hypothermia 24 h post-transfection, instead of rapid cell division, cell growth in TGE at 32C 
was maintained at a relatively constant level and cells experienced a longer stationary phase than 
those that were stably transfected at both temperatures examined. However, cell viability was higher 
in the SGE system than in the TGE system at 36.5C.  The prolonged cell viability had a direct 
positive impact on specific mAb productivity in TGE and is beneficial during bioprocessing. Despite 
the different cell growth profile due to the early temperature shift in TGE, both cells undergoing SGE 
and TGE at 32C exhibited prolonged cell viability and reduced rate of cell death. It would be 
interesting to examine how the timing of the temperature shift can affect cell metabolism and mAb 
production.   
When examining the impact of transient gene expression on cell metabolism, in contrast to 
the exponential phase of TGE where most of the pyruvate was converted to lactate, the TCA cycle in 
transiently transfected cells at 32C was heavily fuelled by glucose and lactate together at stationary 
phase. This is different from cells in SGE at 32C where the flux from lactate to the TCA cycle was 
higher than that from glucose. On the other hand, cells undergoing TGE at physiological temperature 
consumed a similar amount of glucose during stationary phase but most of it was being converted into 
lactate. Fluxes of amino acids, asparagine in particular, into the system during stationary phase were 
also very high in TGE at both temperatures examined. Carbon backbones of most amino acids were 
fed back into the TCA cycle to prolong stationary growth phase in TGE at 32C, while most amino 
acids were converted into glutamine in TGE at 36.5C, according to the flux balance analysis carried 
out. In addition, metabolic rates calculated as shown in Tables 19 A and 19 B suggest that mAb 
productivity was higher during stationary phase in TGE cells at 32C, while in SGE mAb production 
was higher in exponential phase. The increased amino acid consumption and energy generated from 
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the TCA cycle, together with the reduced need of cells to divert energy towards cell growth, fuelled 
product synthesis in TGE. Our previous study on mild hypothermia in SGE presented in Chapter 4 has 
suggested that more energy was likely to have been channelled towards protein production (Sou et al. 
2014). The same impact was observed in the TGE system at 32C, in which around 40% rise in 
protein productivity was achieved compared to that in TGE cells at 36.5C. As opposed to the results 
for 32C, cells in the TGE system at 36.5C did not exhibit a stationary phase.  
The glycan pattern of the secreted mAb also showed variations between the two expression 
systems. Despite increased glucose metabolism in TGE at 32C during stationary phase, results from 
the FBA showed that overall fluxes towards nucleotide and NSD syntheses were dramatically reduced 
(Tables 18 and 20 B). With a closer examination, metabolic rates for UDP-Gal and UDP-NAG (N-
acetylhexosamines) were 13- and 4- times lower in transient transfectants at 32C respectively, and 
significantly lower at 36.5C, when compared to those in stable transfectants at 36.5C. However, 
metabolic fluxes towards NSD synthesis were comparable among TGE at both temperatures and SGE 
at 32C; this is in agreement with the similar glycan profiles achieved in these three conditions.  
Analysis of experimental NSD data, N-linked glycosyltransferase expression levels, flux 
balance analysis and secreted mAb glycosylation profile provide a thorough picture of the impact of 
TGE at different temperatures on the process of glycosylation. The limitation in protein 
galactosylation observed in TGE when compared to SGE at 36.5C, and variations in the intracellular 
concentration of UDP-Gal in TGE between the two temperatures, suggest that the decreased G1F/G2F 
fractions in TGE at different temperatures can be contributed from different factors. When cells in 
TGE at both temperatures experienced reduced metabolic fluxes towards NSD synthesis, only those at 
32C have their GalT expression downregulated. We can therefore conclude that limited mAb 
galactosylation arise in TGE at 36.5C is mainly due to reduced production of NSDs, while reduced 
expression of glycosyltransferases is the main contributor in reduced product galactosylation in TGE 
cells at 32C. This is further confirmed by the accumulation of UDP-Gal resulting from under-
consumption of the species at this temperature. Despite changes observed in mAb glycosylation 
between the two systems, one can argue that they are within similar magnitude to those observed as a 
result of other cellular (e.g. clonal variation) or environmental perturbations (van Berkel et al. 2009). 
In addition to GalT enzymes, one also has to take into consideration of GnTI and GnTII expression in 
cells cultured under TGE, where their levels of expression also place a crucial impact on generating 
bi-antennary glycan structures. Without these, further mAb processing, to be more specific, mAb 
galactosylation cannot take place. Also, the fact that within the TGE system CHO cells cultured at 
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32C was more capable of galactose addition and expressed more GnTII than at 36.5C, again stresses 
the importance of GnTII in aiding mAb galactosylation during N-linked mAb glycosylation. 
In addition to protein glycosylation, lipids play a significant role in protein transport and 
retention of glycosyltransferases in the Golgi apparatus (Banfield 2011). Reduced metabolic rates 
towards lipid synthesis could affect membrane formation, which, in turn, can impact cell growth and 
product glycosylation.  
Table 21 summarises the differences between the stable and transient gene expression 
systems with and without mild hypothermia. In brief, transiently transfected cells are less 
metabolically robust in early exponential phase owing to their gradual recovery from stresses imposed 
by both the transfection reagent and/or mild hypothermia. During stationary phase, cells in TGE at 
32C concentrated more on energy and recombinant protein production, in contrast to stable 
transfectants at 36.5C where more energy was spent on protein glycosylation. However, cells from 
both expression systems have low carbon fluxes towards NSD synthesis, similar levels of GalT 
expression and, as a result, similar mAb glycan profiles at 32C. On the other hand, despite similar 
glycan profiles in the TGE system at both temperatures, lack of NSD production appeared to be the 
main factor of reduced galactosylation at 36.5C, while decrease in -GalT expression resulted in 
reduced consumption of NSD for mAb glycosylation at 32C and different supplementations showed 
minimal effects. 
 
Table 21. Summary table describing differences between stable and transient gene expression systems, in terms of 
rProtein production, cell metabolism and Fc-glycan profile. 
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6.5. Concluding remarks 
In this chapter we analysed the differences in cell culture behaviour between model SGE and 
TGE processes in terms of cell profile, cell metabolism, recombinant protein synthesis, as well as the 
Fc-glycan pattern of the secreted mAb. Our results showed that CHO cell behaviour varied in 
response to a change in DNA transfection and expression pattern. Firstly CHO cell growth was shown 
to be affected by the addition of mild-toxic transfection chemicals as well as the timing of temperature 
shift. In contrast integrating target DNA into the host cell genome during stable gene expression, the 
expression of mAb as a foreign protein in TGE placed a burden on protein glycosylation and reduced 
availability of NSD species and limited expressions of glycosyltransferases. Among all conditions 
examined in this chapter, the two expression systems that resemble industrial practices the most are: 
IgG-expressing CHO cells cultured at 36.5C in SGE and its parental CHO cell line at 36.5C with 
plasmid transfection on day 1 and with a temperature shift to 32C 24 h post-transfection in TGE. By 
comparing these two model industrial processes, it is evident that there are differences in mAb 
glycoforms between the two conditions. In order to use TGE materials for early stage pre-clinical 
studies or to even replace materials produced through SGE in the future, process optimisation will 
definitely be necessary to attain similar product quantity and quality. Our study identified factors that 
influence product glycosylation in TGE and provides a platform for bioprocess optimisation and 
development. This could involve feeding essential nucleotides or other carbon sources such as 
galactose, lactate or pyruvate, or manipulating glycosyltransferases through cell line engineering. 
Despite the changes observed between the two systems in this chapter, one has to bear in mind that 
changes in protein glycosylation in this study can be cell- or transfection protocol-specific. Our study 
only provides a first-hand comparison between the two expression systems but more investigations on 
different cell culture conditions as well as transient transfection protocols are necessary to draw a 
more concrete conclusion on the differences in mAb glycosylation between SGE and TGE expression 
systems. 
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Chapter 7
Comparison of recombinant 
monoclonal antibody glycosylation 
between SGE and TGE systems 
through computational studies 
In Chapter 6 we compared conditions in the SGE and the TGE systems experimentally, with 
respect to cell growth, cell metabolism and mAb glycosylation. Despite serving as a useful start in 
understanding the difference between the two expression systems, our experimental data alone was 
not sufficient to draw a more meaningful insight into why transient transfectants behaved very 
differently from their stably transfected counterparts. Although the use of flux balance analysis shed 
more light into the metabolic distribution of glucose and amino acid feeds within the cells under the 
four different conditions, it still remains difficult to speculate on the reasons behind the 
experimentally observed differences. As a result, a mathematical model was constructed for the TGE 
system to describe cellular behaviour at physiological and mild hypothermic conditions. The model 
followed same structure as that for the SGE described in Chapter 5 and was adapted to the 
particularities of the TGE system.  
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7.1. TGE model structure 
The TGE model described in this chapter retains the modular characteristics of that presented 
in Chapter 5 and includes descriptions for cell dynamics, NSD metabolism and mAb N-linked 
glycosylation in the Golgi apparatus. Most parts of the model remain the same as that for the SGE 
system, with two changes made introduced in the cell dynamics section. They are: 
 The incorporation of the transfection reagent 25kDa linear polyethylenimine (PEI) into the 
cell growth limitation term finh. 
PEI has been shown to have a toxic effect on cell cultures (Kafil and Omidi 2011) and it 
affects cell growth. The level of PEI and the timing of its addition are controlled by a feeding 
schedule, in which PEI is only introduced once to the model 24 h post transfection. .  
 Unlike stable gene expression where constant DNA copy number of target gene is achieved, 
the DNA levels of heavy and light chains increase upon DNA transfection and their levels 
change along the cell culture period. Such changes are captured and controlled by a feeding 
sequence described in Appendix III Table 1. The copy numbers of heavy and light chains 
indicated in the feeding schedule were experimentally determined through qrt-PCR.  
With the availability of experimental data for HC and LC DNA copy numbers, it is easier to 
incorporate their respective DNA copy numbers in a schedule in gPROMS, most importantly because 
we do not have enough information to predict the transfection efficiency of target genes, but also to 
minimise changes in the model structure that would otherwise be necessary. By keeping the model 
structure of the TGE model similar to that of the SGE model, a more valid comparison between the 
two model outputs is enabled. 
 
 
𝑓𝑖𝑛ℎ = (
𝐾𝐼𝑎𝑚𝑚
𝐾𝐼𝑎𝑚𝑚 + [𝐴𝑚𝑚]
) (
𝐾𝐼𝑙𝑎𝑐
𝐾𝐼𝑙𝑎𝑐 + [𝐿𝑎𝑐]
) (
[𝑃𝐸𝐼]
𝐾𝑃𝐸𝐼 + [𝑃𝐸𝐼]
) …Eq. 63 
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7.2. Comparing model simulation results between SGE and 
TGE systems  
By incorporating the modifications discussed above, the TGE model was simulated in 
gPROMS v.4.0.0 (Process System Enterprise, 1997-2015)  using two sets of parameter values 
estimated separately for each of the two conditions examined in the TGE system: fed-batch TGE at 
36.5C or with a temperature shift to 32C 24 h post DNA transfection, with HC and LC DNA 
transfection taking place on day 1. In this section, model simulations are first compared to the 
experimental data from triplicate experiments under each condition to evaluate the capability of the 
model to represent the TGE system. Estimation of model parameter is perform in gPROMS v.4.0.0, in 
which unknown parameter values in both physical and variance models are simultaneously predicted 
by the maximum likelihood formulation. It maximizes the chance of the model fitting parameter 
values to the experimental data, and provides statistical analysis that indicates the level of uncertainty 
in the estimated values (Process System Enterprise, 1997-2015) . Estimated parameter values for the 
two conditions are then carried followed by a comparison to the CHO cells cultured in the SGE 
system at 36.5C, with an aim to understand how differences in cellular behaviour and product quality 
arise between expression systems.  
7.2.1. Discussion of CHO cell culture dynamics and mAb production 
model 
Figures 51 A - D show simulated viable and total cell growth profiles from our transient 
model against the respective experimental data at different temperatures, as well as comparison of 
model simulations between stable and transient gene expression. By incorporating the inhibitory 
effect of transfection reagent PEI on cell growth, simulated results for both temperatures examined are 
in good agreements with their respective experimental data points. Our TGE model is capable of 
differentiating cell growth at 36.5C from that at 32C: the prolonged stationary growth phase that 
occurred at 32C is also well captured. Despite the reduced viable cell density achieved in cells 
undergoing TGE, the general cell growth profile in TGE at 36.5C is very similar to that in SGE at 
mild hypothermic temperature.  
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Figure 51. Comparison of model simulation to experimental data for viable (A & C) and total cell concentrations (B 
& D) from fed-batch CHO cell cultures in SGE at 36.5C or at 32C TS, and in TGE at 36.5C or at 32C TS. 
In addition, simulation results from the transient model generate good fits to experimental 
inputs for nutrient and amino acid metabolism at both temperatures. Glucose consumption is 
suggested to be temperature dependent. The extracellular glucose profile of cells in TGE at 36.5C is 
comparable to that in SGE at 36.5C, while the profile of glucose in TGE transfectants cultured at 
32C also resembles that of SGE culture with mild hypothermia (Figure 52 A). Despite the similar 
glucose profiles between the SGE and TGE at 32C, their distinctive difference in cell growth, 
however, results in higher consumption of glucose in cells undergoing TGE at 32C (Chapter 6, 
Figure 49). Moreover, lactate and ammonia concentration profiles are described effectively (Figures 
52 B & C), with the model describing well the high lactate production of cells in TGE at 36.5C. In 
addition, simulations from the transient model for amino acid metabolism are in good agreements 
with those that are measured experimentally (Figures 53 A – F), apart from arginine where our model 
under-estimates its consumption under TGE. Other amino acids, namely asparagine, glutamate, 
glutamine, lysine and proline, are correctly described by the model for both temperatures. Our results 
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show that for some amino acids such as Arg and Lys, the concentration profiles are similar between 
expression systems at the same temperature. On the other hand, the concentration profiles of Asn and 
Pro in TGE at 36.5C are comparable to those in SGE regardless of temperatures. It is hard to 
conclude the consumption rate of each amino acid based on their concentration profiles alone. 
However the fold difference between cell growth profile in TGE at 32C and the other three 
conditions examined are always higher, when compared to differences observed in amino acid 
metabolism. Our results suggest that rates of amino acid consumption in cells undergoing TGE at 
32C is therefore higher. With similar trends as those in mAb production (Figure 55), glutamine 
concentration profiles in TGE are lower when compared to those in SGE.  
 
Figure 52. Comparison of model generated fits to experimental data for extracellular glucose (A) extracellular lactate 
(B) and extracellular ammonia (C) concentrations from fed-batch CHO cell cultures in SGE at 36.5C or at 32C TS, 
and in TGE at 36.5C or at 32C TS. 
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Figure 53. Comparison of model generated fits to experimental data for extracellular asparagine (A), arginine (B), 
glutamate (C), glutamine (D), lysine (E) and proline (F) concentrations from fed-batch CHO cell cultures in SGE at 
36.5C or at 32C TS, and in TGE at 36.5C or at 32C TS. 
In the case of mAb synthesis, a different parameter set was required to describe system 
behaviour under the two different temperatures in TGE. Similar to SGE, simulated results of HC 
mRNA expression in TGE are not in complete agreement with experimental data, failing to replicate 
peak expression on days 10 and 11 in TGE at 32C. However, generated results are of the same 
magnitude as our experimental data (Figure 54 A). LC mRNA expression in TGE at both 
temperatures, on the other hand, is well described by our cell dynamics model (Figure 54 B). 
Transcription levels of both HC and LC are pronouncedly reduced in TGE. The same applies to the 
mAb assembly intermediate species: Figure 54 C illustrates that the intracellular H2L2 concentration is 
lower in TGE regardless of culture temperature and the TGE model correctly describes this reduction, 
which is also reflected in decreases in mAb transcription and translation rates. Finally, the TGE model 
accurately simulates the volumetric mAb yield in TGE (Figure 55), which is approximately 5-fold 
lower than that produced in SGE systems.  
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Figure 54. Comparison of model simulation outputs to experimental data for intracellular HC mRNA (A), LC mRNA 
(B), H2L2 polypeptide (C) assembly intermediate concentrations from fed-batch CHO cell cultures in SGE at 36.5C 
or at 32C TS, and in TGE at 36.5C or at 32C TS. 
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Figure 55. Comparison of model simulation outputs to experimental data for secreted volumetric mAb concentration 
in fed-batch CHO cell cultures in SGE at 36.5C or at 32C TS, and in TGE at 36.5C or at 32C TS. 
 Tables 22 and 23 compare estimated parameters for the cell dynamics model in TGE at both 
temperatures to those in SGE at 36.5C or at 32C, respectively. The comparison shows that values of 
max at both temperatures in TGE are higher, with cells in TGE requiring higher growth rates to 
overcome the inhibitory effect of PEI. In line with experimental results, max of cells that undergo 
TGE at 32C is lower than that at 36.5C, which, together with a reduced value of d,max to generate a 
steady and prolonged stationary growth phase. Among all four conditions examined, the rate of cell 
lysis is generally estimated to be lower at 32C in both SGE and TGE where their cell membranes are 
suggested to be more rigid at reduced temperatures. This correlates well with the findings of Tait et al. 
(2013) where cells are suggested to be less shear sensitive at high cell viability.  
On the other hand, estimated synthetic rates of mAb are different among all four conditions. 
mAb assembly rates are estimated to be lower in TGE when compared to cells in SGE at 36.5C, but 
are comparable to that of SGE at 32C. Despite decreases in KA values, estimated rates of 
transcription in TGE at both temperatures are at similar magnitude as those in SGE at 36.5C, but 
relatively lower when compared to those in SGE at 32C. The rates of decay for heavy and light chain 
mRNA are estimated to be lower in the TGE systems. Moreover, translation rates of both heavy and 
light chains are estimated to be higher in all TGE conditions than in the SGE system. When compared 
within TGE systems, the rate of translation at 32C is higher than at 36.5C, which might have 
enhanced the specific mAb productivity in cells undergoing TGE at mild hypothermic temperature. 
Our model outputs demonstrate mAb production in TGE is not highly affected by their transcriptional 
and translational machinery. Reduced levels of HC and LC mRNA and their assembly intermediates 
observed experimentally in TGE illustrated in Figure 44 could be a result of the lower and 
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inconsistent HC and LC DNA copy numbers during TGE culture; or the reduced mAb assembly rates 
under the TGE system.  
Also, the rate of mAb transport from ER to Golgi apparatus in cells undergoing TGE is 
higher, which suggests a higher throughput of mAb species entering the Golgi apparatus during TGE. 
However, mAb molecules appear to be retained longer within this organelle as reflected by decreased 
values in the secretion rate of assembled mAb product from the Golgi apparatus to the extracellular 
matrix (KG) in TGE when compared to those in SGE. The model proposes low secretion rate to be the 
main bottleneck in TGE mAb production. A full list of parameter values for the NSD model can be 
found in Appendix III Table 2. 
 
Table 22. Comparison of estimated parameters between models of SGE at 36.5C and TGE at 36.5C or 32C TS. 
This includes parameter values for cell growth, metabolism and mAb production.  
 
Values 
 
Parameter SGE 36.5 
o
C 
95% conf. 
internals 
TGE 36.5 
o
C 
95% conf. 
internals 
TGE 32 
o
C 
95% conf. 
internals 
Units 
Growth/death related 
max 1.10 x 10
-1
 2.90 x 10
-2
 1.12 1.10 x 10
-2
 1.58 x 10
-1
 2.10 x 10
-3
 h
-1
 
d,max 9.70 x 10
-2
 1.10 x 10
-2
 2.88 x 10
-2
 3.30 x 10
-4
 2.66 x 10
-2
 1.90 x 10
-4
 h
-1
 
Klysis 4.47 x 10
-1
 1.10 x 10
-2
 2.94 x 10
-1
 1.10 x 10
-2
 1.39 x 10
-1
 8.50 x 10
-2
 h
-1
 
Metabolism related 
Ylac,glc 2.00 2.40 x 10
-1
 2.00 1.20 1.11 x 10
-15
 3.30 x 10
-16
 
mmol 
mmol
-1
 
mAb synthesis related 
KA 1.38 x 10
-1
 5.82 x 10
-2
 4.15 x 10
-2
 1.50 x 10
-2
 1.87 x 10
-3
 3.00 x 10
-4
 
molecule 
cell
-1
 h
-1
 
KER 4.56 x 10
2
 3.70 x 10
2
 2.79 x 10
3
 1.10 x 10
3
 3.00 x 10
3
 6.20 x 10
2
 h
-1
 
KG 2.00 x 10
3
 5.73 x 10
2
 1.35 x 10
-3
 2.00 x 10
-3
 7.22 x 10
-3
 2.20 x 10
-3
 h
-1
 
SH 15.90 2.10 14.00 1.80 7.52 5.70 x 10
-1
 
mRNAs 
gene
-1
 h
-1
 
SL 93.10 15.00 2.33 x 10
2
 38.00 46.40 1.60 
mRNAs 
gene
-1
 h
-1
 
TH 1.35 1.20 4.90 3.50 x 10
-1
 4.71 x 10
2
 1.30 x 10
-2
 
chain 
mRNA
-1
 h
-1
 
TL 3.84 x 10
-1
 1.10 x 10
-1
 1.36 3.40 x 10
-1
 4.70 2.70 x 10
-2
 
chain 
mRNA
-1
 h
-1
 
Kh 9.77 x 10
-3
 5.90 x 10
-5
 1.00 x 10
-30
 1.00 x 10
-34
 1.00 x 10
-30
 1.00 x 10
-34
 h
-1
 
Kl 1.15 x 10
-3
 4.75 x 10
-5
 65.00 32.00 9.61 x 10
-1
 6.40 x 10
-1
 h
-1
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Table 23. Comparison of estimated parameters between models of SGE at 32C TS and TGE at 36.5C or 32C TS. 
This includes parameter values for cell growth, metabolism and mAb production.  
Parameter SGE 32
o
C 
95% conf. 
internals 
TGE 36.5
o
C 
95% conf. 
internals 
TGE 32
o
C 
95% conf. 
internals 
Units 
Growth/death related 
max 7.49 x 10
-1
 3.20 x 10
-2
 1.12 1.10 x 10
-2
 1.58 x 10
-1
 2.10 x 10
-3
 h
-1
 
d,max 3.96 x 10
-2
 2.00 x 10
-3
 2.88 x 10
-2
 3.30 x 10
-4
 2.66 x 10
-2
 1.90 x 10
-4
 h
-1
 
Klysis 2.14 x 10
-1
 5.70 x 10
-2
 2.94 x 10
-1
 1.10 x 10
-2
 1.39 x 10
-1
 8.50 x 10
-2
 h
-1
 
Metabolism related 
Ylac,glc 5.32 x 10
-3
 1.30 x 10
-3
 2.00 1.20 1.11 x 10
-15
 3.30 x 10
-16
 
mmol 
mmol
-1
 
mAb synthesis related 
KA 1.94 x 10
-3
 1.80 x 10
-4
 4.15 x 10
-2
 1.50 x 10
-2
 1.87 x 10
-3
 3.00 x 10
-4
 
molecule 
cell
-1
 h
-1
 
KER 9.03 x 10
2
 35.10 2.79 x 10
3
 1.10 x 10
3
 3.00 x 10
3
 6.20 x 10
2
 h
-1
 
KG 2.30 x 10
4
 1.26 x 10
2
 1.35 x 10
-3
 2.00 x 10
-3
 7.22 x 10
-3
 2.20 x 10
-3
 h
-1
 
SH 1.11 x 10
2
 7.40 14.00 1.80 7.52 5.70 x 10
-1
 
mRNAs 
gene
-1
 h
-1
 
SL 1.58 x 10
2
 5.30 2.33 x 10
2
 38.00 46.40 1.60 
mRNAs 
gene
-1
 h
-1
 
TH 2.17 9.50 x 10
-2
 4.90 3.50 x 10
-1
 4.71 x 10
2
 1.30 x 10
-2
 
chain 
mRNA
-1
 h
-1
 
TL 5.66 x 10
-1
 2.80 x 10
-2
 1.36 3.40 x 10
-1
 4.70 2.70 x 10
-2
 
chain 
mRNA
-1
 h
-1
 
Kh 1.68 x 10
-3
 2.30 x 10
-4
 1.00 x 10
-30
 1.00 x 10
-34
 1.00 x 10
-30
 1.00 x 10
-34
 h
-1
 
Kl 1.13 x 10
-3
 3.80 x 10
-4
 65.00 32.00 9.61 x 10
-1
 6.40 x 10
-1
 h
-1
 
 
7.2.2. Discussion of model results for intracellular nucleotide and NSD 
metabolism 
Despite the longer retention time of mAb within the Golgi apparatus estimated by the cell 
dynamics model, it is rather interesting to observe through experiments limited galactosylation on the 
secreted product generated from the TGE processes (Chapter 6, Figure 45). By using the same 
nucleotide and NSD model as for SGE to describe the behaviour of the TGE system, parameter 
estimation NSD model was performed using the maximum likelihood formulation in gPROMS 
v.4.0.0. and the corresponding model simulations were compared to our measured data. 
The nucleotide and NSD concentration profiles from cells undergoing TGE are pronouncedly 
different from their profiles in SGE at either temperature. Figures 56 and 57 show good alignments 
between model simulations and experimental results for 9 different nucleotides and NSD species in 
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TGE at both temperatures. When compared to species in SGE, our results show that net 
concentrations of ATP in TGE are higher; this could be a result of the combination of lower viable 
cell density and a more robust citric acid cycle in cells undergoing TGE, especially at 32C. GTP 
concentrations, however, are significantly lower in the TGE system. Since GTP molecules can be 
readily converted into ATP, our results suggest that the yield of ATP from GTP is probably higher 
than in cells cultured in TGE than in SGE (Figures 56 A & B). Moreover, UTP concentration profiles 
are comparable among all conditions examined. 
In the case of NSD metabolism, our model suggests that the net concentration of UDP-Glc is 
lower in TGE conditions than in SGE at 36.5C. Despite the reduced concentrations of UDP-Glc 
species, comparable levels of UDP-GlcNAc and UDP-GalNAc are observed in cells undergoing TGE 
at physiological temperature, but significantly reduced amounts in TGE at 32C, when compared to 
concentration profiles from SGE at 36.5C. The simulated results are in good agreement with those 
from our FBA studies in Chapter 6, where higher carbon flux is channelled only towards UDP-
HexNAc in cells cultured in TGE at physiological temperature. However when compared to levels in 
SGE at 32C, UDP-Glc concentration is comparative higher in both conditions of TGE, and both 
UDP-HexNAc species possess higher net concentrations in TGE (Figures 57 D, F & G). Despite good 
fits generated from both sets of parameter values in the TGE model, they fail to represent the 
fluctuations of the experimental data points between days 4 to 9, when the levels of UDP-Gal are 
below the detection limit of our HPLC method. Apart from these points, the high level of UDP-Gal at 
lag growth phase and the higher net concentration in TGE at 32C are generally well described by the 
model.  
In addition, the model provides estimates of intracellular glucose and glutamine levels, which 
are essential inputs to NSD synthesis. Simulation results for intracellular glucose in the TGE model 
provide good fits to the experimental data. In line with the increased glucose flux entering the cells in 
TGE at 32C, intracellular glucose concentration is higher in TGE than in SGE (Figure 56 H & Figure 
57 H). However, our model fails to describe the exact concentration profile of intracellular glutamine 
in TGE at 32C, underestimating its peak intracellular concentration on day 12.  
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Figure 56. Comparison of nucleotide and NSD profiles from model simulations to experimental data in fed-batch 
CHO cell cultures in SGE at 36.5C (red), and in TGE at 36.5C or at 32C TS (green). This includes the intracellular 
concentrations of ATP (A), GTP (B), UTP (C), UDP-Glc (D), UDP-Gal (E), UDP-GlcNAc (F), UDP-GalNAc (G), Int-
Glc (H) and Int-Gln (I).   
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Figure 57. Comparison of nucleotide and NSD profiles from model simulations to experimental data in fed-batch 
CHO cell cultures in SGE at 32C TS (pink), and in TGE at 36.5C or at 32C TS (green). This includes the 
intracellular concentrations of ATP (A), GTP (B), UTP (C), UDP-Glc (D), UDP-Gal (E), UDP-GlcNAc (F), UDP-
GalNAc (G), Int-Glc (H) and Int-Gln (I).   
Estimation of the Vmax and Km values for enzymes that are involved in the biosynthesis of 
nucleotides and NSDs are indeed useful in understanding this part of metabolism and comparing the 
synthetic rate of each species when changes in bioprocess conditions are introduced. Tables 24 and 25 
compare the estimated parameter values for the NSD model in TGE at both temperatures, to those 
estimated for the SGE models at 36.5C or 32C, respectively. In line with the measured ATP 
concentrations, the TGE model suggests higher Vmax values in cells that are cultured in TGE. On the 
other hand, GTP species is particularly interesting, as the estimated Vmax values for GTP related 
enzymes from the TGE model are higher than that estimated by the SGE model, despite the lower net 
concentration profile observed experimentally. These estimated Vmax values seem to support our 
initial hypothesis, that the rate of conversion from GTP to ATP is high in TGE; as a result increased 
enzyme efficiency is required to synthesize GTP.  
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As for NSD synthesis, estimated Vmax and Km values of NSD-synthetic enzymes are reflective 
of the concentration profiles of their respective output species. Vmax values of most NSD-related 
enzymes are lower in TGE when compared to those estimated in SGE at 36.5C, with the exception of 
enzymes responsible for UDP-Gal synthetic pathway (Chapter 4, Figure 27) where their Vmax values 
of which in TGE at both 36.5C and 32C are similar to that predicted in SGE at 36.5C. That is also 
in line with their comparable net concentrations of UDP-Gal as discussed above. When compared to 
parameters estimated from the SGE model at 32C, estimated Vmax values of other NSD-related 
enzymes in TGE are mostly slightly lower or similar, and these are well reflected by the comparable 
concentration profiles illustrated in Figure 57. Our experimental results are therefore well represented 
by the TGE model. In addition to enzyme kinetics, the TGE model suggests higher transport rates of 
NSD species entering the ER and Golgi apparatus only at 36.5C. This correlates well with the 
increased levels of mRNA expression of transporters for UDP-Gal and UDP-GlcNAc in TGE at 
36.5C that could have assisted NSD transport (Figure 58), especially when compared to expression 
in SGE at 32C. A full list of parameter values for the NSD model can be found in Appendix III Table 
3. 
 
Figure 58. mRNA expression levels of transporters of UDP-Gal and UDP-GlcNAc, in SGE at 36.5C and 32C TS, 
and in TGE at 36.5C. Results are averaged measurements at 36.5C (n6) and 32C (n3) in SGE; 36.5C (n=3) in 
TGE.  The error bars represent the standard deviation of the samples.  Statistical significance was calculated using a 
Student’s t-test and was represented by: p0.05(*), p0.01(**) and p0.001(***). 
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Table 24. Comparison of estimated parameters from NSD models between two expression systems, among SGE at 
36.5C, and in TGE at 36.5C or at 32C TS. This includes parameter values for nucleotide and NSD syntheses.  
 
Values 
 
Parameter SGE 36.5
o
C 
95% conf. 
internals 
TGE 36.5
o
C 
95% conf. 
internals 
TGE 32
o
C 
95% conf. 
internals 
Units 
Nucleotide related 
Vmax, ATP 
synthetic pathway 
13.70 2.00 x 10
-1
 54.60 26.00 3.20 6.00 x 10
-1
 
mmol Lcell
-1
 
h
-1
 
Vmax, GTP 
synthetic pathway 
44.20 1.10 2.31 x 10
2
 23.00 28.50 3.90 
mmol Lcell
-1
 
h
-1
 
Vmax, UTP 
synthetic pathway 
34.90 1.10 4.74 x 10
2
 1.20 2.46 5.40 x 10
-1
 
mmol Lcell
-1
 
h
-1
 
NSD related 
   
KTP,UDPGlc 
synthetic pathway 
4.11 x 10
-3
 1.90 x 10
-4
 1.00 4.30 x 10
-2
 4.89 x 10
-1
 2.00 x 10
-2
 mM 
KTP,UDPGal 
synthetic pathway 
4.68 x 10
-2
 5.40 x 10
-3
 1.26 x 10
-2
 4.80 x 10
-3
 1.00 x 10
-30
 1.00 x 10
-34
 mM 
KTP,UDPGlcNAc 
synthetic pathway 
1.00 x 10
-30
 1.00 x 10
-34
 61.40 8.10 x 10
-5
 5.02 7.70 x 10
-2
 mM 
Vmax, UDPGlc 
synthetic pathway 
5.00 x 10
-1
 1.25 x 10
-3
 4.86 8.70 x 10
-1
 7.17 x 10
-4
 1.50 x 10
-4
 
mmol Lcell
-1
 
h
-1
 
Vmax, UDPGal 
synthetic pathway 
2.26 x 10
-3
 9.20 x 10
-4
 2.06 x 10
-3
 6.70 x 10
-4
 5.76 x 10
-2
 2.20 x 10
-7
 
mmol Lcell
-1
 
h
-1
 
Vmax, UDPGlcNAc 
synthetic pathway 
2.17 9.00 x 10
-2
 1.00 1.28 x 10
-1
 4.95 x 10
-1
 1.40 x 10
-2
 
mmol Lcell
-1
 
h
-1
 
KUDPGlc,Glc 
synthetic pathway 
6.66 x 10
2
 74.00 9.67 x 10
2
 8.70 x 10
-5
 1.00 x 10
-30
 1.00 x 10
-34
 mM 
KUDPGal,Gal 
synthetic pathway 
4.73 x 10
-1
 9.10 x 10
-3
 5.00 x 10
-1
 4.30 x 10
-2
 2.00 x 10
2
 2.20 x 10
-7
 mM 
KUDPGlcNAc,GlcN
Ac  synthetic 
pathway 
1.82 x 10
-1
 3.00 x 10
-3
 22.20 5.40 1.00 x 10
-30
 1.00 x 10
-34
 mM 
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Table 25. Comparison of estimated parameters from NSD models between two expression systems, among SGE at 
32C TS, and in TGE at 36.5C or at 32C TS. This includes parameter values for nucleotide and NSD syntheses.  
 
Values 
 
Parameter SGE 32
o
C 
95% conf. 
internals 
TGE 36.5
o
C 
95% conf. 
internals 
TGE 32
o
C 
95% conf. 
internals 
Units 
Nucleotide related 
Vmax, ATP 
synthetic pathway 
2.11 5.10 x 10
-1
 54.60 26.00 3.20 6.00 x 10
-1
 
mmol Lcell
-1
 
h
-1
 
Vmax, GTP 
synthetic pathway 
2.68 x 10
3
 4.70 2.31 x 10
2
 23.00 28.50 3.90 
mmol Lcell
-1
 
h
-1
 
Vmax, UTP 
synthetic pathway 
9.26 x 10
2
 21.00 4.74 x 10
2
 1.20 2.46 5.40 x 10
-1
 
mmol Lcell
-1
 
h
-1
 
NSD related 
   
KTP,UDPGlc 
synthetic pathway 
1.00 x 10
-30
 1.00 x 10
-34
 1.00 4.30 x 10
-2
 4.89 x 10
-1
 2.00 x 10
-2
 mM 
KTP,UDPGal 
synthetic pathway 
3.47 x 10
-4
 2.49 x 10
-19
 1.26 x 10
-2
 4.80 x 10
-3
 1.00 x 10
-30
 1.00 x 10
-34
 mM 
KTP,UDPGlcNAc 
synthetic pathway 
9.76 4.80 x 10
-5
 61.40 8.10 x 10
-5
 5.02 7.70 x 10
-2
 mM 
Vmax, UDPGlc 
synthetic pathway 
5.84 x 10
-1
 1.70 x 10
-2
 4.86 8.70 x 10
-1
 7.17 x 10
-4
 1.50 x 10
-4
 
mmol Lcell
-1
 
h
-1
 
Vmax, UDPGal 
synthetic pathway 
1.00 x 10
-30
 1.00 x 10
-34
 2.06 x 10
-3
 6.70 x 10
-4
 5.76 x 10
-2
 2.20 x 10
-7
 
mmol Lcell
-1
 
h
-1
 
Vmax, UDPGlcNAc 
synthetic pathway 
7.66 1.40 x 10
-1
 1.00 1.28 x 10
-1
 4.95 x 10
-1
 1.40 x 10
-2
 
mmol Lcell
-1
 
h
-1
 
KUDPGlc,Glc 
synthetic pathway 
10.50 12.00 9.67 x 10
2
 8.70 x 10
-5
 1.00 x 10
-30
 1.00 x 10
-34
 mM 
KUDPGal,Gal 
synthetic pathway 
4.40 x 10
2
 43.00 5.00 x 10
-1
 4.30 x 10
-2
 2.00 x 10
2
 2.20 x 10
-7
 mM 
KUDPGlcNAc,GlcN
Ac  synthetic 
pathway 
4.53 x 10
-1
 21.00 22.20 5.40 1.00 x 10
-30
 1.00 x 10
-34
 mM 
 
 
7.2.3. Discussion of Golgi N-linked glycosylation model in TGE system  
The third part of the TGE model describes the process of mAb N-linked glycosylation within 
the Golgi apparatus, which is the same as for the SGE system. Model outputs from both cell culture 
dynamics and the NSD model were input into the Golgi N-linked glycosylation model developed by 
Jimenez del Val et al. (2011), and simulation was performed in gPROMS version 4.0.0. The resulting 
model outputs were compared to their respective sets of measured glycan data. We sought to 
investigate the reason of the glycoform difference between SGE and TGE systems, through re-
estimating and comparing key parameters such as enzyme dissociation constants and concentrations 
of glycosyltransferases involved in product glycosylation between the two expression systems.  
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 Figures 59 A and B show the comparison between experimental and simulated distribution of 
the cumulative N-linked mAb Fc-glycan structure on day 10, 12 and 14 in TGE at 36.5C and 32C, 
respectively. Owing to the low mAb titre in TGE, sufficient amounts of mAb for analysis were only 
obtained beyond day 10 of the culture period. To aid comparison between SGE and TGE, results for 
days 10, 12 and 14 were therefore chosen. The model outputs show that the TGE model describes the 
experimental data equally well as the SGE model does, where differences between estimated and 
measured values in both SGE and TGE models are within 3.5% in most species. Moreover, simulation 
results from both sets of parameter values in the TGE model compare reasonably very well to their 
respective experimental inputs. Table 26 shows that the average difference between experimental and 
computational values is around 0.9% and they all lay within/below the limit of 3.5%, with two 
exceptions with discrepancies of 3.7% and 6.1%. Despite the higher percentage differences observed, 
they are both overlapping with error-bars of their respective experimental data. TGE model 
simulations are therefore still within the measured data range. Model simulations of the mAb glycan 
profile between the two conditions in TGE are indeed very comparable and in good agreement with 
our experimental analysis in Chapter 6. 
 
 
Figure 59. Comparison between experimentally and model simulated determined fractions of the cumulative N-
linked glycoforms of secreted mAb for three time points during cell culture, when CHO cells were cultured in TGE at 
36.5C (A), or at 32C (B) when mild hypothermic condition was introduced 24 h post-transfection.  
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Table 26. Percentage differences between model-simulated and experimentally measured values of N-linked glycan 
fractions for mAb Fc-regions, for CHO cells that were cultured at 36.5C and 32C in TGE.  
  Deviation from experimental data (%) 
    Man5 G0 G0F G1F G2 G2F 
36.5C 
Day 10 0.26 0.52 2.02 0.77 0.19 0.29 
Day 12 0.32 0.16 1.03 0.69 0.21 0.06 
Day 14 0.44 1.44 2.65 0.51 0.14 0.12 
32C 
Day 10 0.29 0.79 3.66 2.08 0.07 0.42 
Day 12 0.07 0.65 0.58 0.62 0.11 0.43 
Day 14 0.81 1.11 6.12 3.45 0.15 0.61 
 
To achieve the above results, we re-estimated the Km values and glycosyltransferase 
concentrations in the TGE model. The results can help us shed more light onto the differences in mAb 
N-linked glycan profiles that arise among the four conditions examined in SGE and TGE systems 
(Table 27 & 28). Despite minimal variations in secreted mAb glycosylation in TGE between the two 
temperatures, increased fractions of G0 species and a slight reduction in G0F portion are observed in 
cells undergoing TGE at 32C (Chapter 6, Figure 38). By comparing outputs from the TGE model at 
different temperatures, Man II enzyme concentration is in TGE at 32C suggested to be 7 times higher 
than that at 36.5C, it is also accompanied by significant reduction in the Km value of this enzyme; as 
a result it flavours activity by manosidases, providing more substrates for GnTI and II to act on and 
therefore encourages higher levels of G0 species at 32C. In addition, FucT concentration is also 
suggested to be lower in this condition; the reduced FucT enzyme level at 32C may prevent the 
conversion of G0F and other fucose-bearing-species, G0 profile therefore remains higher.  
When comparing parameter values for both conditions in the TGE system to the set of 
estimated values for the SGE model at 36.5C, parameter values in TGE at 32C suggest that the 
limitation observed experimentally on mAb galactosylation at 32C (Chapter 6, Figure 45 A) could be 
a result of a combination of the reduced GalT enzyme expression and increased values in its Km 
values. However in the case of TGE at 36.5C, the model suggests that the amount of GalT enzyme 
required for mAb galactosylation is of similar level as that in SGE at 36.5C, and reduced availability 
of UDP-Gal species appears more as the key factor that affect mAb galactosylation instead. The 
computational outputs coincide with our experimental results (Chapter 6, Figure 48 A) and distinguish 
reasons for limiting mAb galactosylation in TGE at different temperatures. In addition, the level of 
GnTII is estimated to be higher in TGE at 32C than that in SGE at 36.5C. Despite not exactly 
coordinating with what was observed experimentally (where GnTII mRNA expression levels were 
7.2COMPARING MODEL SIMULATION RESULTS BETWEEN SGE AND TGE SYSTEMS 161 
 
 
comparable), the higher GnTII enzyme concentration estimated here in the model suggested that there 
could be a high possibility that GnTII assisted mAb galactosylation by providing increased number of 
bi-antennary structures for the limited amount of GalT enzymes to work on, so as to achieve a rate of 
mAb galactosylation higher than that of TGE at 36.5C but still remained lower than SGE at 36.5C. 
When comparing mAb glycosylation of TGE to that in SGE at 32C, estimated parameter 
values from the TGE model indicate that the higher Man5 levels observed in Chapter 6 (Figure 45 B), 
is a result of increased Man I enzyme level which converts Man6 to Man5, together with a reduced kd 
value of Man II enzyme at 32C (TGE), meaning that fewer Man5 species are being processed (Table 
28).  The comparable level of mAb galactosylation between molecules produced under SGE at 32C 
and TGE at 36.5C appears to be attributed to the comparable amount of GalT enzyme that is 
estimated to exist under both conditions. The increased fractions of G0 and G2 observed in TGE at 
32C, in contrast to those generated in SGE at 32C, correlate well to the lower concentration of the 
FucT enzyme which limits the activity of FucT for mAb fucosylation; this at the same time limits the 
level of G0F species in TGE at 32C.  
In both comparisons drawn above, it is quite interesting how there are conflicting results 
suggested between model estimation and experimental transcript analysis of GnTI and II. However 
one has to bear in mind that these estimated values has not yet been validated. They only give an idea 
about the kinetics of glycosyltransferase involved but not necessarily 100% reliable. As a result, to 
improve the quality of this work, model validation is indeed extremely important and will be included 
as one of the main future studies.  
 
Table 27. Estimated enzyme concentrations and their respective dissociation constants in SGE at 36.5C, and in TGE 
at 36.5C or at 32C TS. 
 
Parameter SGE 36.5C 
95% conf. 
internals 
TGE 36.5°C 
95% conf. 
internals 
TGE 32°C 
95% conf. 
internals 
Units 
 
Glycosyltransferase concentrations 
Man I 9.70 x 10
-2
 1.31 x 10
-2
 12.60 1.80 x 10
-1
 7.59 4.40 x 10
-1
 M 
Man II 1.82 x 10
-1
 3.50 x 10
-2
 3.20 x 10
-1
 4.50 x 10
-2
 2.32 1.70 x 10
-1
 M 
GnT I 6.05 2.10 x 10
-1
 3.73 8.5 x 10
-2
 5.24 4.60 x 10
-2
 M 
GnT II 1.14 2.50 x 10
-1
 2.94 9.70 x 10
-5
 2.79 4.40 x 10
-4
 M 
GalT 12.60 1.70 13.00 6.00 x 10
-2
 3.21 5.40 x 10
-1
 M 
FucT 13.30 8.43 8.54 1.00 x 10
-2
 5.49 4.30 x 10
-1
 M 
Substrate Enzyme dissociation constants 
   
Man6 Kd,Man I D 4.44 x 10
-1
 1.60 x 10
-2
 3.93 x 10
2
 3.10 x 10
-2
 64.90 3.10 x 10
-2
 M 
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Man5 Kd,Man II A 3.45 x 10
-5
 1.84 x 10
-6
 5.91 x 10
2
 6.40 x 10
-7
 6.75 x 10
-8
 2.50 x 10
-10
 M 
CoreGlcNAc1 Kd,GnT II 5.31 4.20 x 10
-1
 1.40 x 10
3
 46.00 1.08 x 10
4
 4.40 x 10
-4
 M 
CoreGlcNAc2 
(-1,3 arm) 
Kd,GalT a1A 3.00 x 10
4
 1.95 x 10
3
 5.18 x 10
3
 1.50 x 10
-5
 4.60 x 10
3
 1.10 x 10
-3
 M 
CoreGlcNAc2 
(-1,6 arm) 
Kd,GalT a1B 6.26 2.73 9.69 x 10
3
 3.10 x 10
-6
 4.19 x 10
3
 2.40 x 10
3
 M 
CoreGlcNAc2
Gal1 (-1,6 
arm) 
Kd,GalT a2A 2.23 x 10
3
 2.67 x 10
2
 3.98 x 10
2
 2.00 x 10
-4
 6.98 x 10
3
 7.10 x 10
-4
 M 
CoreGlcNAc2 Kd,Fuc A 1.34 x 10
4
 9.34 x 10
2
 1.24 x 10
2
 5.30 x 10
-4
 2.05 3.90 x 10
-2
 M 
 
Table 28. Estimated enzyme concentrations and their respective dissociation constants in SGE at 32C TS, and in 
TGE at 36.5C or at 32C TS. 
 
Parameter SGE 32C 
95% conf. 
internals 
TGE 36.5°C 
95% conf. 
internals 
TGE 32°C 
95% conf. 
internals 
Units 
 
Glycosyltransferase concentrations 
 
Man I 1.24 x 10
-1
 8.50 x 10
-2
 12.60 1.80 x 10
-1
 7.59 4.40 x 10
-1
 M 
 
Man II 1.94 x 10
-1
 7.30 x 10
-3
 3.20 x 10
-1
 4.50 x 10
-2
 2.32 1.70 x 10
-1
 M 
 
GnT I 7.69 x 10
-1
 6.80 x 10
-4
 3.73 8.5 x 10
-2
 5.24 4.60 x 10
-2
 M 
 
GnT II 7.75 x 10
-1
 1.30 x 10
-4
 2.94 9.70 x 10
-5
 2.79 4.40 x 10
-4
 M 
 
GalT 6.66 4.10 x 10
-2
 13.00 6.00 x 10
-2
 3.21 5.40 x 10
-1
 M 
 
FucT 45.54 5.96 8.54 1.00 x 10
-2
 5.49 4.30 x 10
-1
 M 
Substrate Enzyme dissociation constants 
   
Man6 Kd,Man I D 2.67 x 10
-1
 3.10 x 10
-2
 3.93 x 10
2
 3.10 x 10
-2
 64.90 3.10 x 10
-2
 M 
Man5 Kd,Man II A 4.44 x 10
-5
 4.71 x 10
-9
 5.91 x 10
2
 6.40 x 10
-7
 6.75 x 10
-8
 2.50 x 10
-10
 M 
CoreGlcNAc1 Kd,GnT II 1.16 x 10
2
 13.00 1.40 x 10
3
 46.00 1.08 x 10
4
 4.40 x 10
-4
 M 
CoreGlcNAc2 
(-1,3 arm) 
Kd,GalT a1A 2.29 x 10
4
 3.15 x 10
3
 5.18 x 10
3
 1.50 x 10
-5
 4.60 x 10
3
 1.10 x 10
-3
 M 
CoreGlcNAc2 
(-1,6 arm) 
Kd,GalT a1B 11.60 2.54 9.69 x 10
3
 3.10 x 10
-6
 4.19 x 10
3
 2.40 x 10
3
 M 
CoreGlcNAc2
Gal1 (-1,6 
arm) 
Kd,GalT a2A 3.38 x 10
2
 4.80 x 10
2
 3.98 x 10
2
 2.00 x 10
-4
 6.98 x 10
3
 7.10 x 10
-4
 M 
CoreGlcNAc2 Kd,Fuc A 1.34 x 10
4
 3.00 x 10
2
 1.24 x 10
2
 5.30 x 10
-4
 2.05 3.90 x 10
-2
 M 
Despite providing more information about the kinetics properties of enzymes involved in 
protein glycosylation, estimated parameters such as enzyme concentration, kcat and Km values are 
correlated. As a result, it is difficult to provide unique estimates of either of these parameters. Since 
galactosylation is important in mAb production, there is a high potential for glyco-engineering. It is 
therefore essential to test the reliability of the sets of estimated parameters describing enzyme kinetics 
and to identify if variation in GalT enzymatic activity is solely contributed from changes in kcat value, 
or from a combinatorial effect by the protein expression of GalT. To test the hypothesis, a comparison 
in glycosyltransferase concentrations between model outputs and measured concentrations were 
performed. Protein expression of galactosyltransferase (GalT) is experimentally determined in 
Chapter 6 (Figure 48 A & B). Firstly, outputs from the TGE model propose that GalT concentration in 
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TGE at 32C to be around 39% lower than that at 36.5C; this correlates reasonably well with our 
experimentally measured results where the average GalT protein expression is approximately 31% 
lower at 32C. Tables 29 A and 29 B compare the average percentage difference of GalT enzyme 
concentration among all four conditions examined in this chapter, through experimentally analysis 
and model estimation, respectively. Our results show that variations between experimentally 
measured data and estimated model outputs are indeed very marginal, where differences between 
most values in the Tables 29 A and 29 B are within 8%, with the exception of a 20% difference 
between SGE at 2°C and TGE at 36.5°C. Despite that fact that both models are not validated by 
separate sets of experiment data, the comparability between the estimated and measured values 
suggested in Tables 29 A and 29 B already demonstrates the high capability of both models in 
representing the underlying biological systems.  
 
Table 29. Percentage difference of GalT enzyme concentration among all four conditions examined, that are (A) 
experimentally measured, or (B) estimated by the SGE and TGE models.  
A. 
Average percentage difference of experimentally 
determined GalT protein expression among all 
conditions (%) 
 
SGE 36.5C SGE 32C TGE 32C 
TGE 36.5C 17.7% 48.2% 30.5% 
TGE 32C 42.7% 14.3% - 
 
B. 
Average percentage difference of model estimated 
GalT protein concentration among all conditions (%) 
 
SGE 36.5C SGE 32C TGE 32C 
TGE 36.5C 16.6% 68.0% 38.7% 
TGE 32C 48.9% 3.0% - 
 
 Comparison of N-linked Golgi model outputs between the two expression systems suggests 
that the reduced levels of mAb galactosylation in TGE when compared to those in SGE, are mainly 
due to reduced expression of GalT enzymes. Our model suggests that enzyme concentrations and 
kinetics properties of other glycosyltransferases also play a role in altering the mAb glycan structures, 
such as mAb core-fucose and high mannose structures. Despite such findings, it can always be argued 
that decreases in the expression of glycosyltransferases might only be a result of reduced mAb 
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volumetric yield in the TGE system; however the comparable concentrations of GalT between SGE at 
36.5C and TGE at 36.5C for instance, show that the concentration profiles of these enzymes are not 
entirely dependent on the amount of mAb molecules produced, but more expression system and 
temperature dependent. Therefore, in addition to feedings of NSD precursors and amino acids, one 
can attempt to manipulate the expression of different glycosyltransferases to improve both the quality 
of the secreted mAb products. Since the expression of GnTI and GnTII are shown in previous 
chapters to be important enzymes that determine the branching of mAb N-linked, and we are 
experiencing conflicting results between model estimation of GnTII expression and experimentally 
determined mRNA expression, it is therefore necessary to validate these estimations from the model 
by analysing the protein expression of glycosyltransferases, preferably GnTI and II.  
7.3. Conclusions 
The first part of this chapter analysed CHO cell performance in terms of cell metabolisms and 
mAb Fc N-linked glycosylation in cultures that undergo transient gene expression at physiological 
temperature or with a temperature shift to 32C 24 hours post DNA plasmid transfection through a 
mechanistic mathematical model. The latter was based on the SGE model presented in Chapter 5 with 
slight modifications in the cell dynamics model and re-estimated key parameter sets for each 
temperature examined in the TGE system. Our results showed that our TGE model is capable of 
describing experimental results well in all aspects under both conditions. The second part of the 
chapter compared model outputs between the SGE and the TGE models, with an aim to identify 
differences in mAb productivity and glycan profiles between the two expression systems. The 
tremendous difference in mAb productivity between SGE and TGE was not only a consequence of the 
lower IVCC; the cell dynamics model proposed that reduced transcription rates of both heavy and 
light chains were the bottlenecks for mAb production in the TGE system. On the other hand, major 
variations in mAb Fc-glycosylation appear between products that were produced in cells undergoing 
SGE at 36.5C and at both temperatures examined in TGE. Most enzymes that were involved in NSD 
synthesis, their enzymatic efficiencies, GalT in particular, were suggested by the NSD model to be 
lower. This correlated well with the reduced metabolic fluxes for nucleotide and NSD production 
calculated for TGE in Chapter 7. In addition, the N-linked Golgi glycosylation module of the model 
identified that the enzyme concentrations of GalT, FucT and GnTI were lower and their kinetics 
slower. The combination of the less efficient NSD synthetic network and reduced expression of key 
glycosyltransferases, such as GnTI, II and GalTs contributed to limiting bi-antennary structures of 
mAb, which are required for further N-linked glycan processing including mAb galactosylation.  
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Based on the comparison of model outputs between SGE and TGE, rather than modifying the 
bioprocess through a “Quality by Testing” approach, one can now target a specific area through 
tailored feeds, cell line modification, or altering other bioprocess conditions, according to the outputs 
of the model. Not only does it aim to improve the production yield or product quality, such an 
approach also enables the application of Quality by Design (QbD) in pharmaceuticals. 
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Chapter 8
Manipulating expression of N-linked 
galactosyltransferases to improve 
monoclonal antibody galactosylation 
Both experimental and computational studies on mAb glycosylation in mild hypothermic 
conditions in Chapter 4 - 7 suggest that expression levels of glycosyltransferases, 
galactosyltransferases in particular, are contributing factors that lead to variations in mAb glycan 
profiles. To improve mAb galactosylation in these conditions, manipulating expression levels of 
enzymes related to N-linked glycosylation can be an approach. This chapter attempts to manipulate 
the expression level of galactosyltransferase, through increasing the level of three micro-RNAs 
(miRNAs) that were reported to regulate expression of -1,4 galactosyltransferases. 
8.1. Background and aim 
When it comes to process optimisation to improve mAb glycosylation, there are a number of 
possible approaches; these include feeding with nutrients such as glucose, glutamine or galactose 
(Grainger and James 2013; Gramer et al. 2011; Kim do et al. 2013; Seo et al. 2014), nucleotide or 
NSD precursor supplementation (Bergfeld et al. 2012; Gramer et al. 2011; Gu and Wang 1998; Wong 
et al. 2010), or other chemical supplements such as manganese chloride (Gramer et al. 2011) or 
butyrate (Lee et al. 2014). N-linked enzyme manipulation through cell-line engineering, including the 
gene knockout (Malphettes et al. 2010; Sealover et al. 2013) or overexpression (Onitsuka et al. 2012; 
Zhang et al. 2010a). The latter option appears to be favourable, especially in bulk rProtein production 
when large volumes of external feedings can be costly and extensive dilution can be an issue.  
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Glyco-engineering in different host cell lines is an advent approach to produce humanised 
antibodies. mAb fucosylation and bisecting GlcNAc addition are often targets in glycoengineering, to 
increase binding affinity between mAb Fc region and their activating receptors. An overexpression of 
N-acetylglucosaminyltransferase III (GnT III) in eukaryotes was firstly introduced in 1999 to include 
bisecting GlcNAc in the secreted product, but the results of it had greatly impeded cell growth 
(Umana et al. 1999a). With advances in protein engineering, Roche GlycArt AG had successfully 
generated a genetically modified host cell that altered expression levels of enzymes including β(1,4)-
N-acetylglucosaminyltransferase III, β(1,4)-N-acetylglucosaminyltransferase V, β(1,4)-
galactosyltransferase, α-mannosidase II, and core α-1,6-fucosyltransferase (Pablo Umaña and Jean-
Mairet 2012), which was shown to enhance antibody-dependent cellular cytotoxicity with no 
significant negative impacts on cell growth. In addition, this technology is widely employed in other 
host cells such as yeast that are incapable of performing human-like glycosylation (Potgieter et al. 
2009), and overexpression of manosidases are necessary to prevent hypermannosylation.  
 
Figure 60. Regulation of miRNA mediated suppression and activation in different cell cycle stages. Figure is adopted 
from Valinezhad Orang et al. (2014). In brief, protein GW182 is the key regulator cells, where binding to Ago in 
proliferating cells encourages the slicing of ORF of target gene and suppresses gene expression. While the release of 
GW182 from the Ago complex in G0 cell cycle stage, especially when cells are undergoing cell cycle arrest, attracts a 
different protein Fxr1 and prevents the slicing of the open reading frame, resulting in the activation of target gene.  
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On the other hand an emerging candidate, miRNA, was proven to be useful for 
pharmaceutical bioprocessing. miRNAs are short non-coding RNA molecules (~ 20 to 25 nts) that are 
processed by the RNase III endonuclease Dicer complex in the nucleus and are coupled to RNA-
induced silencing complex (RICS) to form mi-RISCs. They possess a degree of complementarity to 
their target mRNAs and bind to the 3’-UTR (untranslated region) of their target sequences, recruiting 
an Argonaute (Ago) protein to modulate transcriptional expression. The traditional role of miRNAs 
involves gene silencing and repression through mRNA promoter attenuation. However recent studies 
show the ability of miRNAs is not only limited to gene suppression, but they can also activate gene 
translation during specific cell conditions or with or without certain stimulators (Vasudevan et al. 
2007). The most investigated case involves cell quiescence. It was reported and Figure 60 illustrates 
that when cells were arrested in G1/G0 state, miRNA binds to target mRNA and recruited argonaute 
RISC catalytic component 2 (Ago2) and fragile X mental retardation-related protein 1 (Fxr1), this 
inhibited the interaction between Ago2 and GW182, an important candidate that mediates gene-
repression, and thus promoted activation of gene translation (Valinezhad Orang et al. 2014).  
 Within the past two decades, a vast number of studies showed the application of miRNAs in 
cellular processes, ranged from cell growth and cell development (Chen et al. 2006; Cheng et al. 
2005; Croce and Calin 2005; Johnston and Hobert 2003; Matsushima et al. 2011), to modulation of 
cell metabolism and protein secretion (Filipowicz 2005; Poy et al. 2004). Recently the understanding 
of the CHO cell genome has enabled scientists to extend the ability of miRNA to improvement in 
recombinant protein bioprocessing. Jadhav et al. (2014b) demonstrated that stable overexpression of 
miR-17 increased the Erythropoietin-Fc fusion protein (EpoFc) titre by 3-fold and also enhanced 
CHO cell growth. Site-specific miRNA editing is evolutionarily conserved among species (Warnefors 
et al. 2014) and through lectin microarrays experiments, Agrawal et al. (2014) identified miRNAs or a 
combination of different miRNA that related to specific glycan biosynthetic enzymes, specifically 
miRNAs cgr-miR-500, cgr-miR-501-5p and cgr-miR-181d which are shown to be related to and 
regulate (1,4)-galactose addition during protein glycosylation. By incorporating each of the three 
pre-miRNA in separate mammalian expression vector that functions with a CMV promoter, and co-
transfecting these three pre-miRNAs into an IgG expressing CHO cell line, in this chapter we have 
decided to make use of the regulatory mechanisms of miRNA between gene activation and repression 
during cell cycle arrest, and investigated two aspects here: the effect of co-overexpressing that 
combination of three miRNAs that were suggested to relate (1,4)-galactosylation on 
galactosyltransferase expression; and whether they imposed any changes in mAb glycosylation.   
 
8.2RESULTS 169 
 
 
8.2. Results 
8.2.1. CHO cell culture behaviour upon miRNA overexpression 
In this chapter we examined four sets of experimental conditions: 1. CHO cell fed-batch 
culture at 36.5C (Control 36.5C), or 2. with a temperature shift from 36.5C to 32C on day 6 
during late exponential phase (Control 32C TS); 3. miRNA combination transfected - CHO cell fed-
batch culture with a temperature shift to 32C (miRNA 32C TS), or 4. empty vector transfected-cell 
culture with a temperature shift to 32C (null-vector 32C TS). Firstly, we examined differences in 
CHO cell growth among all conditions. Figures 61 A and B show the viable cell concentration and 
viability, and total cell density of CHO cell cultures in all conditions, respectively.  As suggested in 
Chapter 4, CHO cells possess prolonged cell viability when cultured at 32C.  A similar cell growth 
profile is observed when a null-vector is transfected and mild hypothermia was introduced. 
Conversely, viable cell density increases upon the co-transfection of the three pre-miRNA vectors at 
32C, but with cell viability above 75%, which is similar to their non-transfected counterparts at 
32C. Increased in time-course viable cell density is also reflected by a 18% rise in the IVCC of 
miRNA-transfected species when compared to that of the non-transfected species at 32C; at the same 
time the IVCC of pre-miRNA transfected cells is very comparable to that of the control cells cultured 
at 36.5C (Figure 61 C).  
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Figure 61. Cell growth profiles of control cells at 36.5C and with a temperature shift to 32C, together with miRNA 
or null-vector transfected CHO cell culture under mild hypothermic conditions. (A). Viable cell concentration and 
cell viability profiles were measured along the period of cell culture in all conditions examined, together with the total 
cell concentration profile in (B). IVCC profiles of respective conditions (C). Results are average measurements 
control cells at 36.5C (n=2) and 32C (n=2), or miRNA-transfection (n=2) and null-vector transfected (n=2) at 32C. 
The error bars represent the standard deviation of the samples. TS: Temperature shift. 
8.2.2. mAb production in miRNA-transfectants 
Accompanied by the variation in CHO cell growth profile, the volumetric and specific mAb 
productivities in miRNA transfected cells are shown to be higher (Figure 62 A). Correlated well with 
previous results observed in Chapter 4, higher specific mAb productivity (qmab) is achieved when 
biphasic culture temperatures are introduced during cell culture process (Figure 62 B). Upon co-
transfection of pre-miRNAs, qmAb value of mAb molecules generated from miRNA transfectants is 
comparable to that of the control species cultured at 32C (Figure 62 C). At the same time, the 
miRNA-transfected species show a 7.8% increase in its qmAb when compared to cells transfected with 
a null-vector (Figure 62 D). The increase in mAb production appears to be related to the improved 
cell growth and cell viability upon the miRNA transfection. However further investigation into CHO 
cell metabolism is required to identify the underlying factors for improved mAb production.  
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Figure 62. (A). Volumetric and specific mAb productivities when control cells are culture under all four conditions 
examined, including a comparison between control cells at both temperatures (B), between control cells and miRNA-
transfectants at 32C (C), and between miRNA- and null-vector- transfected cells at 32C (D). Results were average 
measurements at 36.5C (n=2) and 32C TS (n=2) in control cells, miRNA and null-vector transfectants. The error 
bars represent the standard deviation of the samples. TS: Temperature shift. 
8.2.3. The impact of miRNA overexpression on CHO cell metabolism  
Firstly we examined changes in nutrient metabolism upon miRNA transfection. As a result of 
increase in viable cell density in miRNA-transfectants, transfected cultures consumed a higher amount 
of glucose than the control and the null-vector transfected cultures at 32C, and the rate of 
consumption in miRNA transfectants was comparable to that of the control cells at 36.5C (Figures 63 
A & D). On the other hand, Figure 63 B shows that lactate metabolism shifts from predominantly 
lactate production to lactate consumption upon the induction of mild hypothermia during cell culture 
in control cells, with a 53% increase in lactate consumption on day 6 which correlates well with 
previous results demonstrated in Chapter 4. A similar concentration profile is observed when a null-
vector is transfected to CHO cells at 32C. Interestingly, lactate concentration profile of miRNA 
transfectants at 32C resembles that of the control cells at 36.5C on day 6 and day 7 shortly after the 
reduction of culture temperature to 32C. Lactate production is reduced from day 8 (stationary growth 
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phase) of cell culture in miRNA transfectants. Figure 63 C shows that the rate of lactate consumption 
is high between day 9 and day 11. The final net concentration of lactate in miRNA transfected cells on 
day 12 is comparable to those in control cells at 32C, which is 44% lower than that in control cells at 
36.5C. Unlike control cells at 36.5C which utilise predominantly glucose, the behaviour of miRNA-
transfected cells towards lactate metabolism sits between control cells cultured at 36.5C and 32C: 
they consume a higher level of glucose but at the same time the uptake rate of lactate increases. Our 
results suggest that the amount of carbon required increases upon the co-transfection of pre-miRNA 
vectors to fuel cellular activities such as glycolysis and the TCA cycle. However, it still remains 
difficult to speculate whether these extra carbon molecules are consumed towards protein synthesis or 
glycosylation. 
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Figure 63. Nutrient metabolism in CHO cells under all four conditions examined. (A). Concentration profile of 
extracellular glucose. (B). Concentration profile of extracellular lactate. (C). Rate of lactate production/consumption 
per viable cell under all four conditions. (D). Rate of glucose production/consumption per viable cell. Results were 
average measurements at 36.5C (n=2) and 32C TS (n=2) in control cells, miRNA and null-vector transfectants. The 
error bars represent the standard deviation of the samples. TS: Temperature shift. 
In addition to increased glucose and lactate uptakes, amino acid utilization was also examined 
in miRNA transfectants. Figures 64 A – F show the concentration profiles and consumption rates of 
six amino acids that contribute 5 - 9% and above of the total mAb peptide sequence, namely valine, 
threonine, leucine, proline, lysine and glutamate. Their amino acid concentration profiles resemble 
that of glucose, where in most cases the extracellular concentrations of control cells at 32C and null-
vector transfectants are higher than those observed in control cells at 36.5C and in miRNA 
transfectants. Variations in extracellular concentration are without doubt related to changes in viable 
cell density among the four conditions, rates of amino acid consumption per viable cell are therefore 
considered. In most cases, rates of consumption of the six amino acids are higher in miRNA 
transfectants than in control cells that are cultured under mild hypothermic temperature, with 
percentage increase ranges from 24% to 70%. Not only do these amino acids fuel the TCA cycle for 
energy generation, they also account for at least 40% of the mAb peptide sequence; increased rates of 
consumption in these amino acids upon miRNA transfection have a positive effect on mAb synthesis.  
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Figure 64. Amino acid metabolism in CHO cells under all four conditions examined. Extracellular concentration and 
consumption rate profiles of (A). valine, (B). threonine, (C). leucine, (D). proline, (E). lysine and (F). glutamate. 
Results were average measurements at 36.5C (n=2) and 32C TS (n=2) in control cells, miRNA and null-vector 
transfectants. The error bars represent the standard deviation of the samples. TS: Temperature shift. 
NSD synthesis is directly impacted by changes in carbon and amino acid metabolism. Figures 
65 A – F show net concentration profiles of five NSD species, including UDP-Glc, UDP-Gal, UDP-
GlcNAc, GDP-Man and GDP-Fuc. Our results suggest that by co-transfecting vectors bearing pre-
miRNAs into cells that are cultured under mild hypothermic conditions, significant reduction in the 
net concentration of UDP-Glc, UDP-Gal and GDP-Man are observed when compared to the control 
cells at 32C (Figures 65 A, B & D); while comparable levels of UDP-GlcNAc and GDP-Fuc are 
achieved in all conditions examined (Figures 65 C & E). Again, one has to bear in mind that zero 
values of GDP-Man on Figure 65 E represent results that are under the detection limit of the current 
HPLC method. On the other hand, flux balance analysis results suggests that the difference in carbon 
flux towards NSD between miRNA transfected cells and control cells at 32C is only 5%. The tiny 
difference in NSD metabolic flux between the two conditions demonstrates that differences observed 
in experimentally measured NSD concentrations are more likely due to the consumption instead of 
extra production of the NSD species in miRNA transfected CHO cells.  
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Figure 65. Net concentration profiles of five NSD species under all conditions examined. Concentrations of UDP-Glc 
(A), UDP-Gal (B), UDP-GlcNAc (C), GDP-Fuc (D) and GDP-Man (E) are measured experimentally. Results were 
average measurements at 36.5C (n=2) and 32C TS (n=2) in control cells, miRNA and null-vector transfectants. The 
error bars represent the standard deviation of the samples. TS: Temperature shift. 
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8.2.4. Impact of miRNA transfection on expression of N-glycosylation 
related genes  
The aim of co-transfection of three pre-miRNAs was to indirectly manipulate the expression 
of galactosyltransferases in CHO cells that are cultured at 32C. Both mRNA and protein expression 
of the enzyme were experimentally quantified and results of the miRNA transfectants were compared 
to those in the non-transfected species. Figures 66 A – G examine transcript levels of six 
glycosyltransferases and one NSD transporter in N-linked protein glycosylation. As expected, not all 
enzymes are affected upon pre-miRNA co-transfections. Our results show that mRNA expression 
levels of GalT I, GalT II and GalT III are higher in miRNA transfectants than in control cells at 32C, 
with an average increase of 46% (Figures 66 E – G). In fact, mRNA expression levels are comparable 
to those observed in control cells cultured at 36.5C. Although miRNA vectors were co-transfected on 
day 5 during cell culture, significant increases in GalT transcript levels were only observed beyond 
day 6, when the temperature was shifted from 36.5C to 32C. This temperature-dependent increase 
in GalT mRNA levels coincides with research carried out by Vasudevan et al. (2007), which 
suggested a switch of miRNA regulation from transcription repression to expression when cells were 
arrested in G1/G0 state, which is common in mild hypothermic conditions (Marchant et al. 2008).  
Despite higher UDP-Gal transporter mRNA level observed in miRNA transfected cells 
(Figure 66 C), the increase was only significant on one incident (on day 8 of cell culture). There is no 
evidence in this study which suggests that the co-transfected miRNAs impact on the expression of 
UDP-GalT transporter. Surprisingly, the transcript level of GnT I was also shown to increase in 
miRNA transfected species (Figure 66 A), while the mRNA expression of other enzymes including 
GnT II and FucT, did not show significant variation in miRNA transfected CHO cells (Figures 66 B 
& D).  
Protein expression level of GalT III was further quantified through Western blotting and fold 
difference of its expression levels was compared among all conditions examined (Figure 67). Despite 
significant increases in mRNA expression levels of GalTIII, time-course increases in protein 
expression of GalT III were not as pronounced. Figure 67 shows that significant changes in GalTIII 
protein expression between miRNA transfected and non-transfected cells at 32C are only observed 
on day 8 and 9, where their relative differences only vary by 13% and 18%, respectively. Minor 
increases in GalT protein expression might minimize the impact of miRNA overexpression on Fc-
glycosylation of the secreted product.   
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Figure 66. mRNA Expression profile of the enzymes involved in N-linked glycosylation under 4 conditions. 
Transcript levels of (A). GnT I, (B). GnT II, (C). UDP-Gal transporter, (D). FucT, (E). GalT I, (F). GalT II and (G). 
GalT III. Results were average measurements at 36.5C (n=2) and 32C TS (n=2) in control cells, miRNA and null-
vector transfectants. The error bars represent the standard deviation of the samples. TS: Temperature shift. 
Statistical significance was calculated using a Student’s t-test and was represented by: p0.05(*), p0.01(**) and 
p0.001(***).TS: Temperature shift. 
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Figure 67. The relative difference in galactosyltransferase III (-GalTIII) protein expression under all conditions 
examined. Results were average measurements at 36.5C (n=2) and 32C TS (n=2) in control cells, miRNA and null-
vector transfectants. The error bars represent the standard deviation of the samples. TS: Temperature shift. 
Statistical significance was calculated using a Student’s t-test and was represented by: p0.05(*), p0.01(**) and 
p0.001(***).TS: Temperature shift. 
8.2.5. The impact of overexpressing miRNAs on mAb Fc-glycosylation 
Despite higher mRNA expression of galactosyltransferases and increased consumption of 
UDP-Gal in miRNA transfectants, only negligible changes of mAb Fc-galactosylation were observed. 
Figures 68 A – F show profiles of six glycoforms, including Man5, G0, G0F, G1F, G2 and G2F. 
Firstly, no significant changes are observed in the amount of G0 species between miRNA-transfected 
and control cells at 32C (Figures 68 A & B). In addition, fractions of Man5 are higher in cells 
undergoing mild hypothermia than those that are cultured at 36.5C, which correlates well with the 
study on mild hypothermic conditions in Chapter 4. When comparing glycan patterns achieved in 
mAb generated in miRNA transfected and control cells under mild hypothermic conditions, the 
proportions of G0F glycoforms are reduced by approximately 2% to 3% on day 8, 10 and 11 (Figure 
68 C). On the other hand, galactose-bearing species G1F, G2 and G2F, their glycan fractions 
increased upon the miRNA transfection, but only by minimal fractions of roughly 3% increase. There 
is some confidence in our results of the miRNA experiment that the amount of non-galactosylated 
mAb, when compared to mAb of control cells at 32C, is lower (Figure 69 C). However when 
compared to control at 36.5C, the rate of mAb galactosylation still remains lower, improvement in 
galactosylation is indeed very small, and we fail to attain similar rate of mAb galactosylation as of the 
control cells at 36.5C, and the amount of non-galactosylated species still remains higher under 
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miRNA-treated condition (Figure 69 B & D). One hypothesis is generated according to our analyses, 
that despite observing comparable levels of G0F in our secreted mAb between control 36.5C and 
miRNA treated conditions (Figure 68 C), it appears that the drop on G0F level is not entirely 
attributed by higher galactosylation but by higher level of Man5 species that are not being further 
processed (Figure 69 E). This questions our current experimental strategy and suggests the 
manipulation of GnTs.   
 
 
 
Figure 68. Glycan profile of the secreted IgG under four conditions examined. Fractions of 6 glycan structures: (A). 
Man5, (B). G0, (C). G0F, (D). G1F, (E). G2 and (F). G2F on the secreted IgG products were determined under each 
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condition on day 8, 10, 11 and 12 along the 12-day cell culture period. Results were average measurements at 36.5C 
(n=2) and 32C TS (n=2) in control cells, miRNA and null-vector transfectants. The error bars represent the 
standard deviation of the samples. TS: Temperature shift. Statistical significance was calculated using a Student’s t-
test and was represented by: p0.05(*), p0.01(**) and p0.001(***).TS: Temperature shift. 
 
              
Figure 69. Calculated rate of mAb galactosylation. Comparison between (A). miRNA transfected cells and control 
cells at 32C; or (B). between miRNA transfected cells under mild hypothermic temperature and control cells 
cultured at 36.5C. Amount of mAb that are not galactosylated. Comparison between (C). Control vs. miRNA 
transfection at 32C; or (D). Control at 36.5C vs. miRNA transfection at 32C. (E). Quantity of mAb bearing Man5 
structure between Control cells 36.5C and miRNA transfection at 32C. Results were average measurements at 
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36.5C (n=2) and 32C TS (n=2) in control cells, miRNA and null-vector transfectants. The error bars represent the 
standard deviation of the samples. TS: Temperature shift. Statistical significance was calculated using a Student’s t-
test and was represented by: p0.05(*), p0.01(**) and p0.001(***).TS: Temperature shift. 
To further clarify if the failure in increasing Fc-galactosylation in the miRNA experiment is 
related to the amount of miRNAs transfected, we increased the concentration of the each transfected 
miRNA from 5 M to 10, 25 and 50 M. Table 30 shows the Fc-galactosylation index of mAb under 
different concentrations of miRNAs examined. Our results show that increase in the concentration of 
transfected miRNAs (above 5 M) did not provide further significant increase in Fc-galactosylation in 
the mAb product. Their galactosylation levels remain 3% – 4% higher than control condition at 32C.  
 
Table 30. Calculated Fc-galactosylation index in conditions with increased concentrations of miRNA.  
 
Fc-galactosylation index 
 
Control 
(32°C) 
5 M miRNA 
(32°C) 
10 M miRNA 
(32°C) 
25 M miRNA 
(32°C) 
50 M miRNA 
(32°C) 
Day 10 0.21 0.24 * 0.24 * 0.24 * 0.23 * 
Day 12 0.21 0.23 * 0.24 * 0.23 * 0.22 
Day 14 0.18 0.21 * 0.22 * 0.21 * 0.20 
* Statistical significance of p0.05, when calculated using a Student’s t-test. Comparison was drawn between 
each miRNA-transfected species and non-transfected control species.  
8.3. Discussion 
This proof-of-concept study attempts to increase the expression of galactosyltransferases 
through manipulating endogenous amounts of miRNAs that are related to GalT enzyme expression. 
Despite not achieving huge success in elevating the amount of protein galactosylation in the secreted 
products, overexpressing three miRNAs that impose effects on CHO cell growth, cell metabolism and 
product generation.  
Increase in cell growth in miRNA transfected cells was one of the first changes that we 
experimentally observed. This also served as an indication of changes in CHO cell metabolism. The 
variation observed in cell growth was most likely independent from the increase in culture osmolarity 
induced by NaCl used during transfection, since CHO cell growth was not observed to be uplifted in 
null-vector transfected species in which the same amount of NaCl was added to the culture. Increase 
in cell growth was therefore a consequence of the overexpression of the miRNAs cgr-miR-500, cgr-
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miR-501-5p and cgr-miR-181d bundle. One can speculate that this combination of miRNAs is not 
restricted to a single target and it might have encouraged the translation of host cell proteins that 
promoted cell growth, such as the expression of anti-apoptotic proteins or other chaperone proteins, 
but host cell proteomic analysis is needed to support this hypothesis.   
On the other hand, metabolic changes that were imposed by the transfection of this miRNA 
bundle occurred partially to maintain the increased viable cell growth, as well as to increase the 
specific productivity of the recombinant product. Not only did the higher rates of glucose and lactate 
uptake in miRNA transfected CHO cells generate more energy to sustain cell growth and cellular 
activities, increased carbon pool within a cell could encourage DNA and RNA syntheses that were 
advantageous in recombinant mAb production. In addition, a higher amount of amino acids were 
consumed and catabolized into pyruvate or other TCA cycle intermediates in order to fuel and to 
maintain the efficiency of the TCA cycle. Moreover, new amino acids generated were also utilized in 
host cell and recombinant protein synthesis. Therefore, increased rates of consumption of various 
amino acids definitely imposed a positive effect in protein production. Despite higher uptake rates of 
glucose, lactate and amino acids, NSD synthesis in miRNA transfectants remained comparable to that 
of control cells at 32C, where only 5% increase in carbon fluxes towards NSD synthesis was 
suggested by the FBA study. This further confirmed that most nutrients were utilized towards cell 
growth and energy production.  
Despite the little success in rescuing mAb terminal galactosylation through overexpressing of 
miRNAs that regulate -1,4galactosyltransferase expression, our results demonstrated uplifting of the 
transfected species in GalT expression at transcriptional level, and at translational level to a certain 
extent. There are three possible hypotheses behind these changes. Firstly, the natural gene repression 
capability of miRNA could have been inhibited and encouraged translational activation by the 
induction of mild hypothermia, in which cells were most likely to be arrested at G0/G1 stages of cell 
cycle (Vasudevan et al. 2007). Moreover, the complementary sequences between the double stranded 
miRNA and the promoter region of the targeted GalT could have led to RNA activation, which 
increased gene induction of the target gene (Place et al. 2008). The fact that terminal galactosylation 
was only improved by a very tiny fraction (which was even smaller than changes observed within cell 
line variations might be owing to the very small differences detected in GalTIII protein expression. In 
addition, failure to further increase Fc-galactosylation when miRNA concentrations were raised to a 
maximum level of 50 M suggests either the amount of miRNA expressed is limited by the low 
transfection efficiency of the non-optimised transient transfection protocol, or the partial cell-cycle 
arrest was not sufficient enough to completely avert the mechanism of miRNA overexpression from 
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translation inhibition to up-regulation. With higher levels of non-galactosylated mAbs, particularly in 
the amount of Man5 structures, and the fact that rate of mAb galactosylation still remains lower than 
that of the control at 36.5C, all together suggest that in addition to raising the expression level of 
GalT, we might want to extend our focus further and also increase the expression of GnT enzymes, so 
as to ensure sufficient amount of bi-antennary glycan profiles for GalT enzymes to work on in the 
later stage of N-linked glycan processing. Of course, future investigation is necessary to test these 
hypotheses. Despite the lack of evidence, potential co-localisation of GalT with other 
glycosyltransferase may affect the potency to overexpress GalT, if overexpression of all co-localised 
enzymes would be required for effective result.   
8.4. Concluding remarks 
In this study, we demonstrated that the overexpression of the miRNAs cgr-miR-500, cgr-miR-
501-5p and cgr-miR-181d bundle imposed changes to cell growth, cell metabolism, GalTIII 
expression and mAb Fc-glycosylation by a very small level. Upon the transfection of the miRNA 
bundle, cells remodeled their carbon and nitrogen metabolism to sustain cell growth and increase 
protein production. Despite the common nature of miRNA in gene translation repression, our study 
showed that mRNA and protein expression of target gene could be improved through overexpressing 
miRNAs that had high complementary to the target gene promoter. Hence, our study here confirm that 
the concept of increasing GalT expression through miRNA manipulation under mild hypothermia is 
possible, but the transfection method will have to be optimized in order to increase the protein 
expression level of the target gene and to elevate product galactosylation under mild hypothermia.  
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Chapter 9
Concluding Remarks and future studies 
9.1. Summary of results 
This thesis has examined the impact of two chosen bioprocess conditions on recombinant 
mAb productivity and the resulting Fc N-linked glycosylation, namely mild hypothermia and transient 
gene expression. It was done through detailed examination of changes in cell metabolism as well as 
intracellular protein processing machinery in each condition by both experimental and computational 
approaches. 
The thesis first presented the current situation in biopharmaceutical production. This was 
followed by a thorough review of relevant existing literature that discussed about the relationship 
between bioprocess conditions and mAb production, and to a lesser extent, mAb Fc-glycosylation. 
From the background research, limitations in the current drug manufacturing processes were 
identified and the employment of the Quality by Design paradigm was discussed as necessary to 
improve the efficiency of the bioproduction process. Within this, the mild hypothermic culture 
temperature and transient gene expression system became the main focus in this research work. A 
brief review on potential experimental and computational analytic approaches that could be used to 
examine CHO cell metabolism and characterise the N-linked glycan profiles of the secreted mAb 
molecules were also discussed in the thesis.   
 Following that, we commenced our research study with examining the impact of mild 
hypothermia on the Fc-glycosylation of mAb molecules that were stably expressed in CHO cells with 
respect to both experimental findings and modelling approaches. Our results showed that a 25% 
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increase in mAb productivity was achieved in mild hypothermic conditions, but significant limitation 
in Fc-terminal galactosylation was observed in the glycan profile of mAb produced at 32C. 
Contributing factors for changes observed in mAb Fc-galactosylation were identified through flux 
balance analysis and computational studies. Results from the FBA demonstrated changes in cellular 
carbon distribution upon the introduction of mild hypothermic culture temperature, where a reduced 
flux of carbon was channelled towards NSD synthesis and mAb glycosylation to compensate for the 
increase in energy and carbon consumption towards mAb synthesis for a higher qmAb. The modular 
mathematical model estimated reduced rates of NSD production and galactosyltransferase (GalT) 
expression in CHO cells during mild hypothermia. Both findings have successfully established the 
impact of mild hypothermia on mAb Fc-glycosylation for the cell line under study. In addition, the 
modular mathematical model represented the time-course data well in all aspects, including cell 
growth, cell metabolism, mAb synthesis, as well as reproducing the N-linked glycosylation profiles of 
mAb produced under mild hypothermia. Model estimation of reduced GalT concentration expression 
was then confirmed by the experimental measurements of GalT expression levels, thus show the 
capability of our model in representing the biological system. However, parameter re-estimation will 
be necessary when the model is performed on a different cell line.  
On the other hand, the experimental and model comparison drawn between SGE and TGE 
processes with respect to their cellular behaviour, recombinant protein synthesis and the Fc-glycan 
pattern of the secreted mAb showed evident variations in all aspects mentioned above between the 
two expression systems. The expression of mAb as a foreign protein in TGE placed a burden on 
protein glycosylation. The combination of lowered carbon flux towards NSD production observed in 
the FBS study, and the less efficient NSD synthetic network in terms of reduced carbon flux and 
activities of enzymes in the NSD synthetic pathway, as well as the limited expression of 
glycosyltransferases suggested by the TGE mathematical model, served as contributing factors for 
changes in mAb Fc-glycan pattern observed between the two expression systems. By adapting the 
modular model entity of SGE to the particularities of the TGE system, the TGE model was capable of 
describing experimental results well in all aspect under all conditions examined in TGE, with 
discrepancies of 5% or less between experimentally measured and estimated N-linked glycan profiles 
of mAb molecules. Moreover, enzymatic properties estimated by the TGE model were in good 
correlation with our experimentally quantified data.  
Based on the experimental results and model outputs in this work, expression of 
galactosyltransferase was suggested to be the key contributing factor to changes in glycan profiles 
under the mild hypothermic conditions in this cell line. We attempted to manipulate the expression of 
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the GalT enzyme by exploiting the level of a group of GalT-related miRNAs. Despite showing little 
success in increasing the level of terminal galactosylation in the secreted mAb products in this proof-
of-concept study, results showed a slight increase in GalT expression, which might indicate the 
potential of employing this strategy in enzyme manipulation if the method is to be optimised, or when 
it is incorporated with the expression of other glycosyltransferase, e.g. GnTs. 
9.2. Main conclusions  
The followings are conclusions that can be drawn from the above findings: 
1. As shown through literature, following the Quality by Design paradigm is certainly a way to 
improve the overall yield and the quality of the recombinant protein. To do so, it is of 
paramount importance to understand fully the influence of each bioprocess condition on host 
cell metabolic pathways and relevant cellular activities that would pose an impact on product 
production. 
 
2. Experimentation on its own is useful in identifying variations among different process 
conditions, but it can reveal more information regarding intracellular behaviour and activities 
when experimental data is coupled with computational tools, namely flux balance analysis 
and quantitative mechanistic models. While FBA studies allows the exploitation of 
intracellular carbon and nitrogen distributions under each condition examined, the 
mathematical model is particularly important in providing information on changes in cellular 
activities, which aids our understanding on fundamental mechanisms that impact mAb 
glycosylation. Moreover, the modelling approach will allow the implementation of quality 
control throughout the fermentation process if the model is validated, which satisfies the 
Quality by Design paradigm. 
 
3. Galactosyltranferase (GalT) expression was identified in our work by both experimentation 
and mathematical model as one of the main contributing factors for reduced terminal 
galactosylation in mAb products under mild hypothermia in this cell line, regardless of the 
expression system. However, our work also indicated that GnTs can also be a high potential 
target for glycol-engineering, given that their transcript expressions are quite different even 
within the TGE, or between SGE and TGE systems.    
 
4. The availability of nucleotide sugar donors especially UDP-Gal species was suggested in this 
work to be critical in mAb Fc-terminal galactosylation in the TGE, but not in the SGE system. 
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5. In this study, heavy and light chain mRNA transcription was demonstrated to be the 
bottleneck in TGE during mAb protein synthesis. 
 
6. Adapted and modified from models developed by Kontoravdi et al. (2005) and Jimenez del 
Val (2013), modular mathematical models presented in this work mechanistically relates 
much information on the external variation and nutrient availability during the process of cell 
culture to mAb synthesis and N-linked glycosylation, through  cell metabolism, this includes 
amino acid, nucleotide and NSD metabolism. 
 
7. Modular mathematical models developed in this work have high capability in representing 
biological processes under mild hypothermia or under different gene expression scenarios, 
with respect to cellular behaviour, mAb synthesis, NSD metabolism and N-linked Fc 
glycosylation. The developed models also possess high fidelity in estimating unknown 
parameters within the system under conditions mentioned above. When fully validated, these 
models will be of great help in predicting cell behaviour and mAb N-linked glycan patterns of 
a given species and generating estimation on possible ranges of process inputs that will be 
necessary for optimal mAb production. 
 
8. The proof-of-concept study conducted in this work shows some potential of indirect 
manipulation of -1,4 galactosyltransferase expression through control of endogenous levels 
of GalT related miRNAs. However, a more optimised transfection protocol is required in 
order to improve its efficiency towards N-linked glycan editing. And potential co-
overexpression with GnT enzymes will ensure enough bi-antennary glycan substrates for 
GalT to work on.  
 
9.3. Main contributions  
1. Instead of looking at the impact of different bioprocess conditions on Fc-glycosylation 
through “black-box” or “trial-and-error” approaches, in this thesis we employed a 
combination of experimentation, flux balance analysis and mathematical modelling to 
systematically identify contributing factors of each condition examined on the host cell 
dynamics, which subsequently affect the process of Fc-glycosylation. This approach identifies 
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major variations within the metabolic pathway in each bioprocess condition which aids future 
process optimisation.  
 
2. More importantly, the mathematical model developed in this study allows the identification of 
bottlenecks within cellular processes for a specific quality attribute of the secreted product, by 
estimating a range of model parameters that satisfy specific conditions. By incorporating 
measures specific for increasing the capacity of the identified bottlenecks, process 
optimisation and improvements in product quality can therefore be achieved. This approaches 
aims to satisfy both the QbD paradigm proposed by the FDA, as well as providing the 
industry with a more efficient and effective way in running their manufacturing processes. 
 
3. By extending existing models to include and link external factors (e.g. changes in nutrient 
availability) during the process of cell culture to mAb synthesis and N-linked glycosylation 
for CHO cells through cellular metabolic pathway, our model encourages the possibility of in 
silico experiments prior to any laboratorial experiments, where the model aims to generate an 
estimated range of product quality based on model inputs of the experiment. 
 
4. With promising results generated from the model in this thesis, there is a high potential to 
refine our model and apply it onto industrially relevant projects, which can be mAb-based 
processes or extend our model application to other protein production lines.  
 
9.4. Suggestions for future studies 
Based on the results and conclusions of work conducted in this thesis, the following are 
suggestions of future work that can be carried to improve current research: 
9.4.1. Consideration of other cell lines 
Examination carried out in the thesis regarding the impact of mild hypothermia on mAb 
glycosylation in SGE were based on one single high producing cell line, conclusions drawn in this 
study may only be relevant to this particular cell clone. With research suggesting changes in cell 
metabolism among high, medium and low producing cell lines (Chusainow et al. 2009), it is therefore 
worthwhile to investigate if the impact of mild hypothermia on cell metabolism and mAb 
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glycosylation that we observed on the high producer will vary on the medium and the low producers. 
Moreover, comparative results between the SGE and the TGE systems might change if compared to a 
different stable cell line. Moreover, results that we observed in this study could be product specific. In 
addition to examining different cell lines, it will be worthwhile to also investigate in cell line 
expressing a different product.  
9.4.2. Examination with optimised transfection protocols 
Despite revealing significant differences between SGE and TGE systems with a non-
optimised transfection protocol, one could argue that a set of results could be achieved if transfection 
method used was optimised. Analysing mAb Fc glycan patterns from transient transfectants generated 
from different transfection protocols (e.g. different transfection reagents, transfection density, gene to 
reagent ratio, electroporation) will widen our knowledge on mAb glycosylation in TGE system; it also 
allows generating a clearer vision of how different approaches within the TGE system contribute to 
changes in their cell metabolism and mAb glycosylation. By comparing different transient 
transfection protocols, we can examine the relationship among transfection efficiency, qP and the Fc-
glycoforms on the product.  
9.4.3. Importance of vector construction 
In addition, the actual vector construction is also a crucial element that places a big impact 
especially on the target gene expression. For instance, if the vector expresses a viral element of 
Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA-1), it is a vector that controls gene replication and 
transcription activity. In the case, changes in host cell growth induced by different bioprocess 
conditions will therefore affect the expression of recombinant genes that are expressed in the same 
vector as EBNA-1 element, thus affecting qP. As a result, it is important to take into account elements 
involved in the vectors used in this thesis. 
9.4.4. Strategies to improve protein galactosylation  
 Results in our work suggested two ways in which product galactosylation can be improved: 
by increasing expression levels of GalTs, or by tailoring culture feeds by including specific NSD 
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precursors for UDP-Gal synthesis. Firstly, GalT expression levels can be increased by traditional 
overexpression of the enzyme through cell line engineering (Pablo Umaña and Jean-Mairet 2012).  
Manipulation of GalT expression through miRNA exploitation was attempted in this work, 
but results were not promising even when higher miRNA concentrations were attempted. Instead of 
manipulating miRNA levels in a transient manner in which its transfection efficiency is limited, one 
can try overexpressing these miRNAs stably and have it controlled by a temperature sensitive 
promoter such as CHO S100a6 promoter in mild hypothermic conditions to control the timing of 
overexpression (Thaisuchat et al. 2011).   
 In addition to focusing on GalT overexpression, in the case of IgG one has to remember that 
GalT enzyme cannot perform galactose addition without sufficient quantity of bi-antennary glycan 
structures as substrates. Co-expression of both GnTs and GalT will be a more ideal experimental 
strategy to improve mAb galactosylation. 
In addition to overexpressing GalT enzyme, one can also couple this strategy with tailored 
feeding of uridine, magnesium and galactose to increase the intracellular amount of UDP-Gal level as 
suggested in Gramer et al. (2011). As our model outputs suggested reduced enzymatic activities of 
enzymes related to UDP-Gal synthesis during mild hypothermia and in TGE experiments, one can try 
to overexpress these enzymes during cell culture (Fridovich-Keil and Jinks-Robertson 1993; 
Heidenreich 1995).  
9.4.5. Improvement in modular mathematical models 
The current modular mathematical model certainly has space for improvement. Firstly, the 
current model (SGE or TGE) describes each module in mild hypothermic condition with a separate set 
of parameter values. The model is applicable to mild hypothermic temperature at 32C, but a different 
set of parameter values will have to be used to represent conditions at a different temperature. The 
fidelity of the model can be improved and to truly represent the impact on culture temperature if mass 
balances within the model are constructed as a function of temperature rather than relying on 
distinctive sets of parameter values. To do so, experimental data at different temperatures will be 
necessary to train the model with all sets of experimental data to estimate a common set of parameter 
value.  
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In addition, the current nucleotide and NSD part of the model was constructed based on a 
simplified NSD synthetic network, by merging all sequential reactions along one given NSD branch 
into a single reaction. Other intermediate reactions along a NSD branch might impose regulatory 
effects and therefore if possible, the model should be expanded to include relevant species.  
Data analysis using FBA and mathematical approaches in this work identified contributing 
factors of bioprocess conditions on mAb glycosylation, but they were not able to distinguish which of 
the two is dominant, lowered GalT enzymatic activity or reduced NSD synthesis. It will be of more 
use if the flux distribution can be implemented into the current model to identify the dominating 
factor. In addition, radioactive labelling experiments can be carried out to validate results obtained 
from the FBA study. This way instead of constraining the model through experimental data, data of 
real-time intracellular metabolites can be used to increase the fidelity of the model.  
9.4.6. Model validation 
Not all parameter values estimated our models in this work were validated. Since the 
comparisons drawn between different bioprocess conditions are based on parameter estimation, model 
validation with a separate set of experimental data is therefore necessary to test the model fidelity and 
to improve the confidence of parameter values estimated by our models. For instance, we can validate 
the model by carrying out a separate set of experiment using a different mAb product with or without 
mild hypothermia. If the model is valid, it should be able to capture any change in consumption rate 
of nutrients and metabolites in response to the change of environment (in our case mild hypothermia 
and gene expression system), as well as relating this change to product yield and Fc-glycosylation.  
9.5. Closing remarks 
Our work in this thesis managed to bring us one step closer to better but cheaper production 
of drugs, through understanding the effect of each bioprocess condition on the fundamental cellular 
activities and the relationship among each individual cellular network. By identifying bottlenecks 
within cellular processes, more efficient processes with better quality control on the end products can 
be achieved at reduced manufacturing costs, which will definitely be beneficial to all sectors including 
the manufactures, the drug control authorities as well as the patients. 
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Appendix Figure 1. Typical HPAEC chromatogram of intracellular nucleotide and NSD species. The chromatogram 
shows the elution profile of nucleotide AMP, CTP, ADP, ATP, UTP and GTP and NSD CMA-Neu5Ac, UDP-GalNAc, 
UDP-GlcNAc, UDP-Gal, UDP-Glc, GDP-Fuc, GDP-Man, GDP-Glc and UDP-GlcA.  
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Appendix Table 1. FBA reactions of CHO cells included in the model. 
# Reaction Reversibility 
 Glycolysis  
1 [c] : Glc + ATP --> G6P + ADP Irreversible 
2 [c] : G6P <==> F6P Reversible 
3 [c] : F6P + ATP --> DHAP + GAP + ADP Irreversible 
4 [c] : DHAP <==> GAP Reversible 
5 [c] : GAP + NAD + ADP <==> 3PG + NADH + ATP Reversible 
6 [c] : 3PG + ADP --> Pyr + ATP Irreversible 
 TCA cycle  
7 [c] : Pyr + NAD + CoASH --> AcCoA + CO2 + NADH Irreversible 
8 [c] : AcCoA + Oxal --> Cit + CoASH Irreversible 
9 [c] : Cit + NADP --> αKG + CO2 + NADPH Irreversible 
10 [c] : αKG + CoASH + NAD --> SucCoA + CO2 + NADH Irreversible 
11 [c] : SucCoA + GDP <==> Succ + GTP + CoASH Reversible 
12 [c] : Succ + FAD <==>  Fum + FADH2 Reversible 
13 [c] : Fum <==>  Mal Reversible 
14 [c] : Mal + NAD <==>  Oxal + NADH Reversible 
 Pyruvate fates  
15 [c] : Pyr + NADH <==>  Lac + NAD Reversible 
16 [c] : Pyr + Glu <==>  Ala + αKG Reversible 
 Pentose Phosphate Pathway  
17 [c] : (3) G6P + (6) NADP --> (3) CO2 + (3) R5P + (6) NADPH Irreversible 
 Anaplerotic Reaction  
18 [c] : Mal + NADP <==>  Pyr + HCO3 + NADPH Reversible 
 Amino Acid Metabolism  
19 [c] : Glu + NADP <==>  αKG + NH4 + NADPH Reversible 
20 [c] : Oxal + Glu <==>  Asp + αKG Reversible 
21 [c] : Gln + ADP <==>  Glu + ATP + NH4 Reversible 
22 [c] : Thr + NAD + CoASH --> Gly + NADH + AcCoA Irreversible 
23 [c] : Ser + THF + NADP <==>  Gly + NADPH + N10FTHF Reversible 
24 [c] : N10FTHF + ADP <==>  ATP + Formate + THF Reversible 
25 [c] : Ser --> Pyr + NH4 Irreversible 
26 [c] : Thr -->  αKb + NH4 Irreversible 
27 [c] : αKb + CoASH + NAD + HCO3 + ATP --> SucCoA + ADP + NADH + CO2 Irreversible 
28 [c] : Trp --> Ala + (2) CO2 + αKa Irreversible 
29 [c] : Lys + (2) αKG + (3) NADP + FAD --> αKa + (2) Glu + (3) NADPH + FADH2 Irreversible 
30 [c] : αKa + (2) CoASH + (2) NAD --> (2) AcCoA + (2) NADH + (2) CO2 Irreversible 
31 [c] : Val + αKG + CoASH + NAD --> IsobutCoA + Glu + CO2 + NADH Irreversible 
32 [c] : IsobutCoA + FAD + (2) NAD + HCO3 + ATP --> SucCoA + ADP + FADH2 + (2) NADH + CO2 Irreversible 
33 [c] : IsobutCoA --> Isobut Irreversible 
34 [c] : Ile + αKG + (2) CoASH + (2) NAD + FAD + HCO3 + ATP --> AcCoA + SucCoA + ADP + Glu + CO2 + (2) 
NADH + FADH2 
Irreversible 
35 [c] : Leu + αKG + CoASH + NAD --> IsovalCoA + Glu + CO2 + NADH Irreversible 
36 [c] : IsovalCoA + FAD + ATP + CO2 + SucCoA + CoASH --> (3) AcCoA + Succ + FADH2 + ADP Irreversible 
37 [c] : IsovalCoA --> Isoval Irreversible 
38 [c] : Phe + NADH --> Tyr + NAD Irreversible 
39 [c] : Tyr + αKG + SucCoA + CoASH --> Fum + (2) AcCoA + Succ + Glu + CO2 Irreversible 
40 [c] : Met + Ser + ATP --> αKb + NH4 + AMP Irreversible 
41 [c] : Asn <==>  Asp + NH4 Reversible 
42 [c] : Pro + NADP <==>  Glu + NADPH Reversible 
43 [c] : Arg + αKG + NADP --> (2) Glu + NADPH + Urea Irreversible 
44 [c] : His --> Glu + NH4 Irreversible 
45 [c] : Arg -->  Orn +  Urea Irreversible 
46 [c] : Orn -->  PTRSC +  CO2 Irreversible 
47 [c] : Met +  ATP -->  SAM Irreversible 
48 [c] : SAM -->  DSAM +  CO2 Irreversible 
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49 [c] : DSAM +  PTRSC -->  5MTA +  SPRMD Irreversible 
50 [c] : 5MTA + SPRM --> DSAM + SPRMD Irreversible 
 Glycogen Synthesis  
51 [c] : G6P --> G1P Irreversible 
52 [c] : G1P + UMPRN + (2) ATP --> UDPG + (2) ADP Irreversible 
53 [c] : UDPG --> Glycogen + UDP Irreversible 
 Nucleotide Synthesis  
54 [c] : R5P + ATP --> PRPP + AMP Irreversible 
55 [c] : PRPP + (2) Gln + Gly + Asp + (5) ATP + CO2 + (2) N10FTHF --> IMP + (2) Glu + Fum + (5) ADP + (2) THF Irreversible 
56 [c] : IMP + Asp + GTP --> AMPRN + Fum + GDP Irreversible 
57 [c] : IMP + Gln + ATP + NAD --> GMPRN + Glu + AMP + NADH Irreversible 
58 [c] : HCO3 + NH4 + Asp + (2) ATP + NAD --> Orotate + (2) ADP + NADH Irreversible 
59 [c] : Orotate + PRPP --> UMPRN + CO2 Irreversible 
60 [c] : UMPRN + Gln + ATP --> CMPRN + Glu + ADP Irreversible 
61 [c] : AMPRN --> dAMP Irreversible 
62 [c] : GMPRN --> dGMP Irreversible 
63 [c] : CMPRN --> dCMP Irreversible 
64 [c] : UMPRN --> dTMP Irreversible 
 Lipid Synthesis  
65 [c] : Choline + ATP --> Pcholine + ADP Irreversible 
66 [c] : Pcholine + (18) AcCoA + Glyc3P + (22) ATP + (33) NADH --> PC + (16) ADP + (6) AMP + (33) NAD + (18) 
CoASH 
Irreversible 
67 [c] : PC + Ser <==>  PS + Choline Reversible 
68 [c] : PS --> PE + CO2 Irreversible 
69 [c] : Choline + Glyc3P <==>  Glyc3PC Reversible 
70 [c] : G6P --> Inositol Irreversible 
71 [c] : Inositol + (18) AcCoA + Glyc3P + (22) ATP + (33) NADH --> PI + (16) ADP + (6) AMP + (33) NAD + (18) 
CoASH 
Irreversible 
72 [c] : (18) AcCoA + (2) Glyc3P + (22) ATP + (33) NADH --> PG + (16) ADP + (6) AMP + (33) NAD + (18) CoASH Irreversible 
73 [c] : (2) PG --> DPG + Glyc Irreversible 
74 [c] : (16) AcCoA + Ser + Choline + (16) ATP + (29) NADPH --> SM + (2) CO2 + (14) ADP + (2) AMP + (29) 
NADP + (16) CoASH 
Irreversible 
75 [c] : (18) AcCoA + (18) ATP + (14) NADPH --> Cholesterol + (9) CO2 + (18) ADP + (14) NADP + (18) CoASH Irreversible 
 Biomass Formation  
76 For 36.5C 
[c] : (88.038) Ala + (54.1149) Arg + (54.6624) Asn + (101.835) Asp + (60.4002) Gln + (143.2041) Glu + 
(90.2061) Gly + (15.1986) His + (44.8731) Ile + (91.3887) Leu + (103.7403) Lys + (23.0388) Met + (41.61) 
Phe + (51.8592) Pro + (66.6198) Ser + (54.6843) Thr + (7.01895) Trp + (22.8855) Tyr + (65.3934) Val + 
(9450.507) ATP + (11.043513) AMPRN + (3.055269) Cholesterol + (8.038614) CMPRN + (3.721686) dAMP 
+ (2.665668) dCMP + (2.79444) dGMP + (0.5913) DPG + (3.696063) dTMP + (94.6299) Glycogen  + 
(7.437459) GMPRN + (11.622111) PC + (4.407156) PE + (0.22119) PG + (1.59651) PI + (0.438) PS + 
(1.382985) SM + (11.006064) UMPRN + (0.47085) NAD + (0.02847) NADP + (0.00219) FAD + (0.01095) 
NADH + (0.0876) NADPH + (0.001314) SucCoA + (0.01095) AcCoA + (0.012264) CoASH + (10.95) MTHF + 
(7.665) PTRSC + (1.533) SPRMD + (1.8615) Neu5Ac + (19.1596666087446) GlcNAc + (4.43910147525) 
GalNAc + (14.3965857576054) Mann + (6.32724069101717) Gal + (4.52592703789134) Fuc  --> (1) 
Biomass + (9450.507) ADP 
For 32C TS 
[c] : (88.038) Ala + (54.1149) Arg + (54.6624) Asn + (101.835) Asp + (60.4002) Gln + (143.2041) Glu + 
(90.2061) Gly + (15.1986) His + (44.8731) Ile + (91.3887) Leu + (103.7403) Lys + (23.0388) Met + (41.61) 
Phe + (51.8592) Pro + (66.6198) Ser + (54.6843) Thr + (7.01895) Trp + (22.8855) Tyr + (65.3934) Val + 
(9450.507) ATP + (11.043513) AMPRN + (3.055269) Cholesterol + (8.038614) CMPRN + (3.721686) dAMP 
+ (2.665668) dCMP + (2.79444) dGMP + (0.5913) DPG + (3.696063) dTMP + (94.6299) Glycogen  + 
(7.437459) GMPRN + (11.622111) PC + (4.407156) PE + (0.22119) PG + (1.59651) PI + (0.438) PS + 
(1.382985) SM + (11.006064) UMPRN + (0.47085) NAD + (0.02847) NADP + (0.00219) FAD + (0.01095) 
NADH + (0.0876) NADPH + (0.001314) SucCoA + (0.01095) AcCoA + (0.012264) CoASH + (10.95) MTHF + 
(7.665) PTRSC + (1.533) SPRMD + (1.8615) Neu5Ac + (19.1750013522) GlcNAc + (4.43910147525) GalNAc 
+ (14.38125101415) Mann + (5.40043757441596) Gal + (4.48368385448878) Fuc  --> (1) Biomass + 
(9450.507) ADP 
Irreversible 
 Other by-products  
77 [c] : AcCoA + AMP <==>  Acetate + CoASH + ATP Reversible 
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78 [c] : DHAP + NADH <==>  Glyc3P + NAD Reversible 
79 [c] : Glyc3P <==>  Glyc Reversible 
 Glycosylation  
80 [c] : UDPG <==>  UDPGal Reversible 
81 [c] : Glc + ATP + GTP --> GDPMann + ADP Irreversible 
82 [c] : F6P + Gln + AcCoA + UTP --> UDPNAG + Glu + CoASH Irreversible 
83 [c] : UDPNAG + ATP + 3PG + CTP --> CMPNeu5Ac + UDP + ADP Irreversible 
84 [c] : GDPMann + NADPH --> GDPFuc + NADP Irreversible 
85 [c] : UDPNAG <==>  UDP +  GlcNAc Reversible 
86 [c] : UDPNAG <==>  UDPGalNAc Reversible 
87 [c] : UDPGalNAc <==> GalNAc + UDP Reversible 
88 [c] : GDPMann <==>  Mann + GDP Reversible 
89 [c] : UDPGal <==> Gal + UDP Reversible 
90 [c] : CMPNeu5Ac <==>  CMP +  Neu5Ac Reversible 
91 [c] : GDPFuc <==>  GDP +  Fuc Reversible 
92 [c] : CMPNeu5Ac <==>  CMPNeu5Gc Reversible 
93 [c] : CMPNeu5Gc <==> CMP + Neu5Gc Reversible 
 Vitamin metabolism  
94 [c] : Fol +  NADH -->  THF +  NAD Reversible 
95 [c] : Gly +  THF +  NAD <==>  METTHF +  NH4 +  CO2 +  NADH Reversible 
96 [c] : MTHF +  NADP <==>  METTHF +  NADPH Reversible 
 IgG Formation  
97 [c] : (423.795512610944) Ala + (266.385750784022) Arg + (314.819523653844) Asn + 
(302.711080436388) Asp + (363.253296523666) Gln + (363.253296523666) Glu + (581.205274437866) 
Gly + (133.192875392011) His + (605.422160872777) Leu + (520.663058350588) Lys + 
(72.6506593047332) Met + (266.385750784022) Phe + (532.771501568043) Pro + (1138.19366244082) 
Ser + (593.313717655321) Thr + (121.084432174555) Trp + (387.470182958577) Tyr + 
(690.181263394965) Val + (10.992)  GDPFuc + (54.962) UDPNAG + (32.977) GDPMann + (21.985) UDPGal 
+ (21.985) CMPNeu5Ac --> (32.977) GDP + (21.985) UDP + (21.985) CMP + (1) IgG 
Irreversible 
 Transport Reactions  
98 Acetate[e] <==> Reversible 
99 ADP[e] <==> Reversible 
100 Ala[e] <==> Reversible 
101 AMP[e] <==> Reversible 
102 Arg[e] <==> Reversible 
103 Asn[e] <==> Reversible 
104 Asp[e] <==> Reversible 
105 ATP[e] <==> Reversible 
106 Biomass[e] <==> Reversible 
107 Choline[e] <==> Reversible 
108 Cit[e] <==> Reversible 
109 CMP[e] <==> Reversible 
110 CO2[e] <==> Reversible 
111 CoASH[e] <==> Reversible 
112 CTP[e] <==> Reversible 
113 FAD[e] <==> Reversible 
114 FADH2[e] <==> Reversible 
115 Fol[e] <==> Reversible 
116 Formate[e] <==> Reversible 
117 Fum[e] <==> Reversible 
118 GDP[e] <==> Reversible 
119 Glc[e] <==> Reversible 
120 Gln[e] <==> Reversible 
121 Glu[e] <==> Reversible 
122 Gly[e] <==> Reversible 
123 Glyc[e] <==> Reversible 
124 Glyc3PC[e] <==> Reversible 
125 GTP[e] <==> Reversible 
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126 His[e] <==> Reversible 
127 IgG[e] <==> Reversible 
128 Ile[e] <==> Reversible 
129 Isobut[e] <==> Reversible 
130 Isoval[e] <==> Reversible 
131 Lac[e] <==> Reversible 
132 Leu[e] <==> Reversible 
133 Lys[e] <==> Reversible 
134 Mal[e] <==> Reversible 
135 Met[e] <==> Reversible 
136 NAD[e] <==> Reversible 
137 NADH[e] <==> Reversible 
138 NADP[e] <==> Reversible 
139 NADPH[e] <==> Reversible 
140 NH4[e] <==> Reversible 
141 Pcholine[e] <==> Reversible 
142 Phe[e] <==> Reversible 
143 Pro[e] <==> Reversible 
144 Pyr[e] <==> Reversible 
145 Ser[e] <==> Reversible 
146 SPRM[e] <==> Reversible 
147 Succ[e] <==>  Reversible 
148 Thr[e] <==> Reversible 
149 Trp[e] <==> Reversible 
150 Tyr[e] <==> Reversible 
151 UDP[e] <==> Reversible 
152 Urea[e] <==> Reversible 
153 UTP[e] <==> Reversible 
154 Val[e] <==> Reversible 
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Appendix Table 1. Feeding schedules used in gPROMS for both conditions.  
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Appendix Table 2. List of parameters used in cell dynamic models for both temperatures.  
Parameter 
 
Values Units 
  
36.5 
o
C 32 
o
C (Day 6) 
 Growth/death related 
max

1.10E-01 7.49E-01 h
-1
 
d,max

9.70E-02 3.96E-02 h
-1
 
Kglc 
 
1.82E+00 4.90E+01 mM 
Klac 
 
3.87E+00 5.80E-03 mM 
Karg 
 
3.80E-02 2.90E-01 mM 
Kasn 
 
1.07E-02 1.41E-01 mM 
Kasp 
 
1.00E-10 2.18E-01 mM 
Kglu 
 
1.55E-01 2.92E-01 mM 
Klys 
 
1.00E-08 1.78E+00 mM 
Kpro 
 
4.09E-07 6.54E-01 mM 
KIlac  3.87E+00 3.79E+01 mM 
KIamm 
 
2.75E+00 3.86E+00 mM 
Kd,amm 
 
8.04E+00 3.43E-04 mM 
Klysis  4.47E-01 2.14E-01 
h
-1
 
Metabolism related  
  Yarg,glu 
 
1.59E-02 1.10E-01 mmol mmol
-1
 
Yasp,asn 
 
9.50E-04 7.92E-01 mmol mmol
-1
 
Ygln,glu 
 
1.00E+00 1.00E+00 mmol mmol
-1
 
Yglu,gln 
 
1.00E-10 7.47E-01 mmol mmol
-1
 
Ylac,glc  2.00E+00 5.32E-03 
mmol mmol
-1
 
Ylys,glu 
 
1.19E-01 1.13E-01 mmol mmol
-1
 
Ypro,glu 
 
8.10E-01 7.95E-01 mmol mmol
-1
 
YmAb, 
 
4.40E-01 4.33E-01 mg h
-1
 
Yx,amm 
 
2.21E+10 1.00E+19 cell mmol
-1
 
Yx,arg 
 
2.64E+10 1.74E+13 cell mmol
-1
 
Yx,asn 
 
7.76E+10 4.84E+10 cell mmol
-1
 
Yx,asp 
 
3.59E+09 9.93E+14 cell mmol
-1
 
Yx,gln 
 
3.20E+12 4.01E+14 cell mmol
-1
 
Yx,glu 
 
6.10E+09 3.43E+09 cell mmol
-1
 
Yx,lac 
 
6.10E+13 4.57E+09 cell mmol
-1
 
Yx,lys 
 
1.75E+10 9.86E+14 cell mmol
-1
 
Yx,pro 
 
3.26E+11 6.40E+12 cell mmol
-1
 
Yx,glc  9.00E+08 4.45E+10 
cell mmol
-1
 
mglc 
 
1.48E-11 1.07E-11 mmol cell
−1
 h
−1
 
pgln 
 
3.11E-12 4.87E-11 mmol cell
−1
 h
−1
 
KT,[asn_ext] 
 
4.37E-12 1.68E-11 h
-1
 
KT,[lac_ext] 
 
5.83E-12 5.27E-13 h
-1
 
Kmamm,gln 
 
0.00E+00 1.34E+00 mM 
Kmlac, 
 
3.05E+00 1.72E-01 mM 
mAb synthesis related  
  KA 
 
1.38E-01 1.94E-03 molecule cell
-1
 h
-1
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KER 
 
4.56E+02 9.03E+02 h
-1
 
KG  2.00E+03 2.30E+04 
h
-1
 
NH  1.20E+02 1.20E+02 
gene cell
-1
 
NL  1.02E+02 1.02E+02 
gene cell
-1
 
SH  1.59E+01 1.11E+02 
mRNAs gene
-1
 h
-1
 
SL  9.31E+01 1.58E+02 
mRNAs gene
-1
 h
-1
 
TH  1.35E+00 2.17E+00 
chain mRNA
-1
 h
-1
 
TL  3.84E-01 5.66E-01 
chain mRNA
-1
 h
-1
 
1

1.00E+00 7.46E-01 n/a 
Kh 
 
9.77E-03 1.68E-03 h
-1
 
Kl 
 
1.15E-03 1.13E-03 h
-1
 
mAb secretion related  
  2

1.11E+01 6.14E+00 n/a 
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Appendix Table 3. List of parameters used in NSD models for both temperatures. 
Parameter Values Units 
  
 
36.5 
o
C 32 
o
C (Day 6)   
Nucleotide related  
KT,glc 8.25E-01 8.25E-01 
mmolglc(int) (dm
2
cell 
mmolglc(ext) h)
-1
 
KT,gln 2.56E+00 2.56E+00 
mmolglc(int) (dm
2
cell 
mmolglc(ext) h)
-1
 
Kglc,ATP 2.71E+00 3.02E-03 mM 
Kgln,ATP 2.04E+01 8.34E+00 mM 
Vmax, ATP 1.37E+01 2.11E+00 mmol Lcell
-1
 h
-1
 
Vmax, GTP 4.42E+01 2.68E+03 mmol Lcell
-1
 h
-1
 
Vmax, UTP 3.49E+01 9.26E+02 mmol Lcell
-1
 h
-1
 
Vmax, CTP 8.09E-03 7.61E+01 mmol Lcell
-1
 h
-1
 
NATP, GTP 2.00E+00 2.00E+00 mmol mmol
-1
 
NATP, UTP 4.00E+00 4.00E+00 mmol mmol
-1
 
NATP,CTP 1.00E+00 1.00E+00 mmol mmol
-1
 
KCTP,ATP 1.00E-04 4.46E+02 mM 
KCTP,UTP 0.00E+00 2.83E+01 mM 
KGTP,ATP 1.00E-10 5.00E+03 mM 
KUTP,ATP 8.47E+01 1.45E+00 mM 
KCTP,Gln 1.00E-04 1.07E+04 mM 
KGTP,Glc 1.48E+01 8.85E+00 mM 
KGTP,Gln 1.36E+02 2.51E+00 mM 
KUTP,Glc 1.01E+00 1.45E+03 mM 
KUTP,Gln 1.36E+02 2.01E+02 mM 
NSD related  
KTP,UDPGlc 4.11E-03 0.00E+00 mM 
KTP,UDPGal 4.68E-02 3.47E-04 mM 
KTP,UDPGlcNAc 0.00E+00 9.76E+00 mM 
KTP,UDPGalNAc 1.26E-02 9.69E+00 mM 
KTP,GDPMan 1.00E-02 1.40E+00 mM 
KTP,GDPFuc 1.25E-01 7.42E-02 mM 
KTP,CMPNeu5Ac 1.90E+01 9.98E+01 mM 
Vmax, UDPGlc 5.00E-01 5.84E-01 mmol Lcell
-1
 h
-1
 
Vmax, UDPGal 2.26E-03 0.00E+00 mmol Lcell
-1
 h
-1
 
Vmax, UDPGlcNAc 2.17E+00 7.66E+00 mmol Lcell
-1
 h
-1
 
Vmax, UDPGalNAc 6.23E-03 7.18E+01 mmol Lcell
-1
 h
-1
 
Vmax,GDPMan 6.57E-01 2.18E-01 mmol Lcell
-1
 h
-1
 
Vmax,GDPFuc 1.17E+01 5.28E+01 mmol Lcell
-1
 h
-1
 
Vmax,CMPNeu5Ac 4.04E-02 5.37E+00 mmol Lcell
-1
 h
-1
 
KUDPGlc 6.66E+02 1.05E+01 mM 
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 KUDPGal 4.73E-01 4.40E+02 mM 
KUDPGlcNAc 1.82E-01 4.53E-01 mM 
KUDPGalNAc 1.73E-02 4.57E+02 mM 
KGDPMan 1.71E+02 3.48E+01 mM 
KGDPFuc 8.80E+02 5.62E+03 mM 
KCMPNeu5Ac 1.50E+03 6.19E+03 mM 
Nglyc,cell 1.72E-12 5.27E-12 mmol cell
-1
  
NUDPGlc,glyc 5.04E-01 1.00E+00 mmol mmol
-1
  
NUDPGal,glyc 1.07E+00 5.14E-01 mmol mmol
-1
  
NUDPGlcNAc,glyc 5.47E-01 9.98E-01 mmol mmol
-1
  
NUDPGalNAc,glyc 0.00E+00 0.00E+00 mmol mmol
-1
  
NGDPMan,glyc 9.00E+00 9.00E+00 mmol mmol
-1
  
NGDPFuc,glyc 3.97E-01 3.97E-01 mmol mmol
-1
  
NCMPNeu5Ac,glyc 9.73E-02 9.73E-02 mmol mmol
-1
  
Nglyc,mAb 2.00E+00 2.00E+00 molglyc molmAbFc
-1
 
NUDPGlc,mAb 3.00E+00 3.00E+00 
mmolNSD mmolmAb
-
1
  
NUDPGal,mAb 3.79E-01 1.91E-01 
mmolNSD mmolmAb
-
1
  
NUDPGlcNAc,mAb 3.88E+00 2.00E+00 
mmolNSD mmolmAb
-
1
  
NGDPMan,mAb 9.00E+00 9.00E+00 
mmolNSD mmolmAb
-
1
  
NGDPFuc,mAb 9.32E-01 9.25E-01 
mmolNSD mmolmAb
-
1
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Appendix Table 1. Feeding schedules used in gPROMS for all TGE conditions.  
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Appendix Table 2. List of parameters used in cell dynamics models for both temperatures in TGE. 
Symbol 
 
Values Units 
  
TGE 36.5 
o
C TGE 32 
o
C 
 Growth/death related     
max

1.12E+00 1.58E-01 h
-1
 
d,max

2.88E-02 2.66E-02 h
-1
 
Kglc 
 
0.00E+00 1.49E-02 mM 
Klac 
 
1.15E+01 2.15E+01 mM 
Karg 
 
0.00E+00 3.66E-08 mM 
Kasn 
 
6.04E-01 9.51E-03 mM 
Kasp 
 
6.81E-05 4.62E-01 mM 
Kglu 
 
0.00E+00 5.69E-07 mM 
Klys 
 
2.90E+00 5.75E-07 mM 
Kpro 
 
2.48E+00 1.22E-02 mM 
KIlac  4.47E+00 1.00E+03 mM 
KIamm 
 
1.25E+02 7.20E-01 mM 
Kd,amm 
 
1.00E+00 5.67E+00 mM 
Klysis  1.39E-01 2.94E-01 
h
-1
 
KIPEI  8.74E+03 1.00E+04 mM 
Metabolism related  
  Yarg,glu 
 
2.41E-01 1.80E-02 mmol mmol
-1
 
Yasp,asn 
 
5.42E-02 1.00E-03 mmol mmol
-1
 
Ygln,glu 
 
4.85E-01 1.00E+00 mmol mmol
-1
 
Yglu,gln 
 
2.84E-03 1.00E+00 mmol mmol
-1
 
Ylac,glc  2.00E+00 1.11E-15 
mmol mmol
-1
 
Ylys,glu 
 
8.08E-01 2.90E-01 mmol mmol
-1
 
Ypro,glu 
 
1.00E+00 9.28E-01 mmol mmol
-1
 
YmAb, 
 
9.54E-01 1.00E+01 mg 
Yx,amm 
 
4.79E+10 1.95E+09 cell mmol
-1
 
Yx,arg 
 
2.98E+10 2.76E+10 cell mmol
-1
 
Yx,asn 
 
9.40E+19 1.57E+10 cell mmol
-1
 
Yx,asp 
 
1.00E+07 2.01E+09 cell mmol
-1
 
Yx,gln 
 
8.91E+16 5.59E+10 cell mmol
-1
 
Yx,glu 
 
1.78E+10 4.10E+09 cell mmol
-1
 
Yx,lac 
 
1.45E+08 1.00E+14 cell mmol
-1
 
Yx,lys 
 
2.24E+10 9.50E+09 cell mmol
-1
 
Yx,pro 
 
2.54E+10 1.09E+10 cell mmol
-1
 
Yx,glc  9.20E+08 6.54E+08 
cell mmol
-1
 
mglc 
 
3.26E-11 9.66E-12 mmol cell
−1
 h
−1
 
pgln 
 
1.91E-10 2.63E-12 mmol cell
−1
 h
−1
 
KT,[asn_ext] 
 
4.29E-12 5.07E-12 h
-1
 
KT,[lac_ext] 
 
9.52E-13 7.63E-12 h
-1
 
Kmamm,gln 
 
3.68E+02 1.85E-01 mM 
Kmlac, 
 
3.95E+01 2.99E+02 mM 
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mAb synthesis related  
  
KA 
 
4.15E-02 1.87E-03 
molecule cell
-1
 
h
-1
 
KER 
 
2.79E+03 3.00E+03 h
-1
 
KG  1.35E-03 7.22E-03 
h
-1
 
NH  variable variable 
gene cell
-1
 
NL  variable variable 
gene cell
-1
 
SH  1.40E+01 7.52E+00 
mRNAs gene
-1
 
h
-1
 
SL  2.33E+02 4.64E+01 
mRNAs gene
-1
 
h
-1
 
TH  4.90E+00 4.71E+02 
chain mRNA
-1
 
h
-1
 
TL  1.36E+00 4.70E+00 
chain mRNA
-1
 
h
-1
 
1

1.00E+00 1.00E+00 n/a 
Kh 
 
0.00E+00 0.00E+00 h
-1
 
Kl 
 
1.80E-01 1.00E-12 h
-1
 
mAb secretion related  
  2  6.50E+01 9.61E-01 n/a 
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Appendix Table 3. List of parameters used in NSD models for both temperatures in TGE. 
Parameter Values Units 
  
TGE 36.5 
o
C TGE 32 
o
C 
 Nucleotide related  
KT,glc 8.25E-01 8.25E-01 
mmolglc(int) (dm
2
cell 
mmolglc(ext) h)
-1
 
KT,gln 2.56E+00 2.56E+00 
mmolglc(int) (dm
2
cell 
mmolglc(ext) h)
-1
 
Kglc,ATP 3.05E-13 6.13E+00 mM 
Kgln,ATP 1.00E+00 6.57E+00 mM 
Vmax, ATP 5.46E+01 3.20E+00 mmol Lcell
-1
 h
-1
 
Vmax, GTP 2.31E+02 2.85E+01 mmol Lcell
-1
 h
-1
 
Vmax, UTP 4.74E+02 2.46E+00 mmol Lcell
-1
 h
-1
 
Vmax, CTP 1.00E+02 1.87E-01 mmol Lcell
-1
 h
-1
 
NATP, GTP 2.00E+00 2.00E+00 mmol mmol
-1
 
NATP, UTP 4.00E+00 4.00E+00 mmol mmol
-1
 
NATP,CTP 1.00E+00 1.00E+00 mmol mmol
-1
 
KCTP,ATP 1.20E+01 1.00E-06 mM 
KCTP,UTP 0.00E+00 0.00E+00 mM 
KGTP,ATP 5.36E+00 0.00E+00 mM 
KUTP,ATP 2.38E+01 9.76E+00 mM 
KCTP,Gln 3.20E+02 9.53E-01 mM 
KGTP,Glc 3.32E+04 2.55E+03 mM 
KGTP,Gln 6.95E+02 0.00E+00 mM 
KUTP,Glc 2.34E+00 0.00E+00 mM 
KUTP,Gln 2.33E+01 1.00E-02 mM 
NSD related  
KTP,UDPGlc 1.00E+00 4.89E-01 mM 
KTP,UDPGal 1.26E-02 0.00E+00 mM 
KTP,UDPGlcNAc 5.02E+00 6.14E+01 mM 
KTP,UDPGalNAc 1.26E-02 1.26E-02 mM 
KTP,GDPMan 1.00E-02 1.00E-02 mM 
KTP,GDPFuc 1.00E-05 1.00E-05 mM 
KTP,CMPNeu5Ac 8.01E-02 7.03E-01 mM 
Vmax, UDPGlc 4.86E+00 7.17E-04 mmol Lcell
-1
 h
-1
 
Vmax, UDPGal 2.06E-03 5.76E-02 mmol Lcell
-1
 h
-1
 
Vmax, UDPGlcNAc 1.00E+00 4.95E-01 mmol Lcell
-1
 h
-1
 
Vmax, UDPGalNAc 3.35E-03 2.65E-03 mmol Lcell
-1
 h
-1
 
Vmax,GDPMan 1.00E-10 2.45E+01 mmol Lcell
-1
 h
-1
 
Vmax,GDPFuc 2.16E-01 5.82E+00 mmol Lcell
-1
 h
-1
 
Vmax,CMPNeu5Ac 3.28E-07 3.28E-07 mmol Lcell
-1
 h
-1
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KUDPGlc 9.67E+02 0.00E+00 mM 
KUDPGal 5.00E-01 2.00E+02 mM 
KUDPGlcNAc 2.22E+01 0.00E+00 mM 
KUDPGalNAc 1.02E-02 9.91E-04 mM 
KGDPMan 0.00E+00 4.98E+01 mM 
KGDPFuc 4.50E+00 5.98E+01 mM 
KCMPNeu5Ac 1.50E+03 4.50E+00 mM 
Nglyc,cell 1.41E-11 3.44E-10 mmol cell
-1
  
NUDPGlc,glyc 1.99E+00 5.00E+00 mmol mmol
-1
  
NUDPGal,glyc 1.88E+00 1.00E-01 mmol mmol
-1
  
NUDPGlcNAc,glyc 7.93E+00 1.00E-10 mmol mmol
-1
  
NUDPGalNAc,glyc 8.32E-01 8.32E-01 mmol mmol
-1
  
NGDPMan,glyc 1.51E+00 1.51E+00 mmol mmol
-1
  
NGDPFuc,glyc 6.68E-02 6.68E-02 mmol mmol
-1
  
NCMPNeu5Ac,glyc 1.03E+00 1.03E+00 mmol mmol
-1
  
Nglyc,mAb 2.00E+00 2.00E+00 molglyc molmAbFc
-1
 
NUDPGlc,mAb 3.00E+00 3.00E+00 mmolNSD mmolmAb
-1
  
NUDPGal,mAb 2.15E-01 2.15E-01 mmolNSD mmolmAb
-1
  
NUDPGlcNAc,mAb 4.01E+00 4.01E+00 mmolNSD mmolmAb
-1
  
NGDPMan,mAb 9.00E+00 9.00E+00 mmolNSD mmolmAb
-1
  
NGDPFuc,mAb 8.33E-01 8.33E-01 mmolNSD mmolmAb
-1
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